Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,3429612,ED50s,"The induction of cleft palate demonstrated a linear dose-response by probit analysis: The ED50s were 143.6 mg/kg and 512.0 mg/kg for B10A and B10 mice, respectively.",Hydrocortisone-induced embryotoxicity and embryonic drug disposition in H-2 congenic mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3429612/),[mg] / [kg],143.6,485,DB00741,Hydrocortisone
,3429612,ED50s,"The induction of cleft palate demonstrated a linear dose-response by probit analysis: The ED50s were 143.6 mg/kg and 512.0 mg/kg for B10A and B10 mice, respectively.",Hydrocortisone-induced embryotoxicity and embryonic drug disposition in H-2 congenic mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3429612/),[mg] / [kg],512.0,486,DB00741,Hydrocortisone
,16398336,maximum levels,"Cortisol peaked at 20 min after administration of CRH in both cycling gilts and castrated boars with maximum levels of 149.3 +/- 16.5 nmol/l and 138.3 +/- 10.1 nmol/l, respectively.",Effect of ACTH and CRH on plasma levels of cortisol and prostaglandin F2alpha metabolite in cycling gilts and castrated boars. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16398336/),[nM] / [l],149.3,1623,DB00741,Hydrocortisone
,16398336,maximum levels,"Cortisol peaked at 20 min after administration of CRH in both cycling gilts and castrated boars with maximum levels of 149.3 +/- 16.5 nmol/l and 138.3 +/- 10.1 nmol/l, respectively.",Effect of ACTH and CRH on plasma levels of cortisol and prostaglandin F2alpha metabolite in cycling gilts and castrated boars. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16398336/),[nM] / [l],138.3,1624,DB00741,Hydrocortisone
,3961034,t1/2,The half-life of dexamethasone was markedly lower in five DST nonsuppressors (t1/2 = 160 +/- 33 minutes) than in six DST suppressors (t1/2 = 422 +/- 172 minutes).,The plasma dexamethasone variable in depression: test-retest studies and early biophase kinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3961034/),min,160,3256,DB00741,Hydrocortisone
,3961034,t1/2,The half-life of dexamethasone was markedly lower in five DST nonsuppressors (t1/2 = 160 +/- 33 minutes) than in six DST suppressors (t1/2 = 422 +/- 172 minutes).,The plasma dexamethasone variable in depression: test-retest studies and early biophase kinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3961034/),min,422,3257,DB00741,Hydrocortisone
,11294518,flow rate,"The mobile phase consisted of 16% isopropanol in water containing 0.1% trifluoroacetic acid, set at a flow rate of 1.2 mL/min.","Simultaneous determination of plasma prednisolone, prednisone, and cortisol levels by high-performance liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294518/),[ml] / [min],1.2,3291,DB00741,Hydrocortisone
,11294518,imprecision,"Mean intra-assay and interassay imprecision levels were 6.0% and 7.2%, respectively, for prednisolone, 5.8% and 7.2% for prednisone, and 5.6% and 7.9% for cortisol.","Simultaneous determination of plasma prednisolone, prednisone, and cortisol levels by high-performance liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294518/),%,7.2,3292,DB00741,Hydrocortisone
,11294518,imprecision,"Mean intra-assay and interassay imprecision levels were 6.0% and 7.2%, respectively, for prednisolone, 5.8% and 7.2% for prednisone, and 5.6% and 7.9% for cortisol.","Simultaneous determination of plasma prednisolone, prednisone, and cortisol levels by high-performance liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294518/),%,5.8,3293,DB00741,Hydrocortisone
,11294518,imprecision,"Mean intra-assay and interassay imprecision levels were 6.0% and 7.2%, respectively, for prednisolone, 5.8% and 7.2% for prednisone, and 5.6% and 7.9% for cortisol.","Simultaneous determination of plasma prednisolone, prednisone, and cortisol levels by high-performance liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294518/),%,5.6,3294,DB00741,Hydrocortisone
,11294518,imprecision,"Mean intra-assay and interassay imprecision levels were 6.0% and 7.2%, respectively, for prednisolone, 5.8% and 7.2% for prednisone, and 5.6% and 7.9% for cortisol.","Simultaneous determination of plasma prednisolone, prednisone, and cortisol levels by high-performance liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294518/),%,7.9,3295,DB00741,Hydrocortisone
,11294518,recoveries,"Corticosteroid recoveries were 73%, 74%, and 90% for prednisolone, prednisone, and cortisol, respectively.","Simultaneous determination of plasma prednisolone, prednisone, and cortisol levels by high-performance liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294518/),%,73,3296,DB00741,Hydrocortisone
,11294518,recoveries,"Corticosteroid recoveries were 73%, 74%, and 90% for prednisolone, prednisone, and cortisol, respectively.","Simultaneous determination of plasma prednisolone, prednisone, and cortisol levels by high-performance liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294518/),%,74,3297,DB00741,Hydrocortisone
,11294518,recoveries,"Corticosteroid recoveries were 73%, 74%, and 90% for prednisolone, prednisone, and cortisol, respectively.","Simultaneous determination of plasma prednisolone, prednisone, and cortisol levels by high-performance liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294518/),%,90,3298,DB00741,Hydrocortisone
,3947503,half-life,Administration of rifapentine (600 mg 48 h-1) for 10 days resulted in a significant reduction in antipyrine half-life (from 13.2 +/- 1.0 h to 7.7 +/- 0.4 h) and a corresponding increase in its total body clearance (from 41.8 +/- 5.5 ml min-1 to 67.4 +/- 5.6 ml min-1).,"Induction of mixed function oxidase activity in man by rifapentine (MDL 473), a long-acting rifamycin derivative. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3947503/),h,13.2,3495,DB00741,Hydrocortisone
,3947503,half-life,Administration of rifapentine (600 mg 48 h-1) for 10 days resulted in a significant reduction in antipyrine half-life (from 13.2 +/- 1.0 h to 7.7 +/- 0.4 h) and a corresponding increase in its total body clearance (from 41.8 +/- 5.5 ml min-1 to 67.4 +/- 5.6 ml min-1).,"Induction of mixed function oxidase activity in man by rifapentine (MDL 473), a long-acting rifamycin derivative. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3947503/),h,7.7,3496,DB00741,Hydrocortisone
,3947503,total body clearance,Administration of rifapentine (600 mg 48 h-1) for 10 days resulted in a significant reduction in antipyrine half-life (from 13.2 +/- 1.0 h to 7.7 +/- 0.4 h) and a corresponding increase in its total body clearance (from 41.8 +/- 5.5 ml min-1 to 67.4 +/- 5.6 ml min-1).,"Induction of mixed function oxidase activity in man by rifapentine (MDL 473), a long-acting rifamycin derivative. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3947503/),[ml] / [min],41.8,3497,DB00741,Hydrocortisone
,3947503,total body clearance,Administration of rifapentine (600 mg 48 h-1) for 10 days resulted in a significant reduction in antipyrine half-life (from 13.2 +/- 1.0 h to 7.7 +/- 0.4 h) and a corresponding increase in its total body clearance (from 41.8 +/- 5.5 ml min-1 to 67.4 +/- 5.6 ml min-1).,"Induction of mixed function oxidase activity in man by rifapentine (MDL 473), a long-acting rifamycin derivative. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3947503/),[ml] / [min],67.4,3498,DB00741,Hydrocortisone
,8157047,IC50,A mean IC50 value (fluocortolone plasma concentration at which the circadian secretion of cortisol is inhibited by 50%) of 15.5 ng.,Pharmacodynamic modeling of cortisol suppression from fluocortolone. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8157047/),ng,15.5,3521,DB00741,Hydrocortisone
,11085188,GC-R,"Mean GC-R numbers were 5814+/-1574 and 6816+/-1647; mean Kd values were 3.6+/-1.5 nM and 4.2+/-0.7 nM in patient and control groups, respectively.",Glucocorticoid receptors in patients with congenital adrenal hyperplasia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11085188/),,5814,6172,DB00741,Hydrocortisone
,11085188,GC-R,"Mean GC-R numbers were 5814+/-1574 and 6816+/-1647; mean Kd values were 3.6+/-1.5 nM and 4.2+/-0.7 nM in patient and control groups, respectively.",Glucocorticoid receptors in patients with congenital adrenal hyperplasia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11085188/),,6816,6173,DB00741,Hydrocortisone
,11085188,numbers,"Mean GC-R numbers were 5814+/-1574 and 6816+/-1647; mean Kd values were 3.6+/-1.5 nM and 4.2+/-0.7 nM in patient and control groups, respectively.",Glucocorticoid receptors in patients with congenital adrenal hyperplasia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11085188/),,5814,6174,DB00741,Hydrocortisone
,11085188,numbers,"Mean GC-R numbers were 5814+/-1574 and 6816+/-1647; mean Kd values were 3.6+/-1.5 nM and 4.2+/-0.7 nM in patient and control groups, respectively.",Glucocorticoid receptors in patients with congenital adrenal hyperplasia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11085188/),,6816,6175,DB00741,Hydrocortisone
,11085188,Kd,"Mean GC-R numbers were 5814+/-1574 and 6816+/-1647; mean Kd values were 3.6+/-1.5 nM and 4.2+/-0.7 nM in patient and control groups, respectively.",Glucocorticoid receptors in patients with congenital adrenal hyperplasia. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11085188/),nM,3.6,6176,DB00741,Hydrocortisone
,11085188,Kd,"Mean GC-R numbers were 5814+/-1574 and 6816+/-1647; mean Kd values were 3.6+/-1.5 nM and 4.2+/-0.7 nM in patient and control groups, respectively.",Glucocorticoid receptors in patients with congenital adrenal hyperplasia. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11085188/),nM,4.2,6177,DB00741,Hydrocortisone
,6830010,half time of elimination,"After IV administration, the half time of elimination was similar (120 to 140 minutes) for both formulations.",Pharmacokinetics of dexamethasone and its effect on adrenal gland function in the dog. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6830010/),min,120 to 140,7494,DB00741,Hydrocortisone
,6830010,Bioavailability,"Bioavailability was approximately 100% for DXM alcohol, but limited (40%) for DXM 21-isonicotinate.",Pharmacokinetics of dexamethasone and its effect on adrenal gland function in the dog. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6830010/),%,100,7495,DB00741,Hydrocortisone
,6830010,Bioavailability,"Bioavailability was approximately 100% for DXM alcohol, but limited (40%) for DXM 21-isonicotinate.",Pharmacokinetics of dexamethasone and its effect on adrenal gland function in the dog. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6830010/),%,40,7496,DB00741,Hydrocortisone
,15509026,terminal elimination half-life,The pharmacokinetic parameters of the two-compartment pharmacokinetic model for the lowest intravenous dose (mean+/-SD) were as follows: terminal elimination half-life 8.17 +/- 1.79 h; total body clearance 100.7 +/- 52.1 (ml/h)/kg; volume of distribution at steady state 0.95 +/- 0.23 L/kg; and volume of the central compartment 0.22 +/- 0.07 L/kg.,Pharmacokinetics and pharmacodynamics of dexamethasone after intravenous administration in camels: effect of dose. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15509026/),h,8.17,7823,DB00741,Hydrocortisone
,15509026,total body clearance,The pharmacokinetic parameters of the two-compartment pharmacokinetic model for the lowest intravenous dose (mean+/-SD) were as follows: terminal elimination half-life 8.17 +/- 1.79 h; total body clearance 100.7 +/- 52.1 (ml/h)/kg; volume of distribution at steady state 0.95 +/- 0.23 L/kg; and volume of the central compartment 0.22 +/- 0.07 L/kg.,Pharmacokinetics and pharmacodynamics of dexamethasone after intravenous administration in camels: effect of dose. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15509026/),[ml] / [h)·kg],100.7,7824,DB00741,Hydrocortisone
,15509026,volume of distribution at steady state,The pharmacokinetic parameters of the two-compartment pharmacokinetic model for the lowest intravenous dose (mean+/-SD) were as follows: terminal elimination half-life 8.17 +/- 1.79 h; total body clearance 100.7 +/- 52.1 (ml/h)/kg; volume of distribution at steady state 0.95 +/- 0.23 L/kg; and volume of the central compartment 0.22 +/- 0.07 L/kg.,Pharmacokinetics and pharmacodynamics of dexamethasone after intravenous administration in camels: effect of dose. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15509026/),[l] / [kg],0.95,7825,DB00741,Hydrocortisone
,15509026,volume of the central compartment,The pharmacokinetic parameters of the two-compartment pharmacokinetic model for the lowest intravenous dose (mean+/-SD) were as follows: terminal elimination half-life 8.17 +/- 1.79 h; total body clearance 100.7 +/- 52.1 (ml/h)/kg; volume of distribution at steady state 0.95 +/- 0.23 L/kg; and volume of the central compartment 0.22 +/- 0.07 L/kg.,Pharmacokinetics and pharmacodynamics of dexamethasone after intravenous administration in camels: effect of dose. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15509026/),[l] / [kg],0.22,7826,DB00741,Hydrocortisone
,15509026,plasma protein binding,The extent of plasma protein binding was linear over the concentration range 5-100 ng/ml and averaged 75% +/- 2%.,Pharmacokinetics and pharmacodynamics of dexamethasone after intravenous administration in camels: effect of dose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15509026/),%,75,7827,DB00741,Hydrocortisone
,15509026,IC50,"The estimated IC50 of dexamethasone for cortisol and lymphocytes for the lowest dose were 3.74 +/- 2.44 and 5.58 +/- 8.37 ng/ml, respectively and the EC50 values for neutrophils and glucose were 45.8 +/- 36.9 and 1.17 +/- 0.71 ng/ml, respectively.",Pharmacokinetics and pharmacodynamics of dexamethasone after intravenous administration in camels: effect of dose. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15509026/),[ng] / [ml],3.74,7828,DB00741,Hydrocortisone
,15509026,IC50,"The estimated IC50 of dexamethasone for cortisol and lymphocytes for the lowest dose were 3.74 +/- 2.44 and 5.58 +/- 8.37 ng/ml, respectively and the EC50 values for neutrophils and glucose were 45.8 +/- 36.9 and 1.17 +/- 0.71 ng/ml, respectively.",Pharmacokinetics and pharmacodynamics of dexamethasone after intravenous administration in camels: effect of dose. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15509026/),[ng] / [ml],5.58,7829,DB00741,Hydrocortisone
,15509026,EC50,"The estimated IC50 of dexamethasone for cortisol and lymphocytes for the lowest dose were 3.74 +/- 2.44 and 5.58 +/- 8.37 ng/ml, respectively and the EC50 values for neutrophils and glucose were 45.8 +/- 36.9 and 1.17 +/- 0.71 ng/ml, respectively.",Pharmacokinetics and pharmacodynamics of dexamethasone after intravenous administration in camels: effect of dose. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15509026/),[ng] / [ml],45.8,7830,DB00741,Hydrocortisone
,15509026,EC50,"The estimated IC50 of dexamethasone for cortisol and lymphocytes for the lowest dose were 3.74 +/- 2.44 and 5.58 +/- 8.37 ng/ml, respectively and the EC50 values for neutrophils and glucose were 45.8 +/- 36.9 and 1.17 +/- 0.71 ng/ml, respectively.",Pharmacokinetics and pharmacodynamics of dexamethasone after intravenous administration in camels: effect of dose. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15509026/),[ng] / [ml],1.17,7831,DB00741,Hydrocortisone
,27819157,Tmax,"The in vivo studies showed good colon-targeting of HSS-DRM (Tmax = 0.97 h, Cmax = 118.28 µg/mL of HSS; Tmax = 2.16 h, Cmax = 64.47 µg/mL of HSS-DRM).",Improvement of side-effects and treatment on the experimental colitis in mice of a resin microcapsule-loading hydrocortisone sodium succinate. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27819157/),h,0.97,7878,DB00741,Hydrocortisone
,27819157,Cmax,"The in vivo studies showed good colon-targeting of HSS-DRM (Tmax = 0.97 h, Cmax = 118.28 µg/mL of HSS; Tmax = 2.16 h, Cmax = 64.47 µg/mL of HSS-DRM).",Improvement of side-effects and treatment on the experimental colitis in mice of a resin microcapsule-loading hydrocortisone sodium succinate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27819157/),[μg] / [ml],118.28,7879,DB00741,Hydrocortisone
,27819157,Tmax,"The in vivo studies showed good colon-targeting of HSS-DRM (Tmax = 0.97 h, Cmax = 118.28 µg/mL of HSS; Tmax = 2.16 h, Cmax = 64.47 µg/mL of HSS-DRM).",Improvement of side-effects and treatment on the experimental colitis in mice of a resin microcapsule-loading hydrocortisone sodium succinate. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27819157/),h,2.16,7880,DB00741,Hydrocortisone
,27819157,Cmax,"The in vivo studies showed good colon-targeting of HSS-DRM (Tmax = 0.97 h, Cmax = 118.28 µg/mL of HSS; Tmax = 2.16 h, Cmax = 64.47 µg/mL of HSS-DRM).",Improvement of side-effects and treatment on the experimental colitis in mice of a resin microcapsule-loading hydrocortisone sodium succinate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27819157/),[μg] / [ml],64.47,7881,DB00741,Hydrocortisone
,23073666,K(I),"DX-619 was a mechanism-based inhibitor of CYP3A4, with K(I) and k(inact) of 67.9 ± 7.3 μmol/l and 0.0730 ± 0.0033 min(-1), respectively.","Effect of the fluoroquinolone antibacterial agent DX-619 on the apparent formation and renal clearances of 6β-hydroxycortisol, an endogenous probe for CYP3A4 inhibition, in healthy subjects. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23073666/),[μM] / [l],67.9,8650,DB00741,Hydrocortisone
,23073666,k(inact),"DX-619 was a mechanism-based inhibitor of CYP3A4, with K(I) and k(inact) of 67.9 ± 7.3 μmol/l and 0.0730 ± 0.0033 min(-1), respectively.","Effect of the fluoroquinolone antibacterial agent DX-619 on the apparent formation and renal clearances of 6β-hydroxycortisol, an endogenous probe for CYP3A4 inhibition, in healthy subjects. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23073666/),1/[min],0.0730,8651,DB00741,Hydrocortisone
,23073666,K(m),"6β-hydroxycortisol was a substrate of OAT3 (K(m) = 183 ± 25 μmol/l), OCT2, MATE1, and MATE2-K.","Effect of the fluoroquinolone antibacterial agent DX-619 on the apparent formation and renal clearances of 6β-hydroxycortisol, an endogenous probe for CYP3A4 inhibition, in healthy subjects. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23073666/),[μM] / [l],183,8652,DB00741,Hydrocortisone
,23073666,Maximum unbound concentration,Maximum unbound concentration of DX-619 (9.1 ± 0.4 μmol/l) was above K(i) of DX-619 for MATE1 (4.32 ± 0.79 μmol/l).,"Effect of the fluoroquinolone antibacterial agent DX-619 on the apparent formation and renal clearances of 6β-hydroxycortisol, an endogenous probe for CYP3A4 inhibition, in healthy subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23073666/),[μM] / [l],9.1,8653,DB00741,Hydrocortisone
,23073666,K(i),Maximum unbound concentration of DX-619 (9.1 ± 0.4 μmol/l) was above K(i) of DX-619 for MATE1 (4.32 ± 0.79 μmol/l).,"Effect of the fluoroquinolone antibacterial agent DX-619 on the apparent formation and renal clearances of 6β-hydroxycortisol, an endogenous probe for CYP3A4 inhibition, in healthy subjects. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23073666/),[μM] / [l],4.32,8654,DB00741,Hydrocortisone
,3912192,plasma clearance,After i.v. administration the plasma clearance was 0.921/min and the apparent volume of distribution was 2.81/kg.,Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3912192/),1/[min],0.921,8913,DB00741,Hydrocortisone
,3912192,apparent volume of distribution,After i.v. administration the plasma clearance was 0.921/min and the apparent volume of distribution was 2.81/kg.,Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3912192/),1/[kg],2.81,8914,DB00741,Hydrocortisone
,3912192,time to reach the peak plasma level,"After nasal administration, the time to reach the peak plasma level was approximately 30 min, and the systemic availability was 102%.",Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3912192/),min,30,8915,DB00741,Hydrocortisone
,3912192,systemic availability,"After nasal administration, the time to reach the peak plasma level was approximately 30 min, and the systemic availability was 102%.",Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3912192/),%,102,8916,DB00741,Hydrocortisone
,11823756,half-life,The half-life of betamethasone in mothers with twin pregnancies was significantly shorter than that in mothers with singleton pregnancies (7.2 +/-2.4 versus 9.0 +/- 2.7 hours; P <.017).,Pharmacokinetics of betamethasone in twin and singleton pregnancy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11823756/),h,7.2,10466,DB00741,Hydrocortisone
,11823756,half-life,The half-life of betamethasone in mothers with twin pregnancies was significantly shorter than that in mothers with singleton pregnancies (7.2 +/-2.4 versus 9.0 +/- 2.7 hours; P <.017).,Pharmacokinetics of betamethasone in twin and singleton pregnancy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11823756/),h,9.0,10467,DB00741,Hydrocortisone
,11823756,Clearance,Clearance of betamethasone in the twin pregnancies appeared greater than in singleton pregnancies (8.4 +/- 6.4 versus 5.7+/- 3.1 L/h; P =.06) but did not reach statistical significance.,Pharmacokinetics of betamethasone in twin and singleton pregnancy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11823756/),[l] / [h],8.4,10468,DB00741,Hydrocortisone
,11823756,Clearance,Clearance of betamethasone in the twin pregnancies appeared greater than in singleton pregnancies (8.4 +/- 6.4 versus 5.7+/- 3.1 L/h; P =.06) but did not reach statistical significance.,Pharmacokinetics of betamethasone in twin and singleton pregnancy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11823756/),[l] / [h],5.7,10469,DB00741,Hydrocortisone
,27511886,AUC0-∞,"However, diplotype analysis suggested that CYP3A5 expressers with the CYP3A4*1/*1G genotype (n = 3) had significantly lower midazolam AUC0-∞ values (210·0 ± 33·5 vs. 313·9 ± 204·6 h∙ng/mL, P = 0·044) and higher CL/F values (1·16 ± 0·16 vs. 0·88 ± 0·48 L/h/kg, P = 0·005) compared to subjects with the CYP3A4*1/*1 genotype (n = 4), which is consistent with some previous studies with tacrolimus.",Associations of the CYP3A5*3 and CYP3A4*1G polymorphisms with the pharmacokinetics of oral midazolam and the urinary 6β-hydroxycortisol/cortisol ratio as markers of CYP3A activity in healthy male Chinese. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27511886/),[h∙ng] / [ml],210·0,13881,DB00741,Hydrocortisone
,27511886,AUC0-∞,"However, diplotype analysis suggested that CYP3A5 expressers with the CYP3A4*1/*1G genotype (n = 3) had significantly lower midazolam AUC0-∞ values (210·0 ± 33·5 vs. 313·9 ± 204·6 h∙ng/mL, P = 0·044) and higher CL/F values (1·16 ± 0·16 vs. 0·88 ± 0·48 L/h/kg, P = 0·005) compared to subjects with the CYP3A4*1/*1 genotype (n = 4), which is consistent with some previous studies with tacrolimus.",Associations of the CYP3A5*3 and CYP3A4*1G polymorphisms with the pharmacokinetics of oral midazolam and the urinary 6β-hydroxycortisol/cortisol ratio as markers of CYP3A activity in healthy male Chinese. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27511886/),[h∙ng] / [ml],313·9,13882,DB00741,Hydrocortisone
,27511886,CL/F,"However, diplotype analysis suggested that CYP3A5 expressers with the CYP3A4*1/*1G genotype (n = 3) had significantly lower midazolam AUC0-∞ values (210·0 ± 33·5 vs. 313·9 ± 204·6 h∙ng/mL, P = 0·044) and higher CL/F values (1·16 ± 0·16 vs. 0·88 ± 0·48 L/h/kg, P = 0·005) compared to subjects with the CYP3A4*1/*1 genotype (n = 4), which is consistent with some previous studies with tacrolimus.",Associations of the CYP3A5*3 and CYP3A4*1G polymorphisms with the pharmacokinetics of oral midazolam and the urinary 6β-hydroxycortisol/cortisol ratio as markers of CYP3A activity in healthy male Chinese. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27511886/),[l] / [h·kg],1·16,13883,DB00741,Hydrocortisone
,27511886,CL/F,"However, diplotype analysis suggested that CYP3A5 expressers with the CYP3A4*1/*1G genotype (n = 3) had significantly lower midazolam AUC0-∞ values (210·0 ± 33·5 vs. 313·9 ± 204·6 h∙ng/mL, P = 0·044) and higher CL/F values (1·16 ± 0·16 vs. 0·88 ± 0·48 L/h/kg, P = 0·005) compared to subjects with the CYP3A4*1/*1 genotype (n = 4), which is consistent with some previous studies with tacrolimus.",Associations of the CYP3A5*3 and CYP3A4*1G polymorphisms with the pharmacokinetics of oral midazolam and the urinary 6β-hydroxycortisol/cortisol ratio as markers of CYP3A activity in healthy male Chinese. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27511886/),[l] / [h·kg],0·88,13884,DB00741,Hydrocortisone
,25611194,flow rate,"The chromatographic separation was achieved on a Chromolith RP18e column using a mixture of acetonitrile and 2 mm ammonium formate (70:30, v/v) as the mobile phase at a flow rate of 0.7 mL/min.",A highly sensitive method for the quantification of fludrocortisone in human plasma using ultra-high-performance liquid chromatography tandem mass spectrometry and its pharmacokinetic application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25611194/),[ml] / [min],0.7,14278,DB00741,Hydrocortisone
,25611194,m/,"The precursors to product ion transitions monitored for fludrocortisone and IS were m/z 381.2 → 343.2 and 386.2 → 348.4, respectively.",A highly sensitive method for the quantification of fludrocortisone in human plasma using ultra-high-performance liquid chromatography tandem mass spectrometry and its pharmacokinetic application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25611194/),,381.2,14279,DB00741,Hydrocortisone
,25611194,m/,"The precursors to product ion transitions monitored for fludrocortisone and IS were m/z 381.2 → 343.2 and 386.2 → 348.4, respectively.",A highly sensitive method for the quantification of fludrocortisone in human plasma using ultra-high-performance liquid chromatography tandem mass spectrometry and its pharmacokinetic application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25611194/),,386.2,14280,DB00741,Hydrocortisone
,15041734,T(1/2),Pharmacokinetic analysis showed that rMETase was eliminated with a T(1/2) of 2.49 h.,"Pharmacokinetics, methionine depletion, and antigenicity of recombinant methioninase in primates. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15041734/),h,2.49,14364,DB00741,Hydrocortisone
,21336389,flow-rate,"Chromatographic separation was carried out on a Nucleosil 100 C(18) analytical column using a mixture of acetonitrile and water (30 : 70, v/v) as a mobile phase at a flow-rate of 1 mL min(-1).","Simultaneous determination of urinary cortisol, cortisone and corticosterone in parachutists, depressed patients and healthy controls in view of biomedical and pharmacokinetic studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21336389/),[ml] / [min],1,14882,DB00741,Hydrocortisone
above,21336389,absolute recoveries,The absolute recoveries of glucocorticoids were above 94.6%.,"Simultaneous determination of urinary cortisol, cortisone and corticosterone in parachutists, depressed patients and healthy controls in view of biomedical and pharmacokinetic studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21336389/),%,94.6,14883,DB00741,Hydrocortisone
,21336389,limits of detection (LOD),"The limits of detection (LOD) and quantification (LOQ) were 0.5 and 2 ng mL(-1), respectively, for all analytes.","Simultaneous determination of urinary cortisol, cortisone and corticosterone in parachutists, depressed patients and healthy controls in view of biomedical and pharmacokinetic studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21336389/),[ng] / [ml],0.5,14884,DB00741,Hydrocortisone
,21336389,quantification (LOQ),"The limits of detection (LOD) and quantification (LOQ) were 0.5 and 2 ng mL(-1), respectively, for all analytes.","Simultaneous determination of urinary cortisol, cortisone and corticosterone in parachutists, depressed patients and healthy controls in view of biomedical and pharmacokinetic studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21336389/),[ng] / [ml],2,14885,DB00741,Hydrocortisone
,25386671,half-life,"Mean (SD) cortisol half-life and Cmax were 1.01 (0.20) hours and 24.4 (5.4) μg/dL, respectively.","Interrelationships among cortisol, 17-hydroxyprogesterone, and androstenendione exposures in the management of children with congenital adrenal hyperplasia. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25386671/),h,1.01,15325,DB00741,Hydrocortisone
,25386671,Cmax,"Mean (SD) cortisol half-life and Cmax were 1.01 (0.20) hours and 24.4 (5.4) μg/dL, respectively.","Interrelationships among cortisol, 17-hydroxyprogesterone, and androstenendione exposures in the management of children with congenital adrenal hyperplasia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25386671/),[μg] / [dl],24.4,15326,DB00741,Hydrocortisone
,25386671,AUCs,"The AUCs for cortisol, 17-hydroxyprogesterone and androstenedione were 40.8 (14.5) μg hour/dL, 29,490 (23,539) ng hour/dL, and 680 (795) ng hour/dL, respectively.","Interrelationships among cortisol, 17-hydroxyprogesterone, and androstenendione exposures in the management of children with congenital adrenal hyperplasia. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25386671/),[h·μg] / [dl],40.8,15327,DB00741,Hydrocortisone
,25386671,AUCs,"The AUCs for cortisol, 17-hydroxyprogesterone and androstenedione were 40.8 (14.5) μg hour/dL, 29,490 (23,539) ng hour/dL, and 680 (795) ng hour/dL, respectively.","Interrelationships among cortisol, 17-hydroxyprogesterone, and androstenendione exposures in the management of children with congenital adrenal hyperplasia. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25386671/),[h·ng] / [dl],"29,490",15328,DB00741,Hydrocortisone
,25386671,AUCs,"The AUCs for cortisol, 17-hydroxyprogesterone and androstenedione were 40.8 (14.5) μg hour/dL, 29,490 (23,539) ng hour/dL, and 680 (795) ng hour/dL, respectively.","Interrelationships among cortisol, 17-hydroxyprogesterone, and androstenendione exposures in the management of children with congenital adrenal hyperplasia. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25386671/),[h·ng] / [dl],680,15329,DB00741,Hydrocortisone
,20594087,bioavailability,Mean bioavailability of dexamethasone ranged from 28% to 66% but was not significantly different among horses receiving either formulation PO in the unfed or fed state.,Pharmacokinetics and pharmacodynamics of dexamethasone after oral administration in apparently healthy horses. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20594087/),%,28,18410,DB00741,Hydrocortisone
,20594087,bioavailability,Mean bioavailability of dexamethasone ranged from 28% to 66% but was not significantly different among horses receiving either formulation PO in the unfed or fed state.,Pharmacokinetics and pharmacodynamics of dexamethasone after oral administration in apparently healthy horses. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20594087/),%,66,18411,DB00741,Hydrocortisone
,9115056,return AUC,"The return AUC of cortisol (425 +/- 357 ng.hr/mL [elderly] versus 854 +/- 216 ng.mL [young]) and the total AUC 764 +/- 340 ng.h/mL [elderly] versus 1,230 +/- 258 ng.hr/mL [young]) were significantly lower in the older men.",Cortisol pharmacodynamics after methylprednisolone administration in young and elderly males. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9115056/),[h·ng] / [ml],425,19357,DB00741,Hydrocortisone
,9115056,return AUC,"The return AUC of cortisol (425 +/- 357 ng.hr/mL [elderly] versus 854 +/- 216 ng.mL [young]) and the total AUC 764 +/- 340 ng.h/mL [elderly] versus 1,230 +/- 258 ng.hr/mL [young]) were significantly lower in the older men.",Cortisol pharmacodynamics after methylprednisolone administration in young and elderly males. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9115056/),ml·ng,854,19358,DB00741,Hydrocortisone
,9115056,total AUC,"The return AUC of cortisol (425 +/- 357 ng.hr/mL [elderly] versus 854 +/- 216 ng.mL [young]) and the total AUC 764 +/- 340 ng.h/mL [elderly] versus 1,230 +/- 258 ng.hr/mL [young]) were significantly lower in the older men.",Cortisol pharmacodynamics after methylprednisolone administration in young and elderly males. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9115056/),[h·ng] / [ml],764,19359,DB00741,Hydrocortisone
,9115056,total AUC,"The return AUC of cortisol (425 +/- 357 ng.hr/mL [elderly] versus 854 +/- 216 ng.mL [young]) and the total AUC 764 +/- 340 ng.h/mL [elderly] versus 1,230 +/- 258 ng.hr/mL [young]) were significantly lower in the older men.",Cortisol pharmacodynamics after methylprednisolone administration in young and elderly males. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9115056/),[h·ng] / [ml],"1,230",19360,DB00741,Hydrocortisone
,9115056,suppression ratio,"The suppression ratio was significantly greater in the elderly men (mean, 0.38 versus 0.58 in young), which indicates a greater degree of adrenal suppression after administration of methylprednisolone.",Cortisol pharmacodynamics after methylprednisolone administration in young and elderly males. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9115056/),,0.38,19361,DB00741,Hydrocortisone
,9115056,suppression ratio,"The suppression ratio was significantly greater in the elderly men (mean, 0.38 versus 0.58 in young), which indicates a greater degree of adrenal suppression after administration of methylprednisolone.",Cortisol pharmacodynamics after methylprednisolone administration in young and elderly males. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9115056/),,0.58,19362,DB00741,Hydrocortisone
,9115056,AUC,"Exposure to methylprednisolone, as measured by AUC, was 554 +/- 215 ng.hr/kg (elderly) and 389 +/- 102 ng.hr/kg (young).",Cortisol pharmacodynamics after methylprednisolone administration in young and elderly males. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9115056/),[h·ng] / [kg],554,19363,DB00741,Hydrocortisone
,9115056,AUC,"Exposure to methylprednisolone, as measured by AUC, was 554 +/- 215 ng.hr/kg (elderly) and 389 +/- 102 ng.hr/kg (young).",Cortisol pharmacodynamics after methylprednisolone administration in young and elderly males. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9115056/),[h·ng] / [kg],389,19364,DB00741,Hydrocortisone
,17472657,terminal half-life,"After intravenous injection at a dosage of 0.02 mg/kg bw, the terminal half-life was 73.8+/-19.9 min (mean+/-SD), the apparent volume of distribution 5.22+/-1.01 L/kg, and total body clearance 79.1+/-18.5 mL/min/kg.","Clinical pharmacology of buprenorphine in healthy, lactating goats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17472657/),min,73.8,19613,DB00741,Hydrocortisone
,17472657,apparent volume of distribution,"After intravenous injection at a dosage of 0.02 mg/kg bw, the terminal half-life was 73.8+/-19.9 min (mean+/-SD), the apparent volume of distribution 5.22+/-1.01 L/kg, and total body clearance 79.1+/-18.5 mL/min/kg.","Clinical pharmacology of buprenorphine in healthy, lactating goats. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17472657/),[l] / [kg],5.22,19614,DB00741,Hydrocortisone
,17472657,total body clearance,"After intravenous injection at a dosage of 0.02 mg/kg bw, the terminal half-life was 73.8+/-19.9 min (mean+/-SD), the apparent volume of distribution 5.22+/-1.01 L/kg, and total body clearance 79.1+/-18.5 mL/min/kg.","Clinical pharmacology of buprenorphine in healthy, lactating goats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17472657/),[ml] / [kg·min],79.1,19615,DB00741,Hydrocortisone
,17472657,clearance,"After intramuscular administration of buprenorphine at the same dosage, bioavailability was complete and clearance was 54.7+/-16.6 mL/min/kg.","Clinical pharmacology of buprenorphine in healthy, lactating goats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17472657/),[ml] / [kg·min],54.7,19616,DB00741,Hydrocortisone
,19808952,area under the concentration-time curve ratios,Triiodothyronine administration significantly reduced the area under the concentration-time curve ratios for 1'-hydroxymidazolam/midazolam from 0.36 to 0.25 (P < .05) and urinary ratios of 6 beta-hydroxycortisol/free cortisol from 6.92 to 5.88 (P < .05).,Effect of thyroid hormone on the activity of CYP3A enzyme in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19808952/),,0.,21070,DB00741,Hydrocortisone
<,9164416,steady,"In the rifampin group, delavirdine oral clearance increased by about 27-fold (p = 0.022), resulting in virtually negligible (< 0.09 mumol/L) steady-state through drug concentrations in all patients after 2 weeks of concurrent dosing of delavirdine mesylate and rifampin.",Pharmacokinetic study of the interaction between rifampin and delavirdine mesylate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9164416/),,0,21792,DB00741,Hydrocortisone
,9164416,elimination half-life,The ratio of metabolite formation to elimination clearance for desalkyldelavirdine was significantly higher (3.9 +/- 1.2 versus 0.23 +/- 0.10) and delavirdine elimination half-life was significantly shorter (1.7 +/- 1.4 versus 4.3 +/- 1.3 hours) when delavirdine mesylate was taken with rifampin.,Pharmacokinetic study of the interaction between rifampin and delavirdine mesylate. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9164416/),h,1.7,21793,DB00741,Hydrocortisone
,9164416,elimination half-life,The ratio of metabolite formation to elimination clearance for desalkyldelavirdine was significantly higher (3.9 +/- 1.2 versus 0.23 +/- 0.10) and delavirdine elimination half-life was significantly shorter (1.7 +/- 1.4 versus 4.3 +/- 1.3 hours) when delavirdine mesylate was taken with rifampin.,Pharmacokinetic study of the interaction between rifampin and delavirdine mesylate. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9164416/),h,4.3,21794,DB00741,Hydrocortisone
,6662178,plasma clearance,"The plasma clearance of betamethasone phosphate (mean = 980 ml/min) and its apparent distribution volume (mean = 5.61) were both higher than previously found for nonpregnant subjects, but its half-life (mean = 4.6 min) was unchanged.",Disposition of betamethasone in parturient women after intravenous administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6662178/),[ml] / [min],980,22296,DB00741,Hydrocortisone
,6662178,apparent distribution volume,"The plasma clearance of betamethasone phosphate (mean = 980 ml/min) and its apparent distribution volume (mean = 5.61) were both higher than previously found for nonpregnant subjects, but its half-life (mean = 4.6 min) was unchanged.",Disposition of betamethasone in parturient women after intravenous administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6662178/),,5.61,22297,DB00741,Hydrocortisone
,6662178,half-life,"The plasma clearance of betamethasone phosphate (mean = 980 ml/min) and its apparent distribution volume (mean = 5.61) were both higher than previously found for nonpregnant subjects, but its half-life (mean = 4.6 min) was unchanged.",Disposition of betamethasone in parturient women after intravenous administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6662178/),min,4.6,22298,DB00741,Hydrocortisone
,6662178,terminal half-life,"Plasma concentrations of betamethasone reached a peak 5-37 min after dosing with betamethasone phosphate, then declined biexponentially with a mean terminal half-life of 262 min.",Disposition of betamethasone in parturient women after intravenous administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6662178/),min,262,22299,DB00741,Hydrocortisone
,6662178,Plasma clearance,Plasma clearance in pregnant patients (mean = 287 ml/min) was higher than previously reported for nonpregnant subjects.,Disposition of betamethasone in parturient women after intravenous administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6662178/),[ml] / [min],287,22300,DB00741,Hydrocortisone
,11851646,AUC,"The treatment with rifampicin reduced the mean (+/- s.d.) AUC of nilvadipine from 17.4 +/- 8.4 to 0.6 +/- 0.4 microg l-1 h (mean difference -16.8 microg l-1 h, 95% CI -9.4, 24.2 microg l-1 h).",The effects of rifampicin on the pharmacokinetics and pharmacodynamics of orally administered nilvadipine to healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11851646/),[h·μg] / [l],17.4,23022,DB00741,Hydrocortisone
,11851646,AUC,"The treatment with rifampicin reduced the mean (+/- s.d.) AUC of nilvadipine from 17.4 +/- 8.4 to 0.6 +/- 0.4 microg l-1 h (mean difference -16.8 microg l-1 h, 95% CI -9.4, 24.2 microg l-1 h).",The effects of rifampicin on the pharmacokinetics and pharmacodynamics of orally administered nilvadipine to healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11851646/),[h·μg] / [l],0.6,23023,DB00741,Hydrocortisone
,21219346,terminal half-life,"In the adult goats after intravenous administration the terminal half-life was 10.9 ± 1.7 h, steady-state volume of distribution was 0.245 ± 0.06 L/kg, and total body clearance was 17.9 ± 4.3 mL/h/kg.",Pharmacokinetics of meloxicam in adult goats and its analgesic effect in disbudded kids. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21219346/),h,10.9,23319,DB00741,Hydrocortisone
,21219346,steady-state volume of distribution,"In the adult goats after intravenous administration the terminal half-life was 10.9 ± 1.7 h, steady-state volume of distribution was 0.245 ± 0.06 L/kg, and total body clearance was 17.9 ± 4.3 mL/h/kg.",Pharmacokinetics of meloxicam in adult goats and its analgesic effect in disbudded kids. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21219346/),[l] / [kg],0.245,23320,DB00741,Hydrocortisone
,21219346,total body clearance,"In the adult goats after intravenous administration the terminal half-life was 10.9 ± 1.7 h, steady-state volume of distribution was 0.245 ± 0.06 L/kg, and total body clearance was 17.9 ± 4.3 mL/h/kg.",Pharmacokinetics of meloxicam in adult goats and its analgesic effect in disbudded kids. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21219346/),[ml] / [h·kg],17.9,23321,DB00741,Hydrocortisone
,21219346,bioavailability,"After oral administration bioavailability was 79 ± 19%, C(max) was 736 ± 184 ng/mL, T(max) was 15 ±5 h, although the terminal half-life was similar to the intravenous value, 11.8 ± 1.7 h.",Pharmacokinetics of meloxicam in adult goats and its analgesic effect in disbudded kids. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21219346/),%,79,23322,DB00741,Hydrocortisone
,21219346,C(max),"After oral administration bioavailability was 79 ± 19%, C(max) was 736 ± 184 ng/mL, T(max) was 15 ±5 h, although the terminal half-life was similar to the intravenous value, 11.8 ± 1.7 h.",Pharmacokinetics of meloxicam in adult goats and its analgesic effect in disbudded kids. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21219346/),[ng] / [ml],736,23323,DB00741,Hydrocortisone
,21219346,T(max),"After oral administration bioavailability was 79 ± 19%, C(max) was 736 ± 184 ng/mL, T(max) was 15 ±5 h, although the terminal half-life was similar to the intravenous value, 11.8 ± 1.7 h.",Pharmacokinetics of meloxicam in adult goats and its analgesic effect in disbudded kids. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21219346/),h,15,23324,DB00741,Hydrocortisone
,21219346,terminal half-life,"After oral administration bioavailability was 79 ± 19%, C(max) was 736 ± 184 ng/mL, T(max) was 15 ±5 h, although the terminal half-life was similar to the intravenous value, 11.8 ± 1.7 h.",Pharmacokinetics of meloxicam in adult goats and its analgesic effect in disbudded kids. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21219346/),h,11.8,23325,DB00741,Hydrocortisone
,17437510,Cmax,"After IV administration, Cmax ranged from 715 to 8313 nmol/l, area under the curve (AUC) from 1112 to 12 177 nmol h/l and cortisol clearance had a median (range) of 0.267 (0.076-0.540) l/h/kg.",Variability in hydrocortisone plasma and saliva pharmacokinetics following intravenous and oral administration to patients with adrenal insufficiency. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17437510/),[nM] / [l],715 to 8313,25267,DB00741,Hydrocortisone
,17437510,area under the curve (AUC),"After IV administration, Cmax ranged from 715 to 8313 nmol/l, area under the curve (AUC) from 1112 to 12 177 nmol h/l and cortisol clearance had a median (range) of 0.267 (0.076-0.540) l/h/kg.",Variability in hydrocortisone plasma and saliva pharmacokinetics following intravenous and oral administration to patients with adrenal insufficiency. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17437510/),[h·nM] / [l],1112 to 12 177,25268,DB00741,Hydrocortisone
,17437510,clearance,"After IV administration, Cmax ranged from 715 to 8313 nmol/l, area under the curve (AUC) from 1112 to 12 177 nmol h/l and cortisol clearance had a median (range) of 0.267 (0.076-0.540) l/h/kg.",Variability in hydrocortisone plasma and saliva pharmacokinetics following intravenous and oral administration to patients with adrenal insufficiency. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17437510/),[l] / [h·kg],0.267,25269,DB00741,Hydrocortisone
,17437510,Cmax,"After oral administration, Cmax ranged from 422 to 1554 nmol/l, AUC 1081-5471 nmol h/l and oral clearance had a median (range) of 0.267 (0.081-0.363) l/h/kg.",Variability in hydrocortisone plasma and saliva pharmacokinetics following intravenous and oral administration to patients with adrenal insufficiency. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17437510/),[nM] / [l],422 to 1554,25270,DB00741,Hydrocortisone
,17437510,AUC,"After oral administration, Cmax ranged from 422 to 1554 nmol/l, AUC 1081-5471 nmol h/l and oral clearance had a median (range) of 0.267 (0.081-0.363) l/h/kg.",Variability in hydrocortisone plasma and saliva pharmacokinetics following intravenous and oral administration to patients with adrenal insufficiency. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17437510/),[h·nM] / [l],1081-5471,25271,DB00741,Hydrocortisone
,17437510,oral clearance,"After oral administration, Cmax ranged from 422 to 1554 nmol/l, AUC 1081-5471 nmol h/l and oral clearance had a median (range) of 0.267 (0.081-0.363) l/h/kg.",Variability in hydrocortisone plasma and saliva pharmacokinetics following intravenous and oral administration to patients with adrenal insufficiency. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17437510/),[l] / [h·kg],0.267,25272,DB00741,Hydrocortisone
,2373136,half-lives,"Following the i.v. injection, plasma terguride levels declined biphasically, with half-lives of 0.2 and 1.5 h; total clearance was 17 ml.min-1.kg-1.",Pharmacokinetics and endocrine effects of terguride in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2373136/),h,0.2,25680,DB00741,Hydrocortisone
,2373136,half-lives,"Following the i.v. injection, plasma terguride levels declined biphasically, with half-lives of 0.2 and 1.5 h; total clearance was 17 ml.min-1.kg-1.",Pharmacokinetics and endocrine effects of terguride in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2373136/),h,1.5,25681,DB00741,Hydrocortisone
,2373136,total clearance,"Following the i.v. injection, plasma terguride levels declined biphasically, with half-lives of 0.2 and 1.5 h; total clearance was 17 ml.min-1.kg-1.",Pharmacokinetics and endocrine effects of terguride in healthy subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2373136/),[ml] / [kg·min],17,25682,DB00741,Hydrocortisone
,2373136,oral bioavailability,The oral bioavailability of terguride over all doses was about 20%.,Pharmacokinetics and endocrine effects of terguride in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2373136/),%,20,25683,DB00741,Hydrocortisone
,3091779,peak ulcers,"These doses produced peak ulcers of 0.15 to 0.22 cm2, respectively, one to five days after injection.",Mitomycin C skin toxicity studies in mice: reduced ulceration and altered pharmacokinetics with topical dimethyl sulfoxide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3091779/),cm2,0.15,26156,DB00741,Hydrocortisone
,3091779,peak ulcers,"These doses produced peak ulcers of 0.15 to 0.22 cm2, respectively, one to five days after injection.",Mitomycin C skin toxicity studies in mice: reduced ulceration and altered pharmacokinetics with topical dimethyl sulfoxide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3091779/),cm2,0.22,26157,DB00741,Hydrocortisone
,3091779,area X time,The integrated ulcer area X time values (area under the curve [AUC] ulceration) were 0.89 and 3.11 cm2 X d.,Mitomycin C skin toxicity studies in mice: reduced ulceration and altered pharmacokinetics with topical dimethyl sulfoxide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3091779/),cm2·d,0.89,26158,DB00741,Hydrocortisone
,3091779,area X time,The integrated ulcer area X time values (area under the curve [AUC] ulceration) were 0.89 and 3.11 cm2 X d.,Mitomycin C skin toxicity studies in mice: reduced ulceration and altered pharmacokinetics with topical dimethyl sulfoxide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3091779/),cm2·d,3.11,26159,DB00741,Hydrocortisone
,3091779,area under the curve [AUC],The integrated ulcer area X time values (area under the curve [AUC] ulceration) were 0.89 and 3.11 cm2 X d.,Mitomycin C skin toxicity studies in mice: reduced ulceration and altered pharmacokinetics with topical dimethyl sulfoxide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3091779/),cm2·d,0.89,26160,DB00741,Hydrocortisone
,3091779,area under the curve [AUC],The integrated ulcer area X time values (area under the curve [AUC] ulceration) were 0.89 and 3.11 cm2 X d.,Mitomycin C skin toxicity studies in mice: reduced ulceration and altered pharmacokinetics with topical dimethyl sulfoxide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3091779/),cm2·d,3.11,26161,DB00741,Hydrocortisone
,3091779,AUC,DMSO significantly increased the AUC for MMC in skin from 0.89 to 2.25 ng/h/mL of tissue (P less than .05).,Mitomycin C skin toxicity studies in mice: reduced ulceration and altered pharmacokinetics with topical dimethyl sulfoxide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3091779/),[ng] / [h·ml],0.89,26162,DB00741,Hydrocortisone
,3091779,AUC,DMSO significantly increased the AUC for MMC in skin from 0.89 to 2.25 ng/h/mL of tissue (P less than .05).,Mitomycin C skin toxicity studies in mice: reduced ulceration and altered pharmacokinetics with topical dimethyl sulfoxide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3091779/),[ng] / [h·ml],2,26163,DB00741,Hydrocortisone
,3455371,steady state concentrations,"Infusion of aldosterone at a constant rate of 0.17 mg/h over 4.5 h produced steady state concentrations after 2 h, with no difference before and after rifampicin treatment (mean +/- SD, 1649 +/- 144 vs 1586 +/- 80 pg/ml, respectively).",Pharmacokinetics of aldosterone in patients with Addison's disease: effect of rifampicin treatment on glucocorticoid and mineralocorticoid metabolism. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3455371/),[pg] / [ml],1649,26474,DB00741,Hydrocortisone
,3455371,steady state concentrations,"Infusion of aldosterone at a constant rate of 0.17 mg/h over 4.5 h produced steady state concentrations after 2 h, with no difference before and after rifampicin treatment (mean +/- SD, 1649 +/- 144 vs 1586 +/- 80 pg/ml, respectively).",Pharmacokinetics of aldosterone in patients with Addison's disease: effect of rifampicin treatment on glucocorticoid and mineralocorticoid metabolism. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3455371/),[pg] / [ml],1586,26475,DB00741,Hydrocortisone
,3455371,alpha-phase,"No change could be observed in the plasma half-lives (alpha-phase 29 +/- 1.9 min vs 30 +/- 1.5 min, beta-phase 129 +/- 3.2 min vs 126 +/- 4.3 min), the MCR (1.47 +/- 0.1 l/h/kg vs 1.46 +/- 0.1 l/h/kg), and the volume of distribution (9.9 +/- 1.9 vs 10.2 +/- 0.3 l).",Pharmacokinetics of aldosterone in patients with Addison's disease: effect of rifampicin treatment on glucocorticoid and mineralocorticoid metabolism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3455371/),min,29,26476,DB00741,Hydrocortisone
,3455371,alpha-phase,"No change could be observed in the plasma half-lives (alpha-phase 29 +/- 1.9 min vs 30 +/- 1.5 min, beta-phase 129 +/- 3.2 min vs 126 +/- 4.3 min), the MCR (1.47 +/- 0.1 l/h/kg vs 1.46 +/- 0.1 l/h/kg), and the volume of distribution (9.9 +/- 1.9 vs 10.2 +/- 0.3 l).",Pharmacokinetics of aldosterone in patients with Addison's disease: effect of rifampicin treatment on glucocorticoid and mineralocorticoid metabolism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3455371/),min,30,26477,DB00741,Hydrocortisone
,3455371,beta-phase,"No change could be observed in the plasma half-lives (alpha-phase 29 +/- 1.9 min vs 30 +/- 1.5 min, beta-phase 129 +/- 3.2 min vs 126 +/- 4.3 min), the MCR (1.47 +/- 0.1 l/h/kg vs 1.46 +/- 0.1 l/h/kg), and the volume of distribution (9.9 +/- 1.9 vs 10.2 +/- 0.3 l).",Pharmacokinetics of aldosterone in patients with Addison's disease: effect of rifampicin treatment on glucocorticoid and mineralocorticoid metabolism. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3455371/),min,129,26478,DB00741,Hydrocortisone
,3455371,beta-phase,"No change could be observed in the plasma half-lives (alpha-phase 29 +/- 1.9 min vs 30 +/- 1.5 min, beta-phase 129 +/- 3.2 min vs 126 +/- 4.3 min), the MCR (1.47 +/- 0.1 l/h/kg vs 1.46 +/- 0.1 l/h/kg), and the volume of distribution (9.9 +/- 1.9 vs 10.2 +/- 0.3 l).",Pharmacokinetics of aldosterone in patients with Addison's disease: effect of rifampicin treatment on glucocorticoid and mineralocorticoid metabolism. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3455371/),min,126,26479,DB00741,Hydrocortisone
,3455371,MCR,"No change could be observed in the plasma half-lives (alpha-phase 29 +/- 1.9 min vs 30 +/- 1.5 min, beta-phase 129 +/- 3.2 min vs 126 +/- 4.3 min), the MCR (1.47 +/- 0.1 l/h/kg vs 1.46 +/- 0.1 l/h/kg), and the volume of distribution (9.9 +/- 1.9 vs 10.2 +/- 0.3 l).",Pharmacokinetics of aldosterone in patients with Addison's disease: effect of rifampicin treatment on glucocorticoid and mineralocorticoid metabolism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3455371/),[l] / [h·kg],1.47,26480,DB00741,Hydrocortisone
,3455371,MCR,"No change could be observed in the plasma half-lives (alpha-phase 29 +/- 1.9 min vs 30 +/- 1.5 min, beta-phase 129 +/- 3.2 min vs 126 +/- 4.3 min), the MCR (1.47 +/- 0.1 l/h/kg vs 1.46 +/- 0.1 l/h/kg), and the volume of distribution (9.9 +/- 1.9 vs 10.2 +/- 0.3 l).",Pharmacokinetics of aldosterone in patients with Addison's disease: effect of rifampicin treatment on glucocorticoid and mineralocorticoid metabolism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3455371/),[l] / [h·kg],1.46,26481,DB00741,Hydrocortisone
,3455371,volume of distribution,"No change could be observed in the plasma half-lives (alpha-phase 29 +/- 1.9 min vs 30 +/- 1.5 min, beta-phase 129 +/- 3.2 min vs 126 +/- 4.3 min), the MCR (1.47 +/- 0.1 l/h/kg vs 1.46 +/- 0.1 l/h/kg), and the volume of distribution (9.9 +/- 1.9 vs 10.2 +/- 0.3 l).",Pharmacokinetics of aldosterone in patients with Addison's disease: effect of rifampicin treatment on glucocorticoid and mineralocorticoid metabolism. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3455371/),l,9.9,26482,DB00741,Hydrocortisone
,3455371,volume of distribution,"No change could be observed in the plasma half-lives (alpha-phase 29 +/- 1.9 min vs 30 +/- 1.5 min, beta-phase 129 +/- 3.2 min vs 126 +/- 4.3 min), the MCR (1.47 +/- 0.1 l/h/kg vs 1.46 +/- 0.1 l/h/kg), and the volume of distribution (9.9 +/- 1.9 vs 10.2 +/- 0.3 l).",Pharmacokinetics of aldosterone in patients with Addison's disease: effect of rifampicin treatment on glucocorticoid and mineralocorticoid metabolism. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3455371/),l,10.2,26483,DB00741,Hydrocortisone
,3455371,half-life,The antipyrine half-life decreased significantly from 12.2 +/- 2.6 h to 7.6 +/- 0.9 h (P less than 0.05) with a rise in antipyrine clearance from 0.38 +/- 0.07 to 0.80 +/- 0.23 ml/min/kg (P less than 0.05) and no change in the volume of distribution.,Pharmacokinetics of aldosterone in patients with Addison's disease: effect of rifampicin treatment on glucocorticoid and mineralocorticoid metabolism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3455371/),h,12.2,26484,DB00741,Hydrocortisone
,3455371,half-life,The antipyrine half-life decreased significantly from 12.2 +/- 2.6 h to 7.6 +/- 0.9 h (P less than 0.05) with a rise in antipyrine clearance from 0.38 +/- 0.07 to 0.80 +/- 0.23 ml/min/kg (P less than 0.05) and no change in the volume of distribution.,Pharmacokinetics of aldosterone in patients with Addison's disease: effect of rifampicin treatment on glucocorticoid and mineralocorticoid metabolism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3455371/),h,7.6,26485,DB00741,Hydrocortisone
,3455371,clearance,The antipyrine half-life decreased significantly from 12.2 +/- 2.6 h to 7.6 +/- 0.9 h (P less than 0.05) with a rise in antipyrine clearance from 0.38 +/- 0.07 to 0.80 +/- 0.23 ml/min/kg (P less than 0.05) and no change in the volume of distribution.,Pharmacokinetics of aldosterone in patients with Addison's disease: effect of rifampicin treatment on glucocorticoid and mineralocorticoid metabolism. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3455371/),[ml] / [kg·min],0.38,26486,DB00741,Hydrocortisone
,3455371,clearance,The antipyrine half-life decreased significantly from 12.2 +/- 2.6 h to 7.6 +/- 0.9 h (P less than 0.05) with a rise in antipyrine clearance from 0.38 +/- 0.07 to 0.80 +/- 0.23 ml/min/kg (P less than 0.05) and no change in the volume of distribution.,Pharmacokinetics of aldosterone in patients with Addison's disease: effect of rifampicin treatment on glucocorticoid and mineralocorticoid metabolism. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3455371/),[ml] / [kg·min],0.80,26487,DB00741,Hydrocortisone
,11250647,peak cortisol concentration,"Following administration of the evening hydrocortisone dose, median peak cortisol concentration of 499 nmol/l (range: 333-736 nmol/l) was attained also at 1.2 h (range: 0.3-3.0 h) and subsequently declined gradually, reaching undetectable concentrations at 9 h (5-12 h) after administration of the oral dose.",Bioavailability of oral hydrocortisone in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11250647/),[nM] / [l],499,26880,DB00741,Hydrocortisone
,11250647,peak serum total cortisol concentration,After the intravenous hydrocortisone bolus a median peak serum total cortisol concentration of 1930 nmol/l (range: 1124-2700 nmol/l) was observed at 10 min (range: 10-20 min).,Bioavailability of oral hydrocortisone in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11250647/),[nM] / [l],1930,26881,DB00741,Hydrocortisone
,11250647,absolute bioavailability,The absolute bioavailability of oral hydrocortisone in the morning was 94.2% (90% confidence interval (CI): 82.8-105.5%) whereas the apparent bioavailability in the evening was estimated to be 128.0% (90% CI: 119.0-138.0%).,Bioavailability of oral hydrocortisone in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11250647/),%,94.2,26882,DB00741,Hydrocortisone
,11250647,apparent bioavailability,The absolute bioavailability of oral hydrocortisone in the morning was 94.2% (90% confidence interval (CI): 82.8-105.5%) whereas the apparent bioavailability in the evening was estimated to be 128.0% (90% CI: 119.0-138.0%).,Bioavailability of oral hydrocortisone in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11250647/),%,128.0,26883,DB00741,Hydrocortisone
,8382708,apparent elimination half-life,The apparent elimination half-life at the higher doses was 3.7 hours.,"Evaluation of the pharmacokinetics and tolerability of tirilazad mesylate, a 21-aminosteroid free radical scavenger: I. Single-dose administration. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8382708/),h,3.7,27652,DB00741,Hydrocortisone
,3367304,plasma,"Base-line plasma theophylline clearance was 30% lower in old compared with young nonsmokers (34.0 +/- 2.5 vs. 48.8 +/- 2.6 ml/hr/kg, P less than .001), whereas the small age difference between old and young smokers (86.0 +/- 8.4 vs. 72.4 +/- 8.0 ml/hr/kg) was not significant.",Aging and drug interactions. Effect of phenytoin and smoking on the oxidation of theophylline and cortisol in healthy men. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3367304/),[ml] / [h·kg],34.0,30124,DB00741,Hydrocortisone
,3367304,plasma,"Base-line plasma theophylline clearance was 30% lower in old compared with young nonsmokers (34.0 +/- 2.5 vs. 48.8 +/- 2.6 ml/hr/kg, P less than .001), whereas the small age difference between old and young smokers (86.0 +/- 8.4 vs. 72.4 +/- 8.0 ml/hr/kg) was not significant.",Aging and drug interactions. Effect of phenytoin and smoking on the oxidation of theophylline and cortisol in healthy men. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3367304/),[ml] / [h·kg],48.8,30125,DB00741,Hydrocortisone
,3367304,clearance,"Base-line plasma theophylline clearance was 30% lower in old compared with young nonsmokers (34.0 +/- 2.5 vs. 48.8 +/- 2.6 ml/hr/kg, P less than .001), whereas the small age difference between old and young smokers (86.0 +/- 8.4 vs. 72.4 +/- 8.0 ml/hr/kg) was not significant.",Aging and drug interactions. Effect of phenytoin and smoking on the oxidation of theophylline and cortisol in healthy men. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3367304/),[ml] / [h·kg],34.0,30126,DB00741,Hydrocortisone
,3367304,clearance,"Base-line plasma theophylline clearance was 30% lower in old compared with young nonsmokers (34.0 +/- 2.5 vs. 48.8 +/- 2.6 ml/hr/kg, P less than .001), whereas the small age difference between old and young smokers (86.0 +/- 8.4 vs. 72.4 +/- 8.0 ml/hr/kg) was not significant.",Aging and drug interactions. Effect of phenytoin and smoking on the oxidation of theophylline and cortisol in healthy men. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3367304/),[ml] / [h·kg],48.8,30127,DB00741,Hydrocortisone
,3367304,clearance,"Base-line plasma theophylline clearance was 30% lower in old compared with young nonsmokers (34.0 +/- 2.5 vs. 48.8 +/- 2.6 ml/hr/kg, P less than .001), whereas the small age difference between old and young smokers (86.0 +/- 8.4 vs. 72.4 +/- 8.0 ml/hr/kg) was not significant.",Aging and drug interactions. Effect of phenytoin and smoking on the oxidation of theophylline and cortisol in healthy men. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3367304/),,86.0,30128,DB00741,Hydrocortisone
,3367304,clearance,"Base-line plasma theophylline clearance was 30% lower in old compared with young nonsmokers (34.0 +/- 2.5 vs. 48.8 +/- 2.6 ml/hr/kg, P less than .001), whereas the small age difference between old and young smokers (86.0 +/- 8.4 vs. 72.4 +/- 8.0 ml/hr/kg) was not significant.",Aging and drug interactions. Effect of phenytoin and smoking on the oxidation of theophylline and cortisol in healthy men. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3367304/),,72.,30129,DB00741,Hydrocortisone
,9300934,half-life,"Administration of fluconazole resulted in a significant increase in the half-life of zidovudine and antipyrine (0.97 +/- 0.17 h prior to vs. 1.11 +/- 0. 14 h after fluconazole administration and 11.9 +/- 1.9 h prior to vs. 13.7 +/- 3.0 h after fluconazole, respectively) while the 6-beta-hydroxycortisol excretion decreased significantly (472.3 +/- 80.6 microg/24 h before and 340.6 +/- 82.1 microg/24 h after administration of fluconazole).",Pharmacokinetic interaction of fluconazole and zidovudine in HIV-positive patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9300934/),h,0.97,31295,DB00741,Hydrocortisone
,9300934,half-life,"Administration of fluconazole resulted in a significant increase in the half-life of zidovudine and antipyrine (0.97 +/- 0.17 h prior to vs. 1.11 +/- 0. 14 h after fluconazole administration and 11.9 +/- 1.9 h prior to vs. 13.7 +/- 3.0 h after fluconazole, respectively) while the 6-beta-hydroxycortisol excretion decreased significantly (472.3 +/- 80.6 microg/24 h before and 340.6 +/- 82.1 microg/24 h after administration of fluconazole).",Pharmacokinetic interaction of fluconazole and zidovudine in HIV-positive patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9300934/),h,1.11,31296,DB00741,Hydrocortisone
,9300934,half-life,"Administration of fluconazole resulted in a significant increase in the half-life of zidovudine and antipyrine (0.97 +/- 0.17 h prior to vs. 1.11 +/- 0. 14 h after fluconazole administration and 11.9 +/- 1.9 h prior to vs. 13.7 +/- 3.0 h after fluconazole, respectively) while the 6-beta-hydroxycortisol excretion decreased significantly (472.3 +/- 80.6 microg/24 h before and 340.6 +/- 82.1 microg/24 h after administration of fluconazole).",Pharmacokinetic interaction of fluconazole and zidovudine in HIV-positive patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9300934/),h,11.9,31297,DB00741,Hydrocortisone
,9300934,half-life,"Administration of fluconazole resulted in a significant increase in the half-life of zidovudine and antipyrine (0.97 +/- 0.17 h prior to vs. 1.11 +/- 0. 14 h after fluconazole administration and 11.9 +/- 1.9 h prior to vs. 13.7 +/- 3.0 h after fluconazole, respectively) while the 6-beta-hydroxycortisol excretion decreased significantly (472.3 +/- 80.6 microg/24 h before and 340.6 +/- 82.1 microg/24 h after administration of fluconazole).",Pharmacokinetic interaction of fluconazole and zidovudine in HIV-positive patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9300934/),h,13.7,31298,DB00741,Hydrocortisone
,9300934,excretion,"Administration of fluconazole resulted in a significant increase in the half-life of zidovudine and antipyrine (0.97 +/- 0.17 h prior to vs. 1.11 +/- 0. 14 h after fluconazole administration and 11.9 +/- 1.9 h prior to vs. 13.7 +/- 3.0 h after fluconazole, respectively) while the 6-beta-hydroxycortisol excretion decreased significantly (472.3 +/- 80.6 microg/24 h before and 340.6 +/- 82.1 microg/24 h after administration of fluconazole).",Pharmacokinetic interaction of fluconazole and zidovudine in HIV-positive patients. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9300934/),[μg] / [24·h],472.3,31299,DB00741,Hydrocortisone
,9300934,excretion,"Administration of fluconazole resulted in a significant increase in the half-life of zidovudine and antipyrine (0.97 +/- 0.17 h prior to vs. 1.11 +/- 0. 14 h after fluconazole administration and 11.9 +/- 1.9 h prior to vs. 13.7 +/- 3.0 h after fluconazole, respectively) while the 6-beta-hydroxycortisol excretion decreased significantly (472.3 +/- 80.6 microg/24 h before and 340.6 +/- 82.1 microg/24 h after administration of fluconazole).",Pharmacokinetic interaction of fluconazole and zidovudine in HIV-positive patients. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9300934/),[μg] / [24·h],340.6,31300,DB00741,Hydrocortisone
,9300934,half-life,"Administration of zidovudine did, however, result in a significant reduction in antipyrine half-life (11.7 +/- 2.0 h before vs. 9.9 +/- 2.3h after ZDV) and a significant increase in 6-beta-hydroxycortisol excretion (438,7 +/- 138.2 microg/24 h before and 684.6 +/- 157.3 microg/24 h after ZDV).",Pharmacokinetic interaction of fluconazole and zidovudine in HIV-positive patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9300934/),h,11.7,31301,DB00741,Hydrocortisone
,9300934,half-life,"Administration of zidovudine did, however, result in a significant reduction in antipyrine half-life (11.7 +/- 2.0 h before vs. 9.9 +/- 2.3h after ZDV) and a significant increase in 6-beta-hydroxycortisol excretion (438,7 +/- 138.2 microg/24 h before and 684.6 +/- 157.3 microg/24 h after ZDV).",Pharmacokinetic interaction of fluconazole and zidovudine in HIV-positive patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9300934/),h,9.9,31302,DB00741,Hydrocortisone
,9300934,excretion,"Administration of zidovudine did, however, result in a significant reduction in antipyrine half-life (11.7 +/- 2.0 h before vs. 9.9 +/- 2.3h after ZDV) and a significant increase in 6-beta-hydroxycortisol excretion (438,7 +/- 138.2 microg/24 h before and 684.6 +/- 157.3 microg/24 h after ZDV).",Pharmacokinetic interaction of fluconazole and zidovudine in HIV-positive patients. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9300934/),[μg] / [24·h],"438,7",31303,DB00741,Hydrocortisone
,9300934,excretion,"Administration of zidovudine did, however, result in a significant reduction in antipyrine half-life (11.7 +/- 2.0 h before vs. 9.9 +/- 2.3h after ZDV) and a significant increase in 6-beta-hydroxycortisol excretion (438,7 +/- 138.2 microg/24 h before and 684.6 +/- 157.3 microg/24 h after ZDV).",Pharmacokinetic interaction of fluconazole and zidovudine in HIV-positive patients. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9300934/),[μg] / [24·h],684.6,31304,DB00741,Hydrocortisone
,11140433,AUC50),"The systemic exposure to FP that resulted in half the maximum possible reduction in plasma cortisol levels (AUC50) was 3.2 microg/L x h (95% CI: 2.8, 3.7 microg/L x h); this equates approximately to the plasma FP concentration obtained after administration of a 1000 microg inhaled dose.",The relationship between systemic exposure to fluticasone propionate and cortisol reduction in healthy male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11140433/),[μg] / [h·l],3.2,31633,DB00741,Hydrocortisone
,33159976,time to maximum plasma concentration,"At steady state, ACT-539313 was rapidly absorbed with a median time to maximum plasma concentration of 1.8-2.3 h and eliminated with a mean half-life of 3.8-6.5 h.",Multiple-dose clinical pharmacology of the selective orexin-1 receptor antagonist ACT-539313. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33159976/),h,1.8-2.3,31779,DB00741,Hydrocortisone
,33159976,half-life,"At steady state, ACT-539313 was rapidly absorbed with a median time to maximum plasma concentration of 1.8-2.3 h and eliminated with a mean half-life of 3.8-6.5 h.",Multiple-dose clinical pharmacology of the selective orexin-1 receptor antagonist ACT-539313. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33159976/),h,3.8-6.5,31780,DB00741,Hydrocortisone
,22204290,production rate,"The mean ± SD 24-hour cortisol concentration was significantly lower in foals (20 ± 4 ng/mL) than in horses (26 ± 6 ng/mL), but the daily cortisol production rate was significantly greater in foals (6,710 ± 320 ng/kg/d) than in horses (2,140 ± 400 ng/kg/d).",Daily endogenous cortisol production and hydrocortisone pharmacokinetics in adult horses and neonatal foals. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22204290/),[ng] / [d·kg],"6,710",32754,DB00741,Hydrocortisone
,22204290,production rate,"The mean ± SD 24-hour cortisol concentration was significantly lower in foals (20 ± 4 ng/mL) than in horses (26 ± 6 ng/mL), but the daily cortisol production rate was significantly greater in foals (6,710 ± 320 ng/kg/d) than in horses (2,140 ± 400 ng/kg/d).",Daily endogenous cortisol production and hydrocortisone pharmacokinetics in adult horses and neonatal foals. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22204290/),[ng] / [d·kg],"2,140",32755,DB00741,Hydrocortisone
,22204290,volume of distribution at steady state,"For hydrocortisone, foals had a significantly greater volume of distribution at steady state (1.92 ± 1.11 L/kg) and total body clearance (1.39 ± 0.108 L/kg/h) and significantly lower peak plasma concentration (1,051 ± 343 ng/mL) than did horses (0.58 ± 0.15 L/kg, 0.349 ± 0.065 L/kg/h, and 8,934 ± 3,843 ng/mL, respectively).",Daily endogenous cortisol production and hydrocortisone pharmacokinetics in adult horses and neonatal foals. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22204290/),[l] / [kg],1.92,32756,DB00741,Hydrocortisone
,22204290,total body clearance,"For hydrocortisone, foals had a significantly greater volume of distribution at steady state (1.92 ± 1.11 L/kg) and total body clearance (1.39 ± 0.108 L/kg/h) and significantly lower peak plasma concentration (1,051 ± 343 ng/mL) than did horses (0.58 ± 0.15 L/kg, 0.349 ± 0.065 L/kg/h, and 8,934 ± 3,843 ng/mL, respectively).",Daily endogenous cortisol production and hydrocortisone pharmacokinetics in adult horses and neonatal foals. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22204290/),[l] / [h·kg],1.39,32757,DB00741,Hydrocortisone
,22204290,peak plasma concentration,"For hydrocortisone, foals had a significantly greater volume of distribution at steady state (1.92 ± 1.11 L/kg) and total body clearance (1.39 ± 0.108 L/kg/h) and significantly lower peak plasma concentration (1,051 ± 343 ng/mL) than did horses (0.58 ± 0.15 L/kg, 0.349 ± 0.065 L/kg/h, and 8,934 ± 3,843 ng/mL, respectively).",Daily endogenous cortisol production and hydrocortisone pharmacokinetics in adult horses and neonatal foals. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22204290/),[ng] / [ml],"1,051",32758,DB00741,Hydrocortisone
,22204290,peak plasma concentration,"For hydrocortisone, foals had a significantly greater volume of distribution at steady state (1.92 ± 1.11 L/kg) and total body clearance (1.39 ± 0.108 L/kg/h) and significantly lower peak plasma concentration (1,051 ± 343 ng/mL) than did horses (0.58 ± 0.15 L/kg, 0.349 ± 0.065 L/kg/h, and 8,934 ± 3,843 ng/mL, respectively).",Daily endogenous cortisol production and hydrocortisone pharmacokinetics in adult horses and neonatal foals. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22204290/),[l] / [kg],0.58,32759,DB00741,Hydrocortisone
,22204290,peak plasma concentration,"For hydrocortisone, foals had a significantly greater volume of distribution at steady state (1.92 ± 1.11 L/kg) and total body clearance (1.39 ± 0.108 L/kg/h) and significantly lower peak plasma concentration (1,051 ± 343 ng/mL) than did horses (0.58 ± 0.15 L/kg, 0.349 ± 0.065 L/kg/h, and 8,934 ± 3,843 ng/mL, respectively).",Daily endogenous cortisol production and hydrocortisone pharmacokinetics in adult horses and neonatal foals. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22204290/),[l] / [h·kg],0.349,32760,DB00741,Hydrocortisone
,22204290,peak plasma concentration,"For hydrocortisone, foals had a significantly greater volume of distribution at steady state (1.92 ± 1.11 L/kg) and total body clearance (1.39 ± 0.108 L/kg/h) and significantly lower peak plasma concentration (1,051 ± 343 ng/mL) than did horses (0.58 ± 0.15 L/kg, 0.349 ± 0.065 L/kg/h, and 8,934 ± 3,843 ng/mL, respectively).",Daily endogenous cortisol production and hydrocortisone pharmacokinetics in adult horses and neonatal foals. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22204290/),[ng] / [ml],"8,934",32761,DB00741,Hydrocortisone
,8159595,suppression half-life,"After the drug was administered, cortisol declined in a linear fashion with a mean suppression half-life of 2.4 +/- 0.9 hours.",Cortisol pharmacodynamic response to long-term methylprednisolone in renal transplant recipients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8159595/),h,2.4,32908,DB00741,Hydrocortisone
,8159595,area under the curve (AUC-Cret),The return cortisol area under the curve (AUC-Cret) was noted in all patients and ranged from 57-987 ng.hr/ml.,Cortisol pharmacodynamic response to long-term methylprednisolone in renal transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8159595/),[h·ng] / [ml],57-987,32909,DB00741,Hydrocortisone
,8159595,area under the curve,The total cortisol area under the curve was greater in patients who had been transplanted for longer than 2 years (1676 +/- 252 vs 836 +/- 405 ng.hr/ml; p < 0.05) compared with more recently transplanted patients.,Cortisol pharmacodynamic response to long-term methylprednisolone in renal transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8159595/),[h·ng] / [ml],1676,32910,DB00741,Hydrocortisone
,8159595,area under the curve,The total cortisol area under the curve was greater in patients who had been transplanted for longer than 2 years (1676 +/- 252 vs 836 +/- 405 ng.hr/ml; p < 0.05) compared with more recently transplanted patients.,Cortisol pharmacodynamic response to long-term methylprednisolone in renal transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8159595/),[h·ng] / [ml],836,32911,DB00741,Hydrocortisone
,8159595,clearance,Methylprednisolone clearance ranged from 100-1181 ml/hr/kg with a mean volume of distribution of 1.3 +/- 0.6 L/kg.,Cortisol pharmacodynamic response to long-term methylprednisolone in renal transplant recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8159595/),[ml] / [h·kg],100-1181,32912,DB00741,Hydrocortisone
,8159595,volume of distribution,Methylprednisolone clearance ranged from 100-1181 ml/hr/kg with a mean volume of distribution of 1.3 +/- 0.6 L/kg.,Cortisol pharmacodynamic response to long-term methylprednisolone in renal transplant recipients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8159595/),[l] / [kg],1.3,32913,DB00741,Hydrocortisone
,8159595,half-life,The methylprednisolone half-life ranged from 1.2-4.7 hours.,Cortisol pharmacodynamic response to long-term methylprednisolone in renal transplant recipients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8159595/),h,1.2-4.7,32914,DB00741,Hydrocortisone
,2804250,elimination half-life,The average elimination half-life for the prodrug was 3.7 min indicating rapid hydrolysis.,Pharmacokinetics and dose linearity testing of methylprednisolone phosphate. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2804250/),min,3.7,35801,DB00741,Hydrocortisone
,2804250,total body clearance,"The total body clearance was 21 1h-1, the terminal half-life 2.8 h.",Pharmacokinetics and dose linearity testing of methylprednisolone phosphate. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2804250/),1/[1h],21,35802,DB00741,Hydrocortisone
,2804250,terminal half-life,"The total body clearance was 21 1h-1, the terminal half-life 2.8 h.",Pharmacokinetics and dose linearity testing of methylprednisolone phosphate. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2804250/),h,2.8,35803,DB00741,Hydrocortisone
,2804250,saliva/plasma ratio,The mean saliva/plasma ratio was 0.22.,Pharmacokinetics and dose linearity testing of methylprednisolone phosphate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2804250/),,0.22,35804,DB00741,Hydrocortisone
,17596104,terminal elimination half-life,"The mean terminal elimination half-life of bevirimat ranged from 56.3 to 69.5 hours, and the mean clearance ranged from 173.9 to 185.8 mL/hour.","Multiple-dose pharmacokinetics and safety of bevirimat, a novel inhibitor of HIV maturation, in healthy volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17596104/),h,56.3 to 69.5,35898,DB00741,Hydrocortisone
,17596104,clearance,"The mean terminal elimination half-life of bevirimat ranged from 56.3 to 69.5 hours, and the mean clearance ranged from 173.9 to 185.8 mL/hour.","Multiple-dose pharmacokinetics and safety of bevirimat, a novel inhibitor of HIV maturation, in healthy volunteers. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17596104/),[ml] / [h],173.9 to 185.8,35899,DB00741,Hydrocortisone
,17596104,Maximum plasma concentrations,Maximum plasma concentrations ranged from 8 to 58 microg/mL at day 10.,"Multiple-dose pharmacokinetics and safety of bevirimat, a novel inhibitor of HIV maturation, in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17596104/),[μg] / [ml],8 to 58,35900,DB00741,Hydrocortisone
,12022896,half-life,"Everolimus half-life was reduced significantly, from an average of 32 hours to 24 hours.",Effect of rifampin on apparent clearance of everolimus. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12022896/),h,32,36262,DB00741,Hydrocortisone
,12022896,half-life,"Everolimus half-life was reduced significantly, from an average of 32 hours to 24 hours.",Effect of rifampin on apparent clearance of everolimus. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12022896/),h,24,36263,DB00741,Hydrocortisone
,8622081,overall survival time,"The median overall survival time for all patients is 31 weeks (95% confidence interval [CI], 23 to 51).",Suramin in hormone-refractory metastatic prostate cancer: a drug with limited efficacy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8622081/),weeks,31,36570,DB00741,Hydrocortisone
,12008748,peak,"However, the increment in plasma 17-OHP in patients both in terms of peak [13.76 +/- 2.52, 4.77 +/- 0.30ng/ml, mean +/- S.E.M, p < 0.001] and area under the curve [190 +/- 46, 96.75 +/- 32 ng/ml/h, p < 0.001] were significantly higher than that of the controls.",Twenty-four hour 17-hydroxyprogesterone response to adrenocorticotropine in adrenal incidentalomas: augmented response after adrenalectomy in two patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12008748/),[ng] / [ml],13.76,36625,DB00741,Hydrocortisone
,12008748,peak,"However, the increment in plasma 17-OHP in patients both in terms of peak [13.76 +/- 2.52, 4.77 +/- 0.30ng/ml, mean +/- S.E.M, p < 0.001] and area under the curve [190 +/- 46, 96.75 +/- 32 ng/ml/h, p < 0.001] were significantly higher than that of the controls.",Twenty-four hour 17-hydroxyprogesterone response to adrenocorticotropine in adrenal incidentalomas: augmented response after adrenalectomy in two patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12008748/),[ng] / [ml],4.77,36626,DB00741,Hydrocortisone
,12008748,area under the curve,"However, the increment in plasma 17-OHP in patients both in terms of peak [13.76 +/- 2.52, 4.77 +/- 0.30ng/ml, mean +/- S.E.M, p < 0.001] and area under the curve [190 +/- 46, 96.75 +/- 32 ng/ml/h, p < 0.001] were significantly higher than that of the controls.",Twenty-four hour 17-hydroxyprogesterone response to adrenocorticotropine in adrenal incidentalomas: augmented response after adrenalectomy in two patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12008748/),[ng] / [h·ml],190,36627,DB00741,Hydrocortisone
,12008748,area under the curve,"However, the increment in plasma 17-OHP in patients both in terms of peak [13.76 +/- 2.52, 4.77 +/- 0.30ng/ml, mean +/- S.E.M, p < 0.001] and area under the curve [190 +/- 46, 96.75 +/- 32 ng/ml/h, p < 0.001] were significantly higher than that of the controls.",Twenty-four hour 17-hydroxyprogesterone response to adrenocorticotropine in adrenal incidentalomas: augmented response after adrenalectomy in two patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12008748/),[ng] / [h·ml],96.75,36628,DB00741,Hydrocortisone
,3072558,saliva/plasma ratio,Methylprednisolone saliva levels paralleled plasma levels; the average saliva/plasma ratio was 0.22.,Comparative pharmacokinetics of methylprednisolone phosphate and hemisuccinate in high doses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3072558/),,0.22,36773,DB00741,Hydrocortisone
,3072558,Renal clearance,Renal clearance was 24 ml/min and not dose or prodrug dependent.,Comparative pharmacokinetics of methylprednisolone phosphate and hemisuccinate in high doses. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3072558/),[ml] / [min],24,36774,DB00741,Hydrocortisone
,8653994,clearance,"Methylprednisolone clearance was significantly decreased in the women who used OC steroids (0.298 versus 0.447 L/hr/kg), resulting in a longer elimination half-life (2.20 versus 1.72 hours).",Oral contraceptive effects on methylprednisolone pharmacokinetics and pharmacodynamics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8653994/),[l] / [h·kg],0.298,37033,DB00741,Hydrocortisone
,8653994,clearance,"Methylprednisolone clearance was significantly decreased in the women who used OC steroids (0.298 versus 0.447 L/hr/kg), resulting in a longer elimination half-life (2.20 versus 1.72 hours).",Oral contraceptive effects on methylprednisolone pharmacokinetics and pharmacodynamics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8653994/),[l] / [h·kg],0.447,37034,DB00741,Hydrocortisone
,8653994,elimination half-life,"Methylprednisolone clearance was significantly decreased in the women who used OC steroids (0.298 versus 0.447 L/hr/kg), resulting in a longer elimination half-life (2.20 versus 1.72 hours).",Oral contraceptive effects on methylprednisolone pharmacokinetics and pharmacodynamics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8653994/),h,2.20,37035,DB00741,Hydrocortisone
,8653994,elimination half-life,"Methylprednisolone clearance was significantly decreased in the women who used OC steroids (0.298 versus 0.447 L/hr/kg), resulting in a longer elimination half-life (2.20 versus 1.72 hours).",Oral contraceptive effects on methylprednisolone pharmacokinetics and pharmacodynamics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8653994/),h,1.72,37036,DB00741,Hydrocortisone
,8653994,area under the response curve,"Greater net suppression of basophils was observed in the users of OC steroids (area under the response curve, 694 versus 401 ng x hr/ml).",Oral contraceptive effects on methylprednisolone pharmacokinetics and pharmacodynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8653994/),[h·ng] / [ml],694,37037,DB00741,Hydrocortisone
,8653994,area under the response curve,"Greater net suppression of basophils was observed in the users of OC steroids (area under the response curve, 694 versus 401 ng x hr/ml).",Oral contraceptive effects on methylprednisolone pharmacokinetics and pharmacodynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8653994/),[h·ng] / [ml],401,37038,DB00741,Hydrocortisone
,11397874,clearance,"Mean clearance was significantly higher in the pubertal group (mean, 427.0 mL/min; SD, 133.4) compared with the prepubertal (mean, 248.7 mL/min; SD, 100.6) and postpubertal (mean, 292.4 mL/min; SD, 106.3) (one-way ANOVA, F = 9.8, P < 0.001) groups.",Congenital adrenal hyperplasia due to 21-hydroxylase deficiency: alterations in cortisol pharmacokinetics at puberty. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11397874/),[ml] / [min],427.0,37207,DB00741,Hydrocortisone
,11397874,clearance,"Mean clearance was significantly higher in the pubertal group (mean, 427.0 mL/min; SD, 133.4) compared with the prepubertal (mean, 248.7 mL/min; SD, 100.6) and postpubertal (mean, 292.4 mL/min; SD, 106.3) (one-way ANOVA, F = 9.8, P < 0.001) groups.",Congenital adrenal hyperplasia due to 21-hydroxylase deficiency: alterations in cortisol pharmacokinetics at puberty. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11397874/),[ml] / [min],248.7,37208,DB00741,Hydrocortisone
,11397874,clearance,"Mean clearance was significantly higher in the pubertal group (mean, 427.0 mL/min; SD, 133.4) compared with the prepubertal (mean, 248.7 mL/min; SD, 100.6) and postpubertal (mean, 292.4 mL/min; SD, 106.3) (one-way ANOVA, F = 9.8, P < 0.001) groups.",Congenital adrenal hyperplasia due to 21-hydroxylase deficiency: alterations in cortisol pharmacokinetics at puberty. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11397874/),[ml] / [min],292.4,37209,DB00741,Hydrocortisone
,11397874,volume of distribution,"The mean volume of distribution was also significantly higher in the pubertal (mean, 49.5 L; SD, 12.2) than the prepubertal (mean, 27.1 L; SD, 8.4) patients but not in the postpubertal (mean, 40.8 L; SD, 16) (ANOVA, F = 15.2, P < 0.001) patients.",Congenital adrenal hyperplasia due to 21-hydroxylase deficiency: alterations in cortisol pharmacokinetics at puberty. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11397874/),l,49.5,37210,DB00741,Hydrocortisone
,11397874,volume of distribution,"The mean volume of distribution was also significantly higher in the pubertal (mean, 49.5 L; SD, 12.2) than the prepubertal (mean, 27.1 L; SD, 8.4) patients but not in the postpubertal (mean, 40.8 L; SD, 16) (ANOVA, F = 15.2, P < 0.001) patients.",Congenital adrenal hyperplasia due to 21-hydroxylase deficiency: alterations in cortisol pharmacokinetics at puberty. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11397874/),l,27.1,37211,DB00741,Hydrocortisone
,11397874,volume of distribution,"The mean volume of distribution was also significantly higher in the pubertal (mean, 49.5 L; SD, 12.2) than the prepubertal (mean, 27.1 L; SD, 8.4) patients but not in the postpubertal (mean, 40.8 L; SD, 16) (ANOVA, F = 15.2, P < 0.001) patients.",Congenital adrenal hyperplasia due to 21-hydroxylase deficiency: alterations in cortisol pharmacokinetics at puberty. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11397874/),l,40.8,37212,DB00741,Hydrocortisone
,11397874,half-life,"There was no significant difference in mean half-life of total cortisol in prepubertal (mean, 80.2 min; SD, 19.4), pubertal (mean, 84.4 min; SD, 24.9), and postpubertal (mean, 96.7 min; SD, 9.9) patients.",Congenital adrenal hyperplasia due to 21-hydroxylase deficiency: alterations in cortisol pharmacokinetics at puberty. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11397874/),min,80.2,37213,DB00741,Hydrocortisone
,11397874,half-life,"There was no significant difference in mean half-life of total cortisol in prepubertal (mean, 80.2 min; SD, 19.4), pubertal (mean, 84.4 min; SD, 24.9), and postpubertal (mean, 96.7 min; SD, 9.9) patients.",Congenital adrenal hyperplasia due to 21-hydroxylase deficiency: alterations in cortisol pharmacokinetics at puberty. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11397874/),min,84.4,37214,DB00741,Hydrocortisone
,11397874,half-life,"There was no significant difference in mean half-life of total cortisol in prepubertal (mean, 80.2 min; SD, 19.4), pubertal (mean, 84.4 min; SD, 24.9), and postpubertal (mean, 96.7 min; SD, 9.9) patients.",Congenital adrenal hyperplasia due to 21-hydroxylase deficiency: alterations in cortisol pharmacokinetics at puberty. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11397874/),min,96.7,37215,DB00741,Hydrocortisone
,30402291,Peak concentrations (Cmax),"Peak concentrations (Cmax) of 21.799 ± 1.993 ng/ml and 20.844 ± 2.661 ng/ml were achieved after 6 ± 0.23 h and 6 ± 0.35 h (Tmax), respectively, for capsules A and B.",Potential of Cocoa Pod Husk Pectin-Based Modified Release Capsules as a Carrier for Chronodelivery of Hydrocortisone in Sprague-Dawley Rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30402291/),[ng] / [ml],21.799,38738,DB00741,Hydrocortisone
,30402291,Peak concentrations (Cmax),"Peak concentrations (Cmax) of 21.799 ± 1.993 ng/ml and 20.844 ± 2.661 ng/ml were achieved after 6 ± 0.23 h and 6 ± 0.35 h (Tmax), respectively, for capsules A and B.",Potential of Cocoa Pod Husk Pectin-Based Modified Release Capsules as a Carrier for Chronodelivery of Hydrocortisone in Sprague-Dawley Rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30402291/),[ng] / [ml],20.844,38739,DB00741,Hydrocortisone
,30402291,Tmax,"Peak concentrations (Cmax) of 21.799 ± 1.993 ng/ml and 20.844 ± 2.661 ng/ml were achieved after 6 ± 0.23 h and 6 ± 0.35 h (Tmax), respectively, for capsules A and B.",Potential of Cocoa Pod Husk Pectin-Based Modified Release Capsules as a Carrier for Chronodelivery of Hydrocortisone in Sprague-Dawley Rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30402291/),h,6,38740,DB00741,Hydrocortisone
,30402291,Tmax,"Peak concentrations (Cmax) of 21.799 ± 1.993 ng/ml and 20.844 ± 2.661 ng/ml were achieved after 6 ± 0.23 h and 6 ± 0.35 h (Tmax), respectively, for capsules A and B.",Potential of Cocoa Pod Husk Pectin-Based Modified Release Capsules as a Carrier for Chronodelivery of Hydrocortisone in Sprague-Dawley Rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30402291/),h,6,38741,DB00741,Hydrocortisone
,30402291,peak concentration,The immediate release formulation had a peak concentration of 15.322 ± 0.313 ng/ml within 1 ± 0.2 h.,Potential of Cocoa Pod Husk Pectin-Based Modified Release Capsules as a Carrier for Chronodelivery of Hydrocortisone in Sprague-Dawley Rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30402291/),[ng] / [ml],15.322,38742,DB00741,Hydrocortisone
,30402291,relative bioavailability,"The relative bioavailability of the CPH pectin-based capsules A and B was 213% and 274%, respectively.",Potential of Cocoa Pod Husk Pectin-Based Modified Release Capsules as a Carrier for Chronodelivery of Hydrocortisone in Sprague-Dawley Rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30402291/),%,213,38743,DB00741,Hydrocortisone
,30402291,relative bioavailability,"The relative bioavailability of the CPH pectin-based capsules A and B was 213% and 274%, respectively.",Potential of Cocoa Pod Husk Pectin-Based Modified Release Capsules as a Carrier for Chronodelivery of Hydrocortisone in Sprague-Dawley Rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30402291/),%,274,38744,DB00741,Hydrocortisone
,23735179,maximum heart rate,"Mean maximum heart rate (0 - 4 hours) was comparable between placebo, VI 12.5 and 25 μg over 7 days of dosing; for single dosing of FF/VI 800/50 and VI 50 μg, heart rate was comparable (70 and 73 bpm, respectively) and this was higher than FF 800 μg (66 bpm) or placebo (64 bpm), but the difference was not clinically significant.","The safety, pharmacokinetics and pharmacodynamics of a combination of fluticasone furoate and vilanterol in healthy Japanese subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23735179/),bpm,66,38793,DB00741,Hydrocortisone
,23735179,heart rate,"Mean maximum heart rate (0 - 4 hours) was comparable between placebo, VI 12.5 and 25 μg over 7 days of dosing; for single dosing of FF/VI 800/50 and VI 50 μg, heart rate was comparable (70 and 73 bpm, respectively) and this was higher than FF 800 μg (66 bpm) or placebo (64 bpm), but the difference was not clinically significant.","The safety, pharmacokinetics and pharmacodynamics of a combination of fluticasone furoate and vilanterol in healthy Japanese subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23735179/),bpm,70,38794,DB00741,Hydrocortisone
,23735179,heart rate,"Mean maximum heart rate (0 - 4 hours) was comparable between placebo, VI 12.5 and 25 μg over 7 days of dosing; for single dosing of FF/VI 800/50 and VI 50 μg, heart rate was comparable (70 and 73 bpm, respectively) and this was higher than FF 800 μg (66 bpm) or placebo (64 bpm), but the difference was not clinically significant.","The safety, pharmacokinetics and pharmacodynamics of a combination of fluticasone furoate and vilanterol in healthy Japanese subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23735179/),bpm,73,38795,DB00741,Hydrocortisone
,23735179,heart rate,"Mean maximum heart rate (0 - 4 hours) was comparable between placebo, VI 12.5 and 25 μg over 7 days of dosing; for single dosing of FF/VI 800/50 and VI 50 μg, heart rate was comparable (70 and 73 bpm, respectively) and this was higher than FF 800 μg (66 bpm) or placebo (64 bpm), but the difference was not clinically significant.","The safety, pharmacokinetics and pharmacodynamics of a combination of fluticasone furoate and vilanterol in healthy Japanese subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23735179/),bpm,66,38796,DB00741,Hydrocortisone
,23735179,heart rate,"Mean maximum heart rate (0 - 4 hours) was comparable between placebo, VI 12.5 and 25 μg over 7 days of dosing; for single dosing of FF/VI 800/50 and VI 50 μg, heart rate was comparable (70 and 73 bpm, respectively) and this was higher than FF 800 μg (66 bpm) or placebo (64 bpm), but the difference was not clinically significant.","The safety, pharmacokinetics and pharmacodynamics of a combination of fluticasone furoate and vilanterol in healthy Japanese subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23735179/),bpm,64,38797,DB00741,Hydrocortisone
,14605865,excretion,All subjects demonstrated a marked induction of hepatic microsomal CYP3A analyzed by the excretion ratio of 6beta-hydroxycortisol to cortisol from a mean baseline concentration of 5.6 U to 50.5 U.,"Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14605865/),,50,40758,DB00741,Hydrocortisone
,1827622,clearance,"The addition of ketoconazole did not significantly change the clearance (96 +/- 11 versus 90 +/- 11 ml/hr/kg), mean residence time (4.29 +/- 0.43 versus 4.45 +/- 0.59 hours), volume of distribution (0.41 +/- 0.02 versus 0.40 +/- 0.02 L/kg), or plasma protein binding characteristics of prednisolone.",Lack of pharmacokinetic and pharmacodynamic interactions between ketoconazole and prednisolone. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1827622/),[ml] / [h·kg],96,42037,DB00741,Hydrocortisone
,1827622,clearance,"The addition of ketoconazole did not significantly change the clearance (96 +/- 11 versus 90 +/- 11 ml/hr/kg), mean residence time (4.29 +/- 0.43 versus 4.45 +/- 0.59 hours), volume of distribution (0.41 +/- 0.02 versus 0.40 +/- 0.02 L/kg), or plasma protein binding characteristics of prednisolone.",Lack of pharmacokinetic and pharmacodynamic interactions between ketoconazole and prednisolone. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1827622/),[ml] / [h·kg],90,42038,DB00741,Hydrocortisone
,1827622,mean residence time,"The addition of ketoconazole did not significantly change the clearance (96 +/- 11 versus 90 +/- 11 ml/hr/kg), mean residence time (4.29 +/- 0.43 versus 4.45 +/- 0.59 hours), volume of distribution (0.41 +/- 0.02 versus 0.40 +/- 0.02 L/kg), or plasma protein binding characteristics of prednisolone.",Lack of pharmacokinetic and pharmacodynamic interactions between ketoconazole and prednisolone. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1827622/),h,4.29,42039,DB00741,Hydrocortisone
,1827622,mean residence time,"The addition of ketoconazole did not significantly change the clearance (96 +/- 11 versus 90 +/- 11 ml/hr/kg), mean residence time (4.29 +/- 0.43 versus 4.45 +/- 0.59 hours), volume of distribution (0.41 +/- 0.02 versus 0.40 +/- 0.02 L/kg), or plasma protein binding characteristics of prednisolone.",Lack of pharmacokinetic and pharmacodynamic interactions between ketoconazole and prednisolone. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1827622/),h,4.45,42040,DB00741,Hydrocortisone
,1827622,volume of distribution,"The addition of ketoconazole did not significantly change the clearance (96 +/- 11 versus 90 +/- 11 ml/hr/kg), mean residence time (4.29 +/- 0.43 versus 4.45 +/- 0.59 hours), volume of distribution (0.41 +/- 0.02 versus 0.40 +/- 0.02 L/kg), or plasma protein binding characteristics of prednisolone.",Lack of pharmacokinetic and pharmacodynamic interactions between ketoconazole and prednisolone. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1827622/),[l] / [kg],0.41,42041,DB00741,Hydrocortisone
,1827622,volume of distribution,"The addition of ketoconazole did not significantly change the clearance (96 +/- 11 versus 90 +/- 11 ml/hr/kg), mean residence time (4.29 +/- 0.43 versus 4.45 +/- 0.59 hours), volume of distribution (0.41 +/- 0.02 versus 0.40 +/- 0.02 L/kg), or plasma protein binding characteristics of prednisolone.",Lack of pharmacokinetic and pharmacodynamic interactions between ketoconazole and prednisolone. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1827622/),[l] / [kg],0.40,42042,DB00741,Hydrocortisone
,725320,t1/2,In vitro hydrolysis of methylprednisolone acetate at 37 degrees C in human whole blood is rapid (average t1/2 = 19 min).,Preliminary in vitro and in vivo investigations on methylprednisolone and its acetate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/725320/),min,19,43905,DB00741,Hydrocortisone
,725320,bioavailabilities,"In one cat, the bioavailabilities of methylprednisolone acetate rectally was 13% and of methylprednisolone (alcohol) rectally was 26%, relative to intravenous administration of methylprednisolone.",Preliminary in vitro and in vivo investigations on methylprednisolone and its acetate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/725320/),%,13,43906,DB00741,Hydrocortisone
,725320,bioavailabilities,"In one cat, the bioavailabilities of methylprednisolone acetate rectally was 13% and of methylprednisolone (alcohol) rectally was 26%, relative to intravenous administration of methylprednisolone.",Preliminary in vitro and in vivo investigations on methylprednisolone and its acetate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/725320/),%,26,43907,DB00741,Hydrocortisone
,725320,bioavailabilities,"In the same cat, the bioavailabilities of methylprednisolone acetate orally was 93% and of methylprednisolone was 82%, relative to intravenous administration of methylprednisolone.",Preliminary in vitro and in vivo investigations on methylprednisolone and its acetate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/725320/),%,93,43908,DB00741,Hydrocortisone
,725320,bioavailabilities,"In the same cat, the bioavailabilities of methylprednisolone acetate orally was 93% and of methylprednisolone was 82%, relative to intravenous administration of methylprednisolone.",Preliminary in vitro and in vivo investigations on methylprednisolone and its acetate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/725320/),%,82,43909,DB00741,Hydrocortisone
,30725418,T1/2,Pharmacokinetic analysis showed that rMETase was eliminated with a T1/2 of 2.49 h.,Safety and Toxicity of Recombinant Methioninase and Polyethylene Glycol (PEG) Recombinant Methioninase in Primates. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30725418/),h,2.49,44036,DB00741,Hydrocortisone
,30725418,biological half-life,"In pharmacokinetic studies, a single 4000 units/kg dose showed that MEGC-PEG-rMETase holoenzyme activity was eliminated with a biological half-life of 1.3 h, and the MEGC-PEG-rMETase apoenzyme was eliminated with a biological half-life of 90 h, a 36-fold increase compared with non-PEGylated rMETase.",Safety and Toxicity of Recombinant Methioninase and Polyethylene Glycol (PEG) Recombinant Methioninase in Primates. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30725418/),h,1.3,44037,DB00741,Hydrocortisone
,30725418,biological half-life,"In pharmacokinetic studies, a single 4000 units/kg dose showed that MEGC-PEG-rMETase holoenzyme activity was eliminated with a biological half-life of 1.3 h, and the MEGC-PEG-rMETase apoenzyme was eliminated with a biological half-life of 90 h, a 36-fold increase compared with non-PEGylated rMETase.",Safety and Toxicity of Recombinant Methioninase and Polyethylene Glycol (PEG) Recombinant Methioninase in Primates. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30725418/),h,90,44038,DB00741,Hydrocortisone
<,30725418,steady-state depletion,A 7-day i.v. administration of 4000 units/kg every 12 h resulted in a steady-state depletion of plasma MET to <5 μmol/L.,Safety and Toxicity of Recombinant Methioninase and Polyethylene Glycol (PEG) Recombinant Methioninase in Primates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30725418/),μmo,5,44039,DB00741,Hydrocortisone
,17230452,flow rate,"The chromatographic separation was achieved on an Agilent Zorbax SB-C(18) column (250 x 4.6 mm, 5 microm) at 35 degrees C, with a linear gradient of acetonitrile and 0.03% aqueous phosphoric acid (v/v), at a flow rate of 1.0 mL/min.",HPLC method for the determination and pharmacokinetic studies of four triterpenoids in rat plasma after oral administration of Ganoderma lucidum extract. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17230452/),[ml] / [min],1.0,44655,DB00741,Hydrocortisone
,17230452,extract recovery,"The extract recovery for the four triterpenoids and internal standard ranged from 95 to 67%, and the QC samples were found to be stable according to the results of the stability study.",HPLC method for the determination and pharmacokinetic studies of four triterpenoids in rat plasma after oral administration of Ganoderma lucidum extract. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17230452/),%,95 to 67,44656,DB00741,Hydrocortisone
,12723457,clearance,"Population estimates of the PK parameters of clearance and volume of distribution were 396 L/h (64.8% co-efficient of variation [CV]) and 1190 L (41.2% CV), respectively.",Population pharmacokinetics and pharmacodynamics of ciclesonide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12723457/),[l] / [h],396,46550,DB00741,Hydrocortisone
,12723457,volume of distribution,"Population estimates of the PK parameters of clearance and volume of distribution were 396 L/h (64.8% co-efficient of variation [CV]) and 1190 L (41.2% CV), respectively.",Population pharmacokinetics and pharmacodynamics of ciclesonide. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12723457/),l,1190,46551,DB00741,Hydrocortisone
,12723457,maximum cortisol release rate,"Pharmacodynamic population estimates included maximum cortisol release rate, 3140 ng/h (5.4% CV).",Population pharmacokinetics and pharmacodynamics of ciclesonide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12723457/),[ng] / [h],3140,46552,DB00741,Hydrocortisone
,12723457,EC50,The EC50 of CIC-AP was 0.88 ng/mL.,Population pharmacokinetics and pharmacodynamics of ciclesonide. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12723457/),[ng] / [ml],0.88,46553,DB00741,Hydrocortisone
,6705451,plasma t 1/2,"The plasma t 1/2, distribution volume (V beta), and plasma clearance for epimer 22R were (mean +/- SD) 2.66 +/- 0.57 hr, 425 +/- 100 l, and 117 +/- 40 l/hr.",Kinetics of the epimeric glucocorticoid budesonide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6705451/),h,2.66,49773,DB00741,Hydrocortisone
,6705451,distribution volume (V beta),"The plasma t 1/2, distribution volume (V beta), and plasma clearance for epimer 22R were (mean +/- SD) 2.66 +/- 0.57 hr, 425 +/- 100 l, and 117 +/- 40 l/hr.",Kinetics of the epimeric glucocorticoid budesonide. ,Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6705451/),l,425,49774,DB00741,Hydrocortisone
,6705451,plasma clearance,"The plasma t 1/2, distribution volume (V beta), and plasma clearance for epimer 22R were (mean +/- SD) 2.66 +/- 0.57 hr, 425 +/- 100 l, and 117 +/- 40 l/hr.",Kinetics of the epimeric glucocorticoid budesonide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6705451/),[l] / [h],117,49775,DB00741,Hydrocortisone
less,15102872,t(max),All formulations were rapidly absorbed (t(max) less than 1 h).,Intranasal loteprednol etabonate in healthy male subjects: pharmacokinetics and effects on endogenous cortisol. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15102872/),h,1,50060,DB00741,Hydrocortisone
,15102872,terminal half-lives,"The rather short mean terminal half-lives of 2.2 +/- 1.5 hours and 1.8 +/- 1.0 hours for LE 400 microg and LE 800 microg, respectively, and 4.2 +/- 1.8 hours for the 200-microg FP treatment explained the lack of any accumulation.",Intranasal loteprednol etabonate in healthy male subjects: pharmacokinetics and effects on endogenous cortisol. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15102872/),h,2.2,50061,DB00741,Hydrocortisone
,15102872,terminal half-lives,"The rather short mean terminal half-lives of 2.2 +/- 1.5 hours and 1.8 +/- 1.0 hours for LE 400 microg and LE 800 microg, respectively, and 4.2 +/- 1.8 hours for the 200-microg FP treatment explained the lack of any accumulation.",Intranasal loteprednol etabonate in healthy male subjects: pharmacokinetics and effects on endogenous cortisol. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15102872/),h,1.8,50062,DB00741,Hydrocortisone
,15102872,terminal half-lives,"The rather short mean terminal half-lives of 2.2 +/- 1.5 hours and 1.8 +/- 1.0 hours for LE 400 microg and LE 800 microg, respectively, and 4.2 +/- 1.8 hours for the 200-microg FP treatment explained the lack of any accumulation.",Intranasal loteprednol etabonate in healthy male subjects: pharmacokinetics and effects on endogenous cortisol. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15102872/),h,4.2,50063,DB00741,Hydrocortisone
,15102872,peak concentrations (C(max)),Mean peak concentrations (C(max)) were 139 +/- 57 pg/mL with LE 400 microg and 164 +/- 54 pg/mL with LE 800 microg and thus fairly independent from dose.,Intranasal loteprednol etabonate in healthy male subjects: pharmacokinetics and effects on endogenous cortisol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15102872/),[pg] / [ml],139,50064,DB00741,Hydrocortisone
,15102872,peak concentrations (C(max)),Mean peak concentrations (C(max)) were 139 +/- 57 pg/mL with LE 400 microg and 164 +/- 54 pg/mL with LE 800 microg and thus fairly independent from dose.,Intranasal loteprednol etabonate in healthy male subjects: pharmacokinetics and effects on endogenous cortisol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15102872/),[pg] / [ml],164,50065,DB00741,Hydrocortisone
,15102872,C(max),The 200-microg FP treatment resulted in a C(max) of only 15.5 +/- 5.9 pg/mL.,Intranasal loteprednol etabonate in healthy male subjects: pharmacokinetics and effects on endogenous cortisol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15102872/),[pg] / [ml],15.5,50066,DB00741,Hydrocortisone
,15102872,AUC(0-t),"Mean measured AUC(0-t) values (193 +/- 87 pg/h/mL(-1), 300 +/- 183 pg/h/mL(-1), and 40 +/- 34 pg/h/mL(-1) for LE 400 microg, LE 800 microg, and FP 200 microg, respectively) showed high variability and suggested nonlinear pharmacokinetics for the LE formulations, indicative of a less complete systemic uptake of LE from the 0.2% concentration.",Intranasal loteprednol etabonate in healthy male subjects: pharmacokinetics and effects on endogenous cortisol. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15102872/),[h·pg] / [ml],193,50067,DB00741,Hydrocortisone
,15102872,AUC(0-t),"Mean measured AUC(0-t) values (193 +/- 87 pg/h/mL(-1), 300 +/- 183 pg/h/mL(-1), and 40 +/- 34 pg/h/mL(-1) for LE 400 microg, LE 800 microg, and FP 200 microg, respectively) showed high variability and suggested nonlinear pharmacokinetics for the LE formulations, indicative of a less complete systemic uptake of LE from the 0.2% concentration.",Intranasal loteprednol etabonate in healthy male subjects: pharmacokinetics and effects on endogenous cortisol. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15102872/),[h·pg] / [ml],300,50068,DB00741,Hydrocortisone
,15102872,AUC(0-t),"Mean measured AUC(0-t) values (193 +/- 87 pg/h/mL(-1), 300 +/- 183 pg/h/mL(-1), and 40 +/- 34 pg/h/mL(-1) for LE 400 microg, LE 800 microg, and FP 200 microg, respectively) showed high variability and suggested nonlinear pharmacokinetics for the LE formulations, indicative of a less complete systemic uptake of LE from the 0.2% concentration.",Intranasal loteprednol etabonate in healthy male subjects: pharmacokinetics and effects on endogenous cortisol. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15102872/),[h·pg] / [ml],40,50069,DB00741,Hydrocortisone
,23175666,CLm(6β),CLm(6β) in the 49 healthy subjects was 2.40 ± 0.79 ml/min with an approximately 4-fold interindividual variability of CYP3A activity.,Intraindividual and interindividual variabilities in endogenous cortisol 6β-hydroxylation clearance as an index for in vivo CYP3A phenotyping in humans. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23175666/),[ml] / [min],2.40,50759,DB00741,Hydrocortisone
,23175666,clearance,The mean clearance in the 24 women was 2.50 ± 0.89 ml/min; the value in the women was higher than in the 25 men (2.30 ± 0.69 ml/min) by approximately 9%.,Intraindividual and interindividual variabilities in endogenous cortisol 6β-hydroxylation clearance as an index for in vivo CYP3A phenotyping in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23175666/),[ml] / [min],2.50,50760,DB00741,Hydrocortisone
,23175666,clearance,The mean clearance in the 24 women was 2.50 ± 0.89 ml/min; the value in the women was higher than in the 25 men (2.30 ± 0.69 ml/min) by approximately 9%.,Intraindividual and interindividual variabilities in endogenous cortisol 6β-hydroxylation clearance as an index for in vivo CYP3A phenotyping in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23175666/),[ml] / [min],2.30,50761,DB00741,Hydrocortisone
,23175666,CLm(6β),The mean value for CLm(6β) in each subject for 36-53 days was 2.54 ± 0.76 ml/min (n = 14).,Intraindividual and interindividual variabilities in endogenous cortisol 6β-hydroxylation clearance as an index for in vivo CYP3A phenotyping in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23175666/),[ml] / [min],2.54,50762,DB00741,Hydrocortisone
,23175666,clearance,"The within-day intraindividual clearance variability was 1.1-fold to 2.5-fold (2.45 ± 0.91 ml/min, n = 26).",Intraindividual and interindividual variabilities in endogenous cortisol 6β-hydroxylation clearance as an index for in vivo CYP3A phenotyping in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23175666/),[ml] / [min],2.45,50763,DB00741,Hydrocortisone
,18085156,peak levels,"The lowest mean peak levels of plasma cortisol (82.53 +/- 6.04 nmol l(-1)), the most rapid return of plasma cortisol levels to baseline values (1.92 +/- 1.11 h), and the lowest occurrence of stress behaviours (2.38 +/- 5.83%) were noted in the SLA group.",Stress responses in adult cattle due to surgical dehorning using three different types of anaesthesia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18085156/),[nM] / [l],82.53,50856,DB00741,Hydrocortisone
,18085156,peak levels,"The highest mean peak levels plasma cortisol (113.86 +/- 25.65 nmol l(-1)), the slowest return of plasma cortisol levels to baseline values (3.83 +/- 2.18 h) and the most frequent occurrence of stress behaviours (65.48 +/- 28.72%) were observed in the LA group.",Stress responses in adult cattle due to surgical dehorning using three different types of anaesthesia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18085156/),[nM] / [l],113.86,50857,DB00741,Hydrocortisone
,7131291,ratio,This placental conversion of cortisol to cortisone and the further metabolism and conjugation of cortisol by the fetoplacental unit resulted in a fetal to maternal plasma cortisol ratio of 0.2.,Comparison of the transplacental pharmacokinetics of cortisol and triamcinolone acetonide in the rhesus monkey. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7131291/),,0.2,51824,DB00741,Hydrocortisone
,7131291,ratio,"In contrast, the lack of placental or fetoplacental metabolism of TAC resulted in a fetal to maternal plasma TAC ratio of 0.6.",Comparison of the transplacental pharmacokinetics of cortisol and triamcinolone acetonide in the rhesus monkey. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7131291/),,0.6,51825,DB00741,Hydrocortisone
,11140430,area under the plasma FP concentration-time curve (AUC) to infinite time (AUCinfinity),Systemic exposure to FP after administration of a single 1000 microg inhaled dose of FP via the 2 powder devices was similar; the area under the plasma FP concentration-time curve (AUC) to infinite time (AUCinfinity) was 2.08 microg/L x h [95% confidence intervals (CI): 1.63-2.64] for Diskhaler and 2.49 microg/L x h (95% CI: 2.09-2.96) for Diskus.,Pharmacokinetics of fluticasone propionate inhaled via the Diskhaler and Diskus powder devices in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11140430/),[μg] / [h·l],2.08,52896,DB00741,Hydrocortisone
,11140430,area under the plasma FP concentration-time curve (AUC) to infinite time (AUCinfinity),Systemic exposure to FP after administration of a single 1000 microg inhaled dose of FP via the 2 powder devices was similar; the area under the plasma FP concentration-time curve (AUC) to infinite time (AUCinfinity) was 2.08 microg/L x h [95% confidence intervals (CI): 1.63-2.64] for Diskhaler and 2.49 microg/L x h (95% CI: 2.09-2.96) for Diskus.,Pharmacokinetics of fluticasone propionate inhaled via the Diskhaler and Diskus powder devices in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11140430/),[μg] / [h·l],2.49,52897,DB00741,Hydrocortisone
,11140430,Maximum plasma FP concentration (Cmax),Maximum plasma FP concentration (Cmax) was 0.34 microg/L for both devices.,Pharmacokinetics of fluticasone propionate inhaled via the Diskhaler and Diskus powder devices in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11140430/),[μg] / [l],0.34,52898,DB00741,Hydrocortisone
,11140430,bioavailability,"Mean bioavailability values via the Diskhaler and Diskus were 11.9% (95% CI: 9.0-15.7%) and 16.6% (95% CI: 13.6-20.3%), respectively.",Pharmacokinetics of fluticasone propionate inhaled via the Diskhaler and Diskus powder devices in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11140430/),%,11.9,52899,DB00741,Hydrocortisone
,11140430,bioavailability,"Mean bioavailability values via the Diskhaler and Diskus were 11.9% (95% CI: 9.0-15.7%) and 16.6% (95% CI: 13.6-20.3%), respectively.",Pharmacokinetics of fluticasone propionate inhaled via the Diskhaler and Diskus powder devices in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11140430/),%,16.6,52900,DB00741,Hydrocortisone
,11140430,AUC up to 12 hours (AUC12h),"After dose 15, the AUC up to 12 hours (AUC12h) was 2.25 microg/L x h and Cmax was 0.38 microg/L.",Pharmacokinetics of fluticasone propionate inhaled via the Diskhaler and Diskus powder devices in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11140430/),[μg] / [h·l],2.25,52901,DB00741,Hydrocortisone
,11140430,Cmax,"After dose 15, the AUC up to 12 hours (AUC12h) was 2.25 microg/L x h and Cmax was 0.38 microg/L.",Pharmacokinetics of fluticasone propionate inhaled via the Diskhaler and Diskus powder devices in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11140430/),[μg] / [l],0.38,52902,DB00741,Hydrocortisone
,11140430,steady-state to single dose accumulation ratio,The mean steady-state to single dose accumulation ratio after twice-daily administration was 1.49 (95% CI: 1.36-1.62).,Pharmacokinetics of fluticasone propionate inhaled via the Diskhaler and Diskus powder devices in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11140430/),,1.49,52903,DB00741,Hydrocortisone
,28083797,plasma half-life,Mean plasma half-life was 1.40 h (95%CI [0.80;2.10]) for fludrocortisone and 2.10 h (95%CI [1.78;2.40]) for hydrocortisone.,Population Pharmacokinetic-Pharmacodynamic Model of Oral Fludrocortisone and Intravenous Hydrocortisone in Healthy Volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28083797/),h,1.40,53564,DB00741,Hydrocortisone
,28083797,plasma half-life,Mean plasma half-life was 1.40 h (95%CI [0.80;2.10]) for fludrocortisone and 2.10 h (95%CI [1.78;2.40]) for hydrocortisone.,Population Pharmacokinetic-Pharmacodynamic Model of Oral Fludrocortisone and Intravenous Hydrocortisone in Healthy Volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28083797/),h,2.10,53565,DB00741,Hydrocortisone
,28083797,Clearance,Clearance was 40.8 L/h (95%CI [33.6;48]) for fludrocortisone and 30 L/h (95%CI [25.3;34.7]) for hydrocortisone.,Population Pharmacokinetic-Pharmacodynamic Model of Oral Fludrocortisone and Intravenous Hydrocortisone in Healthy Volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28083797/),[l] / [h],40.8,53566,DB00741,Hydrocortisone
,28083797,Clearance,Clearance was 40.8 L/h (95%CI [33.6;48]) for fludrocortisone and 30 L/h (95%CI [25.3;34.7]) for hydrocortisone.,Population Pharmacokinetic-Pharmacodynamic Model of Oral Fludrocortisone and Intravenous Hydrocortisone in Healthy Volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28083797/),[l] / [h],30,53567,DB00741,Hydrocortisone
,28083797,plasma concentration,"The plasma concentration of drug producing 50% of maximal inhibition of urinary sodium/potassium (IC50) was about 200 times lower for fludrocortisone (0.08 μg/L, 95%CI [0.035;0.125]) than for hydrocortisone (16.7 μg/L, 95%CI [10.5;22.9]).",Population Pharmacokinetic-Pharmacodynamic Model of Oral Fludrocortisone and Intravenous Hydrocortisone in Healthy Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28083797/),[μg] / [l],0.08,53568,DB00741,Hydrocortisone
,28083797,plasma concentration,"The plasma concentration of drug producing 50% of maximal inhibition of urinary sodium/potassium (IC50) was about 200 times lower for fludrocortisone (0.08 μg/L, 95%CI [0.035;0.125]) than for hydrocortisone (16.7 μg/L, 95%CI [10.5;22.9]).",Population Pharmacokinetic-Pharmacodynamic Model of Oral Fludrocortisone and Intravenous Hydrocortisone in Healthy Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28083797/),[μg] / [l],16.7,53569,DB00741,Hydrocortisone
,24797719,clearance,"Final population estimates for clearance, volume of distribution, and baseline cortisol concentration were 20.2 L/hr, 244 L, and 1.37 ng/mL, respectively.",Population pharmacokinetics of unbound hydrocortisone in critically ill neonates and infants with vasopressor-resistant hypotension. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24797719/),[l] / [h],20.2,53725,DB00741,Hydrocortisone
,24797719,volume of distribution,"Final population estimates for clearance, volume of distribution, and baseline cortisol concentration were 20.2 L/hr, 244 L, and 1.37 ng/mL, respectively.",Population pharmacokinetics of unbound hydrocortisone in critically ill neonates and infants with vasopressor-resistant hypotension. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24797719/),l,244,53726,DB00741,Hydrocortisone
,24797719,volume of distribution,"Final population estimates for clearance, volume of distribution, and baseline cortisol concentration were 20.2 L/hr, 244 L, and 1.37 ng/mL, respectively.",Population pharmacokinetics of unbound hydrocortisone in critically ill neonates and infants with vasopressor-resistant hypotension. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24797719/),[ng] / [ml],1.37,53727,DB00741,Hydrocortisone
,24797719,unbound hydro,"Using the median weight and postmenstrual age of our subjects (i.e., 1.2 kg and 28 wk) in the final model, the typical unbound hydrocortisone clearance and volume of distribution were 1.0 L/hr and 4.2 L, respectively.",Population pharmacokinetics of unbound hydrocortisone in critically ill neonates and infants with vasopressor-resistant hypotension. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24797719/),[l] / [h],1.0,53728,DB00741,Hydrocortisone
,24797719,clearance,"Using the median weight and postmenstrual age of our subjects (i.e., 1.2 kg and 28 wk) in the final model, the typical unbound hydrocortisone clearance and volume of distribution were 1.0 L/hr and 4.2 L, respectively.",Population pharmacokinetics of unbound hydrocortisone in critically ill neonates and infants with vasopressor-resistant hypotension. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24797719/),[l] / [h],1.0,53729,DB00741,Hydrocortisone
,24797719,volume of distribution,"Using the median weight and postmenstrual age of our subjects (i.e., 1.2 kg and 28 wk) in the final model, the typical unbound hydrocortisone clearance and volume of distribution were 1.0 L/hr and 4.2 L, respectively.",Population pharmacokinetics of unbound hydrocortisone in critically ill neonates and infants with vasopressor-resistant hypotension. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24797719/),l,4.2,53730,DB00741,Hydrocortisone
,24797719,half-life,The typical half-life for unbound hydrocortisone was 2.9 hours.,Population pharmacokinetics of unbound hydrocortisone in critically ill neonates and infants with vasopressor-resistant hypotension. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24797719/),h,2.9,53731,DB00741,Hydrocortisone
,26299424,absolute oral bioavailability,"The absolute oral bioavailability of pristimerin is 28.4% at a dose of 1 mg·kg(-1), and the bioavailability was poor.",Absorption and metabolism characteristics of pristimerin as determined by a sensitive and reliable LC-MS/MS method. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26299424/),%,28.4,56116,DB00741,Hydrocortisone
,26299424,half-life,"Pristimerin was stable in S9 fractions but metabolized in HLM with a half-life of 20.4 min, which indicated that pristimerin could be mainly metabolized by phase I enzymes.",Absorption and metabolism characteristics of pristimerin as determined by a sensitive and reliable LC-MS/MS method. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26299424/),min,20.4,56117,DB00741,Hydrocortisone
,31996925,half-life,"In healthy individuals, cortisol half-life was longer when the higher hydrocortisone dose was administered (2.02 ± 0.15 vs 1.81 ± 0.11 hours; P < 0.01), and in patients with AI, the half-life was longer than in healthy individuals given the same hydrocortisone dose.",Perioperative Glucocorticoid Therapy for Patients with Adrenal Insufficiency: Dosing Based on Pharmacokinetic Data. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31996925/),h,2.02,56212,DB00741,Hydrocortisone
,31996925,half-life,"In healthy individuals, cortisol half-life was longer when the higher hydrocortisone dose was administered (2.02 ± 0.15 vs 1.81 ± 0.11 hours; P < 0.01), and in patients with AI, the half-life was longer than in healthy individuals given the same hydrocortisone dose.",Perioperative Glucocorticoid Therapy for Patients with Adrenal Insufficiency: Dosing Based on Pharmacokinetic Data. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31996925/),h,1.81,56213,DB00741,Hydrocortisone
,28814338,nausea behaviour score,The onset of nausea-like behaviour in the placebo-treated group occurred at t3.5h and peaked at t4.75h with nausea behaviour score of 58.5 ± 4.6 mm.,"Anti-nausea effects and pharmacokinetics of ondansetron, maropitant and metoclopramide in a low-dose cisplatin model of nausea and vomiting in the dog: a blinded crossover study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28814338/),,58.5,57067,DB00741,Hydrocortisone
,28814338,terminal half-lives,"The terminal half-lives (harmonic mean ± pseudo SD) for ondansetron, maropitant and metoclopramide were 1.21 ± 0.51, 5.62 ± 0.77 and 0.87 ± 0.17 h respectively.","Anti-nausea effects and pharmacokinetics of ondansetron, maropitant and metoclopramide in a low-dose cisplatin model of nausea and vomiting in the dog: a blinded crossover study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28814338/),h,1.21,57068,DB00741,Hydrocortisone
,28814338,terminal half-lives,"The terminal half-lives (harmonic mean ± pseudo SD) for ondansetron, maropitant and metoclopramide were 1.21 ± 0.51, 5.62 ± 0.77 and 0.87 ± 0.17 h respectively.","Anti-nausea effects and pharmacokinetics of ondansetron, maropitant and metoclopramide in a low-dose cisplatin model of nausea and vomiting in the dog: a blinded crossover study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28814338/),h,5.62,57069,DB00741,Hydrocortisone
,28814338,terminal half-lives,"The terminal half-lives (harmonic mean ± pseudo SD) for ondansetron, maropitant and metoclopramide were 1.21 ± 0.51, 5.62 ± 0.77 and 0.87 ± 0.17 h respectively.","Anti-nausea effects and pharmacokinetics of ondansetron, maropitant and metoclopramide in a low-dose cisplatin model of nausea and vomiting in the dog: a blinded crossover study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28814338/),h,0.87,57070,DB00741,Hydrocortisone
,24619932,terminal half-life,LY2456302 displayed rapid oral absorption and a terminal half-life of approximately 30-40 hours.,"Safety, tolerability, and pharmacokinetic evaluation of single- and multiple-ascending doses of a novel kappa opioid receptor antagonist LY2456302 and drug interaction with ethanol in healthy subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24619932/),h,30-40,57236,DB00741,Hydrocortisone
,15114430,plasma AUC,MFANS produced similar mean plasma AUC (123 pmol/l h) to FPANS (112 pmol/l h).,Bioavailability of fluticasone propionate and mometasone furoate aqueous nasal sprays. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15114430/),[pM] / [h·l],123,57921,DB00741,Hydrocortisone
,15114430,plasma AUC,MFANS produced similar mean plasma AUC (123 pmol/l h) to FPANS (112 pmol/l h).,Bioavailability of fluticasone propionate and mometasone furoate aqueous nasal sprays. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15114430/),[pM] / [h·l],112,57922,DB00741,Hydrocortisone
,19383806,time to reach a clinical,The time to reach a clinically significant plasma concentration of cortisol (>200 nmol/l) was within 20 min and a mean peak of 431 (s.d. 126) nmol/l was obtained within 50 min after administration of the 20 mg tablet.,Improving glucocorticoid replacement therapy using a novel modified-release hydrocortisone tablet: a pharmacokinetic study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19383806/),min,20,58042,DB00741,Hydrocortisone
,19383806,peak,The time to reach a clinically significant plasma concentration of cortisol (>200 nmol/l) was within 20 min and a mean peak of 431 (s.d. 126) nmol/l was obtained within 50 min after administration of the 20 mg tablet.,Improving glucocorticoid replacement therapy using a novel modified-release hydrocortisone tablet: a pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19383806/),[nM] / [l],431,58043,DB00741,Hydrocortisone
,19383806,time to reach 200 nmol/l,"In the fed state the time to reach 200 nmol/l was delayed by 28 and 9 min based on LC-MS/MS and immunoassay, respectively.",Improving glucocorticoid replacement therapy using a novel modified-release hydrocortisone tablet: a pharmacokinetic study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19383806/),min,28,58044,DB00741,Hydrocortisone
,19383806,time to reach 200 nmol/l,"In the fed state the time to reach 200 nmol/l was delayed by 28 and 9 min based on LC-MS/MS and immunoassay, respectively.",Improving glucocorticoid replacement therapy using a novel modified-release hydrocortisone tablet: a pharmacokinetic study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19383806/),min,9,58045,DB00741,Hydrocortisone
,27129362,maximal serum concentration (Cmax),"Mean maximal serum concentration (Cmax) was 82.0 and 178.1ng/mL, while mean area under the concentration-time curve (AUC)0-∞ was 562.8 and 1180.8h×ng/mL with DR-HC 5 and 20mg respectively.",Achieving a physiological cortisol profile with once-daily dual-release hydrocortisone: a pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27129362/),[ng] / [ml],82.0,58887,DB00741,Hydrocortisone
,27129362,maximal serum concentration (Cmax),"Mean maximal serum concentration (Cmax) was 82.0 and 178.1ng/mL, while mean area under the concentration-time curve (AUC)0-∞ was 562.8 and 1180.8h×ng/mL with DR-HC 5 and 20mg respectively.",Achieving a physiological cortisol profile with once-daily dual-release hydrocortisone: a pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27129362/),[ng] / [ml],178.1,58888,DB00741,Hydrocortisone
,27129362,area under the concentration-time curve (AUC)0-∞,"Mean maximal serum concentration (Cmax) was 82.0 and 178.1ng/mL, while mean area under the concentration-time curve (AUC)0-∞ was 562.8 and 1180.8h×ng/mL with DR-HC 5 and 20mg respectively.",Achieving a physiological cortisol profile with once-daily dual-release hydrocortisone: a pharmacokinetic study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27129362/),[h·ng] / [ml],562.8,58889,DB00741,Hydrocortisone
,27129362,area under the concentration-time curve (AUC)0-∞,"Mean maximal serum concentration (Cmax) was 82.0 and 178.1ng/mL, while mean area under the concentration-time curve (AUC)0-∞ was 562.8 and 1180.8h×ng/mL with DR-HC 5 and 20mg respectively.",Achieving a physiological cortisol profile with once-daily dual-release hydrocortisone: a pharmacokinetic study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27129362/),[h·ng] / [ml],1180.8,58890,DB00741,Hydrocortisone
,27638508,Km,"Taurine and GCDCA-S were substrates of OAT1 and OAT3, with Km values of 379 ± 58 and 64.3 ± 3.9 μM, respectively.","Investigation of Endogenous Compounds Applicable to Drug-Drug Interaction Studies Involving the Renal Organic Anion Transporters, OAT1 and OAT3, in Humans. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27638508/),μM,379,59228,DB00741,Hydrocortisone
,27638508,Km,"Taurine and GCDCA-S were substrates of OAT1 and OAT3, with Km values of 379 ± 58 and 64.3 ± 3.9 μM, respectively.","Investigation of Endogenous Compounds Applicable to Drug-Drug Interaction Studies Involving the Renal Organic Anion Transporters, OAT1 and OAT3, in Humans. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27638508/),μM,64.3,59229,DB00741,Hydrocortisone
,27638508,Ki,"The Ki values of probenecid for the OAT1- and OAT3-mediated uptake of taurine and GCDCA-S (9.49 ± 1.27 and 7.40 ± 0.70 μM, respectively) were similar to those of their typical substrate drugs.","Investigation of Endogenous Compounds Applicable to Drug-Drug Interaction Studies Involving the Renal Organic Anion Transporters, OAT1 and OAT3, in Humans. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27638508/),μM,9.49,59230,DB00741,Hydrocortisone
,27638508,Ki,"The Ki values of probenecid for the OAT1- and OAT3-mediated uptake of taurine and GCDCA-S (9.49 ± 1.27 and 7.40 ± 0.70 μM, respectively) were similar to those of their typical substrate drugs.","Investigation of Endogenous Compounds Applicable to Drug-Drug Interaction Studies Involving the Renal Organic Anion Transporters, OAT1 and OAT3, in Humans. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27638508/),μM,7.40,59231,DB00741,Hydrocortisone
,188965,maximal,Constant rate i.v. infusion of synthetic ACTH increased the plasma concentrations of both steroids to maximal values of 0-42 +/- 0-23 mug cortisol/100 ml and 1-06 +/- 0-56 mug corticosterone/100 ml at infusion rates of 1 i.u. ACTH/kg/h.,"Adrenocortical function in a prototherian mammal, Tachyglossus aculeatus (Shaw). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/188965/),μg,0,59823,DB00741,Hydrocortisone
,188965,maximal,Constant rate i.v. infusion of synthetic ACTH increased the plasma concentrations of both steroids to maximal values of 0-42 +/- 0-23 mug cortisol/100 ml and 1-06 +/- 0-56 mug corticosterone/100 ml at infusion rates of 1 i.u. ACTH/kg/h.,"Adrenocortical function in a prototherian mammal, Tachyglossus aculeatus (Shaw). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/188965/),μg,1-06,59824,DB00741,Hydrocortisone
,188965,production rates,"The production rates of corticosterone and cortisol, measured by isotope dilution during constant rate i.v. infusion of 3H-labelled tracers, were only 0-35 +/- 0-21 and 0-56 +/- 0-26 mug/kg/h respectively during saline infusion, and increased to 2-86 +/- 3-47 and 2-74 +/- 2-07 mug/kg/h during the infusion of 1 i.u. ACTH/kg/h.","Adrenocortical function in a prototherian mammal, Tachyglossus aculeatus (Shaw). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/188965/),[μg] / [h·kg],0-35,59825,DB00741,Hydrocortisone
,188965,production rates,"The production rates of corticosterone and cortisol, measured by isotope dilution during constant rate i.v. infusion of 3H-labelled tracers, were only 0-35 +/- 0-21 and 0-56 +/- 0-26 mug/kg/h respectively during saline infusion, and increased to 2-86 +/- 3-47 and 2-74 +/- 2-07 mug/kg/h during the infusion of 1 i.u. ACTH/kg/h.","Adrenocortical function in a prototherian mammal, Tachyglossus aculeatus (Shaw). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/188965/),[μg] / [h·kg],0,59826,DB00741,Hydrocortisone
,188965,production rates,"The production rates of corticosterone and cortisol, measured by isotope dilution during constant rate i.v. infusion of 3H-labelled tracers, were only 0-35 +/- 0-21 and 0-56 +/- 0-26 mug/kg/h respectively during saline infusion, and increased to 2-86 +/- 3-47 and 2-74 +/- 2-07 mug/kg/h during the infusion of 1 i.u. ACTH/kg/h.","Adrenocortical function in a prototherian mammal, Tachyglossus aculeatus (Shaw). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/188965/),[μg] / [h·kg],2-86,59827,DB00741,Hydrocortisone
,188965,production rates,"The production rates of corticosterone and cortisol, measured by isotope dilution during constant rate i.v. infusion of 3H-labelled tracers, were only 0-35 +/- 0-21 and 0-56 +/- 0-26 mug/kg/h respectively during saline infusion, and increased to 2-86 +/- 3-47 and 2-74 +/- 2-07 mug/kg/h during the infusion of 1 i.u. ACTH/kg/h.","Adrenocortical function in a prototherian mammal, Tachyglossus aculeatus (Shaw). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/188965/),[μg] / [h·kg],2-74,59828,DB00741,Hydrocortisone
,14624194,area under the methylprednisolone concentration-time curve,"Following nefazodone administration, the mean (+/-SD) area under the methylprednisolone concentration-time curve was significantly higher (1393 +/- 343 vs. 2966 +/- 928 ug*h/L; P < 0.005), apparent clearance was lower (28.7 +/- 7.2 vs. 14.6 +/- 7.8 L/h; P < 0.02) and the terminal elimination half-life was longer (2.28 +/- 0.49 vs. 3.32 +/- 0.95 hours; P < 0.02).",Nefazodone inhibits methylprednisolone disposition and enhances its adrenal-suppressant effect. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14624194/),[h·ug] / [l],1393,60429,DB00741,Hydrocortisone
,14624194,area under the methylprednisolone concentration-time curve,"Following nefazodone administration, the mean (+/-SD) area under the methylprednisolone concentration-time curve was significantly higher (1393 +/- 343 vs. 2966 +/- 928 ug*h/L; P < 0.005), apparent clearance was lower (28.7 +/- 7.2 vs. 14.6 +/- 7.8 L/h; P < 0.02) and the terminal elimination half-life was longer (2.28 +/- 0.49 vs. 3.32 +/- 0.95 hours; P < 0.02).",Nefazodone inhibits methylprednisolone disposition and enhances its adrenal-suppressant effect. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14624194/),[h·ug] / [l],2966,60430,DB00741,Hydrocortisone
,14624194,apparent clearance,"Following nefazodone administration, the mean (+/-SD) area under the methylprednisolone concentration-time curve was significantly higher (1393 +/- 343 vs. 2966 +/- 928 ug*h/L; P < 0.005), apparent clearance was lower (28.7 +/- 7.2 vs. 14.6 +/- 7.8 L/h; P < 0.02) and the terminal elimination half-life was longer (2.28 +/- 0.49 vs. 3.32 +/- 0.95 hours; P < 0.02).",Nefazodone inhibits methylprednisolone disposition and enhances its adrenal-suppressant effect. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14624194/),[l] / [h],28.7,60431,DB00741,Hydrocortisone
,14624194,apparent clearance,"Following nefazodone administration, the mean (+/-SD) area under the methylprednisolone concentration-time curve was significantly higher (1393 +/- 343 vs. 2966 +/- 928 ug*h/L; P < 0.005), apparent clearance was lower (28.7 +/- 7.2 vs. 14.6 +/- 7.8 L/h; P < 0.02) and the terminal elimination half-life was longer (2.28 +/- 0.49 vs. 3.32 +/- 0.95 hours; P < 0.02).",Nefazodone inhibits methylprednisolone disposition and enhances its adrenal-suppressant effect. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14624194/),[l] / [h],14.6,60432,DB00741,Hydrocortisone
,14624194,terminal elimination half-life,"Following nefazodone administration, the mean (+/-SD) area under the methylprednisolone concentration-time curve was significantly higher (1393 +/- 343 vs. 2966 +/- 928 ug*h/L; P < 0.005), apparent clearance was lower (28.7 +/- 7.2 vs. 14.6 +/- 7.8 L/h; P < 0.02) and the terminal elimination half-life was longer (2.28 +/- 0.49 vs. 3.32 +/- 0.95 hours; P < 0.02).",Nefazodone inhibits methylprednisolone disposition and enhances its adrenal-suppressant effect. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14624194/),h,2.28,60433,DB00741,Hydrocortisone
,14624194,terminal elimination half-life,"Following nefazodone administration, the mean (+/-SD) area under the methylprednisolone concentration-time curve was significantly higher (1393 +/- 343 vs. 2966 +/- 928 ug*h/L; P < 0.005), apparent clearance was lower (28.7 +/- 7.2 vs. 14.6 +/- 7.8 L/h; P < 0.02) and the terminal elimination half-life was longer (2.28 +/- 0.49 vs. 3.32 +/- 0.95 hours; P < 0.02).",Nefazodone inhibits methylprednisolone disposition and enhances its adrenal-suppressant effect. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14624194/),h,3.32,60434,DB00741,Hydrocortisone
,8645883,drug clearance,A three-fold variation in drug clearance ranging from 174 to 638 ml/h/kg with a range in the volume of distribution of 0.83 to 2.24 l/kg and resultant half-lives ranging from 1.20 to 3.02 hours was noted.,Methylprednisolone and cortisol metabolism during the early post-renal transplant period. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8645883/),[ml] / [h·kg],174 to 638,60614,DB00741,Hydrocortisone
,8645883,volume of distribution,A three-fold variation in drug clearance ranging from 174 to 638 ml/h/kg with a range in the volume of distribution of 0.83 to 2.24 l/kg and resultant half-lives ranging from 1.20 to 3.02 hours was noted.,Methylprednisolone and cortisol metabolism during the early post-renal transplant period. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8645883/),l,0.83 to 2.24,60615,DB00741,Hydrocortisone
,8645883,half-lives,A three-fold variation in drug clearance ranging from 174 to 638 ml/h/kg with a range in the volume of distribution of 0.83 to 2.24 l/kg and resultant half-lives ranging from 1.20 to 3.02 hours was noted.,Methylprednisolone and cortisol metabolism during the early post-renal transplant period. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8645883/),h,1.20 to 3.02,60616,DB00741,Hydrocortisone
,8645883,C-AUC12,C-AUC12 ranged from 44.0 to 636 ng.h/ml.,Methylprednisolone and cortisol metabolism during the early post-renal transplant period. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8645883/),[h·ng] / [ml],44.0 to 636,60617,DB00741,Hydrocortisone
,1827621,Total volume of distribution (Vss),"Total volume of distribution (Vss) of methylprednisolone was unchanged (about 120 L), but when normalized for total body weight, Vss per kilogram was less in obesity.",Pharmacokinetics and pharmacodynamics of methylprednisolone in obesity. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1827621/),l,120,61228,DB00741,Hydrocortisone
,6691888,Peak cortisol levels,Peak cortisol levels of 1518 +/- 190 nmol 1(-1) (mean +/- s.e. mean) and 739 +/- 74 nmol 1(-1) were found 1.46 +/- 0.25 and 1.79 +/- 0.16 h after oral cortisol and cortisone acetate respectively.,Plasma cortisol delivery from oral cortisol and cortisone acetate: relative bioavailability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6691888/),nM,1518,61438,DB00741,Hydrocortisone
,6691888,Peak cortisol levels,Peak cortisol levels of 1518 +/- 190 nmol 1(-1) (mean +/- s.e. mean) and 739 +/- 74 nmol 1(-1) were found 1.46 +/- 0.25 and 1.79 +/- 0.16 h after oral cortisol and cortisone acetate respectively.,Plasma cortisol delivery from oral cortisol and cortisone acetate: relative bioavailability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6691888/),nM,739,61439,DB00741,Hydrocortisone
,6691888,relative bioavailability,"The relative bioavailability of oral cortisol and cortisone acetate varied widely (cortisol 26-91%, mean 54 +/- 6.9%, cortisone acetate 21-95%, mean 44 +/- 6.5%) but despite this wide variation there was, in individual subjects, a highly significant correlation between the bioavailability of the two steroids (r = 0.870, P less than 0.001).",Plasma cortisol delivery from oral cortisol and cortisone acetate: relative bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6691888/),%,26-91,61440,DB00741,Hydrocortisone
,6691888,relative bioavailability,"The relative bioavailability of oral cortisol and cortisone acetate varied widely (cortisol 26-91%, mean 54 +/- 6.9%, cortisone acetate 21-95%, mean 44 +/- 6.5%) but despite this wide variation there was, in individual subjects, a highly significant correlation between the bioavailability of the two steroids (r = 0.870, P less than 0.001).",Plasma cortisol delivery from oral cortisol and cortisone acetate: relative bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6691888/),%,54,61441,DB00741,Hydrocortisone
,6691888,relative bioavailability,"The relative bioavailability of oral cortisol and cortisone acetate varied widely (cortisol 26-91%, mean 54 +/- 6.9%, cortisone acetate 21-95%, mean 44 +/- 6.5%) but despite this wide variation there was, in individual subjects, a highly significant correlation between the bioavailability of the two steroids (r = 0.870, P less than 0.001).",Plasma cortisol delivery from oral cortisol and cortisone acetate: relative bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6691888/),%,21-95,61442,DB00741,Hydrocortisone
,6691888,relative bioavailability,"The relative bioavailability of oral cortisol and cortisone acetate varied widely (cortisol 26-91%, mean 54 +/- 6.9%, cortisone acetate 21-95%, mean 44 +/- 6.5%) but despite this wide variation there was, in individual subjects, a highly significant correlation between the bioavailability of the two steroids (r = 0.870, P less than 0.001).",Plasma cortisol delivery from oral cortisol and cortisone acetate: relative bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6691888/),%,44,61443,DB00741,Hydrocortisone
,16353581,area under the curve AUC,The area under the curve AUC for ACTH after clomipramine was 6202 +/- 976 pg/ml x 150 minutes for tile obese before weight loss and 3274 +/- 512 pg/ml x 150 minutes for the controls and the difference was significant at the level of p=0.052.,Hypersensitivity of the corticotropic axis to the serotoninergic agent clomipramine in obese women. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16353581/),[pg] / [150·min·ml],6202,62335,DB00741,Hydrocortisone
,16353581,area under the curve AUC,The area under the curve AUC for ACTH after clomipramine was 6202 +/- 976 pg/ml x 150 minutes for tile obese before weight loss and 3274 +/- 512 pg/ml x 150 minutes for the controls and the difference was significant at the level of p=0.052.,Hypersensitivity of the corticotropic axis to the serotoninergic agent clomipramine in obese women. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16353581/),[pg] / [150·min·ml],3274,62336,DB00741,Hydrocortisone
,16353581,peak value,The cortisol peak value after clomipramine was 163.71 +/- 14.31 ng/ml in the non-obese and 214.66 +/- 12.59 ng/ml in the obese (p=0.025).,Hypersensitivity of the corticotropic axis to the serotoninergic agent clomipramine in obese women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16353581/),[ng] / [ml],163.71,62337,DB00741,Hydrocortisone
,16353581,peak value,The cortisol peak value after clomipramine was 163.71 +/- 14.31 ng/ml in the non-obese and 214.66 +/- 12.59 ng/ml in the obese (p=0.025).,Hypersensitivity of the corticotropic axis to the serotoninergic agent clomipramine in obese women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16353581/),[ng] / [ml],214.66,62338,DB00741,Hydrocortisone
,1501110,elimination half-life,"After DEX at 8 hr, HC production was reduced instantaneously to a minimum level and HC disappeared rapidly from plasma with an elimination half-life of 1.32 +/- 0.28 hr (mean +/- S.D.).","Time-dependent effects of dexamethasone administration on the suppression of plasma hydrocortisone, assessed with a pharmacokinetic model. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1501110/),h,1.32,65491,DB00741,Hydrocortisone
,7026594,areas under the plasma concentration time curve,"Patients with cushingoid habitus more frequently exhibited peak hydrocortisone levels within the normal range (6 of 14 vs. 1 of 13) and had higher areas under the plasma concentration time curve of hydrocortisone (median, range), i.e. 2672 ng/ml.min (0-21, 637 ng/ml.min) vs. 308 ng/ml.min (0-12, 495 ng/ml.min) compared to those without cushingoid appearance (P less than 0.05).","Endogenous hydrocortisone, a possible factor contributing to the genesis of cushingoid habitus in patients on prednisone. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7026594/),[ng] / [min·ml],2672,65833,DB00741,Hydrocortisone
,7026594,areas under the plasma concentration time curve,"Patients with cushingoid habitus more frequently exhibited peak hydrocortisone levels within the normal range (6 of 14 vs. 1 of 13) and had higher areas under the plasma concentration time curve of hydrocortisone (median, range), i.e. 2672 ng/ml.min (0-21, 637 ng/ml.min) vs. 308 ng/ml.min (0-12, 495 ng/ml.min) compared to those without cushingoid appearance (P less than 0.05).","Endogenous hydrocortisone, a possible factor contributing to the genesis of cushingoid habitus in patients on prednisone. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7026594/),[ng] / [min·ml],308,65834,DB00741,Hydrocortisone
,2146819,half-life period,"The content of alpha-atriopeptins in the plasma varies approximately between 4 and 12 pmol/l in the course of 24 hours, the half-life period amounts to 1 to 2 min.","[Various recent findings concerning the formation, mechanism of action and significance of atrial natriuretic peptides (atriopeptins)]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2146819/),min,1 to 2,66386,DB00741,Hydrocortisone
,11361050,absolute bioavailability,Only a very small part of the rectal dose (100 mg) was absorbed; the mean absolute bioavailability was 3.1% in healthy volunteers and 4.5% in patients.,Pharmacokinetics and rectal bioavailability of hydrocortisone acetate after single and multiple administration in healthy subjects and patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11361050/),%,3.1,68024,DB00741,Hydrocortisone
,11361050,absolute bioavailability,Only a very small part of the rectal dose (100 mg) was absorbed; the mean absolute bioavailability was 3.1% in healthy volunteers and 4.5% in patients.,Pharmacokinetics and rectal bioavailability of hydrocortisone acetate after single and multiple administration in healthy subjects and patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11361050/),%,4.5,68025,DB00741,Hydrocortisone
,28012176,terminal t1/2,"Following multiple doses of UE2343, plasma levels were approximately dose proportional and the terminal t1/2 ranged from 10 to 14 h.",Selection and early clinical evaluation of the brain-penetrant 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor UE2343 (Xanamem™). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28012176/),h,10 to 14,68583,DB00741,Hydrocortisone
,22893258,peak cortisol (C(max)),"In the patients, cortisol exposure was significantly higher than in controls: median inter-quartile range (IQR) peak cortisol (C(max)) 174.5 (59.3-837.0) vs. 6.50 (4.7-19.3) nmol/l, p=0.0001; area under the curve (AUC) 390.1 (177.1-928.9) vs. 21.4 (14.6-28.4) minutes*nmol/l, p=0.0001, trough cortisol level (C(min)) 0.49 (0.49-0.96) vs. 0.49 (0.49-0.49) nmol/l, p=0.02, occurring at 480.0 (0.1-660.0) vs. 405.0 (180.0-570.0) min, p=0.56.",Salivary cortisol day curves in Addison's disease in patients on hydrocortisone replacement. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22893258/),[nM] / [l],174.5,71330,DB00741,Hydrocortisone
,22893258,peak cortisol (C(max)),"In the patients, cortisol exposure was significantly higher than in controls: median inter-quartile range (IQR) peak cortisol (C(max)) 174.5 (59.3-837.0) vs. 6.50 (4.7-19.3) nmol/l, p=0.0001; area under the curve (AUC) 390.1 (177.1-928.9) vs. 21.4 (14.6-28.4) minutes*nmol/l, p=0.0001, trough cortisol level (C(min)) 0.49 (0.49-0.96) vs. 0.49 (0.49-0.49) nmol/l, p=0.02, occurring at 480.0 (0.1-660.0) vs. 405.0 (180.0-570.0) min, p=0.56.",Salivary cortisol day curves in Addison's disease in patients on hydrocortisone replacement. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22893258/),[nM] / [l],6.50,71331,DB00741,Hydrocortisone
,22893258,area under the curve (AUC),"In the patients, cortisol exposure was significantly higher than in controls: median inter-quartile range (IQR) peak cortisol (C(max)) 174.5 (59.3-837.0) vs. 6.50 (4.7-19.3) nmol/l, p=0.0001; area under the curve (AUC) 390.1 (177.1-928.9) vs. 21.4 (14.6-28.4) minutes*nmol/l, p=0.0001, trough cortisol level (C(min)) 0.49 (0.49-0.96) vs. 0.49 (0.49-0.49) nmol/l, p=0.02, occurring at 480.0 (0.1-660.0) vs. 405.0 (180.0-570.0) min, p=0.56.",Salivary cortisol day curves in Addison's disease in patients on hydrocortisone replacement. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22893258/),[min·nM] / [l],390.1,71332,DB00741,Hydrocortisone
,22893258,area under the curve (AUC),"In the patients, cortisol exposure was significantly higher than in controls: median inter-quartile range (IQR) peak cortisol (C(max)) 174.5 (59.3-837.0) vs. 6.50 (4.7-19.3) nmol/l, p=0.0001; area under the curve (AUC) 390.1 (177.1-928.9) vs. 21.4 (14.6-28.4) minutes*nmol/l, p=0.0001, trough cortisol level (C(min)) 0.49 (0.49-0.96) vs. 0.49 (0.49-0.49) nmol/l, p=0.02, occurring at 480.0 (0.1-660.0) vs. 405.0 (180.0-570.0) min, p=0.56.",Salivary cortisol day curves in Addison's disease in patients on hydrocortisone replacement. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22893258/),[min·nM] / [l],21.4,71333,DB00741,Hydrocortisone
,22893258,trough cortisol level (C(min)),"In the patients, cortisol exposure was significantly higher than in controls: median inter-quartile range (IQR) peak cortisol (C(max)) 174.5 (59.3-837.0) vs. 6.50 (4.7-19.3) nmol/l, p=0.0001; area under the curve (AUC) 390.1 (177.1-928.9) vs. 21.4 (14.6-28.4) minutes*nmol/l, p=0.0001, trough cortisol level (C(min)) 0.49 (0.49-0.96) vs. 0.49 (0.49-0.49) nmol/l, p=0.02, occurring at 480.0 (0.1-660.0) vs. 405.0 (180.0-570.0) min, p=0.56.",Salivary cortisol day curves in Addison's disease in patients on hydrocortisone replacement. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22893258/),[nM] / [l],0.49,71334,DB00741,Hydrocortisone
,22893258,trough cortisol level (C(min)),"In the patients, cortisol exposure was significantly higher than in controls: median inter-quartile range (IQR) peak cortisol (C(max)) 174.5 (59.3-837.0) vs. 6.50 (4.7-19.3) nmol/l, p=0.0001; area under the curve (AUC) 390.1 (177.1-928.9) vs. 21.4 (14.6-28.4) minutes*nmol/l, p=0.0001, trough cortisol level (C(min)) 0.49 (0.49-0.96) vs. 0.49 (0.49-0.49) nmol/l, p=0.02, occurring at 480.0 (0.1-660.0) vs. 405.0 (180.0-570.0) min, p=0.56.",Salivary cortisol day curves in Addison's disease in patients on hydrocortisone replacement. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22893258/),[nM] / [l],0.49,71335,DB00741,Hydrocortisone
,22893258,trough cortisol level (C(min)),"In the patients, cortisol exposure was significantly higher than in controls: median inter-quartile range (IQR) peak cortisol (C(max)) 174.5 (59.3-837.0) vs. 6.50 (4.7-19.3) nmol/l, p=0.0001; area under the curve (AUC) 390.1 (177.1-928.9) vs. 21.4 (14.6-28.4) minutes*nmol/l, p=0.0001, trough cortisol level (C(min)) 0.49 (0.49-0.96) vs. 0.49 (0.49-0.49) nmol/l, p=0.02, occurring at 480.0 (0.1-660.0) vs. 405.0 (180.0-570.0) min, p=0.56.",Salivary cortisol day curves in Addison's disease in patients on hydrocortisone replacement. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22893258/),,405,71336,DB00741,Hydrocortisone
,22893258,First peak cortisol,"First peak cortisol was 174.5 (53.0-754.7) vs. 6.27 (3.90-8.47) nmol/l, p=0.0001 and second peak cortisol 18.90 (5.22-76.9) vs. 3.12 (1.76-4.79) nmol/l, p=0.0001.",Salivary cortisol day curves in Addison's disease in patients on hydrocortisone replacement. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22893258/),[nM] / [l],174.5,71337,DB00741,Hydrocortisone
,22893258,First peak cortisol,"First peak cortisol was 174.5 (53.0-754.7) vs. 6.27 (3.90-8.47) nmol/l, p=0.0001 and second peak cortisol 18.90 (5.22-76.9) vs. 3.12 (1.76-4.79) nmol/l, p=0.0001.",Salivary cortisol day curves in Addison's disease in patients on hydrocortisone replacement. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22893258/),[nM] / [l],6.27,71338,DB00741,Hydrocortisone
,22893258,second peak cortisol,"First peak cortisol was 174.5 (53.0-754.7) vs. 6.27 (3.90-8.47) nmol/l, p=0.0001 and second peak cortisol 18.90 (5.22-76.9) vs. 3.12 (1.76-4.79) nmol/l, p=0.0001.",Salivary cortisol day curves in Addison's disease in patients on hydrocortisone replacement. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22893258/),[nM] / [l],18.90,71339,DB00741,Hydrocortisone
,22893258,second peak cortisol,"First peak cortisol was 174.5 (53.0-754.7) vs. 6.27 (3.90-8.47) nmol/l, p=0.0001 and second peak cortisol 18.90 (5.22-76.9) vs. 3.12 (1.76-4.79) nmol/l, p=0.0001.",Salivary cortisol day curves in Addison's disease in patients on hydrocortisone replacement. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22893258/),[nM] / [l],3.12,71340,DB00741,Hydrocortisone
,22893258,time to first peak cortisol,"The time to first peak cortisol differed between the 2 groups, 30 (30-75) vs. 0.1 (0.1-30) minutes; p=0.0001.",Salivary cortisol day curves in Addison's disease in patients on hydrocortisone replacement. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22893258/),min,30,71341,DB00741,Hydrocortisone
,22893258,time to first peak cortisol,"The time to first peak cortisol differed between the 2 groups, 30 (30-75) vs. 0.1 (0.1-30) minutes; p=0.0001.",Salivary cortisol day curves in Addison's disease in patients on hydrocortisone replacement. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22893258/),min,0.1,71342,DB00741,Hydrocortisone
,12492736,AUC0-24 h,Systemic exposure to budesonide (AUC0-24 h) after 1 week of oral administration was 41 +/- 21 nmol/L x h (mean +/- s.d.) in children and 35 +/- 20 nmol/L x h in adults.,Pharmacokinetics of budesonide controlled ileal release capsules in children and adults with active Crohn's disease. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492736/),[nM] / [h·l],41,71529,DB00741,Hydrocortisone
,12492736,AUC0-24 h,Systemic exposure to budesonide (AUC0-24 h) after 1 week of oral administration was 41 +/- 21 nmol/L x h (mean +/- s.d.) in children and 35 +/- 20 nmol/L x h in adults.,Pharmacokinetics of budesonide controlled ileal release capsules in children and adults with active Crohn's disease. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492736/),[nM] / [h·l],35,71530,DB00741,Hydrocortisone
,12492736,systemic availability,The estimated systemic availability in children was 9 +/- 5% and in adults 11 +/- 7%.,Pharmacokinetics of budesonide controlled ileal release capsules in children and adults with active Crohn's disease. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492736/),%,9,71531,DB00741,Hydrocortisone
,12492736,systemic availability,The estimated systemic availability in children was 9 +/- 5% and in adults 11 +/- 7%.,Pharmacokinetics of budesonide controlled ileal release capsules in children and adults with active Crohn's disease. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492736/),%,11,71532,DB00741,Hydrocortisone
,17088419,tmax,"Kinetic analysis of both the preparations demonstrated rapid absorption (tmax, 0.6-1.5 h) and low maximum plasma concentrations (peak Cmax, 2.99-5.51 nmol/l) of the steroids; indeed, the terminal half-life of TAA-DHP (13.9 +/- 1.3 h) was very much shorter than that of TAA (125.9 +/- 15.8 h).",Comparison of the hypothalamic-pituitary-adrenal axis susceptibility upon single-dose i.m. depot versus long-acting i.v. triamcinolone acetonide therapy: a direct pharmacokinetic correlation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17088419/),h,0.6-1.5,72211,DB00741,Hydrocortisone
,17088419,maximum,"Kinetic analysis of both the preparations demonstrated rapid absorption (tmax, 0.6-1.5 h) and low maximum plasma concentrations (peak Cmax, 2.99-5.51 nmol/l) of the steroids; indeed, the terminal half-life of TAA-DHP (13.9 +/- 1.3 h) was very much shorter than that of TAA (125.9 +/- 15.8 h).",Comparison of the hypothalamic-pituitary-adrenal axis susceptibility upon single-dose i.m. depot versus long-acting i.v. triamcinolone acetonide therapy: a direct pharmacokinetic correlation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17088419/),[nM] / [l],2.99-5.51,72212,DB00741,Hydrocortisone
,17088419,terminal half-life,"Kinetic analysis of both the preparations demonstrated rapid absorption (tmax, 0.6-1.5 h) and low maximum plasma concentrations (peak Cmax, 2.99-5.51 nmol/l) of the steroids; indeed, the terminal half-life of TAA-DHP (13.9 +/- 1.3 h) was very much shorter than that of TAA (125.9 +/- 15.8 h).",Comparison of the hypothalamic-pituitary-adrenal axis susceptibility upon single-dose i.m. depot versus long-acting i.v. triamcinolone acetonide therapy: a direct pharmacokinetic correlation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17088419/),h,13.9,72213,DB00741,Hydrocortisone
,17088419,terminal half-life,"Kinetic analysis of both the preparations demonstrated rapid absorption (tmax, 0.6-1.5 h) and low maximum plasma concentrations (peak Cmax, 2.99-5.51 nmol/l) of the steroids; indeed, the terminal half-life of TAA-DHP (13.9 +/- 1.3 h) was very much shorter than that of TAA (125.9 +/- 15.8 h).",Comparison of the hypothalamic-pituitary-adrenal axis susceptibility upon single-dose i.m. depot versus long-acting i.v. triamcinolone acetonide therapy: a direct pharmacokinetic correlation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17088419/),h,125.9,72214,DB00741,Hydrocortisone
,17088419,mean residence time,"In addition, the mean residence time differed very much (11 vs 160 h for TAA-DHP and TAA respectively), in line with a delayed elimination of the depot compared with the long-acting formulation.",Comparison of the hypothalamic-pituitary-adrenal axis susceptibility upon single-dose i.m. depot versus long-acting i.v. triamcinolone acetonide therapy: a direct pharmacokinetic correlation. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17088419/),h,11,72215,DB00741,Hydrocortisone
,17088419,mean residence time,"In addition, the mean residence time differed very much (11 vs 160 h for TAA-DHP and TAA respectively), in line with a delayed elimination of the depot compared with the long-acting formulation.",Comparison of the hypothalamic-pituitary-adrenal axis susceptibility upon single-dose i.m. depot versus long-acting i.v. triamcinolone acetonide therapy: a direct pharmacokinetic correlation. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17088419/),h,160,72216,DB00741,Hydrocortisone
,1190711,half-life,"The half-life of cortisol is significantly shortened in hyperthyroidism, as compared to normal subjects (49,5 +/- 6,6 min vs 68,3 +/- 10,5 min) and metabolic clearance rate is increased (418,5 +/- 89,5 L/24 h vs 237,5 +/- 48,5 L/24 h, for normal subjects).","[Proceeding: Production rate, metabolic clearance rate and mean plasma concentration of cortisol in hyperthyroidism (author's transl)]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1190711/),min,"49,5",73351,DB00741,Hydrocortisone
,1190711,half-life,"The half-life of cortisol is significantly shortened in hyperthyroidism, as compared to normal subjects (49,5 +/- 6,6 min vs 68,3 +/- 10,5 min) and metabolic clearance rate is increased (418,5 +/- 89,5 L/24 h vs 237,5 +/- 48,5 L/24 h, for normal subjects).","[Proceeding: Production rate, metabolic clearance rate and mean plasma concentration of cortisol in hyperthyroidism (author's transl)]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1190711/),min,"68,3",73352,DB00741,Hydrocortisone
,1190711,metabolic clearance rate,"The half-life of cortisol is significantly shortened in hyperthyroidism, as compared to normal subjects (49,5 +/- 6,6 min vs 68,3 +/- 10,5 min) and metabolic clearance rate is increased (418,5 +/- 89,5 L/24 h vs 237,5 +/- 48,5 L/24 h, for normal subjects).","[Proceeding: Production rate, metabolic clearance rate and mean plasma concentration of cortisol in hyperthyroidism (author's transl)]. ",CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1190711/),[l] / [24·h],"418,5",73353,DB00741,Hydrocortisone
,1190711,metabolic clearance rate,"The half-life of cortisol is significantly shortened in hyperthyroidism, as compared to normal subjects (49,5 +/- 6,6 min vs 68,3 +/- 10,5 min) and metabolic clearance rate is increased (418,5 +/- 89,5 L/24 h vs 237,5 +/- 48,5 L/24 h, for normal subjects).","[Proceeding: Production rate, metabolic clearance rate and mean plasma concentration of cortisol in hyperthyroidism (author's transl)]. ",CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1190711/),[l] / [24·h],"237,5",73354,DB00741,Hydrocortisone
,1190711,production rate,"The production rate of cortisol, calculated from specific and cumulate activities of THE and THF is increased in hyperthyroidism expressed as mg/24 h or mg/m2/24 h (respectively : 26,7 +/- 7,8 mg/24 h vs 15,7 +/- 3 mg/24 h and 16,9 +/- 4,6 mg/m2/24 h vs 9,5 +/- 1,8 mg/m2/24 h).","[Proceeding: Production rate, metabolic clearance rate and mean plasma concentration of cortisol in hyperthyroidism (author's transl)]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1190711/),[mg] / [24·h],"26,7",73355,DB00741,Hydrocortisone
,1190711,production rate,"The production rate of cortisol, calculated from specific and cumulate activities of THE and THF is increased in hyperthyroidism expressed as mg/24 h or mg/m2/24 h (respectively : 26,7 +/- 7,8 mg/24 h vs 15,7 +/- 3 mg/24 h and 16,9 +/- 4,6 mg/m2/24 h vs 9,5 +/- 1,8 mg/m2/24 h).","[Proceeding: Production rate, metabolic clearance rate and mean plasma concentration of cortisol in hyperthyroidism (author's transl)]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1190711/),[mg] / [24·h],"15,7",73356,DB00741,Hydrocortisone
,1190711,production rate,"The production rate of cortisol, calculated from specific and cumulate activities of THE and THF is increased in hyperthyroidism expressed as mg/24 h or mg/m2/24 h (respectively : 26,7 +/- 7,8 mg/24 h vs 15,7 +/- 3 mg/24 h and 16,9 +/- 4,6 mg/m2/24 h vs 9,5 +/- 1,8 mg/m2/24 h).","[Proceeding: Production rate, metabolic clearance rate and mean plasma concentration of cortisol in hyperthyroidism (author's transl)]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1190711/),[mg] / [24·h·m2],"16,9",73357,DB00741,Hydrocortisone
,1190711,production rate,"The production rate of cortisol, calculated from specific and cumulate activities of THE and THF is increased in hyperthyroidism expressed as mg/24 h or mg/m2/24 h (respectively : 26,7 +/- 7,8 mg/24 h vs 15,7 +/- 3 mg/24 h and 16,9 +/- 4,6 mg/m2/24 h vs 9,5 +/- 1,8 mg/m2/24 h).","[Proceeding: Production rate, metabolic clearance rate and mean plasma concentration of cortisol in hyperthyroidism (author's transl)]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1190711/),[mg] / [24·h·m2],"9,5",73358,DB00741,Hydrocortisone
,1190711,mean,"The mean plasma concentration, calculated as the radio (see article) is not statiscally different in hyperthyroid and normal subjects (6,8 +/- 2,1 microg/100 ml vs 7,3 +/- 1,9 microg/100 ml).","[Proceeding: Production rate, metabolic clearance rate and mean plasma concentration of cortisol in hyperthyroidism (author's transl)]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1190711/),[μg] / [100·ml],"6,8",73359,DB00741,Hydrocortisone
,1190711,plasma concentration,"The mean plasma concentration, calculated as the radio (see article) is not statiscally different in hyperthyroid and normal subjects (6,8 +/- 2,1 microg/100 ml vs 7,3 +/- 1,9 microg/100 ml).","[Proceeding: Production rate, metabolic clearance rate and mean plasma concentration of cortisol in hyperthyroidism (author's transl)]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1190711/),[μg] / [100·ml],"6,8",73360,DB00741,Hydrocortisone
,1190711,plasma concentration,"The mean plasma concentration, calculated as the radio (see article) is not statiscally different in hyperthyroid and normal subjects (6,8 +/- 2,1 microg/100 ml vs 7,3 +/- 1,9 microg/100 ml).","[Proceeding: Production rate, metabolic clearance rate and mean plasma concentration of cortisol in hyperthyroidism (author's transl)]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1190711/),[μg] / [100],"7,3",73361,DB00741,Hydrocortisone
,1190711,T 1/2,"All the values were normalized, without statistically significant difference from control (T 1/2 = 65,4 +/- 18 min, Metb Cl. Rate : 255 +/- 64,5 L/24 h, production rate : 15,6 +/- 1,8 mg/24 h and 9 +/- 1,4 mg/m2/24 h. mean plasma concentration : 6,8 +/- 2,8 microg/100 ml).","[Proceeding: Production rate, metabolic clearance rate and mean plasma concentration of cortisol in hyperthyroidism (author's transl)]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1190711/),min,"65,4",73362,DB00741,Hydrocortisone
,1190711,Cl. Rate,"All the values were normalized, without statistically significant difference from control (T 1/2 = 65,4 +/- 18 min, Metb Cl. Rate : 255 +/- 64,5 L/24 h, production rate : 15,6 +/- 1,8 mg/24 h and 9 +/- 1,4 mg/m2/24 h. mean plasma concentration : 6,8 +/- 2,8 microg/100 ml).","[Proceeding: Production rate, metabolic clearance rate and mean plasma concentration of cortisol in hyperthyroidism (author's transl)]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1190711/),[l] / [24·h],255,73363,DB00741,Hydrocortisone
,1190711,production rate,"All the values were normalized, without statistically significant difference from control (T 1/2 = 65,4 +/- 18 min, Metb Cl. Rate : 255 +/- 64,5 L/24 h, production rate : 15,6 +/- 1,8 mg/24 h and 9 +/- 1,4 mg/m2/24 h. mean plasma concentration : 6,8 +/- 2,8 microg/100 ml).","[Proceeding: Production rate, metabolic clearance rate and mean plasma concentration of cortisol in hyperthyroidism (author's transl)]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1190711/),[mg] / [24·h],"15,6",73364,DB00741,Hydrocortisone
,1190711,production rate,"All the values were normalized, without statistically significant difference from control (T 1/2 = 65,4 +/- 18 min, Metb Cl. Rate : 255 +/- 64,5 L/24 h, production rate : 15,6 +/- 1,8 mg/24 h and 9 +/- 1,4 mg/m2/24 h. mean plasma concentration : 6,8 +/- 2,8 microg/100 ml).","[Proceeding: Production rate, metabolic clearance rate and mean plasma concentration of cortisol in hyperthyroidism (author's transl)]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1190711/),[mg] / [24·h·m2],9,73365,DB00741,Hydrocortisone
,1190711,mean plasma concentration,"All the values were normalized, without statistically significant difference from control (T 1/2 = 65,4 +/- 18 min, Metb Cl. Rate : 255 +/- 64,5 L/24 h, production rate : 15,6 +/- 1,8 mg/24 h and 9 +/- 1,4 mg/m2/24 h. mean plasma concentration : 6,8 +/- 2,8 microg/100 ml).","[Proceeding: Production rate, metabolic clearance rate and mean plasma concentration of cortisol in hyperthyroidism (author's transl)]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1190711/),[μg] / [100·ml],"6,8",73366,DB00741,Hydrocortisone
,2050835,total body clearance,"After IV administration, hydrocortisone was eliminated with a total body clearance of 18 L/hr and a half-life of 1.7 hr.",Pharmacokinetics and oral bioavailability of hydrocortisone. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2050835/),[l] / [h],18,73407,DB00741,Hydrocortisone
,2050835,half-life,"After IV administration, hydrocortisone was eliminated with a total body clearance of 18 L/hr and a half-life of 1.7 hr.",Pharmacokinetics and oral bioavailability of hydrocortisone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2050835/),h,1.7,73408,DB00741,Hydrocortisone
,2050835,volume of distribution,The volume of distribution was 34 L. Oral bioavailability averaged 96%.,Pharmacokinetics and oral bioavailability of hydrocortisone. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2050835/),l,34,73409,DB00741,Hydrocortisone
,2050835,Oral bioavailability,The volume of distribution was 34 L. Oral bioavailability averaged 96%.,Pharmacokinetics and oral bioavailability of hydrocortisone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2050835/),%,96,73410,DB00741,Hydrocortisone
,2050835,maximum hydro,"Absorption was rapid, achieving maximum hydrocortisone levels of 300 ng/mL after 1 hour.",Pharmacokinetics and oral bioavailability of hydrocortisone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2050835/),[ng] / [ml],300,73411,DB00741,Hydrocortisone
,15867239,maximum tolerated dose,The maximum tolerated dose was 295 mg/m2.,"Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15867239/),[mg] / [m2],295,74380,DB00741,Hydrocortisone
,10919683,peak expiratory flow (PEF),"The improvement in mean morning peak expiratory flow (PEF) after 7 days of treatment was approximately 12 l min(-1) in both groups, rising to approximately 22 l min(-1) at the end of the 4-week treatment period.",Clinical efficacy and safety of fluticasone propionate 250 microg twice daily administered via a HFA 134a pressurized metered dose inhaler to patients with mild to moderate asthma. French study group. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10919683/),[l] / [min],12,75309,DB00741,Hydrocortisone
,10919683,peak expiratory flow (PEF),"The improvement in mean morning peak expiratory flow (PEF) after 7 days of treatment was approximately 12 l min(-1) in both groups, rising to approximately 22 l min(-1) at the end of the 4-week treatment period.",Clinical efficacy and safety of fluticasone propionate 250 microg twice daily administered via a HFA 134a pressurized metered dose inhaler to patients with mild to moderate asthma. French study group. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10919683/),[l] / [min],22,75310,DB00741,Hydrocortisone
,2142929,maximum EE2,Mean maximum EE2 levels of 106-129 pg/ml were found 1.6-1.8 h after pill intake and AUC0-4 h accounted for 329-374 pg.h.ml-1.,"Comparison of serum ethinyl estradiol, sex-hormone-binding globulin, corticoid-binding globulin and cortisol levels in women using two low-dose combined oral contraceptives. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2142929/),[pg] / [ml],106-129,75399,DB00741,Hydrocortisone
,2142929,AUC0-4 h,Mean maximum EE2 levels of 106-129 pg/ml were found 1.6-1.8 h after pill intake and AUC0-4 h accounted for 329-374 pg.h.ml-1.,"Comparison of serum ethinyl estradiol, sex-hormone-binding globulin, corticoid-binding globulin and cortisol levels in women using two low-dose combined oral contraceptives. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2142929/),[h·pg] / [ml],329-374,75400,DB00741,Hydrocortisone
,8894119,accumulation ratio,"The accumulation ratio, based on repeated-dose/single-dose ratios of Cmax, AUC(0-12 h), and C(12 h) was approximately two.",Pharmacokinetics of reboxetine in healthy volunteers. Single against repeated oral doses and lack of enzymatic alterations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8894119/),,two,75976,DB00741,Hydrocortisone
,8257135,urinary output,The extent of hepatic enzyme induction by rifampin was confirmed by a significant increase of 6-beta-hydroxycortisol urinary output from 160.8 +/- 41.4 to 544.8 +/- 120.7 micrograms/4 h.,Influence of rifampin on fleroxacin pharmacokinetics. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257135/),[μg] / [4·h],160.8,76179,DB00741,Hydrocortisone
,8257135,urinary output,The extent of hepatic enzyme induction by rifampin was confirmed by a significant increase of 6-beta-hydroxycortisol urinary output from 160.8 +/- 41.4 to 544.8 +/- 120.7 micrograms/4 h.,Influence of rifampin on fleroxacin pharmacokinetics. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257135/),[μg] / [4·h],544.8,76180,DB00741,Hydrocortisone
,8257135,peak fleroxacin concentration,"There were no significant changes in the peak fleroxacin concentration in plasma (6.3 +/- 1.2 versus 6.2 +/- 1.9 mg/liter), time to maximum concentration of fleroxacin in plasma (1.1 +/- 0.9 versus 1.3 +/- 1.1 h), or renal clearance (58.3 +/- 16.4 versus 61.9 +/- 19.2 ml/min).",Influence of rifampin on fleroxacin pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257135/),[mg] / [l],6.3,76181,DB00741,Hydrocortisone
,8257135,peak fleroxacin concentration,"There were no significant changes in the peak fleroxacin concentration in plasma (6.3 +/- 1.2 versus 6.2 +/- 1.9 mg/liter), time to maximum concentration of fleroxacin in plasma (1.1 +/- 0.9 versus 1.3 +/- 1.1 h), or renal clearance (58.3 +/- 16.4 versus 61.9 +/- 19.2 ml/min).",Influence of rifampin on fleroxacin pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257135/),[mg] / [l],6.2,76182,DB00741,Hydrocortisone
,8257135,time to maximum concentration,"There were no significant changes in the peak fleroxacin concentration in plasma (6.3 +/- 1.2 versus 6.2 +/- 1.9 mg/liter), time to maximum concentration of fleroxacin in plasma (1.1 +/- 0.9 versus 1.3 +/- 1.1 h), or renal clearance (58.3 +/- 16.4 versus 61.9 +/- 19.2 ml/min).",Influence of rifampin on fleroxacin pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257135/),h,1.1,76183,DB00741,Hydrocortisone
,8257135,time to maximum concentration,"There were no significant changes in the peak fleroxacin concentration in plasma (6.3 +/- 1.2 versus 6.2 +/- 1.9 mg/liter), time to maximum concentration of fleroxacin in plasma (1.1 +/- 0.9 versus 1.3 +/- 1.1 h), or renal clearance (58.3 +/- 16.4 versus 61.9 +/- 19.2 ml/min).",Influence of rifampin on fleroxacin pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257135/),h,1.3,76184,DB00741,Hydrocortisone
,8257135,renal clearance,"There were no significant changes in the peak fleroxacin concentration in plasma (6.3 +/- 1.2 versus 6.2 +/- 1.9 mg/liter), time to maximum concentration of fleroxacin in plasma (1.1 +/- 0.9 versus 1.3 +/- 1.1 h), or renal clearance (58.3 +/- 16.4 versus 61.9 +/- 19.2 ml/min).",Influence of rifampin on fleroxacin pharmacokinetics. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257135/),[ml] / [min],58.3,76185,DB00741,Hydrocortisone
,8257135,renal clearance,"There were no significant changes in the peak fleroxacin concentration in plasma (6.3 +/- 1.2 versus 6.2 +/- 1.9 mg/liter), time to maximum concentration of fleroxacin in plasma (1.1 +/- 0.9 versus 1.3 +/- 1.1 h), or renal clearance (58.3 +/- 16.4 versus 61.9 +/- 19.2 ml/min).",Influence of rifampin on fleroxacin pharmacokinetics. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257135/),[ml] / [min],61.9,76186,DB00741,Hydrocortisone
,8257135,area under the curve AUC,"The area under the curve AUC (71.4 +/- 15.8 versus 62.2 +/- 13.7 mg.h/liter) and the terminal half-life of fleroxacin (11.4 +/- 2.2 versus 9.2 +/- 1.1 h) decreased (P < 0.05), while the total plasma clearance increased from 97.7 +/- 21.6 to 112.3 +/- 25.8 ml/min (P < 0.01).",Influence of rifampin on fleroxacin pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257135/),[h·mg] / [l],71.4,76187,DB00741,Hydrocortisone
,8257135,area under the curve AUC,"The area under the curve AUC (71.4 +/- 15.8 versus 62.2 +/- 13.7 mg.h/liter) and the terminal half-life of fleroxacin (11.4 +/- 2.2 versus 9.2 +/- 1.1 h) decreased (P < 0.05), while the total plasma clearance increased from 97.7 +/- 21.6 to 112.3 +/- 25.8 ml/min (P < 0.01).",Influence of rifampin on fleroxacin pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257135/),[h·mg] / [l],62.2,76188,DB00741,Hydrocortisone
,8257135,terminal half-life,"The area under the curve AUC (71.4 +/- 15.8 versus 62.2 +/- 13.7 mg.h/liter) and the terminal half-life of fleroxacin (11.4 +/- 2.2 versus 9.2 +/- 1.1 h) decreased (P < 0.05), while the total plasma clearance increased from 97.7 +/- 21.6 to 112.3 +/- 25.8 ml/min (P < 0.01).",Influence of rifampin on fleroxacin pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257135/),h,11.4,76189,DB00741,Hydrocortisone
,8257135,terminal half-life,"The area under the curve AUC (71.4 +/- 15.8 versus 62.2 +/- 13.7 mg.h/liter) and the terminal half-life of fleroxacin (11.4 +/- 2.2 versus 9.2 +/- 1.1 h) decreased (P < 0.05), while the total plasma clearance increased from 97.7 +/- 21.6 to 112.3 +/- 25.8 ml/min (P < 0.01).",Influence of rifampin on fleroxacin pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257135/),h,9.2,76190,DB00741,Hydrocortisone
,8257135,total plasma clearance,"The area under the curve AUC (71.4 +/- 15.8 versus 62.2 +/- 13.7 mg.h/liter) and the terminal half-life of fleroxacin (11.4 +/- 2.2 versus 9.2 +/- 1.1 h) decreased (P < 0.05), while the total plasma clearance increased from 97.7 +/- 21.6 to 112.3 +/- 25.8 ml/min (P < 0.01).",Influence of rifampin on fleroxacin pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257135/),[ml] / [min],97.7,76191,DB00741,Hydrocortisone
,8257135,total plasma clearance,"The area under the curve AUC (71.4 +/- 15.8 versus 62.2 +/- 13.7 mg.h/liter) and the terminal half-life of fleroxacin (11.4 +/- 2.2 versus 9.2 +/- 1.1 h) decreased (P < 0.05), while the total plasma clearance increased from 97.7 +/- 21.6 to 112.3 +/- 25.8 ml/min (P < 0.01).",Influence of rifampin on fleroxacin pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257135/),[ml] / [min],112.3,76192,DB00741,Hydrocortisone
,8257135,Metabolic clearance,"Metabolic clearance by N demethylation was increased ( 6.9 +/- 2.4 versus 12.5 +/- 3.2 ml/min; P < 0.01), whereas clearance by N oxidation did not change (5.8 +/- 1.1 versus 5.8 +/- 1.5 ml/min).",Influence of rifampin on fleroxacin pharmacokinetics. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257135/),[ml] / [min],6.9,76193,DB00741,Hydrocortisone
,8257135,Metabolic clearance,"Metabolic clearance by N demethylation was increased ( 6.9 +/- 2.4 versus 12.5 +/- 3.2 ml/min; P < 0.01), whereas clearance by N oxidation did not change (5.8 +/- 1.1 versus 5.8 +/- 1.5 ml/min).",Influence of rifampin on fleroxacin pharmacokinetics. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257135/),[ml] / [min],12.5,76194,DB00741,Hydrocortisone
,8257135,clearance,"Metabolic clearance by N demethylation was increased ( 6.9 +/- 2.4 versus 12.5 +/- 3.2 ml/min; P < 0.01), whereas clearance by N oxidation did not change (5.8 +/- 1.1 versus 5.8 +/- 1.5 ml/min).",Influence of rifampin on fleroxacin pharmacokinetics. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257135/),[ml] / [min],5.8,76195,DB00741,Hydrocortisone
,8257135,clearance,"Metabolic clearance by N demethylation was increased ( 6.9 +/- 2.4 versus 12.5 +/- 3.2 ml/min; P < 0.01), whereas clearance by N oxidation did not change (5.8 +/- 1.1 versus 5.8 +/- 1.5 ml/min).",Influence of rifampin on fleroxacin pharmacokinetics. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257135/),[ml] / [min],5.8,76196,DB00741,Hydrocortisone
,8077339,peak GH,"Dose-dependent GH secretion was observed with a threshold dose of 0.05 mg/kg (4 of 6 subjects responded with peak GH > 7 micrograms/L), and 0.2 mg/kg produced a response in all 14 subjects tested (mean +/- SE peak GH, 41.0 +/- 6.3 micrograms/L).","Growth hormone response in man to L-692,429, a novel nonpeptide mimic of growth hormone-releasing peptide-6. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8077339/),[μg] / [l],41.0,77714,DB00741,Hydrocortisone
,8077339,peak GH,"The maximum dose of 1.0 mg/kg L-692,429 resulted in a pronounced GH response (peak GH, 82.5 +/- 14.9 micrograms/L; n = 8).","Growth hormone response in man to L-692,429, a novel nonpeptide mimic of growth hormone-releasing peptide-6. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8077339/),[μg] / [l],82.5,77715,DB00741,Hydrocortisone
,8077339,peak PRL,"Small transient increases in cortical and PRL were observed (increases in cortical averaged 182.1 +/- 33.1 nmol/L and peak PRL was 21 +/- 2.6 micrograms/L after 1.0 mg/kg L-692,429, respectively), whereas no significant changes occurred in LH, FSH, TSH, insulin, or glucose concentrations.","Growth hormone response in man to L-692,429, a novel nonpeptide mimic of growth hormone-releasing peptide-6. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8077339/),[μg] / [l],21,77716,DB00741,Hydrocortisone
,8077339,half-life,"Plasma pharmacokinetic analysis revealed dose-related increases in plasma concentrations of L-692,429 and a half-life of 3.8 +/- 0.2 (+/- SE) h, a plasma clearance of 214 +/- 67 mL/min, and a steady state volume of distribution of 14.2 +/- 4.8 L.","Growth hormone response in man to L-692,429, a novel nonpeptide mimic of growth hormone-releasing peptide-6. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8077339/),h,3.8,77717,DB00741,Hydrocortisone
,8077339,plasma clearance,"Plasma pharmacokinetic analysis revealed dose-related increases in plasma concentrations of L-692,429 and a half-life of 3.8 +/- 0.2 (+/- SE) h, a plasma clearance of 214 +/- 67 mL/min, and a steady state volume of distribution of 14.2 +/- 4.8 L.","Growth hormone response in man to L-692,429, a novel nonpeptide mimic of growth hormone-releasing peptide-6. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8077339/),[ml] / [min],214,77718,DB00741,Hydrocortisone
,8077339,steady state volume of distribution,"Plasma pharmacokinetic analysis revealed dose-related increases in plasma concentrations of L-692,429 and a half-life of 3.8 +/- 0.2 (+/- SE) h, a plasma clearance of 214 +/- 67 mL/min, and a steady state volume of distribution of 14.2 +/- 4.8 L.","Growth hormone response in man to L-692,429, a novel nonpeptide mimic of growth hormone-releasing peptide-6. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8077339/),l,14.2,77719,DB00741,Hydrocortisone
,15838928,recovery,The recovery of the 21 GCC when spiked into blank plasma at 5 ng/mL was 45-200% with coefficient of variation (CV) from 0.3-18%.,Simultaneous analysis of twenty-one glucocorticoids in equine plasma by liquid chromatography/tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15838928/),%,45-200,77986,DB00741,Hydrocortisone
,15838928,limit of detection (LOD),"The limit of detection (LOD) and that of quantification (LOQ) for most of the analytes were 50-100 pg/mL and 1 ng/mL, respectively, whereas that of confirmation (LOC) was 100-300 pg/mL depending on the analyte.",Simultaneous analysis of twenty-one glucocorticoids in equine plasma by liquid chromatography/tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15838928/),[pg] / [ml],50-100,77987,DB00741,Hydrocortisone
,8930781,E50,The average E50 was 0.134 ng/mL for total FP concentrations and 0.013 ng/mL for unbound FP concentrations; these results were not dose dependent.,Dynamic modeling of cortisol reduction after inhaled administration of fluticasone propionate. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8930781/),[ng] / [ml],0.134,78139,DB00741,Hydrocortisone
,8930781,E50,The average E50 was 0.134 ng/mL for total FP concentrations and 0.013 ng/mL for unbound FP concentrations; these results were not dose dependent.,Dynamic modeling of cortisol reduction after inhaled administration of fluticasone propionate. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8930781/),[ng] / [ml],0.013,78140,DB00741,Hydrocortisone
,12393312,half-life,"Mean dexamethasone half-life decreased significantly from baseline of 1.92 h on day zero in seven rabbits to 1.17 h on experimental day 17 of induced hypercortisolemia (P < 0.001), while there was no significant change in saline treated controls (n = 3).",Hypercortisolemia decreases dexamethasone half-life in rabbit. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12393312/),h,1.92,78445,DB00741,Hydrocortisone
,12393312,half-life,"Mean dexamethasone half-life decreased significantly from baseline of 1.92 h on day zero in seven rabbits to 1.17 h on experimental day 17 of induced hypercortisolemia (P < 0.001), while there was no significant change in saline treated controls (n = 3).",Hypercortisolemia decreases dexamethasone half-life in rabbit. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12393312/),h,1.17,78446,DB00741,Hydrocortisone
,2319835,half-life,"Decrease of HC in plasma, and hence on plasma proteins, was monophasic from 30-270 min with a half-life of 116 min.",In vivo distribution of hydrocortisone over whole blood: a novel method for the extraction of erythrocytes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2319835/),min,116,80757,DB00741,Hydrocortisone
,6092407,MCR,The difference in duration of effect between hCRF and oCRF may be attributed to an approximately 3-4 times higher MCR of hCRF [7.9 +/- 1.2 (+/- SE) ml/kg min; n = 14] than oCRF (1.9 +/- 0.1 ml/kg min; n = 9) in man.,Human corticotropin-releasing factor in man: pharmacokinetic properties and dose-response of plasma adrenocorticotropin and cortisol secretion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6092407/),[ml] / [kg·min],7.9,82497,DB00741,Hydrocortisone
,6092407,MCR,The difference in duration of effect between hCRF and oCRF may be attributed to an approximately 3-4 times higher MCR of hCRF [7.9 +/- 1.2 (+/- SE) ml/kg min; n = 14] than oCRF (1.9 +/- 0.1 ml/kg min; n = 9) in man.,Human corticotropin-releasing factor in man: pharmacokinetic properties and dose-response of plasma adrenocorticotropin and cortisol secretion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6092407/),[ml] / [kg·min],1.9,82498,DB00741,Hydrocortisone
,3490855,peak time (tmax,The peak time (tmax = 2.04 +/- 0.85 h) and the plasma half-life (t1/2 = 1.53 +/- 0.52 h) were independent of the dose administered.,[Pharmacokinetics of fluocortolone in long term therapy of patients with rheumatic and hematologic diseases]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3490855/),h,2.04,82567,DB00741,Hydrocortisone
,3490855,plasma half-life (t1/2,The peak time (tmax = 2.04 +/- 0.85 h) and the plasma half-life (t1/2 = 1.53 +/- 0.52 h) were independent of the dose administered.,[Pharmacokinetics of fluocortolone in long term therapy of patients with rheumatic and hematologic diseases]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3490855/),h,1.53,82568,DB00741,Hydrocortisone
,124325,metabolic clearance rate,The metabolic clearance rate of progesterone from blood was 3-13 plus or minus 0-35 (S.E.M.) 1/min in ten experiments on six goats; values tended to be slightly higher in pregnant than in non-pregnant goats.,"Metabolic clearance rate, production rate and mammary uptake of progesterone in the goat. ",CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/124325/),[1] / [min],3-13,86668,DB00741,Hydrocortisone
less,124325,production rate,"The production rate of progesterone at oestrus, and at day 3 of the normal cycle, was less than 0-01 mug/min.","Metabolic clearance rate, production rate and mammary uptake of progesterone in the goat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/124325/),[μg] / [min],0-01,86669,DB00741,Hydrocortisone
,124325,production rate,"During the luteal phase of the oestrous cycle the production rate was 8-5 and 14-6 mug/min in 2 animals, and in the second half of pregnancy, 15-3 plus or minus 0-6 mug/min (5 animals).","Metabolic clearance rate, production rate and mammary uptake of progesterone in the goat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/124325/),[μg] / [min],8-5,86670,DB00741,Hydrocortisone
,124325,production rate,"During the luteal phase of the oestrous cycle the production rate was 8-5 and 14-6 mug/min in 2 animals, and in the second half of pregnancy, 15-3 plus or minus 0-6 mug/min (5 animals).","Metabolic clearance rate, production rate and mammary uptake of progesterone in the goat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/124325/),[μg] / [min],14-6,86671,DB00741,Hydrocortisone
,124325,production rate,"During the luteal phase of the oestrous cycle the production rate was 8-5 and 14-6 mug/min in 2 animals, and in the second half of pregnancy, 15-3 plus or minus 0-6 mug/min (5 animals).","Metabolic clearance rate, production rate and mammary uptake of progesterone in the goat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/124325/),[μg] / [min],15-3,86672,DB00741,Hydrocortisone
,124325,production rate,"During the luteal phase of the oestrous cycle the production rate was 8-5 and 14-6 mug/min in 2 animals, and in the second half of pregnancy, 15-3 plus or minus 0-6 mug/min (5 animals).","Metabolic clearance rate, production rate and mammary uptake of progesterone in the goat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/124325/),[μg] / [min],0-6,86673,DB00741,Hydrocortisone
,124325,clearance rate,"The mean clearance rate of progesterone by the udder was 0-279 1/min, 8-8% of the metabolic clearance rate.","Metabolic clearance rate, production rate and mammary uptake of progesterone in the goat. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/124325/),[1] / [min],0-279,86674,DB00741,Hydrocortisone
,124325,Mammary uptake,"Mammary uptake of progesterone in goats with an actively secreting corpus luteum was 0-64 plus or minus 0-29 mug/min, which gave an estimated value of 0-11-1-88 ng/min/g mammary gland.","Metabolic clearance rate, production rate and mammary uptake of progesterone in the goat. ",Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/124325/),[μg] / [min],0-64,86675,DB00741,Hydrocortisone
,124325,Mammary uptake,"Mammary uptake of progesterone in goats with an actively secreting corpus luteum was 0-64 plus or minus 0-29 mug/min, which gave an estimated value of 0-11-1-88 ng/min/g mammary gland.","Metabolic clearance rate, production rate and mammary uptake of progesterone in the goat. ",Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/124325/),[ng] / [g·min],0-11-1-88,86676,DB00741,Hydrocortisone
,1822210,t1/2,"These studies indicated that unbound hydrocortisone levels as determined by the RIA-linked microdialysis (RIALM) technique fluctuated rapidly between each 2-min sampling interval, but nevertheless decreased to predose endogenous concentrations in a first-order fashion (t1/2 = 17-29 min).",RIA-linked microdialysis sampling in the awake rat: application to free-drug pharmacokinetics of hydrocortisone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1822210/),min,17-29,87413,DB00741,Hydrocortisone
,9626121,area under the concentration-time curve (AUC) 0-12 h,"Oral administration of 50 mg DHEA led to restoration of DHEA(S) baseline levels, whereas 100 mg induced supraphysiological concentrations [baseline vs. 50 mg DHEA vs. 100 mg DHEA: area under the concentration-time curve (AUC) 0-12 h DHEA: 280 +/- 85 vs.",Oral dehydroepiandrosterone for adrenal androgen replacement: pharmacokinetics and peripheral conversion to androgens and estrogens in young healthy females after dexamethasone suppression. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9626121/),,280,87582,DB00741,Hydrocortisone
,9626121,AUC 0-12 h,383 +/- 106 nmol/L x h; AUC 0-12 h DHEA(S): 89.1 +/- 48.4 vs. 139.6 +/- 43.5 vs. 213.3 +/- 21.6 mumol/L x h).,Oral dehydroepiandrosterone for adrenal androgen replacement: pharmacokinetics and peripheral conversion to androgens and estrogens in young healthy females after dexamethasone suppression. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9626121/),[μM] / [h·l],89.1,87583,DB00741,Hydrocortisone
,9626121,AUC 0-12 h,383 +/- 106 nmol/L x h; AUC 0-12 h DHEA(S): 89.1 +/- 48.4 vs. 139.6 +/- 43.5 vs. 213.3 +/- 21.6 mumol/L x h).,Oral dehydroepiandrosterone for adrenal androgen replacement: pharmacokinetics and peripheral conversion to androgens and estrogens in young healthy females after dexamethasone suppression. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9626121/),[μM] / [h·l],139.6,87584,DB00741,Hydrocortisone
,9626121,AUC 0-12 h,383 +/- 106 nmol/L x h; AUC 0-12 h DHEA(S): 89.1 +/- 48.4 vs. 139.6 +/- 43.5 vs. 213.3 +/- 21.6 mumol/L x h).,Oral dehydroepiandrosterone for adrenal androgen replacement: pharmacokinetics and peripheral conversion to androgens and estrogens in young healthy females after dexamethasone suppression. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9626121/),[μM] / [h·l],213.3,87585,DB00741,Hydrocortisone
,1975199,elimination half-life,"Pharmacokinetic calculations revealed an elimination half-life of 1.7-2.0 h, an apparent volume of distribution of 3.0-3.5 l kg-1 and a total plasma clearance of 1.1-1.5 l h-1 kg-1.","Pharmacological effects and pharmacokinetics of atipamezole, a novel alpha 2-adrenoceptor antagonist--a randomized, double-blind cross-over study in healthy male volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1975199/),h,1.7-2.0,87894,DB00741,Hydrocortisone
,1975199,apparent volume of distribution,"Pharmacokinetic calculations revealed an elimination half-life of 1.7-2.0 h, an apparent volume of distribution of 3.0-3.5 l kg-1 and a total plasma clearance of 1.1-1.5 l h-1 kg-1.","Pharmacological effects and pharmacokinetics of atipamezole, a novel alpha 2-adrenoceptor antagonist--a randomized, double-blind cross-over study in healthy male volunteers. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1975199/),[l] / [kg],3.0-3.5,87895,DB00741,Hydrocortisone
,1975199,total plasma clearance,"Pharmacokinetic calculations revealed an elimination half-life of 1.7-2.0 h, an apparent volume of distribution of 3.0-3.5 l kg-1 and a total plasma clearance of 1.1-1.5 l h-1 kg-1.","Pharmacological effects and pharmacokinetics of atipamezole, a novel alpha 2-adrenoceptor antagonist--a randomized, double-blind cross-over study in healthy male volunteers. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1975199/),[l] / [h·kg],1.1-1.5,87896,DB00741,Hydrocortisone
,30080272,volume of distribution at steady state,"The volume of distribution at steady state, systemic clearance and elimination half-life was 5.90 ± 0.200 L/kg, 30.7 ± 0.166 mL/min/kg and 4.84 ± 0.83 h respectively.",Pharmacokinetics of intravenous flumetasone and effects on plasma hydrocortisone concentrations and inflammatory mediators in the horse. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30080272/),[l] / [kg],5.90,89618,DB00741,Hydrocortisone
,30080272,systemic clearance,"The volume of distribution at steady state, systemic clearance and elimination half-life was 5.90 ± 0.200 L/kg, 30.7 ± 0.166 mL/min/kg and 4.84 ± 0.83 h respectively.",Pharmacokinetics of intravenous flumetasone and effects on plasma hydrocortisone concentrations and inflammatory mediators in the horse. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30080272/),[ml] / [kg·min],30.7,89619,DB00741,Hydrocortisone
,30080272,elimination half-life,"The volume of distribution at steady state, systemic clearance and elimination half-life was 5.90 ± 0.200 L/kg, 30.7 ± 0.166 mL/min/kg and 4.84 ± 0.83 h respectively.",Pharmacokinetics of intravenous flumetasone and effects on plasma hydrocortisone concentrations and inflammatory mediators in the horse. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30080272/),h,4.84,89620,DB00741,Hydrocortisone
,30080272,Kin,"For cortisol, Kin , Kout and the t1/2out were 30.3 ± 1.56 ng/mL × h, 0.331 ± 0.02 1/h and 2.1 h respectively.",Pharmacokinetics of intravenous flumetasone and effects on plasma hydrocortisone concentrations and inflammatory mediators in the horse. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30080272/),[ng] / [h·ml],30.3,89621,DB00741,Hydrocortisone
,30080272,Kout,"For cortisol, Kin , Kout and the t1/2out were 30.3 ± 1.56 ng/mL × h, 0.331 ± 0.02 1/h and 2.1 h respectively.",Pharmacokinetics of intravenous flumetasone and effects on plasma hydrocortisone concentrations and inflammatory mediators in the horse. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30080272/),[1] / [h],0.331,89622,DB00741,Hydrocortisone
,30080272,t1/2out,"For cortisol, Kin , Kout and the t1/2out were 30.3 ± 1.56 ng/mL × h, 0.331 ± 0.02 1/h and 2.1 h respectively.",Pharmacokinetics of intravenous flumetasone and effects on plasma hydrocortisone concentrations and inflammatory mediators in the horse. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30080272/),h,2.1,89623,DB00741,Hydrocortisone
,19249257,flow-rate,The flow-rate was 1.00 ml/min.,Using total error concept for the validation of a liquid chromatography-tandem mass spectrometry method for the determination of budesonide epimers in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19249257/),[ml] / [min],1.00,90663,DB00741,Hydrocortisone
,19249257,m/z,"The MS/MS ion transitions monitored were m/z 489.3-->357.3 and 463.3-->403.2 for budesonide epimers and hydrocortisone, respectively.",Using total error concept for the validation of a liquid chromatography-tandem mass spectrometry method for the determination of budesonide epimers in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19249257/),,489.3,90664,DB00741,Hydrocortisone
,19249257,m/z,"The MS/MS ion transitions monitored were m/z 489.3-->357.3 and 463.3-->403.2 for budesonide epimers and hydrocortisone, respectively.",Using total error concept for the validation of a liquid chromatography-tandem mass spectrometry method for the determination of budesonide epimers in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19249257/),,357.3,90665,DB00741,Hydrocortisone
,19249257,m/z,"The MS/MS ion transitions monitored were m/z 489.3-->357.3 and 463.3-->403.2 for budesonide epimers and hydrocortisone, respectively.",Using total error concept for the validation of a liquid chromatography-tandem mass spectrometry method for the determination of budesonide epimers in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19249257/),,463.3,90666,DB00741,Hydrocortisone
,19249257,m/z,"The MS/MS ion transitions monitored were m/z 489.3-->357.3 and 463.3-->403.2 for budesonide epimers and hydrocortisone, respectively.",Using total error concept for the validation of a liquid chromatography-tandem mass spectrometry method for the determination of budesonide epimers in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19249257/),,403.2,90667,DB00741,Hydrocortisone
,7097506,Cmax,"Mean Cmax values of 199, 393, and 419 ng/ml were obtained at 1.0, 1.0, and 1.7 hr following the 10-, 30-, and 50-mg doses, respectively.",Oral hydrocortisone pharmacokinetics: a comparison of fluorescence and ultraviolet high-pressure liquid chromatographic assays for hydrocortisone in plasma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7097506/),[ng] / [ml],199,91037,DB00741,Hydrocortisone
,7097506,Cmax,"Mean Cmax values of 199, 393, and 419 ng/ml were obtained at 1.0, 1.0, and 1.7 hr following the 10-, 30-, and 50-mg doses, respectively.",Oral hydrocortisone pharmacokinetics: a comparison of fluorescence and ultraviolet high-pressure liquid chromatographic assays for hydrocortisone in plasma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7097506/),[ng] / [ml],393,91038,DB00741,Hydrocortisone
,7097506,Cmax,"Mean Cmax values of 199, 393, and 419 ng/ml were obtained at 1.0, 1.0, and 1.7 hr following the 10-, 30-, and 50-mg doses, respectively.",Oral hydrocortisone pharmacokinetics: a comparison of fluorescence and ultraviolet high-pressure liquid chromatographic assays for hydrocortisone in plasma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7097506/),[ng] / [ml],419,91039,DB00741,Hydrocortisone
,7097506,elimination half-life,Hydrocortisone was cleared from plasma with an elimination half-life of approximately 1.5 hr.,Oral hydrocortisone pharmacokinetics: a comparison of fluorescence and ultraviolet high-pressure liquid chromatographic assays for hydrocortisone in plasma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7097506/),h,1.5,91040,DB00741,Hydrocortisone
,8227476,clearance (CL),MPHS clearance (CL) was significantly reduced in the CLD group (495 vs. 1389 mL/hr/kg) whereas volume of distribution (Vss) of MPHS (about 0.35 1/kg) did not differ.,Pharmacokinetics of methylprednisolone hemisuccinate and methylprednisolone in chronic liver disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8227476/),[ml] / [h·kg],495,91971,DB00741,Hydrocortisone
,8227476,clearance (CL),MPHS clearance (CL) was significantly reduced in the CLD group (495 vs. 1389 mL/hr/kg) whereas volume of distribution (Vss) of MPHS (about 0.35 1/kg) did not differ.,Pharmacokinetics of methylprednisolone hemisuccinate and methylprednisolone in chronic liver disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8227476/),[ml] / [h·kg],1389,91972,DB00741,Hydrocortisone
,8227476,volume of distribution (Vss),MPHS clearance (CL) was significantly reduced in the CLD group (495 vs. 1389 mL/hr/kg) whereas volume of distribution (Vss) of MPHS (about 0.35 1/kg) did not differ.,Pharmacokinetics of methylprednisolone hemisuccinate and methylprednisolone in chronic liver disease. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8227476/),[1] / [kg],0.35,91973,DB00741,Hydrocortisone
,8227476,"elimination half-life, t1/2 beta","The elimination half-life, t1/2 beta, was significantly longer in CLD (0.61 vs. 0.32 hr).",Pharmacokinetics of methylprednisolone hemisuccinate and methylprednisolone in chronic liver disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8227476/),h,0.61,91974,DB00741,Hydrocortisone
,8227476,"elimination half-life, t1/2 beta","The elimination half-life, t1/2 beta, was significantly longer in CLD (0.61 vs. 0.32 hr).",Pharmacokinetics of methylprednisolone hemisuccinate and methylprednisolone in chronic liver disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8227476/),h,0.32,91975,DB00741,Hydrocortisone
,8227476,percent recovery,The percent recovery of unchanged MPHS in urine was similar (about 9%) in both groups.,Pharmacokinetics of methylprednisolone hemisuccinate and methylprednisolone in chronic liver disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8227476/),%,9,91976,DB00741,Hydrocortisone
,8227476,clearance,"The kinetic parameters of MP did not differ between the two groups for: clearance (about 370 L/hr/kg IBW), Vss (about 1.3 L/kg), and t1/2 beta (about 3.0 hr).",Pharmacokinetics of methylprednisolone hemisuccinate and methylprednisolone in chronic liver disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8227476/),[l] / [h·kg],370,91977,DB00741,Hydrocortisone
,8227476,Vss,"The kinetic parameters of MP did not differ between the two groups for: clearance (about 370 L/hr/kg IBW), Vss (about 1.3 L/kg), and t1/2 beta (about 3.0 hr).",Pharmacokinetics of methylprednisolone hemisuccinate and methylprednisolone in chronic liver disease. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8227476/),[l] / [kg],1.3,91978,DB00741,Hydrocortisone
,8227476,t1/2 beta,"The kinetic parameters of MP did not differ between the two groups for: clearance (about 370 L/hr/kg IBW), Vss (about 1.3 L/kg), and t1/2 beta (about 3.0 hr).",Pharmacokinetics of methylprednisolone hemisuccinate and methylprednisolone in chronic liver disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8227476/),h,3.0,91979,DB00741,Hydrocortisone
,8227476,suppression t1/2,The suppression t1/2 of cortisol after MPHS was longer (3.9 vs. 1.9 hr) indicating metabolic pathways for cortisol and MP are affected differently in CLD.,Pharmacokinetics of methylprednisolone hemisuccinate and methylprednisolone in chronic liver disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8227476/),h,3.9,91980,DB00741,Hydrocortisone
,8227476,suppression t1/2,The suppression t1/2 of cortisol after MPHS was longer (3.9 vs. 1.9 hr) indicating metabolic pathways for cortisol and MP are affected differently in CLD.,Pharmacokinetics of methylprednisolone hemisuccinate and methylprednisolone in chronic liver disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8227476/),h,1.9,91981,DB00741,Hydrocortisone
,1831005,relative extents of absorption (Frel),"The mean +/- SD relative extents of absorption (Frel) of clonidine following dermal pretreatment with hydrocortisone and magnesium-aluminum hydroxide in respect to the transdermal patch alone were 94.84 +/- 45.69% and 97.65 +/- 59.65%, respectively.",Skin pretreatment and the use of transdermal clonidine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1831005/),%,94.84,92589,DB00741,Hydrocortisone
,1831005,relative extents of absorption (Frel),"The mean +/- SD relative extents of absorption (Frel) of clonidine following dermal pretreatment with hydrocortisone and magnesium-aluminum hydroxide in respect to the transdermal patch alone were 94.84 +/- 45.69% and 97.65 +/- 59.65%, respectively.",Skin pretreatment and the use of transdermal clonidine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1831005/),%,97.65,92590,DB00741,Hydrocortisone
,8728344,E50,The data were fitted using a common E50 value of 0.95 +/- 0.22 ng/mL for the mean data.,Pharmacokinetic/pharmacodynamic modeling of cortisol suppression after oral administration of fluocortolone. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8728344/),[ng] / [ml],0.95,93286,DB00741,Hydrocortisone
,11115437,Plasma levels,"Study 2. Plasma levels over days 7 to 28 were 100.3 +/- 5.9 pg/mL (mean +/- SEM) for MF DPI 400 microg bid, and 181.0 +/- 10.9 pg/mL for 800 microg bid.",Mometasone furoate has minimal effects on the hypothalamic-pituitary-adrenal axis when delivered at high doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11115437/),[pg] / [ml],100.3,95830,DB00741,Hydrocortisone
,11115437,Plasma levels,"Study 2. Plasma levels over days 7 to 28 were 100.3 +/- 5.9 pg/mL (mean +/- SEM) for MF DPI 400 microg bid, and 181.0 +/- 10.9 pg/mL for 800 microg bid.",Mometasone furoate has minimal effects on the hypothalamic-pituitary-adrenal axis when delivered at high doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11115437/),[pg] / [ml],181.0,95831,DB00741,Hydrocortisone
,8222483,clearance,Women (luteal phase) exhibited a greater methylprednisolone clearance (0.45 versus 0.29 L/hr/kg) and shorter elimination half-life (1.7 versus 2.6 hours) than men.,Gender-based effects on methylprednisolone pharmacokinetics and pharmacodynamics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8222483/),[l] / [h·kg],0.45,96565,DB00741,Hydrocortisone
,8222483,clearance,Women (luteal phase) exhibited a greater methylprednisolone clearance (0.45 versus 0.29 L/hr/kg) and shorter elimination half-life (1.7 versus 2.6 hours) than men.,Gender-based effects on methylprednisolone pharmacokinetics and pharmacodynamics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8222483/),[l] / [h·kg],0.29,96566,DB00741,Hydrocortisone
,8222483,elimination half-life,Women (luteal phase) exhibited a greater methylprednisolone clearance (0.45 versus 0.29 L/hr/kg) and shorter elimination half-life (1.7 versus 2.6 hours) than men.,Gender-based effects on methylprednisolone pharmacokinetics and pharmacodynamics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8222483/),h,1.7,96567,DB00741,Hydrocortisone
,8222483,elimination half-life,Women (luteal phase) exhibited a greater methylprednisolone clearance (0.45 versus 0.29 L/hr/kg) and shorter elimination half-life (1.7 versus 2.6 hours) than men.,Gender-based effects on methylprednisolone pharmacokinetics and pharmacodynamics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8222483/),h,2.6,96568,DB00741,Hydrocortisone
,8222483,50% inhibitory concentration (IC50),"A significantly smaller 50% inhibitory concentration (IC50) value (0.1 versus 1.7 ng/ml) was seen in the women for suppression of cortisol secretion, indicating increased sensitivity.",Gender-based effects on methylprednisolone pharmacokinetics and pharmacodynamics. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8222483/),[ng] / [ml],0.1,96569,DB00741,Hydrocortisone
,8222483,50% inhibitory concentration (IC50),"A significantly smaller 50% inhibitory concentration (IC50) value (0.1 versus 1.7 ng/ml) was seen in the women for suppression of cortisol secretion, indicating increased sensitivity.",Gender-based effects on methylprednisolone pharmacokinetics and pharmacodynamics. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8222483/),[ng] / [ml],1.7,96570,DB00741,Hydrocortisone
,15090289,half-life,"The following significant changes were observed after Am-B treatment (P < 0.01): increase of antipyrine half-life (12.4 h vs 16.8 h) and the area under the plasma concentration-time curve (27.9 mg min/ml vs 38.1 mg min/ml); decrease of the total body clearance (61.2 ml/min vs 43.7 ml/min); decrease of the renal clearance of antipyrine metabolites - norantipyrine (7.45 ml/min vs 5.31 ml/min), 4-hydroxyantipyrine (15.4 ml/min vs 10.3 ml/min), hydroxymethylantipyrine (4.31 ml/min vs 3.65 ml/min); decrease of urinary 6-beta-hydroxycortisol excretion (453 microg/24h vs 298 microg/24h) and the ratio of 6-beta-hydroycortisol to 17-hydroxycorticosteroids (8.8% vs 6.4%).",Impact of amphotericin B on the cytochrome P450 system in HIV-infected patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15090289/),h,12.4,96676,DB00741,Hydrocortisone
,15090289,half-life,"The following significant changes were observed after Am-B treatment (P < 0.01): increase of antipyrine half-life (12.4 h vs 16.8 h) and the area under the plasma concentration-time curve (27.9 mg min/ml vs 38.1 mg min/ml); decrease of the total body clearance (61.2 ml/min vs 43.7 ml/min); decrease of the renal clearance of antipyrine metabolites - norantipyrine (7.45 ml/min vs 5.31 ml/min), 4-hydroxyantipyrine (15.4 ml/min vs 10.3 ml/min), hydroxymethylantipyrine (4.31 ml/min vs 3.65 ml/min); decrease of urinary 6-beta-hydroxycortisol excretion (453 microg/24h vs 298 microg/24h) and the ratio of 6-beta-hydroycortisol to 17-hydroxycorticosteroids (8.8% vs 6.4%).",Impact of amphotericin B on the cytochrome P450 system in HIV-infected patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15090289/),h,16.8,96677,DB00741,Hydrocortisone
,15090289,area under the plasma concentration-time curve,"The following significant changes were observed after Am-B treatment (P < 0.01): increase of antipyrine half-life (12.4 h vs 16.8 h) and the area under the plasma concentration-time curve (27.9 mg min/ml vs 38.1 mg min/ml); decrease of the total body clearance (61.2 ml/min vs 43.7 ml/min); decrease of the renal clearance of antipyrine metabolites - norantipyrine (7.45 ml/min vs 5.31 ml/min), 4-hydroxyantipyrine (15.4 ml/min vs 10.3 ml/min), hydroxymethylantipyrine (4.31 ml/min vs 3.65 ml/min); decrease of urinary 6-beta-hydroxycortisol excretion (453 microg/24h vs 298 microg/24h) and the ratio of 6-beta-hydroycortisol to 17-hydroxycorticosteroids (8.8% vs 6.4%).",Impact of amphotericin B on the cytochrome P450 system in HIV-infected patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15090289/),[mg·min] / [ml],27.9,96678,DB00741,Hydrocortisone
,15090289,area under the plasma concentration-time curve,"The following significant changes were observed after Am-B treatment (P < 0.01): increase of antipyrine half-life (12.4 h vs 16.8 h) and the area under the plasma concentration-time curve (27.9 mg min/ml vs 38.1 mg min/ml); decrease of the total body clearance (61.2 ml/min vs 43.7 ml/min); decrease of the renal clearance of antipyrine metabolites - norantipyrine (7.45 ml/min vs 5.31 ml/min), 4-hydroxyantipyrine (15.4 ml/min vs 10.3 ml/min), hydroxymethylantipyrine (4.31 ml/min vs 3.65 ml/min); decrease of urinary 6-beta-hydroxycortisol excretion (453 microg/24h vs 298 microg/24h) and the ratio of 6-beta-hydroycortisol to 17-hydroxycorticosteroids (8.8% vs 6.4%).",Impact of amphotericin B on the cytochrome P450 system in HIV-infected patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15090289/),[mg·min] / [ml],38.1,96679,DB00741,Hydrocortisone
,15090289,total body clearance,"The following significant changes were observed after Am-B treatment (P < 0.01): increase of antipyrine half-life (12.4 h vs 16.8 h) and the area under the plasma concentration-time curve (27.9 mg min/ml vs 38.1 mg min/ml); decrease of the total body clearance (61.2 ml/min vs 43.7 ml/min); decrease of the renal clearance of antipyrine metabolites - norantipyrine (7.45 ml/min vs 5.31 ml/min), 4-hydroxyantipyrine (15.4 ml/min vs 10.3 ml/min), hydroxymethylantipyrine (4.31 ml/min vs 3.65 ml/min); decrease of urinary 6-beta-hydroxycortisol excretion (453 microg/24h vs 298 microg/24h) and the ratio of 6-beta-hydroycortisol to 17-hydroxycorticosteroids (8.8% vs 6.4%).",Impact of amphotericin B on the cytochrome P450 system in HIV-infected patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15090289/),[ml] / [min],61.2,96680,DB00741,Hydrocortisone
,15090289,total body clearance,"The following significant changes were observed after Am-B treatment (P < 0.01): increase of antipyrine half-life (12.4 h vs 16.8 h) and the area under the plasma concentration-time curve (27.9 mg min/ml vs 38.1 mg min/ml); decrease of the total body clearance (61.2 ml/min vs 43.7 ml/min); decrease of the renal clearance of antipyrine metabolites - norantipyrine (7.45 ml/min vs 5.31 ml/min), 4-hydroxyantipyrine (15.4 ml/min vs 10.3 ml/min), hydroxymethylantipyrine (4.31 ml/min vs 3.65 ml/min); decrease of urinary 6-beta-hydroxycortisol excretion (453 microg/24h vs 298 microg/24h) and the ratio of 6-beta-hydroycortisol to 17-hydroxycorticosteroids (8.8% vs 6.4%).",Impact of amphotericin B on the cytochrome P450 system in HIV-infected patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15090289/),[ml] / [min],43.7,96681,DB00741,Hydrocortisone
,15090289,renal clearance,"The following significant changes were observed after Am-B treatment (P < 0.01): increase of antipyrine half-life (12.4 h vs 16.8 h) and the area under the plasma concentration-time curve (27.9 mg min/ml vs 38.1 mg min/ml); decrease of the total body clearance (61.2 ml/min vs 43.7 ml/min); decrease of the renal clearance of antipyrine metabolites - norantipyrine (7.45 ml/min vs 5.31 ml/min), 4-hydroxyantipyrine (15.4 ml/min vs 10.3 ml/min), hydroxymethylantipyrine (4.31 ml/min vs 3.65 ml/min); decrease of urinary 6-beta-hydroxycortisol excretion (453 microg/24h vs 298 microg/24h) and the ratio of 6-beta-hydroycortisol to 17-hydroxycorticosteroids (8.8% vs 6.4%).",Impact of amphotericin B on the cytochrome P450 system in HIV-infected patients. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15090289/),[ml] / [min],7.45,96682,DB00741,Hydrocortisone
,15090289,renal clearance,"The following significant changes were observed after Am-B treatment (P < 0.01): increase of antipyrine half-life (12.4 h vs 16.8 h) and the area under the plasma concentration-time curve (27.9 mg min/ml vs 38.1 mg min/ml); decrease of the total body clearance (61.2 ml/min vs 43.7 ml/min); decrease of the renal clearance of antipyrine metabolites - norantipyrine (7.45 ml/min vs 5.31 ml/min), 4-hydroxyantipyrine (15.4 ml/min vs 10.3 ml/min), hydroxymethylantipyrine (4.31 ml/min vs 3.65 ml/min); decrease of urinary 6-beta-hydroxycortisol excretion (453 microg/24h vs 298 microg/24h) and the ratio of 6-beta-hydroycortisol to 17-hydroxycorticosteroids (8.8% vs 6.4%).",Impact of amphotericin B on the cytochrome P450 system in HIV-infected patients. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15090289/),[ml] / [min],5.31,96683,DB00741,Hydrocortisone
,15090289,renal clearance,"The following significant changes were observed after Am-B treatment (P < 0.01): increase of antipyrine half-life (12.4 h vs 16.8 h) and the area under the plasma concentration-time curve (27.9 mg min/ml vs 38.1 mg min/ml); decrease of the total body clearance (61.2 ml/min vs 43.7 ml/min); decrease of the renal clearance of antipyrine metabolites - norantipyrine (7.45 ml/min vs 5.31 ml/min), 4-hydroxyantipyrine (15.4 ml/min vs 10.3 ml/min), hydroxymethylantipyrine (4.31 ml/min vs 3.65 ml/min); decrease of urinary 6-beta-hydroxycortisol excretion (453 microg/24h vs 298 microg/24h) and the ratio of 6-beta-hydroycortisol to 17-hydroxycorticosteroids (8.8% vs 6.4%).",Impact of amphotericin B on the cytochrome P450 system in HIV-infected patients. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15090289/),[ml] / [min],15.4,96684,DB00741,Hydrocortisone
,15090289,renal clearance,"The following significant changes were observed after Am-B treatment (P < 0.01): increase of antipyrine half-life (12.4 h vs 16.8 h) and the area under the plasma concentration-time curve (27.9 mg min/ml vs 38.1 mg min/ml); decrease of the total body clearance (61.2 ml/min vs 43.7 ml/min); decrease of the renal clearance of antipyrine metabolites - norantipyrine (7.45 ml/min vs 5.31 ml/min), 4-hydroxyantipyrine (15.4 ml/min vs 10.3 ml/min), hydroxymethylantipyrine (4.31 ml/min vs 3.65 ml/min); decrease of urinary 6-beta-hydroxycortisol excretion (453 microg/24h vs 298 microg/24h) and the ratio of 6-beta-hydroycortisol to 17-hydroxycorticosteroids (8.8% vs 6.4%).",Impact of amphotericin B on the cytochrome P450 system in HIV-infected patients. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15090289/),[ml] / [min],10.3,96685,DB00741,Hydrocortisone
,15090289,renal clearance,"The following significant changes were observed after Am-B treatment (P < 0.01): increase of antipyrine half-life (12.4 h vs 16.8 h) and the area under the plasma concentration-time curve (27.9 mg min/ml vs 38.1 mg min/ml); decrease of the total body clearance (61.2 ml/min vs 43.7 ml/min); decrease of the renal clearance of antipyrine metabolites - norantipyrine (7.45 ml/min vs 5.31 ml/min), 4-hydroxyantipyrine (15.4 ml/min vs 10.3 ml/min), hydroxymethylantipyrine (4.31 ml/min vs 3.65 ml/min); decrease of urinary 6-beta-hydroxycortisol excretion (453 microg/24h vs 298 microg/24h) and the ratio of 6-beta-hydroycortisol to 17-hydroxycorticosteroids (8.8% vs 6.4%).",Impact of amphotericin B on the cytochrome P450 system in HIV-infected patients. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15090289/),[ml] / [min],4.31,96686,DB00741,Hydrocortisone
,15090289,renal clearance,"The following significant changes were observed after Am-B treatment (P < 0.01): increase of antipyrine half-life (12.4 h vs 16.8 h) and the area under the plasma concentration-time curve (27.9 mg min/ml vs 38.1 mg min/ml); decrease of the total body clearance (61.2 ml/min vs 43.7 ml/min); decrease of the renal clearance of antipyrine metabolites - norantipyrine (7.45 ml/min vs 5.31 ml/min), 4-hydroxyantipyrine (15.4 ml/min vs 10.3 ml/min), hydroxymethylantipyrine (4.31 ml/min vs 3.65 ml/min); decrease of urinary 6-beta-hydroxycortisol excretion (453 microg/24h vs 298 microg/24h) and the ratio of 6-beta-hydroycortisol to 17-hydroxycorticosteroids (8.8% vs 6.4%).",Impact of amphotericin B on the cytochrome P450 system in HIV-infected patients. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15090289/),[ml] / [min],3.65,96687,DB00741,Hydrocortisone
,15090289,renal clearance,"The following significant changes were observed after Am-B treatment (P < 0.01): increase of antipyrine half-life (12.4 h vs 16.8 h) and the area under the plasma concentration-time curve (27.9 mg min/ml vs 38.1 mg min/ml); decrease of the total body clearance (61.2 ml/min vs 43.7 ml/min); decrease of the renal clearance of antipyrine metabolites - norantipyrine (7.45 ml/min vs 5.31 ml/min), 4-hydroxyantipyrine (15.4 ml/min vs 10.3 ml/min), hydroxymethylantipyrine (4.31 ml/min vs 3.65 ml/min); decrease of urinary 6-beta-hydroxycortisol excretion (453 microg/24h vs 298 microg/24h) and the ratio of 6-beta-hydroycortisol to 17-hydroxycorticosteroids (8.8% vs 6.4%).",Impact of amphotericin B on the cytochrome P450 system in HIV-infected patients. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15090289/),[μg] / [24h],298,96688,DB00741,Hydrocortisone
,15090289,excretion,"The following significant changes were observed after Am-B treatment (P < 0.01): increase of antipyrine half-life (12.4 h vs 16.8 h) and the area under the plasma concentration-time curve (27.9 mg min/ml vs 38.1 mg min/ml); decrease of the total body clearance (61.2 ml/min vs 43.7 ml/min); decrease of the renal clearance of antipyrine metabolites - norantipyrine (7.45 ml/min vs 5.31 ml/min), 4-hydroxyantipyrine (15.4 ml/min vs 10.3 ml/min), hydroxymethylantipyrine (4.31 ml/min vs 3.65 ml/min); decrease of urinary 6-beta-hydroxycortisol excretion (453 microg/24h vs 298 microg/24h) and the ratio of 6-beta-hydroycortisol to 17-hydroxycorticosteroids (8.8% vs 6.4%).",Impact of amphotericin B on the cytochrome P450 system in HIV-infected patients. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15090289/),[μg] / [24h],453,96689,DB00741,Hydrocortisone
,15090289,excretion,"The following significant changes were observed after Am-B treatment (P < 0.01): increase of antipyrine half-life (12.4 h vs 16.8 h) and the area under the plasma concentration-time curve (27.9 mg min/ml vs 38.1 mg min/ml); decrease of the total body clearance (61.2 ml/min vs 43.7 ml/min); decrease of the renal clearance of antipyrine metabolites - norantipyrine (7.45 ml/min vs 5.31 ml/min), 4-hydroxyantipyrine (15.4 ml/min vs 10.3 ml/min), hydroxymethylantipyrine (4.31 ml/min vs 3.65 ml/min); decrease of urinary 6-beta-hydroxycortisol excretion (453 microg/24h vs 298 microg/24h) and the ratio of 6-beta-hydroycortisol to 17-hydroxycorticosteroids (8.8% vs 6.4%).",Impact of amphotericin B on the cytochrome P450 system in HIV-infected patients. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15090289/),[μg] / [24h],298,96690,DB00741,Hydrocortisone
,9865456,clearance,"A slower clearance of methylprednisolone was noted in the elderly (mean: 256 mL/hr/Kg) than in the young men (mean: 359 mL/hr/Kg; p < 0.05) during Phase II with no significant difference found between groups for volume of distribution, elimination rate constant or half-life.",CD4+ and CD8+ lymphocyte and cortisol response patterns in elderly and young males after methylprednisolone exposure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9865456/),[ml] / [h·kg],256,97722,DB00741,Hydrocortisone
,9865456,clearance,"A slower clearance of methylprednisolone was noted in the elderly (mean: 256 mL/hr/Kg) than in the young men (mean: 359 mL/hr/Kg; p < 0.05) during Phase II with no significant difference found between groups for volume of distribution, elimination rate constant or half-life.",CD4+ and CD8+ lymphocyte and cortisol response patterns in elderly and young males after methylprednisolone exposure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9865456/),[ml] / [h·kg],359,97723,DB00741,Hydrocortisone
,9865456,co,"A significantly smaller cortisol suppression ratio [0.36+/-0.11 (elderly) versus 0.58+/-0.11 (young), p = 0.01] which indicates a more profound cortisol suppression was noted.",CD4+ and CD8+ lymphocyte and cortisol response patterns in elderly and young males after methylprednisolone exposure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9865456/),,0.36,97724,DB00741,Hydrocortisone
,9865456,co,"A significantly smaller cortisol suppression ratio [0.36+/-0.11 (elderly) versus 0.58+/-0.11 (young), p = 0.01] which indicates a more profound cortisol suppression was noted.",CD4+ and CD8+ lymphocyte and cortisol response patterns in elderly and young males after methylprednisolone exposure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9865456/),,0.58,97725,DB00741,Hydrocortisone
,9865456,suppression ratio,"A significantly smaller cortisol suppression ratio [0.36+/-0.11 (elderly) versus 0.58+/-0.11 (young), p = 0.01] which indicates a more profound cortisol suppression was noted.",CD4+ and CD8+ lymphocyte and cortisol response patterns in elderly and young males after methylprednisolone exposure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9865456/),,0.36,97726,DB00741,Hydrocortisone
,9865456,suppression ratio,"A significantly smaller cortisol suppression ratio [0.36+/-0.11 (elderly) versus 0.58+/-0.11 (young), p = 0.01] which indicates a more profound cortisol suppression was noted.",CD4+ and CD8+ lymphocyte and cortisol response patterns in elderly and young males after methylprednisolone exposure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9865456/),,0.58,97727,DB00741,Hydrocortisone
,11140429,maximum plasma FP concentrations,"The maximum plasma FP concentrations after inhalation via the 2 types of MDI were almost identical (0.56 and 0.54 microg/L for CFC MDI and HFA MDI, respectively); bioavailability values of inhaled FP from the 2 MDIs were also similar (geometric mean values: 26.4% via the CFC MDI and 28.6% via the HFA MDI).",Systemic exposure to fluticasone propionate administered via metered-dose inhaler containing chlorofluorocarbon or hydrofluoroalkane propellant. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11140429/),[μg] / [l],0.56,98123,DB00741,Hydrocortisone
,11140429,maximum plasma FP concentrations,"The maximum plasma FP concentrations after inhalation via the 2 types of MDI were almost identical (0.56 and 0.54 microg/L for CFC MDI and HFA MDI, respectively); bioavailability values of inhaled FP from the 2 MDIs were also similar (geometric mean values: 26.4% via the CFC MDI and 28.6% via the HFA MDI).",Systemic exposure to fluticasone propionate administered via metered-dose inhaler containing chlorofluorocarbon or hydrofluoroalkane propellant. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11140429/),[μg] / [l],0.54,98124,DB00741,Hydrocortisone
,11140429,bioavailability,"The maximum plasma FP concentrations after inhalation via the 2 types of MDI were almost identical (0.56 and 0.54 microg/L for CFC MDI and HFA MDI, respectively); bioavailability values of inhaled FP from the 2 MDIs were also similar (geometric mean values: 26.4% via the CFC MDI and 28.6% via the HFA MDI).",Systemic exposure to fluticasone propionate administered via metered-dose inhaler containing chlorofluorocarbon or hydrofluoroalkane propellant. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11140429/),%,26.4,98125,DB00741,Hydrocortisone
,11140429,bioavailability,"The maximum plasma FP concentrations after inhalation via the 2 types of MDI were almost identical (0.56 and 0.54 microg/L for CFC MDI and HFA MDI, respectively); bioavailability values of inhaled FP from the 2 MDIs were also similar (geometric mean values: 26.4% via the CFC MDI and 28.6% via the HFA MDI).",Systemic exposure to fluticasone propionate administered via metered-dose inhaler containing chlorofluorocarbon or hydrofluoroalkane propellant. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11140429/),%,28.6,98126,DB00741,Hydrocortisone
,29084684,zeta potential,Size of the generated particeles was 290 nm ± 9 nm having a zeta potential of -1.9 mV ± 0.6 mV.,"A stable hydrocortisone nanosuspension for improved dissolution: Preparation, characterization and in vitro evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29084684/),mv,-1.9,99686,DB00741,Hydrocortisone
,29084684,Solubility,"Solubility of hydrocortisone was enhanced by nanonization to 875µg/ml ±2.5, an almost 2.9-fold compared to the raw hydrocortisone.","A stable hydrocortisone nanosuspension for improved dissolution: Preparation, characterization and in vitro evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29084684/),[μg] / [ml],875,99687,DB00741,Hydrocortisone
,29084684,AUC 0-9h,"The bioavailability study resulted in AUC 0-9h for HC nanosuspensions (31.50±2.50), which is significantly (p<0.05) higher compared to the AUC 0-9h (14.85±3.25) resulted for HC solution.","A stable hydrocortisone nanosuspension for improved dissolution: Preparation, characterization and in vitro evaluation. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29084684/),,31.50,99688,DB00741,Hydrocortisone
,29084684,AUC 0-9h,"The bioavailability study resulted in AUC 0-9h for HC nanosuspensions (31.50±2.50), which is significantly (p<0.05) higher compared to the AUC 0-9h (14.85±3.25) resulted for HC solution.","A stable hydrocortisone nanosuspension for improved dissolution: Preparation, characterization and in vitro evaluation. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29084684/),,14.85,99689,DB00741,Hydrocortisone
,1450296,50% cross-reactivity,"In the IgG Corp. radioimmunoassay for plasma DEX, 6 OH-Dex was moderately cross-reactive yielding a 50% cross-reactivity of 10%.",Preliminary studies of 6 beta-hydroxydexamethasone and its importance in the DST. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1450296/),%,10,100556,DB00741,Hydrocortisone
,29256372,maximal plasma concentration (Cmax),"Within the first h after administration, the maximal plasma concentration (Cmax) of the drug was 64.3 ± 9.2 ng/mL (males) and 71.3 ± 3.7 ng/mL (females) in the SRBHigh group; 11.5 ± 3.2 ng/mL (males) and 6.9 ± 0.9 ng/mL (females) in the SRBMedium group; and 2.3 ± 0.8 ng/mL (males) and 2.0 ± 0.5 ng/mL (females) in the SRBLow group.",Pharmacokinetics and Adverse Effects of 3 Sustained-release Buprenorphine Dosages in Healthy Guinea Pigs (Cavia porcellus). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29256372/),[ng] / [ml],64.3,100604,DB00741,Hydrocortisone
,29256372,maximal plasma concentration (Cmax),"Within the first h after administration, the maximal plasma concentration (Cmax) of the drug was 64.3 ± 9.2 ng/mL (males) and 71.3 ± 3.7 ng/mL (females) in the SRBHigh group; 11.5 ± 3.2 ng/mL (males) and 6.9 ± 0.9 ng/mL (females) in the SRBMedium group; and 2.3 ± 0.8 ng/mL (males) and 2.0 ± 0.5 ng/mL (females) in the SRBLow group.",Pharmacokinetics and Adverse Effects of 3 Sustained-release Buprenorphine Dosages in Healthy Guinea Pigs (Cavia porcellus). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29256372/),[ng] / [ml],71.3,100605,DB00741,Hydrocortisone
,29256372,maximal plasma concentration (Cmax),"Within the first h after administration, the maximal plasma concentration (Cmax) of the drug was 64.3 ± 9.2 ng/mL (males) and 71.3 ± 3.7 ng/mL (females) in the SRBHigh group; 11.5 ± 3.2 ng/mL (males) and 6.9 ± 0.9 ng/mL (females) in the SRBMedium group; and 2.3 ± 0.8 ng/mL (males) and 2.0 ± 0.5 ng/mL (females) in the SRBLow group.",Pharmacokinetics and Adverse Effects of 3 Sustained-release Buprenorphine Dosages in Healthy Guinea Pigs (Cavia porcellus). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29256372/),[ng] / [ml],11.5,100606,DB00741,Hydrocortisone
,29256372,maximal plasma concentration (Cmax),"Within the first h after administration, the maximal plasma concentration (Cmax) of the drug was 64.3 ± 9.2 ng/mL (males) and 71.3 ± 3.7 ng/mL (females) in the SRBHigh group; 11.5 ± 3.2 ng/mL (males) and 6.9 ± 0.9 ng/mL (females) in the SRBMedium group; and 2.3 ± 0.8 ng/mL (males) and 2.0 ± 0.5 ng/mL (females) in the SRBLow group.",Pharmacokinetics and Adverse Effects of 3 Sustained-release Buprenorphine Dosages in Healthy Guinea Pigs (Cavia porcellus). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29256372/),[ng] / [ml],6.9,100607,DB00741,Hydrocortisone
,29256372,maximal plasma concentration (Cmax),"Within the first h after administration, the maximal plasma concentration (Cmax) of the drug was 64.3 ± 9.2 ng/mL (males) and 71.3 ± 3.7 ng/mL (females) in the SRBHigh group; 11.5 ± 3.2 ng/mL (males) and 6.9 ± 0.9 ng/mL (females) in the SRBMedium group; and 2.3 ± 0.8 ng/mL (males) and 2.0 ± 0.5 ng/mL (females) in the SRBLow group.",Pharmacokinetics and Adverse Effects of 3 Sustained-release Buprenorphine Dosages in Healthy Guinea Pigs (Cavia porcellus). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29256372/),[ng] / [ml],2.3,100608,DB00741,Hydrocortisone
,29256372,maximal plasma concentration (Cmax),"Within the first h after administration, the maximal plasma concentration (Cmax) of the drug was 64.3 ± 9.2 ng/mL (males) and 71.3 ± 3.7 ng/mL (females) in the SRBHigh group; 11.5 ± 3.2 ng/mL (males) and 6.9 ± 0.9 ng/mL (females) in the SRBMedium group; and 2.3 ± 0.8 ng/mL (males) and 2.0 ± 0.5 ng/mL (females) in the SRBLow group.",Pharmacokinetics and Adverse Effects of 3 Sustained-release Buprenorphine Dosages in Healthy Guinea Pigs (Cavia porcellus). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29256372/),[ng] / [ml],2.0,100609,DB00741,Hydrocortisone
,20828803,half-life,The half-life of AESZ-108 was estimated to be about 2h.,"Dose escalation and pharmacokinetic study of AEZS-108 (AN-152), an LHRH agonist linked to doxorubicin, in women with LHRH receptor-positive tumors. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20828803/),h,2,100942,DB00741,Hydrocortisone
,20828803,maximum tolerated dose,The maximum tolerated dose of AESZ-108 in the absence of supportive medication is 267 mg/m² and this dose is recommended as starting dose for therapeutic Phase II studies.,"Dose escalation and pharmacokinetic study of AEZS-108 (AN-152), an LHRH agonist linked to doxorubicin, in women with LHRH receptor-positive tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20828803/),[mg] / [m²],267,100943,DB00741,Hydrocortisone
,7324480,morning level,Cortisone showed a mean morning level of 440 nmol/l +/- 165 nmol/l and a half life of 4.8 hours.,"[The metabolism of hydrocortisone, prednisolone and fluocortolone (author's transl)]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7324480/),[nM] / [l],440,101953,DB00741,Hydrocortisone
,7324480,half life,Cortisone showed a mean morning level of 440 nmol/l +/- 165 nmol/l and a half life of 4.8 hours.,"[The metabolism of hydrocortisone, prednisolone and fluocortolone (author's transl)]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7324480/),h,4.8,101954,DB00741,Hydrocortisone
,7324480,half life,"The half life of prednisolone was determined after intravenous injection of 25 mg and found to be 2.4 hours and that of fluocortolone, after oral administration of 60 mg, was calculated to be 1.7 hours.","[The metabolism of hydrocortisone, prednisolone and fluocortolone (author's transl)]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7324480/),h,2.4,101955,DB00741,Hydrocortisone
,7324480,half life,"The half life of prednisolone was determined after intravenous injection of 25 mg and found to be 2.4 hours and that of fluocortolone, after oral administration of 60 mg, was calculated to be 1.7 hours.","[The metabolism of hydrocortisone, prednisolone and fluocortolone (author's transl)]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7324480/),h,1.7,101956,DB00741,Hydrocortisone
,17610403,V(d(ss)),"Intravenous salicylate V(d(ss)) was 0.18 L/kg, Cl(B) was 3.36 mL/min/kg and t(1/2 lambda) was 0.63 h.",Attenuation of acute plasma cortisol response in calves following intravenous sodium salicylate administration prior to castration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17610403/),[l] / [kg],0.18,103021,DB00741,Hydrocortisone
,17610403,Cl(B),"Intravenous salicylate V(d(ss)) was 0.18 L/kg, Cl(B) was 3.36 mL/min/kg and t(1/2 lambda) was 0.63 h.",Attenuation of acute plasma cortisol response in calves following intravenous sodium salicylate administration prior to castration. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17610403/),[ml] / [kg·min],3.36,103022,DB00741,Hydrocortisone
,17610403,t(1/2 lambda),"Intravenous salicylate V(d(ss)) was 0.18 L/kg, Cl(B) was 3.36 mL/min/kg and t(1/2 lambda) was 0.63 h.",Attenuation of acute plasma cortisol response in calves following intravenous sodium salicylate administration prior to castration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17610403/),h,0.63,103023,DB00741,Hydrocortisone
<,17610403,Peak salicylate concentrations,Peak salicylate concentrations following oral aspirin administration was <10 microg/mL and failed to attenuate cortisol response.,Attenuation of acute plasma cortisol response in calves following intravenous sodium salicylate administration prior to castration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17610403/),[μg] / [ml],10,103024,DB00741,Hydrocortisone
,30952111,Cmax,"Results Vaginal administration of PN suppositories was not bioequivalent to rectal administration: Cmax and AUC0-360 were significantly lower after vaginal compared to rectal administration: 22 ng/mL (109%) vs 161 ng/mL (28%), P < 0.001; 4390 ng/mL * min (116%) vs 40,302 ng/mL * min (26%), P < 0.001; (mean (coefficient of variation), respectively).",Emergency treatment of adrenal crisis with prednisone suppositories: a bioequivalence study in female patients with Addison's disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30952111/),[ng] / [ml],22,103741,DB00741,Hydrocortisone
,30952111,Cmax,"Results Vaginal administration of PN suppositories was not bioequivalent to rectal administration: Cmax and AUC0-360 were significantly lower after vaginal compared to rectal administration: 22 ng/mL (109%) vs 161 ng/mL (28%), P < 0.001; 4390 ng/mL * min (116%) vs 40,302 ng/mL * min (26%), P < 0.001; (mean (coefficient of variation), respectively).",Emergency treatment of adrenal crisis with prednisone suppositories: a bioequivalence study in female patients with Addison's disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30952111/),[ng] / [ml],161,103742,DB00741,Hydrocortisone
,30952111,Cmax,"Results Vaginal administration of PN suppositories was not bioequivalent to rectal administration: Cmax and AUC0-360 were significantly lower after vaginal compared to rectal administration: 22 ng/mL (109%) vs 161 ng/mL (28%), P < 0.001; 4390 ng/mL * min (116%) vs 40,302 ng/mL * min (26%), P < 0.001; (mean (coefficient of variation), respectively).",Emergency treatment of adrenal crisis with prednisone suppositories: a bioequivalence study in female patients with Addison's disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30952111/),[ng] / [min·ml],4390,103743,DB00741,Hydrocortisone
,30952111,AUC0-360,"Results Vaginal administration of PN suppositories was not bioequivalent to rectal administration: Cmax and AUC0-360 were significantly lower after vaginal compared to rectal administration: 22 ng/mL (109%) vs 161 ng/mL (28%), P < 0.001; 4390 ng/mL * min (116%) vs 40,302 ng/mL * min (26%), P < 0.001; (mean (coefficient of variation), respectively).",Emergency treatment of adrenal crisis with prednisone suppositories: a bioequivalence study in female patients with Addison's disease. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30952111/),[ng] / [min·ml],4390,103744,DB00741,Hydrocortisone
,30952111,AUC0-360,"Results Vaginal administration of PN suppositories was not bioequivalent to rectal administration: Cmax and AUC0-360 were significantly lower after vaginal compared to rectal administration: 22 ng/mL (109%) vs 161 ng/mL (28%), P < 0.001; 4390 ng/mL * min (116%) vs 40,302 ng/mL * min (26%), P < 0.001; (mean (coefficient of variation), respectively).",Emergency treatment of adrenal crisis with prednisone suppositories: a bioequivalence study in female patients with Addison's disease. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30952111/),[ng] / [min·ml],"40,302",103745,DB00741,Hydrocortisone
,15467976,absolute bioavailability,The absolute bioavailability ranged from 12% to 84%.,Pharmacokinetics of m-chlorophenylpiperazine after intravenous and oral administration in healthy male volunteers: implication for the pharmacodynamic profile. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15467976/),%,12,104832,DB00741,Hydrocortisone
,15467976,absolute bioavailability,The absolute bioavailability ranged from 12% to 84%.,Pharmacokinetics of m-chlorophenylpiperazine after intravenous and oral administration in healthy male volunteers: implication for the pharmacodynamic profile. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15467976/),%,84,104833,DB00741,Hydrocortisone
,15467976,elimination half-life,mCPP's elimination half-life ranged from 2.4 h to 6.8 h after intravenous infusion and from 2.6 h to 6.1 h after oral application.,Pharmacokinetics of m-chlorophenylpiperazine after intravenous and oral administration in healthy male volunteers: implication for the pharmacodynamic profile. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15467976/),h,2.4,104834,DB00741,Hydrocortisone
,15467976,elimination half-life,mCPP's elimination half-life ranged from 2.4 h to 6.8 h after intravenous infusion and from 2.6 h to 6.1 h after oral application.,Pharmacokinetics of m-chlorophenylpiperazine after intravenous and oral administration in healthy male volunteers: implication for the pharmacodynamic profile. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15467976/),h,6.8,104835,DB00741,Hydrocortisone
,15467976,elimination half-life,mCPP's elimination half-life ranged from 2.4 h to 6.8 h after intravenous infusion and from 2.6 h to 6.1 h after oral application.,Pharmacokinetics of m-chlorophenylpiperazine after intravenous and oral administration in healthy male volunteers: implication for the pharmacodynamic profile. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15467976/),h,2.6,104836,DB00741,Hydrocortisone
,15467976,elimination half-life,mCPP's elimination half-life ranged from 2.4 h to 6.8 h after intravenous infusion and from 2.6 h to 6.1 h after oral application.,Pharmacokinetics of m-chlorophenylpiperazine after intravenous and oral administration in healthy male volunteers: implication for the pharmacodynamic profile. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15467976/),h,6.1,104837,DB00741,Hydrocortisone
,22796247,morning,"However, morning trough values might have been affected by higher placebo response after morning dosing (18.8 vs 8.8 L/min).","Efficacy and safety profile of fluticasone furoate administered once daily in the morning or evening: a randomized, double-blind, double-dummy, placebo-controlled trial in adult and adolescent patients with persistent bronchial asthma. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22796247/),[l] / [min],18.8,105321,DB00741,Hydrocortisone
,22796247,trough,"However, morning trough values might have been affected by higher placebo response after morning dosing (18.8 vs 8.8 L/min).","Efficacy and safety profile of fluticasone furoate administered once daily in the morning or evening: a randomized, double-blind, double-dummy, placebo-controlled trial in adult and adolescent patients with persistent bronchial asthma. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22796247/),[l] / [min],18.8,105322,DB00741,Hydrocortisone
,22796247,trough,"However, morning trough values might have been affected by higher placebo response after morning dosing (18.8 vs 8.8 L/min).","Efficacy and safety profile of fluticasone furoate administered once daily in the morning or evening: a randomized, double-blind, double-dummy, placebo-controlled trial in adult and adolescent patients with persistent bronchial asthma. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22796247/),[l] / [min],8.8,105323,DB00741,Hydrocortisone
,22796247,Trough PEF,"Trough PEF improved relative to placebo (P ≤ 0.005), with little difference between FF Rotadisk 100 μg morning (19 L/min) and evening (16 L/min) dosing, as with other efficacy measures.","Efficacy and safety profile of fluticasone furoate administered once daily in the morning or evening: a randomized, double-blind, double-dummy, placebo-controlled trial in adult and adolescent patients with persistent bronchial asthma. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22796247/),[l] / [min],19,105324,DB00741,Hydrocortisone
,22796247,Trough PEF,"Trough PEF improved relative to placebo (P ≤ 0.005), with little difference between FF Rotadisk 100 μg morning (19 L/min) and evening (16 L/min) dosing, as with other efficacy measures.","Efficacy and safety profile of fluticasone furoate administered once daily in the morning or evening: a randomized, double-blind, double-dummy, placebo-controlled trial in adult and adolescent patients with persistent bronchial asthma. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22796247/),[l] / [min],16,105325,DB00741,Hydrocortisone
,23980724,AUC,"In dexamethasone-suppressed volunteers (n = 16) receiving a twice-daily 'toothbrush' regimen (20 mg at 23:00 h and 10 mg at 07:00 h), DIURF-006 gave a similar cortisol profile to physiological cortisol levels: DIURF-006 vs physiological, Geomean AUC 5610 vs 4706 h * nmol/l, Geomean Cmax 665 vs 594 nmol/l and Median Tmax 8·5 h vs clock time 08:12 h for peak cortisol.","An oral multiparticulate, modified-release, hydrocortisone replacement therapy that provides physiological cortisol exposure. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23980724/),[h·nM] / [l],5610,105747,DB00741,Hydrocortisone
,23980724,AUC,"In dexamethasone-suppressed volunteers (n = 16) receiving a twice-daily 'toothbrush' regimen (20 mg at 23:00 h and 10 mg at 07:00 h), DIURF-006 gave a similar cortisol profile to physiological cortisol levels: DIURF-006 vs physiological, Geomean AUC 5610 vs 4706 h * nmol/l, Geomean Cmax 665 vs 594 nmol/l and Median Tmax 8·5 h vs clock time 08:12 h for peak cortisol.","An oral multiparticulate, modified-release, hydrocortisone replacement therapy that provides physiological cortisol exposure. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23980724/),[h·nM] / [l],4706,105748,DB00741,Hydrocortisone
,23980724,Cmax,"In dexamethasone-suppressed volunteers (n = 16) receiving a twice-daily 'toothbrush' regimen (20 mg at 23:00 h and 10 mg at 07:00 h), DIURF-006 gave a similar cortisol profile to physiological cortisol levels: DIURF-006 vs physiological, Geomean AUC 5610 vs 4706 h * nmol/l, Geomean Cmax 665 vs 594 nmol/l and Median Tmax 8·5 h vs clock time 08:12 h for peak cortisol.","An oral multiparticulate, modified-release, hydrocortisone replacement therapy that provides physiological cortisol exposure. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23980724/),[nM] / [l],665,105749,DB00741,Hydrocortisone
,23980724,Cmax,"In dexamethasone-suppressed volunteers (n = 16) receiving a twice-daily 'toothbrush' regimen (20 mg at 23:00 h and 10 mg at 07:00 h), DIURF-006 gave a similar cortisol profile to physiological cortisol levels: DIURF-006 vs physiological, Geomean AUC 5610 vs 4706 h * nmol/l, Geomean Cmax 665 vs 594 nmol/l and Median Tmax 8·5 h vs clock time 08:12 h for peak cortisol.","An oral multiparticulate, modified-release, hydrocortisone replacement therapy that provides physiological cortisol exposure. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23980724/),[nM] / [l],594,105750,DB00741,Hydrocortisone
,23980724,Tmax,"In dexamethasone-suppressed volunteers (n = 16) receiving a twice-daily 'toothbrush' regimen (20 mg at 23:00 h and 10 mg at 07:00 h), DIURF-006 gave a similar cortisol profile to physiological cortisol levels: DIURF-006 vs physiological, Geomean AUC 5610 vs 4706 h * nmol/l, Geomean Cmax 665 vs 594 nmol/l and Median Tmax 8·5 h vs clock time 08:12 h for peak cortisol.","An oral multiparticulate, modified-release, hydrocortisone replacement therapy that provides physiological cortisol exposure. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23980724/),h,8·5,105751,DB00741,Hydrocortisone
,23980724,relative bioavailability,"The relative bioavailability of DIURF-006 vs hydrocortisone was 89%, and cortisol levels increased linearly with doses between 5 and 30 mg.","An oral multiparticulate, modified-release, hydrocortisone replacement therapy that provides physiological cortisol exposure. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23980724/),%,89,105752,DB00741,Hydrocortisone
,2877885,peak plasma levels (Cssmax),"After therapy with bisoprolol alone peak plasma levels (Cssmax) of the beta-blocker were 55.5 +/- 6.4 ng/ml (means +/- SEM), area under the plasma level-time curve (AUC tau) was 597 +/- 70 ng/ml.h, total body clearance (CL) 15.8 +/- 1.8 l/h and elimination half-lives (t1/2 beta) 10.1 +/- 1.2 h.",Interaction of bisoprolol with cimetidine and rifampicin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2877885/),[ng] / [ml],55.5,108453,DB00741,Hydrocortisone
,2877885,area under the plasma level-time curve (AUC tau),"After therapy with bisoprolol alone peak plasma levels (Cssmax) of the beta-blocker were 55.5 +/- 6.4 ng/ml (means +/- SEM), area under the plasma level-time curve (AUC tau) was 597 +/- 70 ng/ml.h, total body clearance (CL) 15.8 +/- 1.8 l/h and elimination half-lives (t1/2 beta) 10.1 +/- 1.2 h.",Interaction of bisoprolol with cimetidine and rifampicin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2877885/),[ng] / [h·ml],597,108454,DB00741,Hydrocortisone
,2877885,total body clearance (CL),"After therapy with bisoprolol alone peak plasma levels (Cssmax) of the beta-blocker were 55.5 +/- 6.4 ng/ml (means +/- SEM), area under the plasma level-time curve (AUC tau) was 597 +/- 70 ng/ml.h, total body clearance (CL) 15.8 +/- 1.8 l/h and elimination half-lives (t1/2 beta) 10.1 +/- 1.2 h.",Interaction of bisoprolol with cimetidine and rifampicin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2877885/),[l] / [h],15.8,108455,DB00741,Hydrocortisone
,2877885,elimination half-lives (t1/2 beta),"After therapy with bisoprolol alone peak plasma levels (Cssmax) of the beta-blocker were 55.5 +/- 6.4 ng/ml (means +/- SEM), area under the plasma level-time curve (AUC tau) was 597 +/- 70 ng/ml.h, total body clearance (CL) 15.8 +/- 1.8 l/h and elimination half-lives (t1/2 beta) 10.1 +/- 1.2 h.",Interaction of bisoprolol with cimetidine and rifampicin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2877885/),h,10.1,108456,DB00741,Hydrocortisone
,2877885,Cssmax,"Co-administration of rifampicin resulted in a decrease in Cssmax (43.0 +/- 6.9 ng/ml), AUC tau (397 +/- 54 ng/ml X h) and t1/2 beta (6.2 +/- 0.4 h).",Interaction of bisoprolol with cimetidine and rifampicin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2877885/),[ng] / [ml],43.0,108457,DB00741,Hydrocortisone
,2877885,AUC tau,"Co-administration of rifampicin resulted in a decrease in Cssmax (43.0 +/- 6.9 ng/ml), AUC tau (397 +/- 54 ng/ml X h) and t1/2 beta (6.2 +/- 0.4 h).",Interaction of bisoprolol with cimetidine and rifampicin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2877885/),[ng] / [h·ml],397,108458,DB00741,Hydrocortisone
,2877885,t1/2 beta,"Co-administration of rifampicin resulted in a decrease in Cssmax (43.0 +/- 6.9 ng/ml), AUC tau (397 +/- 54 ng/ml X h) and t1/2 beta (6.2 +/- 0.4 h).",Interaction of bisoprolol with cimetidine and rifampicin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2877885/),h,6.2,108459,DB00741,Hydrocortisone
,2877885,total body clearance,"Accordingly, total body clearance increased to 23.8 +/- 2.5 l/h (p less than 0.05).",Interaction of bisoprolol with cimetidine and rifampicin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2877885/),[l] / [h],23.8,108460,DB00741,Hydrocortisone
,19203724,relative bioavailability,"Whereas systemic exposure to budesonide was markedly lower in healthy subjects after the mouthwash compared to oral dosing (mean relative bioavailability 18%-36%), the systemic concentrations thereafter in patients were as high as those after the identical dose of oral budesonide.",Pharmacokinetics and pharmacodynamic action of budesonide after buccal administration in healthy subjects and patients with oral chronic graft-versus-host disease. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19203724/),%,18,109370,DB00741,Hydrocortisone
,19203724,relative bioavailability,"Whereas systemic exposure to budesonide was markedly lower in healthy subjects after the mouthwash compared to oral dosing (mean relative bioavailability 18%-36%), the systemic concentrations thereafter in patients were as high as those after the identical dose of oral budesonide.",Pharmacokinetics and pharmacodynamic action of budesonide after buccal administration in healthy subjects and patients with oral chronic graft-versus-host disease. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19203724/),%,36,109371,DB00741,Hydrocortisone
,1501111,Bioavailability,Bioavailability of DEX after inhalation was about 27% of DEX i.v. DEX-induced depletion of plasma HC could be predicted with a pharmacokinetic model.,"Kinetic-dynamic modeling of lymphocytopenia induced by the combined action of dexamethasone and hydrocortisone in humans, after inhalation and intravenous administration of dexamethasone. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1501111/),%,27,112514,DB00741,Hydrocortisone
,7626450,elimination half-life,The elimination half-life of ARIMIDEX in humans ranged from 30 to 60 h.,"ARIMIDEX: a new oral, once-a-day aromatase inhibitor. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7626450/),h,30 to 60,113448,DB00741,Hydrocortisone
,157893,urinary excretion,"Following epicutaneous application of the three topicals in quantities containing 30 mg clioquinol each, the urinary excretion of the drug was between 1.2 and 3.6% of the applied dose.",Percutaneous absorption of clioquinol (Vioform). ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/157893/),%,1.2 and 3.6,115391,DB00741,Hydrocortisone
,19223520,peak,"The key variables in the physiological cortisol profile included: peak 15.5 microg/dl (95% reference range 11.7-20.6), acrophase 0832 h (95% confidence interval 0759-0905), nadir less than 2 microg/dl (95% reference range 1.5-2.5), time of nadir 0018 h (95% confidence interval 2339-0058), and quiescent phase (below the mesor) 1943-0531 h.",Modified-release hydrocortisone to provide circadian cortisol profiles. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19223520/),[μg] / [dl],15.5,115674,DB00741,Hydrocortisone
,19223520,acrophase,"The key variables in the physiological cortisol profile included: peak 15.5 microg/dl (95% reference range 11.7-20.6), acrophase 0832 h (95% confidence interval 0759-0905), nadir less than 2 microg/dl (95% reference range 1.5-2.5), time of nadir 0018 h (95% confidence interval 2339-0058), and quiescent phase (below the mesor) 1943-0531 h.",Modified-release hydrocortisone to provide circadian cortisol profiles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19223520/),h,0832,115675,DB00741,Hydrocortisone
less,19223520,nadir,"The key variables in the physiological cortisol profile included: peak 15.5 microg/dl (95% reference range 11.7-20.6), acrophase 0832 h (95% confidence interval 0759-0905), nadir less than 2 microg/dl (95% reference range 1.5-2.5), time of nadir 0018 h (95% confidence interval 2339-0058), and quiescent phase (below the mesor) 1943-0531 h.",Modified-release hydrocortisone to provide circadian cortisol profiles. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19223520/),[μg] / [dl],2,115676,DB00741,Hydrocortisone
,19223520,time of nadir,"The key variables in the physiological cortisol profile included: peak 15.5 microg/dl (95% reference range 11.7-20.6), acrophase 0832 h (95% confidence interval 0759-0905), nadir less than 2 microg/dl (95% reference range 1.5-2.5), time of nadir 0018 h (95% confidence interval 2339-0058), and quiescent phase (below the mesor) 1943-0531 h.",Modified-release hydrocortisone to provide circadian cortisol profiles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19223520/),h,0018,115677,DB00741,Hydrocortisone
,19223520,maximum observed concentration,MR-HC 15 mg demonstrated delayed and sustained release with a mean (sem) maximum observed concentration of 16.6 (1.4) microg/dl at 7.41 (0.57) h after drug.,Modified-release hydrocortisone to provide circadian cortisol profiles. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19223520/),[μg] / [dl],16.6,115678,DB00741,Hydrocortisone
,19223520,Bioavailability,"Bioavailability of MR-HC 5, 10, and 15 mg was 100, 79, and 86% that of immediate-release hydrocortisone.",Modified-release hydrocortisone to provide circadian cortisol profiles. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19223520/),%,100,115679,DB00741,Hydrocortisone
,19223520,Bioavailability,"Bioavailability of MR-HC 5, 10, and 15 mg was 100, 79, and 86% that of immediate-release hydrocortisone.",Modified-release hydrocortisone to provide circadian cortisol profiles. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19223520/),%,79,115680,DB00741,Hydrocortisone
,19223520,Bioavailability,"Bioavailability of MR-HC 5, 10, and 15 mg was 100, 79, and 86% that of immediate-release hydrocortisone.",Modified-release hydrocortisone to provide circadian cortisol profiles. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19223520/),%,86,115681,DB00741,Hydrocortisone
,6492803,ClC,The results showed that plasma clearance and volume of distribution values of TP were respectively 6 and 10 times larger than those of cortisol (ClC = 4.7 l/h/kg and ClTP = 33.3 l/h/kg; VdC = 1.9 l/kg and VdTP = 21.7 l/kg).,Comparative pharmacokinetic studies of tixocortol pivalate and cortisol in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6492803/),[l] / [h·kg],4.7,115682,DB00741,Hydrocortisone
,6492803,ClTP,The results showed that plasma clearance and volume of distribution values of TP were respectively 6 and 10 times larger than those of cortisol (ClC = 4.7 l/h/kg and ClTP = 33.3 l/h/kg; VdC = 1.9 l/kg and VdTP = 21.7 l/kg).,Comparative pharmacokinetic studies of tixocortol pivalate and cortisol in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6492803/),[l] / [h·kg],33.3,115683,DB00741,Hydrocortisone
,6492803,VdC,The results showed that plasma clearance and volume of distribution values of TP were respectively 6 and 10 times larger than those of cortisol (ClC = 4.7 l/h/kg and ClTP = 33.3 l/h/kg; VdC = 1.9 l/kg and VdTP = 21.7 l/kg).,Comparative pharmacokinetic studies of tixocortol pivalate and cortisol in the rat. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6492803/),[l] / [kg],1.9,115684,DB00741,Hydrocortisone
,6492803,VdTP,The results showed that plasma clearance and volume of distribution values of TP were respectively 6 and 10 times larger than those of cortisol (ClC = 4.7 l/h/kg and ClTP = 33.3 l/h/kg; VdC = 1.9 l/kg and VdTP = 21.7 l/kg).,Comparative pharmacokinetic studies of tixocortol pivalate and cortisol in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6492803/),[l] / [kg],21.7,115685,DB00741,Hydrocortisone
,6492803,bioavailability,"By the oral route, the bioavailability of cortisol was complete, whereas that of TP and T was 0.10-0.20.",Comparative pharmacokinetic studies of tixocortol pivalate and cortisol in the rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6492803/),,complete,115686,DB00741,Hydrocortisone
,6492803,bioavailability,"By the oral route, the bioavailability of cortisol was complete, whereas that of TP and T was 0.10-0.20.",Comparative pharmacokinetic studies of tixocortol pivalate and cortisol in the rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6492803/),,0.10-0.20,115687,DB00741,Hydrocortisone
,25369980,half-life,"Mean half-life was 76·5 ± 5·2 (range 40-225·3) min, Cmax 780·7 ± 61·6 nmol/l and tmax 66·7 (range 20-118) min.",Variation in absorption and half-life of hydrocortisone influence plasma cortisol concentrations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25369980/),min,76·5,116487,DB00741,Hydrocortisone
,25369980,Cmax,"Mean half-life was 76·5 ± 5·2 (range 40-225·3) min, Cmax 780·7 ± 61·6 nmol/l and tmax 66·7 (range 20-118) min.",Variation in absorption and half-life of hydrocortisone influence plasma cortisol concentrations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25369980/),[nM] / [l],780·7,116488,DB00741,Hydrocortisone
,25369980,tmax,"Mean half-life was 76·5 ± 5·2 (range 40-225·3) min, Cmax 780·7 ± 61·6 nmol/l and tmax 66·7 (range 20-118) min.",Variation in absorption and half-life of hydrocortisone influence plasma cortisol concentrations. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25369980/),min,66·7,116489,DB00741,Hydrocortisone
,25369980,Time taken,Time taken to a plasma cortisol concentration less than 100 nmol/l was 289 (range 140-540) min.,Variation in absorption and half-life of hydrocortisone influence plasma cortisol concentrations. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25369980/),min,289,116490,DB00741,Hydrocortisone
,25369980,half-life,"Those with a fast half-life and slow tmax took longest to reach a plasma cortisol concentration less than 100 nmol/l (380 ± 34·6 min), compared to those with a slow half-life and fast tmax (298 ± 34·8 min) and those with a fast half-life and fast tmax (249·5 ± 14·4 min) (One-way anovaF = 4·52; P = 0·009).",Variation in absorption and half-life of hydrocortisone influence plasma cortisol concentrations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25369980/),min,298,116491,DB00741,Hydrocortisone
,25369980,tmax,"Those with a fast half-life and slow tmax took longest to reach a plasma cortisol concentration less than 100 nmol/l (380 ± 34·6 min), compared to those with a slow half-life and fast tmax (298 ± 34·8 min) and those with a fast half-life and fast tmax (249·5 ± 14·4 min) (One-way anovaF = 4·52; P = 0·009).",Variation in absorption and half-life of hydrocortisone influence plasma cortisol concentrations. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25369980/),min,298,116492,DB00741,Hydrocortisone
,25369980,tmax,"Those with a fast half-life and slow tmax took longest to reach a plasma cortisol concentration less than 100 nmol/l (380 ± 34·6 min), compared to those with a slow half-life and fast tmax (298 ± 34·8 min) and those with a fast half-life and fast tmax (249·5 ± 14·4 min) (One-way anovaF = 4·52; P = 0·009).",Variation in absorption and half-life of hydrocortisone influence plasma cortisol concentrations. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25369980/),min,249·5,116493,DB00741,Hydrocortisone
,10354967,Cmax,"The Cmax values were about 3 ng/mL, while the tmax occurred at 7 to 9 hours.",Pharmacokinetic and adrenal interactions of IL-10 and prednisone in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10354967/),[ng] / [ml],3,116749,DB00741,Hydrocortisone
,10354967,tmax,"The Cmax values were about 3 ng/mL, while the tmax occurred at 7 to 9 hours.",Pharmacokinetic and adrenal interactions of IL-10 and prednisone in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10354967/),h,7 to 9,116750,DB00741,Hydrocortisone
,10354967,Cmax,"Prednisolone exhibited rapid systemic kinetics with a Cmax of 235 ng/mL, tmax at 1.11 hours, and t1/2 of 2.54 hours with no significant alterations owing to IL-10.",Pharmacokinetic and adrenal interactions of IL-10 and prednisone in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10354967/),[ng] / [ml],235,116751,DB00741,Hydrocortisone
,10354967,tmax,"Prednisolone exhibited rapid systemic kinetics with a Cmax of 235 ng/mL, tmax at 1.11 hours, and t1/2 of 2.54 hours with no significant alterations owing to IL-10.",Pharmacokinetic and adrenal interactions of IL-10 and prednisone in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10354967/),h,1.11,116752,DB00741,Hydrocortisone
,10354967,t1/2,"Prednisolone exhibited rapid systemic kinetics with a Cmax of 235 ng/mL, tmax at 1.11 hours, and t1/2 of 2.54 hours with no significant alterations owing to IL-10.",Pharmacokinetic and adrenal interactions of IL-10 and prednisone in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10354967/),h,2.54,116753,DB00741,Hydrocortisone
,15120956,terminal elimination half-lives,"The pharmacokinetic parameters of the two-compartment pharmacokinetic model for female and male camels, respectively (mean+/-SEM) were as follows: terminal elimination half-lives were 8.02+/-1.15 and 7.33+/-0.80 h, total body clearances were 95.5+/-16.0 and 124.5+/-11.9 ml h(-1) per kg, volumes of distribution at steady state were 0.72+/-0.08 and 0.87+/-0.14 litre kg(-1), and the volumes of the central compartment were 0.12+/-0.02 and 0.17+/-0.02 litre kg(-1).",Lack of gender effect on the pharmacokinetics and pharmacodynamics of dexamethasone in the camel after intravenous administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15120956/),h,8.02,117488,DB00741,Hydrocortisone
,15120956,terminal elimination half-lives,"The pharmacokinetic parameters of the two-compartment pharmacokinetic model for female and male camels, respectively (mean+/-SEM) were as follows: terminal elimination half-lives were 8.02+/-1.15 and 7.33+/-0.80 h, total body clearances were 95.5+/-16.0 and 124.5+/-11.9 ml h(-1) per kg, volumes of distribution at steady state were 0.72+/-0.08 and 0.87+/-0.14 litre kg(-1), and the volumes of the central compartment were 0.12+/-0.02 and 0.17+/-0.02 litre kg(-1).",Lack of gender effect on the pharmacokinetics and pharmacodynamics of dexamethasone in the camel after intravenous administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15120956/),h,7.33,117489,DB00741,Hydrocortisone
,15120956,total body clearances,"The pharmacokinetic parameters of the two-compartment pharmacokinetic model for female and male camels, respectively (mean+/-SEM) were as follows: terminal elimination half-lives were 8.02+/-1.15 and 7.33+/-0.80 h, total body clearances were 95.5+/-16.0 and 124.5+/-11.9 ml h(-1) per kg, volumes of distribution at steady state were 0.72+/-0.08 and 0.87+/-0.14 litre kg(-1), and the volumes of the central compartment were 0.12+/-0.02 and 0.17+/-0.02 litre kg(-1).",Lack of gender effect on the pharmacokinetics and pharmacodynamics of dexamethasone in the camel after intravenous administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15120956/),[ml] / [h·kg],95.5,117490,DB00741,Hydrocortisone
,15120956,total body clearances,"The pharmacokinetic parameters of the two-compartment pharmacokinetic model for female and male camels, respectively (mean+/-SEM) were as follows: terminal elimination half-lives were 8.02+/-1.15 and 7.33+/-0.80 h, total body clearances were 95.5+/-16.0 and 124.5+/-11.9 ml h(-1) per kg, volumes of distribution at steady state were 0.72+/-0.08 and 0.87+/-0.14 litre kg(-1), and the volumes of the central compartment were 0.12+/-0.02 and 0.17+/-0.02 litre kg(-1).",Lack of gender effect on the pharmacokinetics and pharmacodynamics of dexamethasone in the camel after intravenous administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15120956/),[ml] / [h·kg],124.5,117491,DB00741,Hydrocortisone
,15120956,volumes of distribution at steady state,"The pharmacokinetic parameters of the two-compartment pharmacokinetic model for female and male camels, respectively (mean+/-SEM) were as follows: terminal elimination half-lives were 8.02+/-1.15 and 7.33+/-0.80 h, total body clearances were 95.5+/-16.0 and 124.5+/-11.9 ml h(-1) per kg, volumes of distribution at steady state were 0.72+/-0.08 and 0.87+/-0.14 litre kg(-1), and the volumes of the central compartment were 0.12+/-0.02 and 0.17+/-0.02 litre kg(-1).",Lack of gender effect on the pharmacokinetics and pharmacodynamics of dexamethasone in the camel after intravenous administration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15120956/),[l] / [kg],0.72,117492,DB00741,Hydrocortisone
,15120956,volumes of distribution at steady state,"The pharmacokinetic parameters of the two-compartment pharmacokinetic model for female and male camels, respectively (mean+/-SEM) were as follows: terminal elimination half-lives were 8.02+/-1.15 and 7.33+/-0.80 h, total body clearances were 95.5+/-16.0 and 124.5+/-11.9 ml h(-1) per kg, volumes of distribution at steady state were 0.72+/-0.08 and 0.87+/-0.14 litre kg(-1), and the volumes of the central compartment were 0.12+/-0.02 and 0.17+/-0.02 litre kg(-1).",Lack of gender effect on the pharmacokinetics and pharmacodynamics of dexamethasone in the camel after intravenous administration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15120956/),[l] / [kg],0.87,117493,DB00741,Hydrocortisone
,15120956,volumes of the central compartment,"The pharmacokinetic parameters of the two-compartment pharmacokinetic model for female and male camels, respectively (mean+/-SEM) were as follows: terminal elimination half-lives were 8.02+/-1.15 and 7.33+/-0.80 h, total body clearances were 95.5+/-16.0 and 124.5+/-11.9 ml h(-1) per kg, volumes of distribution at steady state were 0.72+/-0.08 and 0.87+/-0.14 litre kg(-1), and the volumes of the central compartment were 0.12+/-0.02 and 0.17+/-0.02 litre kg(-1).",Lack of gender effect on the pharmacokinetics and pharmacodynamics of dexamethasone in the camel after intravenous administration. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15120956/),[l] / [kg],0.12,117494,DB00741,Hydrocortisone
,15120956,volumes of the central compartment,"The pharmacokinetic parameters of the two-compartment pharmacokinetic model for female and male camels, respectively (mean+/-SEM) were as follows: terminal elimination half-lives were 8.02+/-1.15 and 7.33+/-0.80 h, total body clearances were 95.5+/-16.0 and 124.5+/-11.9 ml h(-1) per kg, volumes of distribution at steady state were 0.72+/-0.08 and 0.87+/-0.14 litre kg(-1), and the volumes of the central compartment were 0.12+/-0.02 and 0.17+/-0.02 litre kg(-1).",Lack of gender effect on the pharmacokinetics and pharmacodynamics of dexamethasone in the camel after intravenous administration. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15120956/),[l] / [kg],0.17,117495,DB00741,Hydrocortisone
,15120956,IC50,"The estimated IC50 of dexamethasone for cortisol and lymphocytes for female and male camels were 3.74+/-0.99 and 2.28+/-1.09 and 2.63+/-0.71 and 2.41+/-0.79 ng ml(-1), respectively.",Lack of gender effect on the pharmacokinetics and pharmacodynamics of dexamethasone in the camel after intravenous administration. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15120956/),[ng] / [ml],3.74,117496,DB00741,Hydrocortisone
,15120956,IC50,"The estimated IC50 of dexamethasone for cortisol and lymphocytes for female and male camels were 3.74+/-0.99 and 2.28+/-1.09 and 2.63+/-0.71 and 2.41+/-0.79 ng ml(-1), respectively.",Lack of gender effect on the pharmacokinetics and pharmacodynamics of dexamethasone in the camel after intravenous administration. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15120956/),[ng] / [ml],2.28,117497,DB00741,Hydrocortisone
,15120956,IC50,"The estimated IC50 of dexamethasone for cortisol and lymphocytes for female and male camels were 3.74+/-0.99 and 2.28+/-1.09 and 2.63+/-0.71 and 2.41+/-0.79 ng ml(-1), respectively.",Lack of gender effect on the pharmacokinetics and pharmacodynamics of dexamethasone in the camel after intravenous administration. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15120956/),[ng] / [ml],2.63,117498,DB00741,Hydrocortisone
,15120956,IC50,"The estimated IC50 of dexamethasone for cortisol and lymphocytes for female and male camels were 3.74+/-0.99 and 2.28+/-1.09 and 2.63+/-0.71 and 2.41+/-0.79 ng ml(-1), respectively.",Lack of gender effect on the pharmacokinetics and pharmacodynamics of dexamethasone in the camel after intravenous administration. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15120956/),[ng] / [ml],2.41,117499,DB00741,Hydrocortisone
,15120956,EC50,"The EC50 for neutrophils for female and male camels were 24.5+/-5.83 and 20.2+/-3.82 ng ml(-1), respectively.",Lack of gender effect on the pharmacokinetics and pharmacodynamics of dexamethasone in the camel after intravenous administration. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15120956/),[ng] / [ml],24.5,117500,DB00741,Hydrocortisone
,15120956,EC50,"The EC50 for neutrophils for female and male camels were 24.5+/-5.83 and 20.2+/-3.82 ng ml(-1), respectively.",Lack of gender effect on the pharmacokinetics and pharmacodynamics of dexamethasone in the camel after intravenous administration. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15120956/),[ng] / [ml],20.2,117501,DB00741,Hydrocortisone
,23672956,Cmax,"Serum cortisol increased rapidly and substantially after both i.m. and s.c. injections (Cmax: 110±29 vs 97±28 μg/dl, P=0.27, tmax: 66±51 vs 91±34 min, P=0.17, and tserum cortisol >36 μg/dl: 11±5 vs 22±11 min, P=0.004 respectively).",Subcutaneous hydrocortisone administration for emergency use in adrenal insufficiency. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23672956/),[μg] / [dl],110,118595,DB00741,Hydrocortisone
,23672956,Cmax,"Serum cortisol increased rapidly and substantially after both i.m. and s.c. injections (Cmax: 110±29 vs 97±28 μg/dl, P=0.27, tmax: 66±51 vs 91±34 min, P=0.17, and tserum cortisol >36 μg/dl: 11±5 vs 22±11 min, P=0.004 respectively).",Subcutaneous hydrocortisone administration for emergency use in adrenal insufficiency. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23672956/),[μg] / [dl],97,118596,DB00741,Hydrocortisone
,23672956,tmax,"Serum cortisol increased rapidly and substantially after both i.m. and s.c. injections (Cmax: 110±29 vs 97±28 μg/dl, P=0.27, tmax: 66±51 vs 91±34 min, P=0.17, and tserum cortisol >36 μg/dl: 11±5 vs 22±11 min, P=0.004 respectively).",Subcutaneous hydrocortisone administration for emergency use in adrenal insufficiency. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23672956/),min,66,118597,DB00741,Hydrocortisone
,23672956,tmax,"Serum cortisol increased rapidly and substantially after both i.m. and s.c. injections (Cmax: 110±29 vs 97±28 μg/dl, P=0.27, tmax: 66±51 vs 91±34 min, P=0.17, and tserum cortisol >36 μg/dl: 11±5 vs 22±11 min, P=0.004 respectively).",Subcutaneous hydrocortisone administration for emergency use in adrenal insufficiency. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23672956/),min,91,118598,DB00741,Hydrocortisone
,23672956,tserum,"Serum cortisol increased rapidly and substantially after both i.m. and s.c. injections (Cmax: 110±29 vs 97±28 μg/dl, P=0.27, tmax: 66±51 vs 91±34 min, P=0.17, and tserum cortisol >36 μg/dl: 11±5 vs 22±11 min, P=0.004 respectively).",Subcutaneous hydrocortisone administration for emergency use in adrenal insufficiency. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23672956/),min,11,118599,DB00741,Hydrocortisone
,23672956,tserum,"Serum cortisol increased rapidly and substantially after both i.m. and s.c. injections (Cmax: 110±29 vs 97±28 μg/dl, P=0.27, tmax: 66±51 vs 91±34 min, P=0.17, and tserum cortisol >36 μg/dl: 11±5 vs 22±11 min, P=0.004 respectively).",Subcutaneous hydrocortisone administration for emergency use in adrenal insufficiency. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23672956/),min,22,118600,DB00741,Hydrocortisone
,7840321,Metabolic clearance rates,"Metabolic clearance rates were 3.15 +/- 0.39 and 2.48 +/- 0.36 l/min, respectively.",Biological actions and pharmacokinetics of C-type natriuretic peptide in conscious sheep. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7840321/),[l] / [min],3.15,119041,DB00741,Hydrocortisone
,7840321,Metabolic clearance rates,"Metabolic clearance rates were 3.15 +/- 0.39 and 2.48 +/- 0.36 l/min, respectively.",Biological actions and pharmacokinetics of C-type natriuretic peptide in conscious sheep. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7840321/),[l] / [min],2.48,119042,DB00741,Hydrocortisone
,7840321,plasma half-life,The plasma half-life of CNP on termination of infusion was rapid (1.6 +/- 0.27 min).,Biological actions and pharmacokinetics of C-type natriuretic peptide in conscious sheep. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7840321/),min,1.6,119043,DB00741,Hydrocortisone
,25986188,IC50,"In vitro hydrolysis of carbamazepine-epoxide in human hepatocytes was inhibited by brivaracetam, with an IC50 of 8.2μM.",Brivaracetam and carbamazepine interaction in healthy subjects and in vitro. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25986188/),μM,8.2,119129,DB00741,Hydrocortisone
,7951525,plasma half-lives (T1/2),"The disappearance of MCI-028 from plasma could be fitted to a biexponential decay curve, the plasma half-lives (T1/2) were 0.12 to 0.15 h for alpha phase, and 0.57 to 0.67 h for beta phase.",Diagnostic study of a synthetic human corticotropin-releasing hormone (hCRH) in healthy adult males: its plasma pharmacokinetics and the effects on the urinary excretion of steroid hormones. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7951525/),h,0.12 to 0.15,119376,DB00741,Hydrocortisone
,7951525,plasma half-lives (T1/2),"The disappearance of MCI-028 from plasma could be fitted to a biexponential decay curve, the plasma half-lives (T1/2) were 0.12 to 0.15 h for alpha phase, and 0.57 to 0.67 h for beta phase.",Diagnostic study of a synthetic human corticotropin-releasing hormone (hCRH) in healthy adult males: its plasma pharmacokinetics and the effects on the urinary excretion of steroid hormones. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7951525/),h,0.57 to 0.67,119377,DB00741,Hydrocortisone
exceeds,16159619,time to steady state,Accumulation of fluticasone concentrations suggests that time to steady state exceeds 1 week of treatment with MDI.,Fluticasone propionate plasma concentration and systemic effect: effect of delivery device and duration of administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16159619/),week,1,120351,DB00741,Hydrocortisone
,2294128,peak amplitude,"Cluster analysis of cortisol time series revealed a normal pulse frequency, with significant increases in mean peak amplitude (527 vs. 331 nmol/L; P = 0.001), mean interpulse valley concentrations (384 vs. 204 nmol/L; P less than 0.05), and mean prepeak nadir concentrations (298 vs. 166 nmol/L; P less than 0.05).",Dynamics of 24-hour endogenous cortisol secretion and clearance in primary hypothyroidism assessed before and after partial thyroid hormone replacement. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2294128/),[nM] / [l],527,120787,DB00741,Hydrocortisone
,2294128,peak amplitude,"Cluster analysis of cortisol time series revealed a normal pulse frequency, with significant increases in mean peak amplitude (527 vs. 331 nmol/L; P = 0.001), mean interpulse valley concentrations (384 vs. 204 nmol/L; P less than 0.05), and mean prepeak nadir concentrations (298 vs. 166 nmol/L; P less than 0.05).",Dynamics of 24-hour endogenous cortisol secretion and clearance in primary hypothyroidism assessed before and after partial thyroid hormone replacement. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2294128/),[nM] / [l],331,120788,DB00741,Hydrocortisone
,2294128,interpulse valley concentrations,"Cluster analysis of cortisol time series revealed a normal pulse frequency, with significant increases in mean peak amplitude (527 vs. 331 nmol/L; P = 0.001), mean interpulse valley concentrations (384 vs. 204 nmol/L; P less than 0.05), and mean prepeak nadir concentrations (298 vs. 166 nmol/L; P less than 0.05).",Dynamics of 24-hour endogenous cortisol secretion and clearance in primary hypothyroidism assessed before and after partial thyroid hormone replacement. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2294128/),[nM] / [l],384,120789,DB00741,Hydrocortisone
,2294128,interpulse valley concentrations,"Cluster analysis of cortisol time series revealed a normal pulse frequency, with significant increases in mean peak amplitude (527 vs. 331 nmol/L; P = 0.001), mean interpulse valley concentrations (384 vs. 204 nmol/L; P less than 0.05), and mean prepeak nadir concentrations (298 vs. 166 nmol/L; P less than 0.05).",Dynamics of 24-hour endogenous cortisol secretion and clearance in primary hypothyroidism assessed before and after partial thyroid hormone replacement. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2294128/),[nM] / [l],204,120790,DB00741,Hydrocortisone
,2294128,prepeak nadir concentrations,"Cluster analysis of cortisol time series revealed a normal pulse frequency, with significant increases in mean peak amplitude (527 vs. 331 nmol/L; P = 0.001), mean interpulse valley concentrations (384 vs. 204 nmol/L; P less than 0.05), and mean prepeak nadir concentrations (298 vs. 166 nmol/L; P less than 0.05).",Dynamics of 24-hour endogenous cortisol secretion and clearance in primary hypothyroidism assessed before and after partial thyroid hormone replacement. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2294128/),[nM] / [l],298,120791,DB00741,Hydrocortisone
,2294128,prepeak nadir concentrations,"Cluster analysis of cortisol time series revealed a normal pulse frequency, with significant increases in mean peak amplitude (527 vs. 331 nmol/L; P = 0.001), mean interpulse valley concentrations (384 vs. 204 nmol/L; P less than 0.05), and mean prepeak nadir concentrations (298 vs. 166 nmol/L; P less than 0.05).",Dynamics of 24-hour endogenous cortisol secretion and clearance in primary hypothyroidism assessed before and after partial thyroid hormone replacement. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2294128/),[nM] / [l],166,120792,DB00741,Hydrocortisone
,2294128,half-life of cort,Analysis of data by a multiple parameter deconvolution method demonstrated a normal 24-h endogenous cortisol production rate in the presence of significantly prolonged subject-specific half-life of cortisol disappearance (155 vs. 73 min; P less than 0.05).,Dynamics of 24-hour endogenous cortisol secretion and clearance in primary hypothyroidism assessed before and after partial thyroid hormone replacement. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2294128/),min,155,120793,DB00741,Hydrocortisone
,2294128,half-life of cort,Analysis of data by a multiple parameter deconvolution method demonstrated a normal 24-h endogenous cortisol production rate in the presence of significantly prolonged subject-specific half-life of cortisol disappearance (155 vs. 73 min; P less than 0.05).,Dynamics of 24-hour endogenous cortisol secretion and clearance in primary hypothyroidism assessed before and after partial thyroid hormone replacement. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2294128/),min,73,120794,DB00741,Hydrocortisone
,2294128,peak amplitudes,Partial replacement therapy with levo-T4 caused significant decreases in 1) mean 24-h serum cortisol concentrations (419 vs. 323 nmol/L; P less than 0.05); 2) mean cortisol peak amplitudes (527 vs. 375 nmol/L; P less than 0.05); 3) mean prepeak nadir concentrations (298 vs. 221 nmol/L; P less than 0.05); and 4) mean half-life of cortisol disappearance (155 vs. 112 min; P less than 0.0019).,Dynamics of 24-hour endogenous cortisol secretion and clearance in primary hypothyroidism assessed before and after partial thyroid hormone replacement. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2294128/),[nM] / [l],527,120795,DB00741,Hydrocortisone
,2294128,peak amplitudes,Partial replacement therapy with levo-T4 caused significant decreases in 1) mean 24-h serum cortisol concentrations (419 vs. 323 nmol/L; P less than 0.05); 2) mean cortisol peak amplitudes (527 vs. 375 nmol/L; P less than 0.05); 3) mean prepeak nadir concentrations (298 vs. 221 nmol/L; P less than 0.05); and 4) mean half-life of cortisol disappearance (155 vs. 112 min; P less than 0.0019).,Dynamics of 24-hour endogenous cortisol secretion and clearance in primary hypothyroidism assessed before and after partial thyroid hormone replacement. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2294128/),[nM] / [l],375,120796,DB00741,Hydrocortisone
,2294128,prepeak nadir concentrations,Partial replacement therapy with levo-T4 caused significant decreases in 1) mean 24-h serum cortisol concentrations (419 vs. 323 nmol/L; P less than 0.05); 2) mean cortisol peak amplitudes (527 vs. 375 nmol/L; P less than 0.05); 3) mean prepeak nadir concentrations (298 vs. 221 nmol/L; P less than 0.05); and 4) mean half-life of cortisol disappearance (155 vs. 112 min; P less than 0.0019).,Dynamics of 24-hour endogenous cortisol secretion and clearance in primary hypothyroidism assessed before and after partial thyroid hormone replacement. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2294128/),[nM] / [l],298,120797,DB00741,Hydrocortisone
,2294128,prepeak nadir concentrations,Partial replacement therapy with levo-T4 caused significant decreases in 1) mean 24-h serum cortisol concentrations (419 vs. 323 nmol/L; P less than 0.05); 2) mean cortisol peak amplitudes (527 vs. 375 nmol/L; P less than 0.05); 3) mean prepeak nadir concentrations (298 vs. 221 nmol/L; P less than 0.05); and 4) mean half-life of cortisol disappearance (155 vs. 112 min; P less than 0.0019).,Dynamics of 24-hour endogenous cortisol secretion and clearance in primary hypothyroidism assessed before and after partial thyroid hormone replacement. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2294128/),[nM] / [l],221,120798,DB00741,Hydrocortisone
,2294128,half-life of cortisol disappearance,Partial replacement therapy with levo-T4 caused significant decreases in 1) mean 24-h serum cortisol concentrations (419 vs. 323 nmol/L; P less than 0.05); 2) mean cortisol peak amplitudes (527 vs. 375 nmol/L; P less than 0.05); 3) mean prepeak nadir concentrations (298 vs. 221 nmol/L; P less than 0.05); and 4) mean half-life of cortisol disappearance (155 vs. 112 min; P less than 0.0019).,Dynamics of 24-hour endogenous cortisol secretion and clearance in primary hypothyroidism assessed before and after partial thyroid hormone replacement. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2294128/),min,155,120799,DB00741,Hydrocortisone
,2294128,half-life of cortisol disappearance,Partial replacement therapy with levo-T4 caused significant decreases in 1) mean 24-h serum cortisol concentrations (419 vs. 323 nmol/L; P less than 0.05); 2) mean cortisol peak amplitudes (527 vs. 375 nmol/L; P less than 0.05); 3) mean prepeak nadir concentrations (298 vs. 221 nmol/L; P less than 0.05); and 4) mean half-life of cortisol disappearance (155 vs. 112 min; P less than 0.0019).,Dynamics of 24-hour endogenous cortisol secretion and clearance in primary hypothyroidism assessed before and after partial thyroid hormone replacement. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2294128/),min,112,120800,DB00741,Hydrocortisone
,11961072,central,"Pericardial fluid volumes of catheter-instrumented rats, derived from (initial) central compartment volumes, ranged between 0.5 and 0.9 ml/kg.",Pharmacokinetic advantage of intrapericardially applied substances in the rat. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11961072/),[ml] / [kg],0.5 and 0.9,124368,DB00741,Hydrocortisone
,11961072,per,"After chronic (7 days) intrapericardial infusions with osmotic minipumps, pericardial fluid/plasma concentration ratios (local advantages) were 7 to 10 for the fluorescent proteins and >30 for FITC-heparin.",Pharmacokinetic advantage of intrapericardially applied substances in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11961072/),,7 to 10,124369,DB00741,Hydrocortisone
,11961072,fluid/plasma concentration ratios,"After chronic (7 days) intrapericardial infusions with osmotic minipumps, pericardial fluid/plasma concentration ratios (local advantages) were 7 to 10 for the fluorescent proteins and >30 for FITC-heparin.",Pharmacokinetic advantage of intrapericardially applied substances in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11961072/),,7 to 10,124370,DB00741,Hydrocortisone
>,11961072,fluid/plasma concentration ratios,"After chronic (7 days) intrapericardial infusions with osmotic minipumps, pericardial fluid/plasma concentration ratios (local advantages) were 7 to 10 for the fluorescent proteins and >30 for FITC-heparin.",Pharmacokinetic advantage of intrapericardially applied substances in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11961072/),,30,124371,DB00741,Hydrocortisone
,25847081,Tmax,BTM in plasma had greater Tmax (Tmax 0.8 h) vs. urine (Tmax 7.1 h).,Pharmacokinetics of intra-articular betamethasone sodium phosphate and betamethasone acetate and endogenous hydrocortisone suppression in exercising horses. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25847081/),h,0.8,124835,DB00741,Hydrocortisone
,25847081,Tmax,BTM in plasma had greater Tmax (Tmax 0.8 h) vs. urine (Tmax 7.1 h).,Pharmacokinetics of intra-articular betamethasone sodium phosphate and betamethasone acetate and endogenous hydrocortisone suppression in exercising horses. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25847081/),h,7.1,124836,DB00741,Hydrocortisone
,8501158,production rate,The estimated cortisol production rate for the early group [16.8 +/- 1.3 mumol/m2 x day (6.1 +/- 0.4 mg/m2 x day)] was indistinguishable from that of the late subjects [14.8 +/- 1.4 mumol/m2 x day (5.3 +/- 0.5 mg/m2 x day)].,Estimation of daily cortisol production and clearance rates in normal pubertal males by deconvolution analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8501158/),[μM] / [d·m2],16.8,125174,DB00741,Hydrocortisone
,8501158,production rate,The estimated cortisol production rate for the early group [16.8 +/- 1.3 mumol/m2 x day (6.1 +/- 0.4 mg/m2 x day)] was indistinguishable from that of the late subjects [14.8 +/- 1.4 mumol/m2 x day (5.3 +/- 0.5 mg/m2 x day)].,Estimation of daily cortisol production and clearance rates in normal pubertal males by deconvolution analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8501158/),[mg] / [d·m2],6.1,125175,DB00741,Hydrocortisone
,8501158,production rate,The estimated cortisol production rate for the early group [16.8 +/- 1.3 mumol/m2 x day (6.1 +/- 0.4 mg/m2 x day)] was indistinguishable from that of the late subjects [14.8 +/- 1.4 mumol/m2 x day (5.3 +/- 0.5 mg/m2 x day)].,Estimation of daily cortisol production and clearance rates in normal pubertal males by deconvolution analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8501158/),[μM] / [d·m2],14.8,125176,DB00741,Hydrocortisone
,8501158,production rate,The estimated cortisol production rate for the early group [16.8 +/- 1.3 mumol/m2 x day (6.1 +/- 0.4 mg/m2 x day)] was indistinguishable from that of the late subjects [14.8 +/- 1.4 mumol/m2 x day (5.3 +/- 0.5 mg/m2 x day)].,Estimation of daily cortisol production and clearance rates in normal pubertal males by deconvolution analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8501158/),[mg] / [d·m2],5.3,125177,DB00741,Hydrocortisone
,30956016,half-life,"The plasma concentration of ketamine decreased with a half-life of approximately 12 minutes, which was longer than the dose interval.",The course of plasma cortisol concentration after three different doses of ketamine in xylazine-premedicated calves. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30956016/),min,12,125919,DB00741,Hydrocortisone
,3855472,half-life (t 1/2),[3H]VBL exhibited two phases of elimination: a rapid early phase [half-life (t 1/2) of approximately equal to 30 min] and a prolonged terminal phase (t 1/2 of approximately equal to 17 hr).,Vinca alkaloid skin toxicity: antidote and drug disposition studies in the mouse. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3855472/),min,30,126941,DB00741,Hydrocortisone
,3855472,terminal phase (t 1/2,[3H]VBL exhibited two phases of elimination: a rapid early phase [half-life (t 1/2) of approximately equal to 30 min] and a prolonged terminal phase (t 1/2 of approximately equal to 17 hr).,Vinca alkaloid skin toxicity: antidote and drug disposition studies in the mouse. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3855472/),h,17,126942,DB00741,Hydrocortisone
,1115177,metabolic clearance rates (MCR),"Corresponding values for the metabolic clearance rates (MCR) of cortisol (by the continuous infusion method) were 306 plus or minus 33, 172 plus or minus 18, 136 plus or minus 14, and 258 plus or minus 23 (S. E.) L. per day.",Estrogen and the metabolism of progesterone in vivo. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1115177/),[l] / [d],306,127236,DB00741,Hydrocortisone
,1115177,metabolic clearance rates (MCR),"Corresponding values for the metabolic clearance rates (MCR) of cortisol (by the continuous infusion method) were 306 plus or minus 33, 172 plus or minus 18, 136 plus or minus 14, and 258 plus or minus 23 (S. E.) L. per day.",Estrogen and the metabolism of progesterone in vivo. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1115177/),[l] / [d],172,127237,DB00741,Hydrocortisone
,1115177,metabolic clearance rates (MCR),"Corresponding values for the metabolic clearance rates (MCR) of cortisol (by the continuous infusion method) were 306 plus or minus 33, 172 plus or minus 18, 136 plus or minus 14, and 258 plus or minus 23 (S. E.) L. per day.",Estrogen and the metabolism of progesterone in vivo. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1115177/),[l] / [d],136,127238,DB00741,Hydrocortisone
,1115177,metabolic clearance rates (MCR),"Corresponding values for the metabolic clearance rates (MCR) of cortisol (by the continuous infusion method) were 306 plus or minus 33, 172 plus or minus 18, 136 plus or minus 14, and 258 plus or minus 23 (S. E.) L. per day.",Estrogen and the metabolism of progesterone in vivo. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1115177/),[l] / [d],258,127239,DB00741,Hydrocortisone
,15001641,t(1/2),The plasma Ucn-1 t(1/2) was 52 min based on a one-compartment model.,Urocortin-1 infusion in normal humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15001641/),min,52,127383,DB00741,Hydrocortisone
,33729577,terminal half-life,"Dexamethasone, formulated as sodium phosphate, terminal half-life was 10.4 h in plasma and approximately 16 h in urine, and at 96 h, plasma hydrocortisone concentrations returned to background with dexamethasone levels around the LOQ.",Plasma and urine pharmacokinetics of two formulations of dexamethasone in greyhound dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33729577/),h,10.4,128371,DB00741,Hydrocortisone
,33729577,terminal half-life,"Dexamethasone, formulated as sodium phosphate, terminal half-life was 10.4 h in plasma and approximately 16 h in urine, and at 96 h, plasma hydrocortisone concentrations returned to background with dexamethasone levels around the LOQ.",Plasma and urine pharmacokinetics of two formulations of dexamethasone in greyhound dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33729577/),h,16,128372,DB00741,Hydrocortisone
,33729577,terminal half-life,"Dexamethasone, formulated as phenylpropionate combined with sodium phosphate, terminal half-life, was 25.6 h in plasma and approximately 26 h in urine, and at 96 h, plasma hydrocortisone concentrations returned to background with dexamethasone levels in three of the six greyhounds around the LOQ.",Plasma and urine pharmacokinetics of two formulations of dexamethasone in greyhound dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33729577/),h,25.6,128373,DB00741,Hydrocortisone
,33729577,terminal half-life,"Dexamethasone, formulated as phenylpropionate combined with sodium phosphate, terminal half-life, was 25.6 h in plasma and approximately 26 h in urine, and at 96 h, plasma hydrocortisone concentrations returned to background with dexamethasone levels in three of the six greyhounds around the LOQ.",Plasma and urine pharmacokinetics of two formulations of dexamethasone in greyhound dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33729577/),h,26,128374,DB00741,Hydrocortisone
,3994138,half-life of elimination,"After IV administration of prednisolone 21-sodium succinate, the half-life of elimination was 3.6 +/- 1.177 hours.",Prednisolone succinate and prednisolone acetate in cattle: pharmacokinetics and action on the adrenal gland. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3994138/),h,3.6,129144,DB00741,Hydrocortisone
,3994138,absorption half-life,"After IM administration of prednisolone acetate, absorption was very slow with an absorption half-life of 48 hours, but was still complete.",Prednisolone succinate and prednisolone acetate in cattle: pharmacokinetics and action on the adrenal gland. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3994138/),h,48,129145,DB00741,Hydrocortisone
,6129344,half-life,Antipyrine half-life was shortened in all patients from a mean value of 12.3 +/- 3.9 h to 7.8 +/- 2.0 h and antipyrine clearance was increased from 39.0 +/- 16.0 ml/min to 57.6 +/- 13.7 ml/min.,Enhanced drug metabolism after sulfinpyrazone treatment in patients aged 50 to 60 years. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6129344/),h,12.3,129319,DB00741,Hydrocortisone
,6129344,half-life,Antipyrine half-life was shortened in all patients from a mean value of 12.3 +/- 3.9 h to 7.8 +/- 2.0 h and antipyrine clearance was increased from 39.0 +/- 16.0 ml/min to 57.6 +/- 13.7 ml/min.,Enhanced drug metabolism after sulfinpyrazone treatment in patients aged 50 to 60 years. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6129344/),h,7.8,129320,DB00741,Hydrocortisone
,6129344,clearance,Antipyrine half-life was shortened in all patients from a mean value of 12.3 +/- 3.9 h to 7.8 +/- 2.0 h and antipyrine clearance was increased from 39.0 +/- 16.0 ml/min to 57.6 +/- 13.7 ml/min.,Enhanced drug metabolism after sulfinpyrazone treatment in patients aged 50 to 60 years. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6129344/),[ml] / [min],39.0,129321,DB00741,Hydrocortisone
,6129344,clearance,Antipyrine half-life was shortened in all patients from a mean value of 12.3 +/- 3.9 h to 7.8 +/- 2.0 h and antipyrine clearance was increased from 39.0 +/- 16.0 ml/min to 57.6 +/- 13.7 ml/min.,Enhanced drug metabolism after sulfinpyrazone treatment in patients aged 50 to 60 years. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6129344/),[ml] / [min],57.6,129322,DB00741,Hydrocortisone
,6129344,volume of distribution,"In contrast the volume of distribution of antipyrine was unaffected; the values being 38.0 +/- 8.6 liters and 37.4 +/- 5.7 liters, respectively.",Enhanced drug metabolism after sulfinpyrazone treatment in patients aged 50 to 60 years. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6129344/),l,38.0,129323,DB00741,Hydrocortisone
,6129344,volume of distribution,"In contrast the volume of distribution of antipyrine was unaffected; the values being 38.0 +/- 8.6 liters and 37.4 +/- 5.7 liters, respectively.",Enhanced drug metabolism after sulfinpyrazone treatment in patients aged 50 to 60 years. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6129344/),l,37.4,129324,DB00741,Hydrocortisone
,6129344,excretion,In all patients the excretion of 6-beta-OH-cortisol in the urine went up from 65.0 +/- 25.7 micrograms/24 h to 346.8 +/- 193.4 micrograms/24 h.,Enhanced drug metabolism after sulfinpyrazone treatment in patients aged 50 to 60 years. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6129344/),[μg] / [24·h],65.0,129325,DB00741,Hydrocortisone
,6129344,excretion,In all patients the excretion of 6-beta-OH-cortisol in the urine went up from 65.0 +/- 25.7 micrograms/24 h to 346.8 +/- 193.4 micrograms/24 h.,Enhanced drug metabolism after sulfinpyrazone treatment in patients aged 50 to 60 years. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6129344/),[μg] / [24·h],346.8,129326,DB00741,Hydrocortisone
,6129344,GGT,After 21 days of treatment the GGT increased from 17.4 +/- 4.9 units/liter to 32.6 +/- 12.5 units/liter,Enhanced drug metabolism after sulfinpyrazone treatment in patients aged 50 to 60 years. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6129344/),[units] / [l],17.4,129327,DB00741,Hydrocortisone
,6129344,GGT,After 21 days of treatment the GGT increased from 17.4 +/- 4.9 units/liter to 32.6 +/- 12.5 units/liter,Enhanced drug metabolism after sulfinpyrazone treatment in patients aged 50 to 60 years. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6129344/),[units] / [l],32.6,129328,DB00741,Hydrocortisone
,18341673,t(max),Brivaracetam was rapidly absorbed (t(max) approximately 2 h) and eliminated (t(1/2) 7-8 h).,"The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after multiple increasing oral doses in healthy men. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18341673/),h,2,129384,DB00741,Hydrocortisone
,18341673,t(1/2),Brivaracetam was rapidly absorbed (t(max) approximately 2 h) and eliminated (t(1/2) 7-8 h).,"The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after multiple increasing oral doses in healthy men. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18341673/),h,7-8,129385,DB00741,Hydrocortisone
,8274287,half life,PRED-17-EC was further metabolized with a half life of 1.6 h to prednisolone.,Studies on the pharmacokinetics and metabolism of prednicarbate after cutaneous and oral administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8274287/),h,1.6,133438,DB00741,Hydrocortisone
,7136521,half time of the show phase of elimination,The half time of the show phase of elimination was about 19 h.,Absorption of topically applied hydrocortisone from the eye of the rhesus monkey. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7136521/),h,19,133637,DB00741,Hydrocortisone
,16918954,MRTs,"Elimination of ACTH(1-24) was faster in HDT than in LDT (MRTs of 0.14 vs 0.37, respectively, P = 0.008), but plasma concentrations were higher up to 60 min cortisol production in HDT reaching a higher maximum concentration (Cmax: 1144 vs 960 nmol/l) but delayed in time (75 vs 52.5 min).","Profile, mean residence time of ACTH and cortisol responses after low and standard ACTH tests in healthy volunteers. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16918954/),,0.14,133997,DB00741,Hydrocortisone
,16918954,MRTs,"Elimination of ACTH(1-24) was faster in HDT than in LDT (MRTs of 0.14 vs 0.37, respectively, P = 0.008), but plasma concentrations were higher up to 60 min cortisol production in HDT reaching a higher maximum concentration (Cmax: 1144 vs 960 nmol/l) but delayed in time (75 vs 52.5 min).","Profile, mean residence time of ACTH and cortisol responses after low and standard ACTH tests in healthy volunteers. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16918954/),,0.37,133998,DB00741,Hydrocortisone
,16918954,maximum concentration (Cmax,"Elimination of ACTH(1-24) was faster in HDT than in LDT (MRTs of 0.14 vs 0.37, respectively, P = 0.008), but plasma concentrations were higher up to 60 min cortisol production in HDT reaching a higher maximum concentration (Cmax: 1144 vs 960 nmol/l) but delayed in time (75 vs 52.5 min).","Profile, mean residence time of ACTH and cortisol responses after low and standard ACTH tests in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16918954/),[nM] / [l],1144,133999,DB00741,Hydrocortisone
,16918954,maximum concentration (Cmax,"Elimination of ACTH(1-24) was faster in HDT than in LDT (MRTs of 0.14 vs 0.37, respectively, P = 0.008), but plasma concentrations were higher up to 60 min cortisol production in HDT reaching a higher maximum concentration (Cmax: 1144 vs 960 nmol/l) but delayed in time (75 vs 52.5 min).","Profile, mean residence time of ACTH and cortisol responses after low and standard ACTH tests in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16918954/),[nM] / [l],960,134000,DB00741,Hydrocortisone
,16918954,maximum concentration (Cmax,"Elimination of ACTH(1-24) was faster in HDT than in LDT (MRTs of 0.14 vs 0.37, respectively, P = 0.008), but plasma concentrations were higher up to 60 min cortisol production in HDT reaching a higher maximum concentration (Cmax: 1144 vs 960 nmol/l) but delayed in time (75 vs 52.5 min).","Profile, mean residence time of ACTH and cortisol responses after low and standard ACTH tests in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16918954/),,75,134001,DB00741,Hydrocortisone
,16918954,maximum concentration (Cmax,"Elimination of ACTH(1-24) was faster in HDT than in LDT (MRTs of 0.14 vs 0.37, respectively, P = 0.008), but plasma concentrations were higher up to 60 min cortisol production in HDT reaching a higher maximum concentration (Cmax: 1144 vs 960 nmol/l) but delayed in time (75 vs 52.5 min).","Profile, mean residence time of ACTH and cortisol responses after low and standard ACTH tests in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16918954/),,52.5,134002,DB00741,Hydrocortisone
,6692762,remission rate,"A remission rate of 37% (total and partial remissions) indicated that high-dosage oral treatment with gestagens can be used as ""failure-regime"" in patients at the end of conventional treatment.",[High-dosage oral gestagen therapy as a failure-regime in metastatic breast cancer]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6692762/),%,37,134525,DB00741,Hydrocortisone
,8760200,clearance,"During exercise, clearance and steady-state volume of distribution of total cortisol were greatly increased (338 +/- 95 vs.",Cortisol disposition and production rate in horses during rest and exercise. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8760200/),,338,134579,DB00741,Hydrocortisone
,8760200,clearance,"137 +/- 34 ml.kg-1.h-1 for clearance and 359 +/- 82 vs. 229 +/- 18 ml/kg for volume of distribution), whereas the terminal half-life decreased significantly (0.97 +/- 0.16 vs. 1.55 +/- 0.33 h).",Cortisol disposition and production rate in horses during rest and exercise. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8760200/),[ml] / [h·kg],137,134580,DB00741,Hydrocortisone
,8760200,volume of distribution,"137 +/- 34 ml.kg-1.h-1 for clearance and 359 +/- 82 vs. 229 +/- 18 ml/kg for volume of distribution), whereas the terminal half-life decreased significantly (0.97 +/- 0.16 vs. 1.55 +/- 0.33 h).",Cortisol disposition and production rate in horses during rest and exercise. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8760200/),[ml] / [kg],359,134581,DB00741,Hydrocortisone
,8760200,volume of distribution,"137 +/- 34 ml.kg-1.h-1 for clearance and 359 +/- 82 vs. 229 +/- 18 ml/kg for volume of distribution), whereas the terminal half-life decreased significantly (0.97 +/- 0.16 vs. 1.55 +/- 0.33 h).",Cortisol disposition and production rate in horses during rest and exercise. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8760200/),[ml] / [kg],229,134582,DB00741,Hydrocortisone
,8760200,terminal half-life,"137 +/- 34 ml.kg-1.h-1 for clearance and 359 +/- 82 vs. 229 +/- 18 ml/kg for volume of distribution), whereas the terminal half-life decreased significantly (0.97 +/- 0.16 vs. 1.55 +/- 0.33 h).",Cortisol disposition and production rate in horses during rest and exercise. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8760200/),h,0.97,134583,DB00741,Hydrocortisone
,8760200,terminal half-life,"137 +/- 34 ml.kg-1.h-1 for clearance and 359 +/- 82 vs. 229 +/- 18 ml/kg for volume of distribution), whereas the terminal half-life decreased significantly (0.97 +/- 0.16 vs. 1.55 +/- 0.33 h).",Cortisol disposition and production rate in horses during rest and exercise. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8760200/),h,1.55,134584,DB00741,Hydrocortisone
,8760200,production rate,The estimated cortisol production rate was 4.41 +/- 1.06 micrograms.,Cortisol disposition and production rate in horses during rest and exercise. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8760200/),μg,4.41,134585,DB00741,Hydrocortisone
,30739499,polydispersity index,"The developed NPs showed an average particle size, entrapment efficiency with PDI (polydispersity index) of 201.3 ± 4.6 nm, 77.94 ± 5.01% and 0.253 ± 0.019, respectively.",Brain-targeted glycyrrhizic-acid-loaded surface decorated nanoparticles for treatment of cerebral ischaemia and its toxicity assessment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30739499/),nm,201.3,137799,DB00741,Hydrocortisone
,30739499,polydispersity index,"The developed NPs showed an average particle size, entrapment efficiency with PDI (polydispersity index) of 201.3 ± 4.6 nm, 77.94 ± 5.01% and 0.253 ± 0.019, respectively.",Brain-targeted glycyrrhizic-acid-loaded surface decorated nanoparticles for treatment of cerebral ischaemia and its toxicity assessment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30739499/),%,77.94,137800,DB00741,Hydrocortisone
,30739499,polydispersity index,"The developed NPs showed an average particle size, entrapment efficiency with PDI (polydispersity index) of 201.3 ± 4.6 nm, 77.94 ± 5.01% and 0.253 ± 0.019, respectively.",Brain-targeted glycyrrhizic-acid-loaded surface decorated nanoparticles for treatment of cerebral ischaemia and its toxicity assessment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30739499/),,0.253,137801,DB00741,Hydrocortisone
,30739499,elution time,Higher mucoadhesive property for CS-GA-PCL-NPs as compared to conventional and homogenized nanoformulations was observed whereas an elution time of 0.37 min and m/z of 821.49/113.41 for GA along with an elution time of 1.94 min and m/z of 363.45/121.40 was observed for hydrocortisone i.e. Internal standard (IS).,Brain-targeted glycyrrhizic-acid-loaded surface decorated nanoparticles for treatment of cerebral ischaemia and its toxicity assessment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30739499/),min,0.37,137802,DB00741,Hydrocortisone
,30739499,m/z,Higher mucoadhesive property for CS-GA-PCL-NPs as compared to conventional and homogenized nanoformulations was observed whereas an elution time of 0.37 min and m/z of 821.49/113.41 for GA along with an elution time of 1.94 min and m/z of 363.45/121.40 was observed for hydrocortisone i.e. Internal standard (IS).,Brain-targeted glycyrrhizic-acid-loaded surface decorated nanoparticles for treatment of cerebral ischaemia and its toxicity assessment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30739499/),,821.49,137803,DB00741,Hydrocortisone
,30739499,m/z,Higher mucoadhesive property for CS-GA-PCL-NPs as compared to conventional and homogenized nanoformulations was observed whereas an elution time of 0.37 min and m/z of 821.49/113.41 for GA along with an elution time of 1.94 min and m/z of 363.45/121.40 was observed for hydrocortisone i.e. Internal standard (IS).,Brain-targeted glycyrrhizic-acid-loaded surface decorated nanoparticles for treatment of cerebral ischaemia and its toxicity assessment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30739499/),,113.41,137804,DB00741,Hydrocortisone
,30739499,elution time,Higher mucoadhesive property for CS-GA-PCL-NPs as compared to conventional and homogenized nanoformulations was observed whereas an elution time of 0.37 min and m/z of 821.49/113.41 for GA along with an elution time of 1.94 min and m/z of 363.45/121.40 was observed for hydrocortisone i.e. Internal standard (IS).,Brain-targeted glycyrrhizic-acid-loaded surface decorated nanoparticles for treatment of cerebral ischaemia and its toxicity assessment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30739499/),min,1.94,137805,DB00741,Hydrocortisone
,30739499,m/z,Higher mucoadhesive property for CS-GA-PCL-NPs as compared to conventional and homogenized nanoformulations was observed whereas an elution time of 0.37 min and m/z of 821.49/113.41 for GA along with an elution time of 1.94 min and m/z of 363.45/121.40 was observed for hydrocortisone i.e. Internal standard (IS).,Brain-targeted glycyrrhizic-acid-loaded surface decorated nanoparticles for treatment of cerebral ischaemia and its toxicity assessment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30739499/),-1,363.45,137806,DB00741,Hydrocortisone
,30739499,m/z,Higher mucoadhesive property for CS-GA-PCL-NPs as compared to conventional and homogenized nanoformulations was observed whereas an elution time of 0.37 min and m/z of 821.49/113.41 for GA along with an elution time of 1.94 min and m/z of 363.45/121.40 was observed for hydrocortisone i.e. Internal standard (IS).,Brain-targeted glycyrrhizic-acid-loaded surface decorated nanoparticles for treatment of cerebral ischaemia and its toxicity assessment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30739499/),,121.40,137807,DB00741,Hydrocortisone
,11549205,peak plasma concentration (Cmax),"Mean (+/-SD) values of peak plasma concentration (Cmax), time to Cmax (tmax), area under the plasma concentration-time curve [AUC(0-48)] and elimination half-life (tl/2) of alprazolam were 12.0+/-3.0 ng/ml, 1.5+/-0.9 h, 200+/-41 ng/ml h and 16.0+/-4.3 h, respectively.",No correlations between the urinary ratio of 6beta-hydroxycortisol to free cortisol and pharmacokinetics of alprazolam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11549205/),[ng] / [ml],12.0,138027,DB00741,Hydrocortisone
,11549205,time to Cmax (tmax),"Mean (+/-SD) values of peak plasma concentration (Cmax), time to Cmax (tmax), area under the plasma concentration-time curve [AUC(0-48)] and elimination half-life (tl/2) of alprazolam were 12.0+/-3.0 ng/ml, 1.5+/-0.9 h, 200+/-41 ng/ml h and 16.0+/-4.3 h, respectively.",No correlations between the urinary ratio of 6beta-hydroxycortisol to free cortisol and pharmacokinetics of alprazolam. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11549205/),h,1.5,138028,DB00741,Hydrocortisone
,11549205,time to Cmax (tmax),"Mean (+/-SD) values of peak plasma concentration (Cmax), time to Cmax (tmax), area under the plasma concentration-time curve [AUC(0-48)] and elimination half-life (tl/2) of alprazolam were 12.0+/-3.0 ng/ml, 1.5+/-0.9 h, 200+/-41 ng/ml h and 16.0+/-4.3 h, respectively.",No correlations between the urinary ratio of 6beta-hydroxycortisol to free cortisol and pharmacokinetics of alprazolam. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11549205/),[ng] / [h·ml],200,138029,DB00741,Hydrocortisone
,11549205,area under the plasma concentration-time curve [AUC(0-48)],"Mean (+/-SD) values of peak plasma concentration (Cmax), time to Cmax (tmax), area under the plasma concentration-time curve [AUC(0-48)] and elimination half-life (tl/2) of alprazolam were 12.0+/-3.0 ng/ml, 1.5+/-0.9 h, 200+/-41 ng/ml h and 16.0+/-4.3 h, respectively.",No correlations between the urinary ratio of 6beta-hydroxycortisol to free cortisol and pharmacokinetics of alprazolam. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11549205/),h,1.5,138030,DB00741,Hydrocortisone
,11549205,area under the plasma concentration-time curve [AUC(0-48)],"Mean (+/-SD) values of peak plasma concentration (Cmax), time to Cmax (tmax), area under the plasma concentration-time curve [AUC(0-48)] and elimination half-life (tl/2) of alprazolam were 12.0+/-3.0 ng/ml, 1.5+/-0.9 h, 200+/-41 ng/ml h and 16.0+/-4.3 h, respectively.",No correlations between the urinary ratio of 6beta-hydroxycortisol to free cortisol and pharmacokinetics of alprazolam. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11549205/),[ng] / [h·ml],200,138031,DB00741,Hydrocortisone
,11549205,elimination half-life (tl/2),"Mean (+/-SD) values of peak plasma concentration (Cmax), time to Cmax (tmax), area under the plasma concentration-time curve [AUC(0-48)] and elimination half-life (tl/2) of alprazolam were 12.0+/-3.0 ng/ml, 1.5+/-0.9 h, 200+/-41 ng/ml h and 16.0+/-4.3 h, respectively.",No correlations between the urinary ratio of 6beta-hydroxycortisol to free cortisol and pharmacokinetics of alprazolam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11549205/),h,16.0,138032,DB00741,Hydrocortisone
,11549205,u,Mean (+/-SD) urinary ratio of 6beta-hydroxycortisol to cortisol was 3.28+/-0.67.,No correlations between the urinary ratio of 6beta-hydroxycortisol to free cortisol and pharmacokinetics of alprazolam. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11549205/),,3,138033,DB00741,Hydrocortisone
exceeded,7405924,retention time,"Relative to an intravenous dose, 50--90% of a dose given rectally was available to the systemic circulation in most subjects provided the retention time exceeded eight hours.",Bioavailability of hydrocortisone retention enemas in normal subjects. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7405924/),h,eight,138084,DB00741,Hydrocortisone
,3899153,area under curve (AUCu),Free prednisolone area under curve (AUCu) ranged from 101 to 436 ng ml-1 h and was 6.3 to 15.0% of total prednisolone AUC.,Prednisolone protein binding in renal transplant patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3899153/),[h·ng] / [ml],101 to 436,139028,DB00741,Hydrocortisone
,22937949,T(1/2α),Plasma meloxicam concentrations were detectable for 50 h post-administration and fit a 2-compartment model with a rapid distribution phase (mean T(1/2α) = 0.22 ± 0.087 h) and a slower elimination phase (mean T(1/2β) = 21.86 ± 3.03 h).,Pharmacokinetics and effect of intravenous meloxicam in weaned Holstein calves following scoop dehorning without local anesthesia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22937949/),h,0.22,140198,DB00741,Hydrocortisone
,22937949,T(1/2β),Plasma meloxicam concentrations were detectable for 50 h post-administration and fit a 2-compartment model with a rapid distribution phase (mean T(1/2α) = 0.22 ± 0.087 h) and a slower elimination phase (mean T(1/2β) = 21.86 ± 3.03 h).,Pharmacokinetics and effect of intravenous meloxicam in weaned Holstein calves following scoop dehorning without local anesthesia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22937949/),h,21.86,140199,DB00741,Hydrocortisone
,22937949,plasma SP concentrations,Mean plasma SP concentrations were lower in meloxicam treated calves (71.36 ± 20.84 pg/mL) compared with control calves (114.70 ± 20.84 pg/mL) (P = 0.038).,Pharmacokinetics and effect of intravenous meloxicam in weaned Holstein calves following scoop dehorning without local anesthesia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22937949/),[pg] / [ml],71.36,140200,DB00741,Hydrocortisone
,22937949,plasma SP concentrations,Mean plasma SP concentrations were lower in meloxicam treated calves (71.36 ± 20.84 pg/mL) compared with control calves (114.70 ± 20.84 pg/mL) (P = 0.038).,Pharmacokinetics and effect of intravenous meloxicam in weaned Holstein calves following scoop dehorning without local anesthesia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22937949/),[pg] / [ml],114.70,140201,DB00741,Hydrocortisone
,29795974,bioavailability,"The mean (95% CI) bioavailability of oral hydrocortisone calculated from serum cortisol, unbound serum cortisol and salivary cortisone was 1.00 (0.89-1.14); 0.88 (0.75-1.05); and 0.93 (0.83-1.05), respectively.",Bioavailability of Oral Hydrocortisone Corrected for Binding Proteins and Measured by LC-MS/MS Using Serum Cortisol and Salivary Cortisone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29795974/),,1.00,140496,DB00741,Hydrocortisone
,29795974,bioavailability,"The mean (95% CI) bioavailability of oral hydrocortisone calculated from serum cortisol, unbound serum cortisol and salivary cortisone was 1.00 (0.89-1.14); 0.88 (0.75-1.05); and 0.93 (0.83-1.05), respectively.",Bioavailability of Oral Hydrocortisone Corrected for Binding Proteins and Measured by LC-MS/MS Using Serum Cortisol and Salivary Cortisone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29795974/),,0.88,140497,DB00741,Hydrocortisone
,29795974,bioavailability,"The mean (95% CI) bioavailability of oral hydrocortisone calculated from serum cortisol, unbound serum cortisol and salivary cortisone was 1.00 (0.89-1.14); 0.88 (0.75-1.05); and 0.93 (0.83-1.05), respectively.",Bioavailability of Oral Hydrocortisone Corrected for Binding Proteins and Measured by LC-MS/MS Using Serum Cortisol and Salivary Cortisone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29795974/),,0.93,140498,DB00741,Hydrocortisone
,12008691,clearance,"Treatment with flutamide resulted in a decrease in cortisol clearance from 420 ml/l to 305 ml/l (27% reduction), and a decrease in volume of distribution from 51.61 to 451 (12.9% reduction).",Treatment with flutamide decreases cortisol clearance: implications for therapy in congenital adrenal hyperplasia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12008691/),[ml] / [l],420,142180,DB00741,Hydrocortisone
,12008691,clearance,"Treatment with flutamide resulted in a decrease in cortisol clearance from 420 ml/l to 305 ml/l (27% reduction), and a decrease in volume of distribution from 51.61 to 451 (12.9% reduction).",Treatment with flutamide decreases cortisol clearance: implications for therapy in congenital adrenal hyperplasia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12008691/),[ml] / [l],305,142181,DB00741,Hydrocortisone
,12008691,volume of distribution,"Treatment with flutamide resulted in a decrease in cortisol clearance from 420 ml/l to 305 ml/l (27% reduction), and a decrease in volume of distribution from 51.61 to 451 (12.9% reduction).",Treatment with flutamide decreases cortisol clearance: implications for therapy in congenital adrenal hyperplasia. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12008691/),,51.61,142182,DB00741,Hydrocortisone
,12008691,volume of distribution,"Treatment with flutamide resulted in a decrease in cortisol clearance from 420 ml/l to 305 ml/l (27% reduction), and a decrease in volume of distribution from 51.61 to 451 (12.9% reduction).",Treatment with flutamide decreases cortisol clearance: implications for therapy in congenital adrenal hyperplasia. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12008691/),,451,142183,DB00741,Hydrocortisone
,12008691,half-life,The half-life of cortisol increased from 85.3 min to 102.1 min.,Treatment with flutamide decreases cortisol clearance: implications for therapy in congenital adrenal hyperplasia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12008691/),min,85.3,142184,DB00741,Hydrocortisone
,12008691,half-life,The half-life of cortisol increased from 85.3 min to 102.1 min.,Treatment with flutamide decreases cortisol clearance: implications for therapy in congenital adrenal hyperplasia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12008691/),min,102.1,142185,DB00741,Hydrocortisone
,29436106,terminal elimination half-life,The terminal elimination half-life of triamcinolone in a noncompartmental analysis was 213 hours.,Corticosteroid and Cortisol Serum Levels Following Intra-articular Triamcinolone Acetonide Lumbar Facet Joint Injections. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29436106/),h,213,142926,DB00741,Hydrocortisone
,29436106,peak median triamcinolone concentration,The peak median triamcinolone concentration of 3.6 ng/mL was detected within 24 hours after the injections.,Corticosteroid and Cortisol Serum Levels Following Intra-articular Triamcinolone Acetonide Lumbar Facet Joint Injections. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29436106/),[ng] / [ml],3.6,142927,DB00741,Hydrocortisone
,29436106,terminal elimination half-life,"The median terminal elimination half-life was 213 hours, but baseline cortisol levels were suppressed for an average of 4.4 days.",Corticosteroid and Cortisol Serum Levels Following Intra-articular Triamcinolone Acetonide Lumbar Facet Joint Injections. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29436106/),h,213,142928,DB00741,Hydrocortisone
,17083451,plasma concentration,The mean plasma concentration of KET during the 1.5 mg/kg/h KET CRI was 235 ng/mL.,Pharmacodynamic effects and pharmacokinetic profile of a long-term continuous rate infusion of racemic ketamine in healthy conscious horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17083451/),[ng] / [ml],235,144216,DB00741,Hydrocortisone
,17083451,elimination half-lives (t1/2alpha,"The KET median elimination half-lives (t1/2alpha and t1/2beta) were 2.3 and 67.4 min, respectively.",Pharmacodynamic effects and pharmacokinetic profile of a long-term continuous rate infusion of racemic ketamine in healthy conscious horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17083451/),min,2.3,144217,DB00741,Hydrocortisone
,17083451,t1/2beta,"The KET median elimination half-lives (t1/2alpha and t1/2beta) were 2.3 and 67.4 min, respectively.",Pharmacodynamic effects and pharmacokinetic profile of a long-term continuous rate infusion of racemic ketamine in healthy conscious horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17083451/),min,67.4,144218,DB00741,Hydrocortisone
,17083451,area under the KET,"The area under the KET plasma concentration-time curve (AUC), elimination was 76.0 microg.min/mL.",Pharmacodynamic effects and pharmacokinetic profile of a long-term continuous rate infusion of racemic ketamine in healthy conscious horses. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17083451/),[min·μg] / [ml],76.0,144219,DB00741,Hydrocortisone
,17083451,"plasma concentration-time curve (AUC), elimination","The area under the KET plasma concentration-time curve (AUC), elimination was 76.0 microg.min/mL.",Pharmacodynamic effects and pharmacokinetic profile of a long-term continuous rate infusion of racemic ketamine in healthy conscious horses. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17083451/),[min·μg] / [ml],76.0,144220,DB00741,Hydrocortisone
,17083451,C1,"Volumes of C1 and C2 were 0.24 and 0.79 L/kg, respectively.",Pharmacodynamic effects and pharmacokinetic profile of a long-term continuous rate infusion of racemic ketamine in healthy conscious horses. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17083451/),[l] / [kg],0.24,144221,DB00741,Hydrocortisone
,17083451,C2,"Volumes of C1 and C2 were 0.24 and 0.79 L/kg, respectively.",Pharmacodynamic effects and pharmacokinetic profile of a long-term continuous rate infusion of racemic ketamine in healthy conscious horses. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17083451/),[l] / [kg],0.79,144222,DB00741,Hydrocortisone
,15650985,t(1/2),The median t(1/2) of oxycodone varied from 5.1 to 5.9 hours.,Pharmacodynamics and pharmacokinetics of high-dose oxycodone infusion during and after coronary artery bypass grafting. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15650985/),h,5.1 to 5.9,144396,DB00741,Hydrocortisone
,15650985,times to awakening,"The mean times to awakening were 3.8 hours and 7.0 hours in the groups OX 0.5 and 1.0, respectively.",Pharmacodynamics and pharmacokinetics of high-dose oxycodone infusion during and after coronary artery bypass grafting. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15650985/),h,3.8,144397,DB00741,Hydrocortisone
,15650985,times to awakening,"The mean times to awakening were 3.8 hours and 7.0 hours in the groups OX 0.5 and 1.0, respectively.",Pharmacodynamics and pharmacokinetics of high-dose oxycodone infusion during and after coronary artery bypass grafting. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15650985/),h,7.0,144398,DB00741,Hydrocortisone
,3608158,Detection limits,"Detection limits are 0.5 mg/L for hydrocortisone succinate, 0.2 mg/L for hydrocortisone.","Hydrocortisone succinate and hydrocortisone simultaneously determined in plasma by reversed-phase liquid chromatography, and their pharmacokinetics in asthmatic children. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3608158/),[mg] / [l],0.5,145159,DB00741,Hydrocortisone
,3608158,Detection limits,"Detection limits are 0.5 mg/L for hydrocortisone succinate, 0.2 mg/L for hydrocortisone.","Hydrocortisone succinate and hydrocortisone simultaneously determined in plasma by reversed-phase liquid chromatography, and their pharmacokinetics in asthmatic children. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3608158/),[mg] / [l],0.2,145160,DB00741,Hydrocortisone
,3608158,analytical recoveries,"For five different concentrations the respective mean analytical recoveries were 88.2% and 100.5%, the mean intra-assay CVs for slope 3.9% and 2.1%, and the inter-assay CVs 3.3% and 1.6%.","Hydrocortisone succinate and hydrocortisone simultaneously determined in plasma by reversed-phase liquid chromatography, and their pharmacokinetics in asthmatic children. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3608158/),%,88.2,145161,DB00741,Hydrocortisone
,3608158,analytical recoveries,"For five different concentrations the respective mean analytical recoveries were 88.2% and 100.5%, the mean intra-assay CVs for slope 3.9% and 2.1%, and the inter-assay CVs 3.3% and 1.6%.","Hydrocortisone succinate and hydrocortisone simultaneously determined in plasma by reversed-phase liquid chromatography, and their pharmacokinetics in asthmatic children. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3608158/),%,100.5,145162,DB00741,Hydrocortisone
,3690808,elimination half-life,The elimination half-life was 10.1 +/- 1.7 h (mean +/- SD) after initial dosage; it decreased significantly to 6.9 +/- 1.2 h after 8 weeks of treatment.,Clinical pharmacology of aminoglutethimide in patients with metastatic breast cancer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3690808/),h,10.1,145606,DB00741,Hydrocortisone
,3690808,elimination half-life,The elimination half-life was 10.1 +/- 1.7 h (mean +/- SD) after initial dosage; it decreased significantly to 6.9 +/- 1.2 h after 8 weeks of treatment.,Clinical pharmacology of aminoglutethimide in patients with metastatic breast cancer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3690808/),h,6.9,145607,DB00741,Hydrocortisone
,3690808,area under the curve,The area under the curve of AG concentrations was 92.5 +/- 14.2 micrograms/ml x h.,Clinical pharmacology of aminoglutethimide in patients with metastatic breast cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3690808/),[μg] / [h·ml],92.5,145608,DB00741,Hydrocortisone
,3690808,total clearance rate,The total clearance rate was 5.5 +/- 0.9 1/h and the volume of distribution was 80 +/- 111.,Clinical pharmacology of aminoglutethimide in patients with metastatic breast cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3690808/),[1] / [h],5.5,145609,DB00741,Hydrocortisone
,3690808,volume of distribution,The total clearance rate was 5.5 +/- 0.9 1/h and the volume of distribution was 80 +/- 111.,Clinical pharmacology of aminoglutethimide in patients with metastatic breast cancer. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3690808/),,80,145610,DB00741,Hydrocortisone
,3690808,AG,"A comparison on day 7 of treatment revealed that doses of 1000 and 500 mg yielded AG plasma concentrations of 9.0 +/- 1.2 and 4.5 +/- 0.5 micrograms/ml, respectively.",Clinical pharmacology of aminoglutethimide in patients with metastatic breast cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3690808/),[μg] / [ml],9.0,145611,DB00741,Hydrocortisone
,3690808,plasma concentrations,"A comparison on day 7 of treatment revealed that doses of 1000 and 500 mg yielded AG plasma concentrations of 9.0 +/- 1.2 and 4.5 +/- 0.5 micrograms/ml, respectively.",Clinical pharmacology of aminoglutethimide in patients with metastatic breast cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3690808/),[μg] / [ml],9.0,145612,DB00741,Hydrocortisone
,3690808,plasma concentrations,"A comparison on day 7 of treatment revealed that doses of 1000 and 500 mg yielded AG plasma concentrations of 9.0 +/- 1.2 and 4.5 +/- 0.5 micrograms/ml, respectively.",Clinical pharmacology of aminoglutethimide in patients with metastatic breast cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3690808/),[μg] / [ml],4.5,145613,DB00741,Hydrocortisone
,11762560,terminal half-life,"After a single dose of 1000 microg BUD and 500 microg FP the median estimates of terminal half-life and mean residence time were 3.5 and 3.9 hours for BUD and 10.1 and 12.0 hours for FP, respectively.","Single-dose and steady-state pharmacokinetic and pharmacodynamic evaluation of therapeutically clinically equivalent doses of inhaled fluticasone propionate and budesonide, given as Diskus or Turbohaler dry-powder inhalers to healthy subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11762560/),h,3.5,145765,DB00741,Hydrocortisone
,11762560,mean residence time,"After a single dose of 1000 microg BUD and 500 microg FP the median estimates of terminal half-life and mean residence time were 3.5 and 3.9 hours for BUD and 10.1 and 12.0 hours for FP, respectively.","Single-dose and steady-state pharmacokinetic and pharmacodynamic evaluation of therapeutically clinically equivalent doses of inhaled fluticasone propionate and budesonide, given as Diskus or Turbohaler dry-powder inhalers to healthy subjects. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11762560/),h,3.9,145766,DB00741,Hydrocortisone
,11762560,mean residence time,"After a single dose of 1000 microg BUD and 500 microg FP the median estimates of terminal half-life and mean residence time were 3.5 and 3.9 hours for BUD and 10.1 and 12.0 hours for FP, respectively.","Single-dose and steady-state pharmacokinetic and pharmacodynamic evaluation of therapeutically clinically equivalent doses of inhaled fluticasone propionate and budesonide, given as Diskus or Turbohaler dry-powder inhalers to healthy subjects. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11762560/),h,10.1,145767,DB00741,Hydrocortisone
,11762560,mean residence time,"After a single dose of 1000 microg BUD and 500 microg FP the median estimates of terminal half-life and mean residence time were 3.5 and 3.9 hours for BUD and 10.1 and 12.0 hours for FP, respectively.","Single-dose and steady-state pharmacokinetic and pharmacodynamic evaluation of therapeutically clinically equivalent doses of inhaled fluticasone propionate and budesonide, given as Diskus or Turbohaler dry-powder inhalers to healthy subjects. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11762560/),h,12.0,145768,DB00741,Hydrocortisone
,11762560,mean absorption times (MAT),"Using previously reported intravenous data, the mean absorption times (MAT) were calculated to be around 2 hours and 7 hours for BUD and FP respectively.","Single-dose and steady-state pharmacokinetic and pharmacodynamic evaluation of therapeutically clinically equivalent doses of inhaled fluticasone propionate and budesonide, given as Diskus or Turbohaler dry-powder inhalers to healthy subjects. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11762560/),h,2,145769,DB00741,Hydrocortisone
,11762560,mean absorption times (MAT),"Using previously reported intravenous data, the mean absorption times (MAT) were calculated to be around 2 hours and 7 hours for BUD and FP respectively.","Single-dose and steady-state pharmacokinetic and pharmacodynamic evaluation of therapeutically clinically equivalent doses of inhaled fluticasone propionate and budesonide, given as Diskus or Turbohaler dry-powder inhalers to healthy subjects. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11762560/),h,7,145770,DB00741,Hydrocortisone
,10381769,Cmax,"Cmax values for 125-mg and 75-mg MDMA doses were 236.4 and 130.9 ng/ml, and Tmax was observed at 2.4 and 1.8 h, respectively.","Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4-methylenedioxymethamphetamine in humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10381769/),[ng] / [ml],236.4,146037,DB00741,Hydrocortisone
,10381769,Cmax,"Cmax values for 125-mg and 75-mg MDMA doses were 236.4 and 130.9 ng/ml, and Tmax was observed at 2.4 and 1.8 h, respectively.","Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4-methylenedioxymethamphetamine in humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10381769/),[ng] / [ml],130.9,146038,DB00741,Hydrocortisone
,10381769,Tmax,"Cmax values for 125-mg and 75-mg MDMA doses were 236.4 and 130.9 ng/ml, and Tmax was observed at 2.4 and 1.8 h, respectively.","Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4-methylenedioxymethamphetamine in humans. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10381769/),h,2.4,146039,DB00741,Hydrocortisone
,10381769,Tmax,"Cmax values for 125-mg and 75-mg MDMA doses were 236.4 and 130.9 ng/ml, and Tmax was observed at 2.4 and 1.8 h, respectively.","Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4-methylenedioxymethamphetamine in humans. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10381769/),h,1.8,146040,DB00741,Hydrocortisone
,10381769,Elimination half-life,"Elimination half-life was 8.6 h and 7.7 h for high and low MDMA doses, respectively.","Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4-methylenedioxymethamphetamine in humans. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10381769/),h,8.6,146041,DB00741,Hydrocortisone
,10381769,Elimination half-life,"Elimination half-life was 8.6 h and 7.7 h for high and low MDMA doses, respectively.","Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4-methylenedioxymethamphetamine in humans. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10381769/),h,7.7,146042,DB00741,Hydrocortisone
,10381769,half-life,Amphetamine half-life was 15 h.,"Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4-methylenedioxymethamphetamine in humans. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10381769/),h,15,146043,DB00741,Hydrocortisone
,9449215,"distribution volume of cortisol at steady state (Vd,ss)","The main results, shown as the mean (+/-SD), were: (a) the average distribution volume of cortisol at steady state (Vd,ss), which was 7.1 l/m2 body surface area.",Kinetics of intravenously dosed cortisol in four men. Consequences for calculation of the plasma cortisol production rate. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9449215/),[l] / [m2],7.1,148010,DB00741,Hydrocortisone
,9449215,"distribution volume (Vd,ext)","The extrapolated distribution volume (Vd,ext) was 8.4 l/m2, being 18% higher than the corresponding Vd,ss.",Kinetics of intravenously dosed cortisol in four men. Consequences for calculation of the plasma cortisol production rate. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9449215/),[l] / [m2],8.4,148011,DB00741,Hydrocortisone
,9449215,t1/2(beta),"(d) The half-life of the slow or beta phase was equal for the 2 and 0.8 mg experiments, namely t1/2(beta) = 66 +/- 18 min.",Kinetics of intravenously dosed cortisol in four men. Consequences for calculation of the plasma cortisol production rate. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9449215/),min,66,148012,DB00741,Hydrocortisone
,9449215,half-life of,"The main results with the urinary model were: (a) the half-life of cortisol elimination from the circulation was 40 +/- 11 min, (b) the maximal radioactivity (69 +/- 7% of the dose) in the first pool (liver) was found at 2 +/- 0.3 h, (c) the half-life of the cortisol metabolites in the body was 6.8 +/- 0.7 h.",Kinetics of intravenously dosed cortisol in four men. Consequences for calculation of the plasma cortisol production rate. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9449215/),min,40,148013,DB00741,Hydrocortisone
,9449215,maximal radioactivity,"The main results with the urinary model were: (a) the half-life of cortisol elimination from the circulation was 40 +/- 11 min, (b) the maximal radioactivity (69 +/- 7% of the dose) in the first pool (liver) was found at 2 +/- 0.3 h, (c) the half-life of the cortisol metabolites in the body was 6.8 +/- 0.7 h.",Kinetics of intravenously dosed cortisol in four men. Consequences for calculation of the plasma cortisol production rate. ,Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9449215/),h,2,148014,DB00741,Hydrocortisone
,9449215,half-life,"The main results with the urinary model were: (a) the half-life of cortisol elimination from the circulation was 40 +/- 11 min, (b) the maximal radioactivity (69 +/- 7% of the dose) in the first pool (liver) was found at 2 +/- 0.3 h, (c) the half-life of the cortisol metabolites in the body was 6.8 +/- 0.7 h.",Kinetics of intravenously dosed cortisol in four men. Consequences for calculation of the plasma cortisol production rate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9449215/),h,6.8,148015,DB00741,Hydrocortisone
,9449215,half-lives,It was found that these half-lives were similar with values between 30 and 40 min.,Kinetics of intravenously dosed cortisol in four men. Consequences for calculation of the plasma cortisol production rate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9449215/),min,30 and 40,148016,DB00741,Hydrocortisone
,16597076,forced expiratory volume in 1 second,"Fifteen asthmatic patients (mean +/- SEM forced expiratory volume in 1 second [FEV1], 2.62 +/- 0.21 L; provocative concentration of methacholine causing a 20% decrease in FEV1 [PC20], 1.06 +/- 0.58) were randomized to completion in a placebo-controlled, double-blind, crossover manner to receive Beclate or Qvar at doses of 100 or 400 microg/d for 2 weeks, with a 1-week washout period before each randomized treatment.",A comparison of 2 extrafine hydrofluoroalkane-134a-beclomethasone formulations on methacholine hyperresponsiveness. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16597076/),l,2.62,149135,DB00741,Hydrocortisone
,10426160,elimination half-life,The mean elimination half-life of methylprednisolone was increased from 2.1+/-0.3 hr to 4.8+/-0.8 hr (P<0.001) by itraconazole.,Itraconazole decreases the clearance and enhances the effects of intravenously administered methylprednisolone in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10426160/),h,2.1,150097,DB00741,Hydrocortisone
,10426160,elimination half-life,The mean elimination half-life of methylprednisolone was increased from 2.1+/-0.3 hr to 4.8+/-0.8 hr (P<0.001) by itraconazole.,Itraconazole decreases the clearance and enhances the effects of intravenously administered methylprednisolone in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10426160/),h,4.8,150098,DB00741,Hydrocortisone
,10426160,plasma cortisol concentration,"The mean morning plasma cortisol concentration during the itraconazole phase, measured 24 hr after the administration of methylprednisolone, was only about 9% of that during the placebo phase (11.0+/-9.0 ng/ml versus 117+/-49.2 ng/ml; P<0.001).",Itraconazole decreases the clearance and enhances the effects of intravenously administered methylprednisolone in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10426160/),[ng] / [ml],11.0,150099,DB00741,Hydrocortisone
,10426160,plasma cortisol concentration,"The mean morning plasma cortisol concentration during the itraconazole phase, measured 24 hr after the administration of methylprednisolone, was only about 9% of that during the placebo phase (11.0+/-9.0 ng/ml versus 117+/-49.2 ng/ml; P<0.001).",Itraconazole decreases the clearance and enhances the effects of intravenously administered methylprednisolone in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10426160/),[ng] / [ml],117,150100,DB00741,Hydrocortisone
,2729881,half-life time of the terminal phase,The half-life time of the terminal phase for DXM was 283 min +/- 132 min (mean +/- s.d.).,[Value of determining dexamethasone in the rapid adrenal suppression test]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2729881/),min,283,153041,DB00741,Hydrocortisone
<,11140434,absolute oral bioavailability,At a dose of 10 mg twice daily the absolute oral bioavailability of the drug was <1% when a liquid chromatography-mass spectrometry assay was used to assess plasma concentrations.,Bioavailability of orally administered micronised fluticasone propionate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11140434/),%,1,155342,DB00741,Hydrocortisone
,22632064,Cmax,"Median (range) Cmax for the IAC, IAF, and IAS were 16.9 (14.6-35.4), 23.4 (13.5-73.0), and 46.9 (24.0-72.1) ng/mL, respectively.","Pharmacokinetics of dexamethasone following intra-articular, intravenous, intramuscular, and oral administration in horses and its effects on endogenous hydrocortisone. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22632064/),[ng] / [ml],16.9,156709,DB00741,Hydrocortisone
,22632064,Cmax,"Median (range) Cmax for the IAC, IAF, and IAS were 16.9 (14.6-35.4), 23.4 (13.5-73.0), and 46.9 (24.0-72.1) ng/mL, respectively.","Pharmacokinetics of dexamethasone following intra-articular, intravenous, intramuscular, and oral administration in horses and its effects on endogenous hydrocortisone. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22632064/),[ng] / [ml],23.4,156710,DB00741,Hydrocortisone
,22632064,Cmax,"Median (range) Cmax for the IAC, IAF, and IAS were 16.9 (14.6-35.4), 23.4 (13.5-73.0), and 46.9 (24.0-72.1) ng/mL, respectively.","Pharmacokinetics of dexamethasone following intra-articular, intravenous, intramuscular, and oral administration in horses and its effects on endogenous hydrocortisone. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22632064/),[ng] / [ml],46.9,156711,DB00741,Hydrocortisone
,22632064,Tmax,"The Tmax for IAC, IAF, and IAS were 1.0 (0.75-4.0), 0.62 (0.5-1.0), and 0.25 (0.08-0.25) h, respectively.","Pharmacokinetics of dexamethasone following intra-articular, intravenous, intramuscular, and oral administration in horses and its effects on endogenous hydrocortisone. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22632064/),h,1.0,156712,DB00741,Hydrocortisone
,22632064,Tmax,"The Tmax for IAC, IAF, and IAS were 1.0 (0.75-4.0), 0.62 (0.5-1.0), and 0.25 (0.08-0.25) h, respectively.","Pharmacokinetics of dexamethasone following intra-articular, intravenous, intramuscular, and oral administration in horses and its effects on endogenous hydrocortisone. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22632064/),h,0.62,156713,DB00741,Hydrocortisone
,22632064,Tmax,"The Tmax for IAC, IAF, and IAS were 1.0 (0.75-4.0), 0.62 (0.5-1.0), and 0.25 (0.08-0.25) h, respectively.","Pharmacokinetics of dexamethasone following intra-articular, intravenous, intramuscular, and oral administration in horses and its effects on endogenous hydrocortisone. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22632064/),h,0.25,156714,DB00741,Hydrocortisone
,22632064,elimination half-lives,"Median (range) elimination half-lives for IA and IM administrations were 3.6 (3.0-4.6) h and 3.4 (2.9-3.7) h, respectively.","Pharmacokinetics of dexamethasone following intra-articular, intravenous, intramuscular, and oral administration in horses and its effects on endogenous hydrocortisone. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22632064/),h,3.6,156715,DB00741,Hydrocortisone
,22632064,elimination half-lives,"Median (range) elimination half-lives for IA and IM administrations were 3.6 (3.0-4.6) h and 3.4 (2.9-3.7) h, respectively.","Pharmacokinetics of dexamethasone following intra-articular, intravenous, intramuscular, and oral administration in horses and its effects on endogenous hydrocortisone. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22632064/),h,3.4,156716,DB00741,Hydrocortisone
,22632064,alpha,"A 3-compartment model was fitted to the plasma dexamethasone concentration-time curve following the IV administration of DSP; alpha, beta, and gamma half-lives were 0.03 (0.01-0.05), 1.8 (0.34-2.3), and 5.1 (3.3-5.6) h, respectively.","Pharmacokinetics of dexamethasone following intra-articular, intravenous, intramuscular, and oral administration in horses and its effects on endogenous hydrocortisone. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22632064/),h,0.03,156717,DB00741,Hydrocortisone
,22632064,beta,"A 3-compartment model was fitted to the plasma dexamethasone concentration-time curve following the IV administration of DSP; alpha, beta, and gamma half-lives were 0.03 (0.01-0.05), 1.8 (0.34-2.3), and 5.1 (3.3-5.6) h, respectively.","Pharmacokinetics of dexamethasone following intra-articular, intravenous, intramuscular, and oral administration in horses and its effects on endogenous hydrocortisone. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22632064/),h,1.8,156718,DB00741,Hydrocortisone
,22632064,gamma half-lives,"A 3-compartment model was fitted to the plasma dexamethasone concentration-time curve following the IV administration of DSP; alpha, beta, and gamma half-lives were 0.03 (0.01-0.05), 1.8 (0.34-2.3), and 5.1 (3.3-5.6) h, respectively.","Pharmacokinetics of dexamethasone following intra-articular, intravenous, intramuscular, and oral administration in horses and its effects on endogenous hydrocortisone. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22632064/),h,5.1,156719,DB00741,Hydrocortisone
,22632064,absorption,"Following the PO administration, the median absorption and elimination half-lives were 0.34 (0.29-1.6) and 3.4 (3.1-4.7) h, respectively.","Pharmacokinetics of dexamethasone following intra-articular, intravenous, intramuscular, and oral administration in horses and its effects on endogenous hydrocortisone. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22632064/),h,0.34,156720,DB00741,Hydrocortisone
,22632064,elimination half-lives,"Following the PO administration, the median absorption and elimination half-lives were 0.34 (0.29-1.6) and 3.4 (3.1-4.7) h, respectively.","Pharmacokinetics of dexamethasone following intra-articular, intravenous, intramuscular, and oral administration in horses and its effects on endogenous hydrocortisone. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22632064/),h,3.4,156721,DB00741,Hydrocortisone
,2015172,Elimination half-lives,4. Elimination half-lives (mean +/- s.e. mean) of 10-OH-CZ were unaltered by 2 weeks' therapy with OXC (before 11.3 +/- 1.1 h; after 13.9 +/- 3 h).,Lack of enzyme induction with oxcarbazepine (600 mg daily) in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2015172/),h,11.3,156873,DB00741,Hydrocortisone
,2015172,Elimination half-lives,4. Elimination half-lives (mean +/- s.e. mean) of 10-OH-CZ were unaltered by 2 weeks' therapy with OXC (before 11.3 +/- 1.1 h; after 13.9 +/- 3 h).,Lack of enzyme induction with oxcarbazepine (600 mg daily) in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2015172/),h,13.9,156874,DB00741,Hydrocortisone
,2015172,Trough plasma concentrations,Trough plasma concentrations of 10-OH-CZ at steady-state (31 +/- 2.2 mumol l-1) were higher than predicted (16.5 +/- 4 mumol l-1).,Lack of enzyme induction with oxcarbazepine (600 mg daily) in healthy subjects. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2015172/),[μM] / [l],31,156875,DB00741,Hydrocortisone
,2015172,Trough plasma concentrations,Trough plasma concentrations of 10-OH-CZ at steady-state (31 +/- 2.2 mumol l-1) were higher than predicted (16.5 +/- 4 mumol l-1).,Lack of enzyme induction with oxcarbazepine (600 mg daily) in healthy subjects. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2015172/),[μM] / [l],16.5,156876,DB00741,Hydrocortisone
,12463723,ratios,"The mean +/- SD 6-beta-hydroxycortisol/cortisol ratios before and after treatment were 8.3 +/- 4.4 and 9.4 +/- 4.0, respectively (p = 0.29).",Pioglitazone: effect on CYP3A4 activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12463723/),,8.3,157347,DB00741,Hydrocortisone
,12463723,ratios,"The mean +/- SD 6-beta-hydroxycortisol/cortisol ratios before and after treatment were 8.3 +/- 4.4 and 9.4 +/- 4.0, respectively (p = 0.29).",Pioglitazone: effect on CYP3A4 activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12463723/),,9.4,157348,DB00741,Hydrocortisone
,19805643,excretion,"Cortisol excretion in 24-hour urine was 52 nmol/24 hours (95% CI: 5 to 99 nmol/24 hours; P=0.05) lower, and dopamine and norepinephrine excretions were 0.25 micromol/24 hours (95% CI: 0.01 to 0.48 micromol/24 hours; P=0.04) and 0.22 micromol/24 hours (95% CI: -0.03 to 0.46 micromol/24 hours; P=0.02) lower in patients treated with bedtime aspirin.","Time-dependent effects of low-dose aspirin on plasma renin activity, aldosterone, cortisol, and catecholamines. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19805643/),[nM] / [24·h],52,160613,DB00741,Hydrocortisone
,19805643,excretions,"Cortisol excretion in 24-hour urine was 52 nmol/24 hours (95% CI: 5 to 99 nmol/24 hours; P=0.05) lower, and dopamine and norepinephrine excretions were 0.25 micromol/24 hours (95% CI: 0.01 to 0.48 micromol/24 hours; P=0.04) and 0.22 micromol/24 hours (95% CI: -0.03 to 0.46 micromol/24 hours; P=0.02) lower in patients treated with bedtime aspirin.","Time-dependent effects of low-dose aspirin on plasma renin activity, aldosterone, cortisol, and catecholamines. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19805643/),[μM] / [24·h],0.25,160614,DB00741,Hydrocortisone
,19805643,excretions,"Cortisol excretion in 24-hour urine was 52 nmol/24 hours (95% CI: 5 to 99 nmol/24 hours; P=0.05) lower, and dopamine and norepinephrine excretions were 0.25 micromol/24 hours (95% CI: 0.01 to 0.48 micromol/24 hours; P=0.04) and 0.22 micromol/24 hours (95% CI: -0.03 to 0.46 micromol/24 hours; P=0.02) lower in patients treated with bedtime aspirin.","Time-dependent effects of low-dose aspirin on plasma renin activity, aldosterone, cortisol, and catecholamines. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19805643/),[μM] / [24·h],0.22,160615,DB00741,Hydrocortisone
,15720518,alpha (t(1/2alpha),"The median alpha (t(1/2alpha)), beta (t(1/2beta)), and gamma (t(1/2gamma)) half-lives were 0.33, 2.2, and 10.7 h respectively.",Pharmacokinetics of dexamethasone with pharmacokinetic/pharmacodynamic model of the effect of dexamethasone on endogenous hydrocortisone and cortisone in the horse. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15720518/),h,0.33,161056,DB00741,Hydrocortisone
,15720518,beta (t(1/2beta)),"The median alpha (t(1/2alpha)), beta (t(1/2beta)), and gamma (t(1/2gamma)) half-lives were 0.33, 2.2, and 10.7 h respectively.",Pharmacokinetics of dexamethasone with pharmacokinetic/pharmacodynamic model of the effect of dexamethasone on endogenous hydrocortisone and cortisone in the horse. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15720518/),h,2.2,161057,DB00741,Hydrocortisone
,15720518,area under the DXM plasma concentration curve (AUC),The area under the DXM plasma concentration curve (AUC) was 113.5 ng.h/mL.,Pharmacokinetics of dexamethasone with pharmacokinetic/pharmacodynamic model of the effect of dexamethasone on endogenous hydrocortisone and cortisone in the horse. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15720518/),[h·ng] / [ml],113.5,161058,DB00741,Hydrocortisone
,15720518,plasma concentration,The baseline plasma concentration of COR was 3.5 +/- 0.69 ng/mL and declined significantly (P < 0.02) to 2.9 +/- 0.86 ng/mL at 1 h.,Pharmacokinetics of dexamethasone with pharmacokinetic/pharmacodynamic model of the effect of dexamethasone on endogenous hydrocortisone and cortisone in the horse. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15720518/),[ng] / [ml],3.5,161059,DB00741,Hydrocortisone
,15720518,plasma concentration,The baseline plasma concentration of COR was 3.5 +/- 0.69 ng/mL and declined significantly (P < 0.02) to 2.9 +/- 0.86 ng/mL at 1 h.,Pharmacokinetics of dexamethasone with pharmacokinetic/pharmacodynamic model of the effect of dexamethasone on endogenous hydrocortisone and cortisone in the horse. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15720518/),ng,2.9,161060,DB00741,Hydrocortisone
,15720518,plasma concentration,"The nadir in COR plasma concentration was 0.65 +/- 0.12 ng/mL at 28.8 +/- 9.0 h, and the DXM plasma concentration was 0.19 +/- 0.13 ng/mL.",Pharmacokinetics of dexamethasone with pharmacokinetic/pharmacodynamic model of the effect of dexamethasone on endogenous hydrocortisone and cortisone in the horse. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15720518/),[ng] / [ml],0.65,161061,DB00741,Hydrocortisone
,15720518,plasma concentration,"The nadir in COR plasma concentration was 0.65 +/- 0.12 ng/mL at 28.8 +/- 9.0 h, and the DXM plasma concentration was 0.19 +/- 0.13 ng/mL.",Pharmacokinetics of dexamethasone with pharmacokinetic/pharmacodynamic model of the effect of dexamethasone on endogenous hydrocortisone and cortisone in the horse. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15720518/),[ng] / [ml],0.19,161062,DB00741,Hydrocortisone
,15720518,plasma concentration,Baseline plasma concentration of HYD was 58.8 +/- 11.7 ng/mL and declined significantly (P < 0.001) to 41.1 +/- 14.9 ng/mL at 1 h following DXM administration but recovered to baseline at 96 h.,Pharmacokinetics of dexamethasone with pharmacokinetic/pharmacodynamic model of the effect of dexamethasone on endogenous hydrocortisone and cortisone in the horse. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15720518/),[ng] / [ml],58.8,161063,DB00741,Hydrocortisone
,15720518,plasma concentration,Baseline plasma concentration of HYD was 58.8 +/- 11.7 ng/mL and declined significantly (P < 0.001) to 41.1 +/- 14.9 ng/mL at 1 h following DXM administration but recovered to baseline at 96 h.,Pharmacokinetics of dexamethasone with pharmacokinetic/pharmacodynamic model of the effect of dexamethasone on endogenous hydrocortisone and cortisone in the horse. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15720518/),ng,41.,161064,DB00741,Hydrocortisone
,18719048,Nausea,"Compared to placebo, VAS Nausea increased non-significantly with granisetron [+7.6 mm (-1.3; 16.5)], as opposed to domperidone [+16.2 mm (7.2; 25.2)] and 5-HTP/CBD/placebo [+14.7 mm (5.5; 23.8)].",Enhanced tolerability of the 5-hydroxytryptophane challenge test combined with granisetron. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18719048/),,7,161535,DB00741,Hydrocortisone
,18719048,Nausea,"Compared to placebo, VAS Nausea increased non-significantly with granisetron [+7.6 mm (-1.3; 16.5)], as opposed to domperidone [+16.2 mm (7.2; 25.2)] and 5-HTP/CBD/placebo [+14.7 mm (5.5; 23.8)].",Enhanced tolerability of the 5-hydroxytryptophane challenge test combined with granisetron. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18719048/),,14,161536,DB00741,Hydrocortisone
,18719048,C(max),"Compared with 5-HTP/CBD/placebo, granisetron addition decreased C(max) of 5-HTP statistically significantly different (from 1483 to 1272 ng/ml) without influencing AUC(0- infinity).",Enhanced tolerability of the 5-hydroxytryptophane challenge test combined with granisetron. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18719048/),[ng] / [ml],1483,161537,DB00741,Hydrocortisone
,4018307,t 1/2,"The mean values of t 1/2 of cortisol, prednisolone and dexamethasone in patients with collagen diseases under RFP therapy were 1.8 +/- 0.3 (Mean +/- SD) (p less than 0.05), 1.4 +/- 0.2 (p less than 0.001) and 1.3 +/- 0.3 hours (p less than 0.001), respectively, which were significantly shortened when compared with normal subjects (cortisol, 2.1 +/- 0.2; prednisolone, 2.5 +/- 0.7; dexamethasone, 3.5 +/- 1.0 hours).","[A comparative study of the accelerated metabolism of cortisol, prednisolone and dexamethasone in patients under rifampicin therapy]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4018307/),h,1.8,161897,DB00741,Hydrocortisone
,4018307,t 1/2,"The mean values of t 1/2 of cortisol, prednisolone and dexamethasone in patients with collagen diseases under RFP therapy were 1.8 +/- 0.3 (Mean +/- SD) (p less than 0.05), 1.4 +/- 0.2 (p less than 0.001) and 1.3 +/- 0.3 hours (p less than 0.001), respectively, which were significantly shortened when compared with normal subjects (cortisol, 2.1 +/- 0.2; prednisolone, 2.5 +/- 0.7; dexamethasone, 3.5 +/- 1.0 hours).","[A comparative study of the accelerated metabolism of cortisol, prednisolone and dexamethasone in patients under rifampicin therapy]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4018307/),h,1.4,161898,DB00741,Hydrocortisone
,4018307,t 1/2,"The mean values of t 1/2 of cortisol, prednisolone and dexamethasone in patients with collagen diseases under RFP therapy were 1.8 +/- 0.3 (Mean +/- SD) (p less than 0.05), 1.4 +/- 0.2 (p less than 0.001) and 1.3 +/- 0.3 hours (p less than 0.001), respectively, which were significantly shortened when compared with normal subjects (cortisol, 2.1 +/- 0.2; prednisolone, 2.5 +/- 0.7; dexamethasone, 3.5 +/- 1.0 hours).","[A comparative study of the accelerated metabolism of cortisol, prednisolone and dexamethasone in patients under rifampicin therapy]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4018307/),h,1.3,161899,DB00741,Hydrocortisone
,4018307,t 1/2,"The mean values of t 1/2 of cortisol, prednisolone and dexamethasone in patients with collagen diseases under RFP therapy were 1.8 +/- 0.3 (Mean +/- SD) (p less than 0.05), 1.4 +/- 0.2 (p less than 0.001) and 1.3 +/- 0.3 hours (p less than 0.001), respectively, which were significantly shortened when compared with normal subjects (cortisol, 2.1 +/- 0.2; prednisolone, 2.5 +/- 0.7; dexamethasone, 3.5 +/- 1.0 hours).","[A comparative study of the accelerated metabolism of cortisol, prednisolone and dexamethasone in patients under rifampicin therapy]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4018307/),h,2.1,161900,DB00741,Hydrocortisone
,4018307,t 1/2,"The mean values of t 1/2 of cortisol, prednisolone and dexamethasone in patients with collagen diseases under RFP therapy were 1.8 +/- 0.3 (Mean +/- SD) (p less than 0.05), 1.4 +/- 0.2 (p less than 0.001) and 1.3 +/- 0.3 hours (p less than 0.001), respectively, which were significantly shortened when compared with normal subjects (cortisol, 2.1 +/- 0.2; prednisolone, 2.5 +/- 0.7; dexamethasone, 3.5 +/- 1.0 hours).","[A comparative study of the accelerated metabolism of cortisol, prednisolone and dexamethasone in patients under rifampicin therapy]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4018307/),h,2.5,161901,DB00741,Hydrocortisone
,4018307,t 1/2,"The mean values of t 1/2 of cortisol, prednisolone and dexamethasone in patients with collagen diseases under RFP therapy were 1.8 +/- 0.3 (Mean +/- SD) (p less than 0.05), 1.4 +/- 0.2 (p less than 0.001) and 1.3 +/- 0.3 hours (p less than 0.001), respectively, which were significantly shortened when compared with normal subjects (cortisol, 2.1 +/- 0.2; prednisolone, 2.5 +/- 0.7; dexamethasone, 3.5 +/- 1.0 hours).","[A comparative study of the accelerated metabolism of cortisol, prednisolone and dexamethasone in patients under rifampicin therapy]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4018307/),h,3.5,161902,DB00741,Hydrocortisone
,4018307,MCR,"The MCR of cortisol, prednisolone and dexamethasone in these patients were 139 +/- 57, 141 +/- 53 (p less than 0.01) and 722 +/- 137 l/day/m2 (p less than 0.001), respectively, which were increased when compared with normal subjects (cortisol, 114 +/- 20; prednisolone, 75 +/- 25; dexamethasone, 153 +/- 45 l/day/m2).","[A comparative study of the accelerated metabolism of cortisol, prednisolone and dexamethasone in patients under rifampicin therapy]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4018307/),[l] / [d·m2],139,161903,DB00741,Hydrocortisone
,4018307,MCR,"The MCR of cortisol, prednisolone and dexamethasone in these patients were 139 +/- 57, 141 +/- 53 (p less than 0.01) and 722 +/- 137 l/day/m2 (p less than 0.001), respectively, which were increased when compared with normal subjects (cortisol, 114 +/- 20; prednisolone, 75 +/- 25; dexamethasone, 153 +/- 45 l/day/m2).","[A comparative study of the accelerated metabolism of cortisol, prednisolone and dexamethasone in patients under rifampicin therapy]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4018307/),[l] / [d·m2],141,161904,DB00741,Hydrocortisone
,4018307,MCR,"The MCR of cortisol, prednisolone and dexamethasone in these patients were 139 +/- 57, 141 +/- 53 (p less than 0.01) and 722 +/- 137 l/day/m2 (p less than 0.001), respectively, which were increased when compared with normal subjects (cortisol, 114 +/- 20; prednisolone, 75 +/- 25; dexamethasone, 153 +/- 45 l/day/m2).","[A comparative study of the accelerated metabolism of cortisol, prednisolone and dexamethasone in patients under rifampicin therapy]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4018307/),[l] / [d·m2],722,161905,DB00741,Hydrocortisone
,4018307,MCR,"The MCR of cortisol, prednisolone and dexamethasone in these patients were 139 +/- 57, 141 +/- 53 (p less than 0.01) and 722 +/- 137 l/day/m2 (p less than 0.001), respectively, which were increased when compared with normal subjects (cortisol, 114 +/- 20; prednisolone, 75 +/- 25; dexamethasone, 153 +/- 45 l/day/m2).","[A comparative study of the accelerated metabolism of cortisol, prednisolone and dexamethasone in patients under rifampicin therapy]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4018307/),[l] / [d·m2],114,161906,DB00741,Hydrocortisone
,4018307,MCR,"The MCR of cortisol, prednisolone and dexamethasone in these patients were 139 +/- 57, 141 +/- 53 (p less than 0.01) and 722 +/- 137 l/day/m2 (p less than 0.001), respectively, which were increased when compared with normal subjects (cortisol, 114 +/- 20; prednisolone, 75 +/- 25; dexamethasone, 153 +/- 45 l/day/m2).","[A comparative study of the accelerated metabolism of cortisol, prednisolone and dexamethasone in patients under rifampicin therapy]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4018307/),[l] / [d·m2],75,161907,DB00741,Hydrocortisone
,4018307,MCR,"The MCR of cortisol, prednisolone and dexamethasone in these patients were 139 +/- 57, 141 +/- 53 (p less than 0.01) and 722 +/- 137 l/day/m2 (p less than 0.001), respectively, which were increased when compared with normal subjects (cortisol, 114 +/- 20; prednisolone, 75 +/- 25; dexamethasone, 153 +/- 45 l/day/m2).","[A comparative study of the accelerated metabolism of cortisol, prednisolone and dexamethasone in patients under rifampicin therapy]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4018307/),[l] / [d·m2],153,161908,DB00741,Hydrocortisone
,4018307,t 1/2,"The t 1/2 of cortisol, prednisolone and dexamethasone in patients with tuberculosis alone under RFP therapy were 1.3 +/- 0.3 (p less than 0.001), 1.4 +/- 0.5 (p less than 0.01) and 1.2 +/- 0.3 hours (p less than 0.001), respectively, which were significantly shortened when compared with normal subjects.","[A comparative study of the accelerated metabolism of cortisol, prednisolone and dexamethasone in patients under rifampicin therapy]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4018307/),h,1.3,161909,DB00741,Hydrocortisone
,4018307,t 1/2,"The t 1/2 of cortisol, prednisolone and dexamethasone in patients with tuberculosis alone under RFP therapy were 1.3 +/- 0.3 (p less than 0.001), 1.4 +/- 0.5 (p less than 0.01) and 1.2 +/- 0.3 hours (p less than 0.001), respectively, which were significantly shortened when compared with normal subjects.","[A comparative study of the accelerated metabolism of cortisol, prednisolone and dexamethasone in patients under rifampicin therapy]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4018307/),h,1.4,161910,DB00741,Hydrocortisone
,4018307,t 1/2,"The t 1/2 of cortisol, prednisolone and dexamethasone in patients with tuberculosis alone under RFP therapy were 1.3 +/- 0.3 (p less than 0.001), 1.4 +/- 0.5 (p less than 0.01) and 1.2 +/- 0.3 hours (p less than 0.001), respectively, which were significantly shortened when compared with normal subjects.","[A comparative study of the accelerated metabolism of cortisol, prednisolone and dexamethasone in patients under rifampicin therapy]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4018307/),h,1.2,161911,DB00741,Hydrocortisone
,11055323,plasma concentrations,This steroid sulfate did not accumulate; plasma concentrations 12 hours after the 3beta-acetyl-7-oxo-DHEA dose at 7 and 28 days on the 200 mg/d dose were 15.8 and 16.3 microg/L respectively.,Safety and pharmacokinetic study with escalating doses of 3-acetyl-7-oxo-dehydroepiandrosterone in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11055323/),[μg] / [l],15.8,162229,DB00741,Hydrocortisone
,11055323,plasma concentrations,This steroid sulfate did not accumulate; plasma concentrations 12 hours after the 3beta-acetyl-7-oxo-DHEA dose at 7 and 28 days on the 200 mg/d dose were 15.8 and 16.3 microg/L respectively.,Safety and pharmacokinetic study with escalating doses of 3-acetyl-7-oxo-dehydroepiandrosterone in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11055323/),[μg] / [l],16.3,162230,DB00741,Hydrocortisone
,11055323,time to peak plasma level,The mean time to peak plasma level of 7-oxo-DHEA-S was 2.2 hours; the mean half life was 2.17 hours.,Safety and pharmacokinetic study with escalating doses of 3-acetyl-7-oxo-dehydroepiandrosterone in healthy male volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11055323/),h,2.2,162231,DB00741,Hydrocortisone
,11055323,half life,The mean time to peak plasma level of 7-oxo-DHEA-S was 2.2 hours; the mean half life was 2.17 hours.,Safety and pharmacokinetic study with escalating doses of 3-acetyl-7-oxo-dehydroepiandrosterone in healthy male volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11055323/),h,2.17,162232,DB00741,Hydrocortisone
,11055323,apparent clearance,"The apparent clearance averaged 172 L/h, and the apparent mean volume of distribution was 540 L.",Safety and pharmacokinetic study with escalating doses of 3-acetyl-7-oxo-dehydroepiandrosterone in healthy male volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11055323/),[l] / [h],172,162233,DB00741,Hydrocortisone
,11055323,apparent mean volume of distribution,"The apparent clearance averaged 172 L/h, and the apparent mean volume of distribution was 540 L.",Safety and pharmacokinetic study with escalating doses of 3-acetyl-7-oxo-dehydroepiandrosterone in healthy male volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11055323/),l,540,162234,DB00741,Hydrocortisone
,8068867,clearances,"For the 6-hydroxylation of chlorzoxazone (P450 2E1) the predicted and actual clearances were 110 +/- 77 mL min-1 and 110 mL min-1, respectively.",Predicting the hepatic clearance of xenobiotics in humans from in vitro data. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8068867/),[ml] / [min],110,162611,DB00741,Hydrocortisone
,8068867,clearances,"For the 6-hydroxylation of chlorzoxazone (P450 2E1) the predicted and actual clearances were 110 +/- 77 mL min-1 and 110 mL min-1, respectively.",Predicting the hepatic clearance of xenobiotics in humans from in vitro data. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8068867/),[ml] / [min],110,162612,DB00741,Hydrocortisone
,8068867,CLH,An increase to 72 +/- 25 mL min-1 in the CLH of cortisol to 6 beta-hydroxycortisol was calculated following rifampicin treatment.,Predicting the hepatic clearance of xenobiotics in humans from in vitro data. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8068867/),[ml] / [min],72,162613,DB00741,Hydrocortisone
,12593521,peak plasma concentration (Cmax),"A statistically significantly greater peak plasma concentration (Cmax) of B17MP was reported with BDP via MDI (1,587 pg ml(-1)) compared with BDP 1,600 microg (455 pg ml(-1)) and BDP 3,200 microg suspensions for nebulization (758 pg ml(-1)), and was achieved more rapidly (Tmax) (1.3 h, 3 h, and 2.5 h, respectively).",Comparison of the bioavailability and systemic effects of beclometasone dipropionate suspension for nebulization and beclometasone dipropionate via a metered-dose inhaler after single-dose administration in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12593521/),[pg] / [ml],"1,587",162622,DB00741,Hydrocortisone
,12593521,peak plasma concentration (Cmax),"A statistically significantly greater peak plasma concentration (Cmax) of B17MP was reported with BDP via MDI (1,587 pg ml(-1)) compared with BDP 1,600 microg (455 pg ml(-1)) and BDP 3,200 microg suspensions for nebulization (758 pg ml(-1)), and was achieved more rapidly (Tmax) (1.3 h, 3 h, and 2.5 h, respectively).",Comparison of the bioavailability and systemic effects of beclometasone dipropionate suspension for nebulization and beclometasone dipropionate via a metered-dose inhaler after single-dose administration in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12593521/),[pg] / [ml],455,162623,DB00741,Hydrocortisone
,12593521,peak plasma concentration (Cmax),"A statistically significantly greater peak plasma concentration (Cmax) of B17MP was reported with BDP via MDI (1,587 pg ml(-1)) compared with BDP 1,600 microg (455 pg ml(-1)) and BDP 3,200 microg suspensions for nebulization (758 pg ml(-1)), and was achieved more rapidly (Tmax) (1.3 h, 3 h, and 2.5 h, respectively).",Comparison of the bioavailability and systemic effects of beclometasone dipropionate suspension for nebulization and beclometasone dipropionate via a metered-dose inhaler after single-dose administration in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12593521/),[pg] / [ml],758,162624,DB00741,Hydrocortisone
,12593521,Tmax,"A statistically significantly greater peak plasma concentration (Cmax) of B17MP was reported with BDP via MDI (1,587 pg ml(-1)) compared with BDP 1,600 microg (455 pg ml(-1)) and BDP 3,200 microg suspensions for nebulization (758 pg ml(-1)), and was achieved more rapidly (Tmax) (1.3 h, 3 h, and 2.5 h, respectively).",Comparison of the bioavailability and systemic effects of beclometasone dipropionate suspension for nebulization and beclometasone dipropionate via a metered-dose inhaler after single-dose administration in healthy male volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12593521/),h,1.3,162625,DB00741,Hydrocortisone
,12593521,Tmax,"A statistically significantly greater peak plasma concentration (Cmax) of B17MP was reported with BDP via MDI (1,587 pg ml(-1)) compared with BDP 1,600 microg (455 pg ml(-1)) and BDP 3,200 microg suspensions for nebulization (758 pg ml(-1)), and was achieved more rapidly (Tmax) (1.3 h, 3 h, and 2.5 h, respectively).",Comparison of the bioavailability and systemic effects of beclometasone dipropionate suspension for nebulization and beclometasone dipropionate via a metered-dose inhaler after single-dose administration in healthy male volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12593521/),h,3,162626,DB00741,Hydrocortisone
,12593521,Tmax,"A statistically significantly greater peak plasma concentration (Cmax) of B17MP was reported with BDP via MDI (1,587 pg ml(-1)) compared with BDP 1,600 microg (455 pg ml(-1)) and BDP 3,200 microg suspensions for nebulization (758 pg ml(-1)), and was achieved more rapidly (Tmax) (1.3 h, 3 h, and 2.5 h, respectively).",Comparison of the bioavailability and systemic effects of beclometasone dipropionate suspension for nebulization and beclometasone dipropionate via a metered-dose inhaler after single-dose administration in healthy male volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12593521/),h,2.5,162627,DB00741,Hydrocortisone
,12593521,elimination half-life (t 1/2(el)),"In addition, elimination half-life (t 1/2(el)) was statistically significantly shorter with BDP via MDI (4.6 h) than with both dosages of BDP suspensions for nebulization (7.4 h and 6.3 h with 1600 microg and 3,200 microg, respectively), as was mean residence time (MRT) (5.4 h, 11.1 h, and 10.0 h, respectively).",Comparison of the bioavailability and systemic effects of beclometasone dipropionate suspension for nebulization and beclometasone dipropionate via a metered-dose inhaler after single-dose administration in healthy male volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12593521/),h,4.6,162628,DB00741,Hydrocortisone
,12593521,elimination half-life (t 1/2(el)),"In addition, elimination half-life (t 1/2(el)) was statistically significantly shorter with BDP via MDI (4.6 h) than with both dosages of BDP suspensions for nebulization (7.4 h and 6.3 h with 1600 microg and 3,200 microg, respectively), as was mean residence time (MRT) (5.4 h, 11.1 h, and 10.0 h, respectively).",Comparison of the bioavailability and systemic effects of beclometasone dipropionate suspension for nebulization and beclometasone dipropionate via a metered-dose inhaler after single-dose administration in healthy male volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12593521/),h,7.4,162629,DB00741,Hydrocortisone
,12593521,elimination half-life (t 1/2(el)),"In addition, elimination half-life (t 1/2(el)) was statistically significantly shorter with BDP via MDI (4.6 h) than with both dosages of BDP suspensions for nebulization (7.4 h and 6.3 h with 1600 microg and 3,200 microg, respectively), as was mean residence time (MRT) (5.4 h, 11.1 h, and 10.0 h, respectively).",Comparison of the bioavailability and systemic effects of beclometasone dipropionate suspension for nebulization and beclometasone dipropionate via a metered-dose inhaler after single-dose administration in healthy male volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12593521/),h,6.3,162630,DB00741,Hydrocortisone
,12593521,mean residence time (MRT),"In addition, elimination half-life (t 1/2(el)) was statistically significantly shorter with BDP via MDI (4.6 h) than with both dosages of BDP suspensions for nebulization (7.4 h and 6.3 h with 1600 microg and 3,200 microg, respectively), as was mean residence time (MRT) (5.4 h, 11.1 h, and 10.0 h, respectively).",Comparison of the bioavailability and systemic effects of beclometasone dipropionate suspension for nebulization and beclometasone dipropionate via a metered-dose inhaler after single-dose administration in healthy male volunteers. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12593521/),h,5.4,162631,DB00741,Hydrocortisone
,12593521,mean residence time (MRT),"In addition, elimination half-life (t 1/2(el)) was statistically significantly shorter with BDP via MDI (4.6 h) than with both dosages of BDP suspensions for nebulization (7.4 h and 6.3 h with 1600 microg and 3,200 microg, respectively), as was mean residence time (MRT) (5.4 h, 11.1 h, and 10.0 h, respectively).",Comparison of the bioavailability and systemic effects of beclometasone dipropionate suspension for nebulization and beclometasone dipropionate via a metered-dose inhaler after single-dose administration in healthy male volunteers. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12593521/),h,11.1,162632,DB00741,Hydrocortisone
,12593521,mean residence time (MRT),"In addition, elimination half-life (t 1/2(el)) was statistically significantly shorter with BDP via MDI (4.6 h) than with both dosages of BDP suspensions for nebulization (7.4 h and 6.3 h with 1600 microg and 3,200 microg, respectively), as was mean residence time (MRT) (5.4 h, 11.1 h, and 10.0 h, respectively).",Comparison of the bioavailability and systemic effects of beclometasone dipropionate suspension for nebulization and beclometasone dipropionate via a metered-dose inhaler after single-dose administration in healthy male volunteers. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12593521/),h,10.0,162633,DB00741,Hydrocortisone
,12593521,area under the concentration-time curve: AUCinfinity,"Total systemic exposure to B17MP (as determined by the area under the concentration-time curve: AUCinfinity) was comparable for BDP via MDI (6,883 pg ml(-1) h(-1)) and BDP 3,200 microg suspension for nebulization (8,201 pg ml(-1) h(-1)), but significantly greater than with BDP 1,600 microg suspension for nebulization (4,870 pg ml(-1); P < 0.05 vs BDP via MDI).",Comparison of the bioavailability and systemic effects of beclometasone dipropionate suspension for nebulization and beclometasone dipropionate via a metered-dose inhaler after single-dose administration in healthy male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12593521/),[pg] / [h·ml],"6,883",162634,DB00741,Hydrocortisone
,12593521,area under the concentration-time curve: AUCinfinity,"Total systemic exposure to B17MP (as determined by the area under the concentration-time curve: AUCinfinity) was comparable for BDP via MDI (6,883 pg ml(-1) h(-1)) and BDP 3,200 microg suspension for nebulization (8,201 pg ml(-1) h(-1)), but significantly greater than with BDP 1,600 microg suspension for nebulization (4,870 pg ml(-1); P < 0.05 vs BDP via MDI).",Comparison of the bioavailability and systemic effects of beclometasone dipropionate suspension for nebulization and beclometasone dipropionate via a metered-dose inhaler after single-dose administration in healthy male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12593521/),[pg] / [h·ml],"8,201",162635,DB00741,Hydrocortisone
,12593521,area under the concentration-time curve: AUCinfinity,"Total systemic exposure to B17MP (as determined by the area under the concentration-time curve: AUCinfinity) was comparable for BDP via MDI (6,883 pg ml(-1) h(-1)) and BDP 3,200 microg suspension for nebulization (8,201 pg ml(-1) h(-1)), but significantly greater than with BDP 1,600 microg suspension for nebulization (4,870 pg ml(-1); P < 0.05 vs BDP via MDI).",Comparison of the bioavailability and systemic effects of beclometasone dipropionate suspension for nebulization and beclometasone dipropionate via a metered-dose inhaler after single-dose administration in healthy male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12593521/),[pg] / [ml],"4,870",162636,DB00741,Hydrocortisone
,2840310,apparent half-life,The disappearance of RU486 and its metabolites conformed to a noncompartmental model with a mean apparent half-life of 53.7 +/- 6.9 hours.,Pharmacodynamics of the antiprogesterone RU486 in women after oral administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2840310/),h,53.7,162792,DB00741,Hydrocortisone
,2840310,apparent volume of distribution,"The mean apparent volume of distribution and clearance rate were 1.47 +/- 0.25 l/kg and 1.04 +/- 0.09 1/hour, respectively.",Pharmacodynamics of the antiprogesterone RU486 in women after oral administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2840310/),[l] / [kg],1.47,162793,DB00741,Hydrocortisone
,2840310,clearance rate,"The mean apparent volume of distribution and clearance rate were 1.47 +/- 0.25 l/kg and 1.04 +/- 0.09 1/hour, respectively.",Pharmacodynamics of the antiprogesterone RU486 in women after oral administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2840310/),[1] / [h],1.04,162794,DB00741,Hydrocortisone
,10887750,durations of,"Peak cortisol, progesterone and prostaglandin F2 alpha metabolite levels were reached at 80 +/- 10.0, 80 +/- 10.0 and 46.6 +/- 13.3 min after ACTH administration and the durations of the peaks were 181.8 +/- 19.8, 308.1 +/- 49.7 and 181.8 +/- 7.9 min, respectively.","Plasma levels of cortisol, progesterone, oestradiol-17 beta and prostaglandin F2 alpha metabolite after ACTH (Synacthen Depot) administration in ovariectomized gilts. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10887750/),min,181.8,162806,DB00741,Hydrocortisone
,10887750,durations of,"Peak cortisol, progesterone and prostaglandin F2 alpha metabolite levels were reached at 80 +/- 10.0, 80 +/- 10.0 and 46.6 +/- 13.3 min after ACTH administration and the durations of the peaks were 181.8 +/- 19.8, 308.1 +/- 49.7 and 181.8 +/- 7.9 min, respectively.","Plasma levels of cortisol, progesterone, oestradiol-17 beta and prostaglandin F2 alpha metabolite after ACTH (Synacthen Depot) administration in ovariectomized gilts. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10887750/),min,308.1,162807,DB00741,Hydrocortisone
,10887750,durations of,"Peak cortisol, progesterone and prostaglandin F2 alpha metabolite levels were reached at 80 +/- 10.0, 80 +/- 10.0 and 46.6 +/- 13.3 min after ACTH administration and the durations of the peaks were 181.8 +/- 19.8, 308.1 +/- 49.7 and 181.8 +/- 7.9 min, respectively.","Plasma levels of cortisol, progesterone, oestradiol-17 beta and prostaglandin F2 alpha metabolite after ACTH (Synacthen Depot) administration in ovariectomized gilts. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10887750/),min,181.8,162808,DB00741,Hydrocortisone
,28814143,overall IC50,"After eight days of dosing, post-adrenocorticotropic hormone challenge plasma aldosterone concentration increase was dose-dependently blunted by LY3045697 with high potency with a dose as low as 0.1 mg resulting in substantial effect, and with an overall IC50 of 0.38 ng/ml.",LY3045697: Results from two randomized clinical trials of a novel inhibitor of aldosterone synthase. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28814143/),[ng] / [ml],0.38,164327,DB00741,Hydrocortisone
,7357797,systemic availability,"In a separate study in 12 normal subjects, flunisolide in plasma was quantitated by radioimmunoassay (RIA); average systemic availability was 20%.",Flunisolide metabolism and dynamics of a metabolite. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7357797/),%,20,165309,DB00741,Hydrocortisone
,9834042,volume of distribution at steady state,"The volume of distribution at steady state was 9.81 +/- 3.0 and 15.61 +/- 2.9, and the clearance was 256 +/- 40 mL x min(-1) and 345 +/- 90 mL x min(-1) for the 10-minute and 180-minute intravenous infusion, respectively (P < .05).","Pharmacokinetics, cortisol release, and hemodynamics after intravenous and subcutaneous injection of human corticotropin-releasing factor in humans. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9834042/),,9.81,165736,DB00741,Hydrocortisone
,9834042,volume of distribution at steady state,"The volume of distribution at steady state was 9.81 +/- 3.0 and 15.61 +/- 2.9, and the clearance was 256 +/- 40 mL x min(-1) and 345 +/- 90 mL x min(-1) for the 10-minute and 180-minute intravenous infusion, respectively (P < .05).","Pharmacokinetics, cortisol release, and hemodynamics after intravenous and subcutaneous injection of human corticotropin-releasing factor in humans. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9834042/),,15.61,165737,DB00741,Hydrocortisone
,9834042,clearance,"The volume of distribution at steady state was 9.81 +/- 3.0 and 15.61 +/- 2.9, and the clearance was 256 +/- 40 mL x min(-1) and 345 +/- 90 mL x min(-1) for the 10-minute and 180-minute intravenous infusion, respectively (P < .05).","Pharmacokinetics, cortisol release, and hemodynamics after intravenous and subcutaneous injection of human corticotropin-releasing factor in humans. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9834042/),[ml] / [min],256,165738,DB00741,Hydrocortisone
,9834042,clearance,"The volume of distribution at steady state was 9.81 +/- 3.0 and 15.61 +/- 2.9, and the clearance was 256 +/- 40 mL x min(-1) and 345 +/- 90 mL x min(-1) for the 10-minute and 180-minute intravenous infusion, respectively (P < .05).","Pharmacokinetics, cortisol release, and hemodynamics after intravenous and subcutaneous injection of human corticotropin-releasing factor in humans. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9834042/),[ml] / [min],345,165739,DB00741,Hydrocortisone
,9834042,elimination half-life,Corresponding elimination half-life was 45 +/- 7 minutes and 37 +/- 10 minutes.,"Pharmacokinetics, cortisol release, and hemodynamics after intravenous and subcutaneous injection of human corticotropin-releasing factor in humans. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9834042/),min,45,165740,DB00741,Hydrocortisone
,9834042,elimination half-life,Corresponding elimination half-life was 45 +/- 7 minutes and 37 +/- 10 minutes.,"Pharmacokinetics, cortisol release, and hemodynamics after intravenous and subcutaneous injection of human corticotropin-releasing factor in humans. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9834042/),min,37,165741,DB00741,Hydrocortisone
,9834042,bioavailability,The bioavailability of hCRF after subcutaneous administration was 67% +/- 17%.,"Pharmacokinetics, cortisol release, and hemodynamics after intravenous and subcutaneous injection of human corticotropin-releasing factor in humans. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9834042/),%,67,165742,DB00741,Hydrocortisone
,16579759,transfer half-life (t(1/2t)),"The median transfer half-life (t(1/2t)) of methylprednisolone from the joint to plasma and elimination half-life (t(1/2e)) from plasma were 1.7 and 19.2 hours, respectively.",Pharmacokinetics of methylprednisolone acetate after intra-articular administration and its effect on endogenous hydrocortisone and cortisone secretion in horses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16579759/),h,1.7,165762,DB00741,Hydrocortisone
,16579759,elimination half-life (t(1/2e)),"The median transfer half-life (t(1/2t)) of methylprednisolone from the joint to plasma and elimination half-life (t(1/2e)) from plasma were 1.7 and 19.2 hours, respectively.",Pharmacokinetics of methylprednisolone acetate after intra-articular administration and its effect on endogenous hydrocortisone and cortisone secretion in horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16579759/),h,19.2,165763,DB00741,Hydrocortisone
,16579759,Maximum plasma concentration,"Maximum plasma concentration of methylprednisolone was 7.26 +/- 3.3 ng/mL at 8 hours, which decreased to 0.11 +/- 0.08 ng/mL at 144 hours after injection.",Pharmacokinetics of methylprednisolone acetate after intra-articular administration and its effect on endogenous hydrocortisone and cortisone secretion in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16579759/),[ng] / [ml],7.26,165764,DB00741,Hydrocortisone
,16579759,Maximum plasma concentration,"Maximum plasma concentration of methylprednisolone was 7.26 +/- 3.3 ng/mL at 8 hours, which decreased to 0.11 +/- 0.08 ng/mL at 144 hours after injection.",Pharmacokinetics of methylprednisolone acetate after intra-articular administration and its effect on endogenous hydrocortisone and cortisone secretion in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16579759/),[ng] / [ml],0.11,165765,DB00741,Hydrocortisone
,26799632,half-life,"After multiple doses of 5-200 mg BI 135585, exposure (area under the curve) increased dose-proportionally and half-life was 55-65 h.","Safety, pharmacokinetics and pharmacodynamics of BI 135585, a selective 11β-hydroxysteroid dehydrogenase-1 (HSD1) inhibitor in humans: liver and adipose tissue 11β-HSD1 inhibition after acute and multiple administrations over 2 weeks. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26799632/),h,55-65,167430,DB00741,Hydrocortisone
,6470962,Dissolution,"Dissolution of the tablet formulations, using the official USP test, varied from 7.8 to 93.8% in 30 min.",Bioavailability of hydrocortisone from commercial 20-mg tablets. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6470962/),%,7.8 to 93.8,170086,DB00741,Hydrocortisone
,24010315,AUC(0-t),"After raw and different processed epimediums po. in mice, the main pharmacokinetics parameters were: raw epimedium AUC(0-t) = 184.77 (g/kg) x h, AUC(0-infinity) = 342.30 (g/kg) x h, MRT(0-t) = 5.95 h, MRT (0-infinity) = 28.58 h,Tmax, = 0.75 h, Cmax = 57.67 g/kg; Fried epimedium AUC(0-t) = 208.08 (g/kg) x h, AUC(0-infinity) = 523.95 (g/kg) x h, MRT(0-t) = 5.86 h, MRT(0-infinity) = 22.55h, Tmax = 1 h, Cmax = 62.53 g/kg; Fat-fried epimedium AUC (0-t) = 232.17 (g/kg) x h, AUC(0-infinity) = 629.96 (g/kg) x h, MRT(0-t) = 5.28 h, MRT(0-infinity) = 19.62 h, Tmax = 1.5 h, Cmax = 81.84 g/kg.",[Determination pharmacokinetics parameters of raw and different processed epimediums by pharmacology effect method]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24010315/),[g] / [h·kg)],184.77,170545,DB00741,Hydrocortisone
,24010315,AUC(0-infinity),"After raw and different processed epimediums po. in mice, the main pharmacokinetics parameters were: raw epimedium AUC(0-t) = 184.77 (g/kg) x h, AUC(0-infinity) = 342.30 (g/kg) x h, MRT(0-t) = 5.95 h, MRT (0-infinity) = 28.58 h,Tmax, = 0.75 h, Cmax = 57.67 g/kg; Fried epimedium AUC(0-t) = 208.08 (g/kg) x h, AUC(0-infinity) = 523.95 (g/kg) x h, MRT(0-t) = 5.86 h, MRT(0-infinity) = 22.55h, Tmax = 1 h, Cmax = 62.53 g/kg; Fat-fried epimedium AUC (0-t) = 232.17 (g/kg) x h, AUC(0-infinity) = 629.96 (g/kg) x h, MRT(0-t) = 5.28 h, MRT(0-infinity) = 19.62 h, Tmax = 1.5 h, Cmax = 81.84 g/kg.",[Determination pharmacokinetics parameters of raw and different processed epimediums by pharmacology effect method]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24010315/),[g] / [h·kg)],342.30,170546,DB00741,Hydrocortisone
,24010315,MRT(0-t),"After raw and different processed epimediums po. in mice, the main pharmacokinetics parameters were: raw epimedium AUC(0-t) = 184.77 (g/kg) x h, AUC(0-infinity) = 342.30 (g/kg) x h, MRT(0-t) = 5.95 h, MRT (0-infinity) = 28.58 h,Tmax, = 0.75 h, Cmax = 57.67 g/kg; Fried epimedium AUC(0-t) = 208.08 (g/kg) x h, AUC(0-infinity) = 523.95 (g/kg) x h, MRT(0-t) = 5.86 h, MRT(0-infinity) = 22.55h, Tmax = 1 h, Cmax = 62.53 g/kg; Fat-fried epimedium AUC (0-t) = 232.17 (g/kg) x h, AUC(0-infinity) = 629.96 (g/kg) x h, MRT(0-t) = 5.28 h, MRT(0-infinity) = 19.62 h, Tmax = 1.5 h, Cmax = 81.84 g/kg.",[Determination pharmacokinetics parameters of raw and different processed epimediums by pharmacology effect method]. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24010315/),h,5.95,170547,DB00741,Hydrocortisone
,24010315,MRT (0-infinity),"After raw and different processed epimediums po. in mice, the main pharmacokinetics parameters were: raw epimedium AUC(0-t) = 184.77 (g/kg) x h, AUC(0-infinity) = 342.30 (g/kg) x h, MRT(0-t) = 5.95 h, MRT (0-infinity) = 28.58 h,Tmax, = 0.75 h, Cmax = 57.67 g/kg; Fried epimedium AUC(0-t) = 208.08 (g/kg) x h, AUC(0-infinity) = 523.95 (g/kg) x h, MRT(0-t) = 5.86 h, MRT(0-infinity) = 22.55h, Tmax = 1 h, Cmax = 62.53 g/kg; Fat-fried epimedium AUC (0-t) = 232.17 (g/kg) x h, AUC(0-infinity) = 629.96 (g/kg) x h, MRT(0-t) = 5.28 h, MRT(0-infinity) = 19.62 h, Tmax = 1.5 h, Cmax = 81.84 g/kg.",[Determination pharmacokinetics parameters of raw and different processed epimediums by pharmacology effect method]. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24010315/),h,28.58,170548,DB00741,Hydrocortisone
,24010315,"Tmax,","After raw and different processed epimediums po. in mice, the main pharmacokinetics parameters were: raw epimedium AUC(0-t) = 184.77 (g/kg) x h, AUC(0-infinity) = 342.30 (g/kg) x h, MRT(0-t) = 5.95 h, MRT (0-infinity) = 28.58 h,Tmax, = 0.75 h, Cmax = 57.67 g/kg; Fried epimedium AUC(0-t) = 208.08 (g/kg) x h, AUC(0-infinity) = 523.95 (g/kg) x h, MRT(0-t) = 5.86 h, MRT(0-infinity) = 22.55h, Tmax = 1 h, Cmax = 62.53 g/kg; Fat-fried epimedium AUC (0-t) = 232.17 (g/kg) x h, AUC(0-infinity) = 629.96 (g/kg) x h, MRT(0-t) = 5.28 h, MRT(0-infinity) = 19.62 h, Tmax = 1.5 h, Cmax = 81.84 g/kg.",[Determination pharmacokinetics parameters of raw and different processed epimediums by pharmacology effect method]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24010315/),h,0.75,170549,DB00741,Hydrocortisone
,24010315,Cmax,"After raw and different processed epimediums po. in mice, the main pharmacokinetics parameters were: raw epimedium AUC(0-t) = 184.77 (g/kg) x h, AUC(0-infinity) = 342.30 (g/kg) x h, MRT(0-t) = 5.95 h, MRT (0-infinity) = 28.58 h,Tmax, = 0.75 h, Cmax = 57.67 g/kg; Fried epimedium AUC(0-t) = 208.08 (g/kg) x h, AUC(0-infinity) = 523.95 (g/kg) x h, MRT(0-t) = 5.86 h, MRT(0-infinity) = 22.55h, Tmax = 1 h, Cmax = 62.53 g/kg; Fat-fried epimedium AUC (0-t) = 232.17 (g/kg) x h, AUC(0-infinity) = 629.96 (g/kg) x h, MRT(0-t) = 5.28 h, MRT(0-infinity) = 19.62 h, Tmax = 1.5 h, Cmax = 81.84 g/kg.",[Determination pharmacokinetics parameters of raw and different processed epimediums by pharmacology effect method]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24010315/),[g] / [kg],57.67,170550,DB00741,Hydrocortisone
,24010315,AUC(0-t),"After raw and different processed epimediums po. in mice, the main pharmacokinetics parameters were: raw epimedium AUC(0-t) = 184.77 (g/kg) x h, AUC(0-infinity) = 342.30 (g/kg) x h, MRT(0-t) = 5.95 h, MRT (0-infinity) = 28.58 h,Tmax, = 0.75 h, Cmax = 57.67 g/kg; Fried epimedium AUC(0-t) = 208.08 (g/kg) x h, AUC(0-infinity) = 523.95 (g/kg) x h, MRT(0-t) = 5.86 h, MRT(0-infinity) = 22.55h, Tmax = 1 h, Cmax = 62.53 g/kg; Fat-fried epimedium AUC (0-t) = 232.17 (g/kg) x h, AUC(0-infinity) = 629.96 (g/kg) x h, MRT(0-t) = 5.28 h, MRT(0-infinity) = 19.62 h, Tmax = 1.5 h, Cmax = 81.84 g/kg.",[Determination pharmacokinetics parameters of raw and different processed epimediums by pharmacology effect method]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24010315/),[g] / [h·kg)],208.08,170551,DB00741,Hydrocortisone
,24010315,AUC(0-infinity),"After raw and different processed epimediums po. in mice, the main pharmacokinetics parameters were: raw epimedium AUC(0-t) = 184.77 (g/kg) x h, AUC(0-infinity) = 342.30 (g/kg) x h, MRT(0-t) = 5.95 h, MRT (0-infinity) = 28.58 h,Tmax, = 0.75 h, Cmax = 57.67 g/kg; Fried epimedium AUC(0-t) = 208.08 (g/kg) x h, AUC(0-infinity) = 523.95 (g/kg) x h, MRT(0-t) = 5.86 h, MRT(0-infinity) = 22.55h, Tmax = 1 h, Cmax = 62.53 g/kg; Fat-fried epimedium AUC (0-t) = 232.17 (g/kg) x h, AUC(0-infinity) = 629.96 (g/kg) x h, MRT(0-t) = 5.28 h, MRT(0-infinity) = 19.62 h, Tmax = 1.5 h, Cmax = 81.84 g/kg.",[Determination pharmacokinetics parameters of raw and different processed epimediums by pharmacology effect method]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24010315/),[g] / [h·kg)],523.95,170552,DB00741,Hydrocortisone
,24010315,MRT(0-t),"After raw and different processed epimediums po. in mice, the main pharmacokinetics parameters were: raw epimedium AUC(0-t) = 184.77 (g/kg) x h, AUC(0-infinity) = 342.30 (g/kg) x h, MRT(0-t) = 5.95 h, MRT (0-infinity) = 28.58 h,Tmax, = 0.75 h, Cmax = 57.67 g/kg; Fried epimedium AUC(0-t) = 208.08 (g/kg) x h, AUC(0-infinity) = 523.95 (g/kg) x h, MRT(0-t) = 5.86 h, MRT(0-infinity) = 22.55h, Tmax = 1 h, Cmax = 62.53 g/kg; Fat-fried epimedium AUC (0-t) = 232.17 (g/kg) x h, AUC(0-infinity) = 629.96 (g/kg) x h, MRT(0-t) = 5.28 h, MRT(0-infinity) = 19.62 h, Tmax = 1.5 h, Cmax = 81.84 g/kg.",[Determination pharmacokinetics parameters of raw and different processed epimediums by pharmacology effect method]. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24010315/),h,5.86,170553,DB00741,Hydrocortisone
,24010315,MRT(0-infinity),"After raw and different processed epimediums po. in mice, the main pharmacokinetics parameters were: raw epimedium AUC(0-t) = 184.77 (g/kg) x h, AUC(0-infinity) = 342.30 (g/kg) x h, MRT(0-t) = 5.95 h, MRT (0-infinity) = 28.58 h,Tmax, = 0.75 h, Cmax = 57.67 g/kg; Fried epimedium AUC(0-t) = 208.08 (g/kg) x h, AUC(0-infinity) = 523.95 (g/kg) x h, MRT(0-t) = 5.86 h, MRT(0-infinity) = 22.55h, Tmax = 1 h, Cmax = 62.53 g/kg; Fat-fried epimedium AUC (0-t) = 232.17 (g/kg) x h, AUC(0-infinity) = 629.96 (g/kg) x h, MRT(0-t) = 5.28 h, MRT(0-infinity) = 19.62 h, Tmax = 1.5 h, Cmax = 81.84 g/kg.",[Determination pharmacokinetics parameters of raw and different processed epimediums by pharmacology effect method]. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24010315/),h,22.55,170554,DB00741,Hydrocortisone
,24010315,Tmax,"After raw and different processed epimediums po. in mice, the main pharmacokinetics parameters were: raw epimedium AUC(0-t) = 184.77 (g/kg) x h, AUC(0-infinity) = 342.30 (g/kg) x h, MRT(0-t) = 5.95 h, MRT (0-infinity) = 28.58 h,Tmax, = 0.75 h, Cmax = 57.67 g/kg; Fried epimedium AUC(0-t) = 208.08 (g/kg) x h, AUC(0-infinity) = 523.95 (g/kg) x h, MRT(0-t) = 5.86 h, MRT(0-infinity) = 22.55h, Tmax = 1 h, Cmax = 62.53 g/kg; Fat-fried epimedium AUC (0-t) = 232.17 (g/kg) x h, AUC(0-infinity) = 629.96 (g/kg) x h, MRT(0-t) = 5.28 h, MRT(0-infinity) = 19.62 h, Tmax = 1.5 h, Cmax = 81.84 g/kg.",[Determination pharmacokinetics parameters of raw and different processed epimediums by pharmacology effect method]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24010315/),h,1,170555,DB00741,Hydrocortisone
,24010315,Cmax,"After raw and different processed epimediums po. in mice, the main pharmacokinetics parameters were: raw epimedium AUC(0-t) = 184.77 (g/kg) x h, AUC(0-infinity) = 342.30 (g/kg) x h, MRT(0-t) = 5.95 h, MRT (0-infinity) = 28.58 h,Tmax, = 0.75 h, Cmax = 57.67 g/kg; Fried epimedium AUC(0-t) = 208.08 (g/kg) x h, AUC(0-infinity) = 523.95 (g/kg) x h, MRT(0-t) = 5.86 h, MRT(0-infinity) = 22.55h, Tmax = 1 h, Cmax = 62.53 g/kg; Fat-fried epimedium AUC (0-t) = 232.17 (g/kg) x h, AUC(0-infinity) = 629.96 (g/kg) x h, MRT(0-t) = 5.28 h, MRT(0-infinity) = 19.62 h, Tmax = 1.5 h, Cmax = 81.84 g/kg.",[Determination pharmacokinetics parameters of raw and different processed epimediums by pharmacology effect method]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24010315/),[g] / [kg],62.53,170556,DB00741,Hydrocortisone
,24010315,AUC (0-t),"After raw and different processed epimediums po. in mice, the main pharmacokinetics parameters were: raw epimedium AUC(0-t) = 184.77 (g/kg) x h, AUC(0-infinity) = 342.30 (g/kg) x h, MRT(0-t) = 5.95 h, MRT (0-infinity) = 28.58 h,Tmax, = 0.75 h, Cmax = 57.67 g/kg; Fried epimedium AUC(0-t) = 208.08 (g/kg) x h, AUC(0-infinity) = 523.95 (g/kg) x h, MRT(0-t) = 5.86 h, MRT(0-infinity) = 22.55h, Tmax = 1 h, Cmax = 62.53 g/kg; Fat-fried epimedium AUC (0-t) = 232.17 (g/kg) x h, AUC(0-infinity) = 629.96 (g/kg) x h, MRT(0-t) = 5.28 h, MRT(0-infinity) = 19.62 h, Tmax = 1.5 h, Cmax = 81.84 g/kg.",[Determination pharmacokinetics parameters of raw and different processed epimediums by pharmacology effect method]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24010315/),[g] / [h·kg)],232.17,170557,DB00741,Hydrocortisone
,24010315,AUC(0-infinity),"After raw and different processed epimediums po. in mice, the main pharmacokinetics parameters were: raw epimedium AUC(0-t) = 184.77 (g/kg) x h, AUC(0-infinity) = 342.30 (g/kg) x h, MRT(0-t) = 5.95 h, MRT (0-infinity) = 28.58 h,Tmax, = 0.75 h, Cmax = 57.67 g/kg; Fried epimedium AUC(0-t) = 208.08 (g/kg) x h, AUC(0-infinity) = 523.95 (g/kg) x h, MRT(0-t) = 5.86 h, MRT(0-infinity) = 22.55h, Tmax = 1 h, Cmax = 62.53 g/kg; Fat-fried epimedium AUC (0-t) = 232.17 (g/kg) x h, AUC(0-infinity) = 629.96 (g/kg) x h, MRT(0-t) = 5.28 h, MRT(0-infinity) = 19.62 h, Tmax = 1.5 h, Cmax = 81.84 g/kg.",[Determination pharmacokinetics parameters of raw and different processed epimediums by pharmacology effect method]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24010315/),[g] / [h·kg)],629.96,170558,DB00741,Hydrocortisone
,3067620,concentrations,Mean (+/- SEM) plasma acetaldehyde concentrations of flushers (28.2 +/- 11.8 microM) were significantly greater than nonflushers (1.4 +/- 0.5 microM) following ethanol ingestion (p less than 0.001).,Opiate antagonist nalmefene inhibits ethanol-induced flushing in Asians: a preliminary study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3067620/),μM,28.,171538,DB00741,Hydrocortisone
,3067620,concentrations,Mean (+/- SEM) plasma acetaldehyde concentrations of flushers (28.2 +/- 11.8 microM) were significantly greater than nonflushers (1.4 +/- 0.5 microM) following ethanol ingestion (p less than 0.001).,Opiate antagonist nalmefene inhibits ethanol-induced flushing in Asians: a preliminary study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3067620/),μ,1,171539,DB00741,Hydrocortisone
,3067620,area under the curve (AUC),"Ethanol alone always induced a significant rise in facial skin temperature [mean area under the curve (AUC) = 5142 +/- 648 % delta T x min, p less than 0.01] and of pulse (mean AUC = 1622 +/- 120 bpm x min, p less than 0.001) in flushers compared to water ingestion.",Opiate antagonist nalmefene inhibits ethanol-induced flushing in Asians: a preliminary study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3067620/),%·delta·min·t,5142,171540,DB00741,Hydrocortisone
,3067620,AUC,"Ethanol alone always induced a significant rise in facial skin temperature [mean area under the curve (AUC) = 5142 +/- 648 % delta T x min, p less than 0.01] and of pulse (mean AUC = 1622 +/- 120 bpm x min, p less than 0.001) in flushers compared to water ingestion.",Opiate antagonist nalmefene inhibits ethanol-induced flushing in Asians: a preliminary study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3067620/),bpm·min,1622,171541,DB00741,Hydrocortisone
,831089,half-life,"Cortisol half-life was prolonged from 60 to 78 minutes (P less than 0.01), and metabolic clearance rate was decreased from 359 to 177 liters per day (P less than 0.001).",Cortisol secretion and metabolism in anorexia nervosa. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/831089/),min,60 to 78,171705,DB00741,Hydrocortisone
,831089,metabolic clearance rate,"Cortisol half-life was prolonged from 60 to 78 minutes (P less than 0.01), and metabolic clearance rate was decreased from 359 to 177 liters per day (P less than 0.001).",Cortisol secretion and metabolism in anorexia nervosa. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/831089/),[l] / [d],359 to 177,171706,DB00741,Hydrocortisone
,831089,tetrahy,"These findings, as well as the increased tetrahydrocortisol/tetrahydrocortisone ratio (1.2 vs 0.65, P less than 0.01), also appear in hypothyroid patients.",Cortisol secretion and metabolism in anorexia nervosa. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/831089/),,1.2,171707,DB00741,Hydrocortisone
,831089,tetrahy,"These findings, as well as the increased tetrahydrocortisol/tetrahydrocortisone ratio (1.2 vs 0.65, P less than 0.01), also appear in hypothyroid patients.",Cortisol secretion and metabolism in anorexia nervosa. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/831089/),,0.65,171708,DB00741,Hydrocortisone
,831089,ratio,"These findings, as well as the increased tetrahydrocortisol/tetrahydrocortisone ratio (1.2 vs 0.65, P less than 0.01), also appear in hypothyroid patients.",Cortisol secretion and metabolism in anorexia nervosa. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/831089/),,1.2,171709,DB00741,Hydrocortisone
,831089,ratio,"These findings, as well as the increased tetrahydrocortisol/tetrahydrocortisone ratio (1.2 vs 0.65, P less than 0.01), also appear in hypothyroid patients.",Cortisol secretion and metabolism in anorexia nervosa. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/831089/),,0.65,171710,DB00741,Hydrocortisone
,3189538,production rate,"With the use of clearance values calculated from constant perfusion administration, the 24-h hydrocortisone production rate was estimated at 0.46 +/- 0.08 mg.kg-1.24 h-1.",Hydrocortisone secretion: production rate and pulse characterization by numerical deconvolution. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3189538/),[mg] / [h·kg],0.46,171859,DB00741,Hydrocortisone
,3189538,number,"When this secretory profile was subjected to a pulse analysis program, the number of detected peaks was found to be 17.25 +/- 1.26 and the mean peak duration 34.01 +/- 5.52 min.",Hydrocortisone secretion: production rate and pulse characterization by numerical deconvolution. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3189538/),,17.25,171860,DB00741,Hydrocortisone
,3189538,peak duration,"When this secretory profile was subjected to a pulse analysis program, the number of detected peaks was found to be 17.25 +/- 1.26 and the mean peak duration 34.01 +/- 5.52 min.",Hydrocortisone secretion: production rate and pulse characterization by numerical deconvolution. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3189538/),min,34.01,171861,DB00741,Hydrocortisone
,3189538,total duration of secretory activity,The total duration of secretory activity was estimated at 582.5 +/- 63.97 min.,Hydrocortisone secretion: production rate and pulse characterization by numerical deconvolution. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3189538/),min,582.5,171862,DB00741,Hydrocortisone
,3189538,number of peaks,"By comparison, when the plasma concentration profile was analyzed directly, the number of peaks was only 10.0 +/- 1.41 but their mean duration was much longer, i.e., 105.25 +/- 21.24 min.",Hydrocortisone secretion: production rate and pulse characterization by numerical deconvolution. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3189538/),,10.0,171863,DB00741,Hydrocortisone
,1830266,area under the plasma concentration versus time curve (AUC),"The area under the plasma concentration versus time curve (AUC) for oral EE2 alone was 867 +/- 338 pg/ml x h, for oral EE2 in the presence of gestodene it was 795 +/- 206 pg/ml x h and for oral EE2 in the presence of desogestrel it was 614 +/- 132 pg/ml x h.",The pharmacokinetics of ethynylestradiol in the presence and absence of gestodene and desogestrel. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1830266/),[pg] / [h·ml],867,174414,DB00741,Hydrocortisone
,1830266,area under the plasma concentration versus time curve (AUC),"The area under the plasma concentration versus time curve (AUC) for oral EE2 alone was 867 +/- 338 pg/ml x h, for oral EE2 in the presence of gestodene it was 795 +/- 206 pg/ml x h and for oral EE2 in the presence of desogestrel it was 614 +/- 132 pg/ml x h.",The pharmacokinetics of ethynylestradiol in the presence and absence of gestodene and desogestrel. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1830266/),[pg] / [h·ml],795,174415,DB00741,Hydrocortisone
,1830266,area under the plasma concentration versus time curve (AUC),"The area under the plasma concentration versus time curve (AUC) for oral EE2 alone was 867 +/- 338 pg/ml x h, for oral EE2 in the presence of gestodene it was 795 +/- 206 pg/ml x h and for oral EE2 in the presence of desogestrel it was 614 +/- 132 pg/ml x h.",The pharmacokinetics of ethynylestradiol in the presence and absence of gestodene and desogestrel. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1830266/),[pg] / [h·ml],614,174416,DB00741,Hydrocortisone
,1830266,bioavailability,"Comparing the relative oral and iv doses, the bioavailability of EE2 (alone) was 59.0 +/- 13% (n = 6), for EE2 plus gestodene it was 62.1 +/- 10% and for EE2 in the presence of desogestrel it was 62.1 +/- 4.4%.",The pharmacokinetics of ethynylestradiol in the presence and absence of gestodene and desogestrel. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1830266/),%,59.0,174417,DB00741,Hydrocortisone
,1830266,bioavailability,"Comparing the relative oral and iv doses, the bioavailability of EE2 (alone) was 59.0 +/- 13% (n = 6), for EE2 plus gestodene it was 62.1 +/- 10% and for EE2 in the presence of desogestrel it was 62.1 +/- 4.4%.",The pharmacokinetics of ethynylestradiol in the presence and absence of gestodene and desogestrel. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1830266/),%,62.1,174418,DB00741,Hydrocortisone
,1830266,bioavailability,"Comparing the relative oral and iv doses, the bioavailability of EE2 (alone) was 59.0 +/- 13% (n = 6), for EE2 plus gestodene it was 62.1 +/- 10% and for EE2 in the presence of desogestrel it was 62.1 +/- 4.4%.",The pharmacokinetics of ethynylestradiol in the presence and absence of gestodene and desogestrel. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1830266/),%,62.1,174419,DB00741,Hydrocortisone
,1830266,clearance,The clearance of EE2 (alone) was 19.9 +/- 5.5 l/h and in the presence of gestodene it was 19.4 +/- 9.6 l/h.,The pharmacokinetics of ethynylestradiol in the presence and absence of gestodene and desogestrel. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1830266/),[l] / [h],19.9,174420,DB00741,Hydrocortisone
,1830266,clearance,The clearance of EE2 (alone) was 19.9 +/- 5.5 l/h and in the presence of gestodene it was 19.4 +/- 9.6 l/h.,The pharmacokinetics of ethynylestradiol in the presence and absence of gestodene and desogestrel. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1830266/),[l] / [h],19.4,174421,DB00741,Hydrocortisone
,1830266,clearance,The clearance of EE2 in the presence of desogestrel appeared slightly greater at 27.7 +/- 8.9 l/h but none of these clearance values were significantly different from each other.,The pharmacokinetics of ethynylestradiol in the presence and absence of gestodene and desogestrel. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1830266/),[l] / [h],27.7,174422,DB00741,Hydrocortisone
,3356080,renal,"7.7 +/- 1.6 ml/min/kg, mean +/- SD; P less than 0.001) and renal (0.9 +/- 0.3 vs. 2.9 +/- 0.7 ml/min/kg; P less than 0.001) clearances of unbound prednisolone were lower in the elderly.",Kinetics of prednisolone and endogenous cortisol suppression in the elderly. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3356080/),[ml] / [kg·min],0.9,177087,DB00741,Hydrocortisone
,3356080,renal,"7.7 +/- 1.6 ml/min/kg, mean +/- SD; P less than 0.001) and renal (0.9 +/- 0.3 vs. 2.9 +/- 0.7 ml/min/kg; P less than 0.001) clearances of unbound prednisolone were lower in the elderly.",Kinetics of prednisolone and endogenous cortisol suppression in the elderly. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3356080/),[ml] / [kg·min],2.9,177088,DB00741,Hydrocortisone
,6497132,half-life of elimination,"After dexamethasone alcohol (IV) or dexamethasone 21-isonicotinate (IV), the half-life of elimination was similar (53 minutes) for both formulations.",Dexamethasone and prednisolone in the horse: pharmacokinetics and action on the adrenal gland. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6497132/),min,53,177901,DB00741,Hydrocortisone
,6497132,half-life of elimination,"After prednisolone 21-sodium succinate (IV), the half-life of elimination (99.5 minutes) was significantly (P less than 0.01) longer than that for dexamethasone.",Dexamethasone and prednisolone in the horse: pharmacokinetics and action on the adrenal gland. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6497132/),min,99.5,177902,DB00741,Hydrocortisone
higher,6497132,bioavailability,"Due to the nonlinearity of prednisolone kinetics, a bioavailability higher than 100% was obtained.",Dexamethasone and prednisolone in the horse: pharmacokinetics and action on the adrenal gland. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6497132/),%,100,177903,DB00741,Hydrocortisone
,23900878,tmax,"The multiple-dose pharmacokinetics of macitentan were dose-proportional and were characterized by a median tmax and apparent elimination half-life varying from 6.0 to 8.5 and 14.3 to 18.5 hours, respectively, for the different doses and minimal accumulation.","Safety, tolerability, pharmacokinetics, and pharmacodynamics of macitentan, an endothelin receptor antagonist, in an ascending multiple-dose study in healthy subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23900878/),h,6.0 to 8.5,181101,DB00741,Hydrocortisone
,23900878,apparent elimination half-life,"The multiple-dose pharmacokinetics of macitentan were dose-proportional and were characterized by a median tmax and apparent elimination half-life varying from 6.0 to 8.5 and 14.3 to 18.5 hours, respectively, for the different doses and minimal accumulation.","Safety, tolerability, pharmacokinetics, and pharmacodynamics of macitentan, an endothelin receptor antagonist, in an ascending multiple-dose study in healthy subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23900878/),h,14.3 to 18.5,181102,DB00741,Hydrocortisone
,23900878,half-life,"ACT-132577, a metabolite with lower potency than macitentan, had a half-life of about 48 hours and accumulated approximately 8.5-fold.","Safety, tolerability, pharmacokinetics, and pharmacodynamics of macitentan, an endothelin receptor antagonist, in an ascending multiple-dose study in healthy subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23900878/),h,48,181103,DB00741,Hydrocortisone
,11049012,time to the Cmax,Grapefruit juice delayed the time to the Cmax from 2.0 h to 3.0 h (P < 0.05).,Grapefruit juice can increase the plasma concentrations of oral methylprednisolone. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11049012/),h,2.0,181196,DB00741,Hydrocortisone
,11049012,time to the Cmax,Grapefruit juice delayed the time to the Cmax from 2.0 h to 3.0 h (P < 0.05).,Grapefruit juice can increase the plasma concentrations of oral methylprednisolone. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11049012/),h,3.0,181197,DB00741,Hydrocortisone
,7319961,t 1/2,Serum cortisol had a similar t 1/2 in S (32.5 +/- 2.3 min) and NS (29.2 +/- 3.2 min) cows and did not not differ between sampling periods.,Clearance of serum cortisol in suckled and nonsuckled postpartum beef cows. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7319961/),min,32.5,182320,DB00741,Hydrocortisone
,7319961,t 1/2,Serum cortisol had a similar t 1/2 in S (32.5 +/- 2.3 min) and NS (29.2 +/- 3.2 min) cows and did not not differ between sampling periods.,Clearance of serum cortisol in suckled and nonsuckled postpartum beef cows. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7319961/),min,29.2,182321,DB00741,Hydrocortisone
,7319961,Vd,"Vd did not differ (p greater than .3) between S (248 +/- 29 liters) and NS (199 +/- 14 liters) cows across both periods, but was greater (p less than .05) at period 1 than at period 2 for both S and NS cows.",Clearance of serum cortisol in suckled and nonsuckled postpartum beef cows. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7319961/),l,248,182322,DB00741,Hydrocortisone
,7319961,Vd,"Vd did not differ (p greater than .3) between S (248 +/- 29 liters) and NS (199 +/- 14 liters) cows across both periods, but was greater (p less than .05) at period 1 than at period 2 for both S and NS cows.",Clearance of serum cortisol in suckled and nonsuckled postpartum beef cows. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7319961/),l,199,182323,DB00741,Hydrocortisone
,7319961,Total body clearance,Total body clearance was similar in S (5.2 +/- .4 liters/min) and NS (5.0 +/- .6 liters/min) cows and was similar at both sampling periods.,Clearance of serum cortisol in suckled and nonsuckled postpartum beef cows. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7319961/),[l] / [min],5.2,182324,DB00741,Hydrocortisone
,7319961,Total body clearance,Total body clearance was similar in S (5.2 +/- .4 liters/min) and NS (5.0 +/- .6 liters/min) cows and was similar at both sampling periods.,Clearance of serum cortisol in suckled and nonsuckled postpartum beef cows. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7319961/),[l] / [min],5.0,182325,DB00741,Hydrocortisone
,10950233,plasma area under curve,"After inhalation, geometric mean values were significantly lower in the asthma group than in controls for fluticasone propionate plasma area under curve (1082 [95% CI 850-1451] vs 2815 pg mL(-1) h(-1) [2262-3949], -62% difference [45-72]; p<0.001), maximum concentrations (117 [91-159] vs 383 pg/mL [302-546], -68% [-50 to -81]; p<0.001), and systemic bioavailability (10.1 [7.9-14.0] vs 21.4% [15.4-32.2], -54% [-27 to -70]; p=0.001).",Comparison of pharmacokinetics and systemic effects of inhaled fluticasone propionate in patients with asthma and healthy volunteers: a randomised crossover study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10950233/),[pg] / [h·ml],1082,186017,DB00741,Hydrocortisone
,10950233,plasma area under curve,"After inhalation, geometric mean values were significantly lower in the asthma group than in controls for fluticasone propionate plasma area under curve (1082 [95% CI 850-1451] vs 2815 pg mL(-1) h(-1) [2262-3949], -62% difference [45-72]; p<0.001), maximum concentrations (117 [91-159] vs 383 pg/mL [302-546], -68% [-50 to -81]; p<0.001), and systemic bioavailability (10.1 [7.9-14.0] vs 21.4% [15.4-32.2], -54% [-27 to -70]; p=0.001).",Comparison of pharmacokinetics and systemic effects of inhaled fluticasone propionate in patients with asthma and healthy volunteers: a randomised crossover study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10950233/),[pg] / [h·ml],2815,186018,DB00741,Hydrocortisone
,10950233,maximum concentrations,"After inhalation, geometric mean values were significantly lower in the asthma group than in controls for fluticasone propionate plasma area under curve (1082 [95% CI 850-1451] vs 2815 pg mL(-1) h(-1) [2262-3949], -62% difference [45-72]; p<0.001), maximum concentrations (117 [91-159] vs 383 pg/mL [302-546], -68% [-50 to -81]; p<0.001), and systemic bioavailability (10.1 [7.9-14.0] vs 21.4% [15.4-32.2], -54% [-27 to -70]; p=0.001).",Comparison of pharmacokinetics and systemic effects of inhaled fluticasone propionate in patients with asthma and healthy volunteers: a randomised crossover study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10950233/),[pg] / [ml],117,186019,DB00741,Hydrocortisone
,10950233,maximum concentrations,"After inhalation, geometric mean values were significantly lower in the asthma group than in controls for fluticasone propionate plasma area under curve (1082 [95% CI 850-1451] vs 2815 pg mL(-1) h(-1) [2262-3949], -62% difference [45-72]; p<0.001), maximum concentrations (117 [91-159] vs 383 pg/mL [302-546], -68% [-50 to -81]; p<0.001), and systemic bioavailability (10.1 [7.9-14.0] vs 21.4% [15.4-32.2], -54% [-27 to -70]; p=0.001).",Comparison of pharmacokinetics and systemic effects of inhaled fluticasone propionate in patients with asthma and healthy volunteers: a randomised crossover study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10950233/),[pg] / [ml],383,186020,DB00741,Hydrocortisone
,10950233,systemic bioavailability,"After inhalation, geometric mean values were significantly lower in the asthma group than in controls for fluticasone propionate plasma area under curve (1082 [95% CI 850-1451] vs 2815 pg mL(-1) h(-1) [2262-3949], -62% difference [45-72]; p<0.001), maximum concentrations (117 [91-159] vs 383 pg/mL [302-546], -68% [-50 to -81]; p<0.001), and systemic bioavailability (10.1 [7.9-14.0] vs 21.4% [15.4-32.2], -54% [-27 to -70]; p=0.001).",Comparison of pharmacokinetics and systemic effects of inhaled fluticasone propionate in patients with asthma and healthy volunteers: a randomised crossover study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10950233/),,10.1,186021,DB00741,Hydrocortisone
,10950233,systemic bioavailability,"After inhalation, geometric mean values were significantly lower in the asthma group than in controls for fluticasone propionate plasma area under curve (1082 [95% CI 850-1451] vs 2815 pg mL(-1) h(-1) [2262-3949], -62% difference [45-72]; p<0.001), maximum concentrations (117 [91-159] vs 383 pg/mL [302-546], -68% [-50 to -81]; p<0.001), and systemic bioavailability (10.1 [7.9-14.0] vs 21.4% [15.4-32.2], -54% [-27 to -70]; p=0.001).",Comparison of pharmacokinetics and systemic effects of inhaled fluticasone propionate in patients with asthma and healthy volunteers: a randomised crossover study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10950233/),%,21.4,186022,DB00741,Hydrocortisone
,15317828,total clearance,The total clearance of methylprednisolone for the female subjects was 15.6 +/- 5.99 L/h compared to the males with 21.5 +/- 8.67 L/h (P <.05).,Pharmacokinetics and pharmacodynamic response of methylprednisolone in premenopausal renal transplant recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15317828/),[l] / [h],15.6,187089,DB00741,Hydrocortisone
,15317828,total clearance,The total clearance of methylprednisolone for the female subjects was 15.6 +/- 5.99 L/h compared to the males with 21.5 +/- 8.67 L/h (P <.05).,Pharmacokinetics and pharmacodynamic response of methylprednisolone in premenopausal renal transplant recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15317828/),[l] / [h],21.5,187090,DB00741,Hydrocortisone
,15317828,a,Dose-normalized methylprednisolone a AUC was greater in women (66.1 +/- 19.8 ng*h/mL) than men (46.4 +/- 19.7 ng*h/mL) (P =.174).,Pharmacokinetics and pharmacodynamic response of methylprednisolone in premenopausal renal transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15317828/),[h·ng] / [ml],66.1,187091,DB00741,Hydrocortisone
,15317828,AUC,Dose-normalized methylprednisolone a AUC was greater in women (66.1 +/- 19.8 ng*h/mL) than men (46.4 +/- 19.7 ng*h/mL) (P =.174).,Pharmacokinetics and pharmacodynamic response of methylprednisolone in premenopausal renal transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15317828/),[h·ng] / [ml],66.1,187092,DB00741,Hydrocortisone
,15317828,AUC,Dose-normalized methylprednisolone a AUC was greater in women (66.1 +/- 19.8 ng*h/mL) than men (46.4 +/- 19.7 ng*h/mL) (P =.174).,Pharmacokinetics and pharmacodynamic response of methylprednisolone in premenopausal renal transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15317828/),[h·ng] / [ml],46.4,187093,DB00741,Hydrocortisone
,15317828,AUC,"Despite chronic steroid therapy, 9 of 13 women had a normal cortisol profile and an ACTH AUC of 299 +/- 102 pg*h/mL.",Pharmacokinetics and pharmacodynamic response of methylprednisolone in premenopausal renal transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15317828/),[h·pg] / [ml],299,187094,DB00741,Hydrocortisone
,24388705,serum T1 drug levels,"Patients with grade 3 skin toxicity showed serum T1 drug levels significantly higher than those with grade 0-2 (6.84 [2.28] vs. 3.08 [1.97] μmol/l, respectively, p=0.004) and had longer progression-free and overall survival.","Correlation between erlotinib pharmacokinetics, cutaneous toxicity and clinical outcomes in patients with advanced non-small cell lung cancer (NSCLC). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24388705/),[μM] / [l],6.84,187425,DB00741,Hydrocortisone
,24388705,serum T1 drug levels,"Patients with grade 3 skin toxicity showed serum T1 drug levels significantly higher than those with grade 0-2 (6.84 [2.28] vs. 3.08 [1.97] μmol/l, respectively, p=0.004) and had longer progression-free and overall survival.","Correlation between erlotinib pharmacokinetics, cutaneous toxicity and clinical outcomes in patients with advanced non-small cell lung cancer (NSCLC). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24388705/),[μM] / [l],3.08,187426,DB00741,Hydrocortisone
,820709,Peak TSH response,"Peak TSH response to TRH decreased from 16.4 to 5.8 muU/ml (P less than 0.005), as did TSH reserve from 1.58 to 0.54 mU - min/ml (P less than 0.005).",The effect of glucocorticoid administration on human pituitary secretion of thyrotropin and prolactin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/820709/),[muu] / [ml],16.4 to 5.8,187729,DB00741,Hydrocortisone
,820709,reserve,"Peak TSH response to TRH decreased from 16.4 to 5.8 muU/ml (P less than 0.005), as did TSH reserve from 1.58 to 0.54 mU - min/ml (P less than 0.005).",The effect of glucocorticoid administration on human pituitary secretion of thyrotropin and prolactin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/820709/),[-·min·mu] / [ml],1.58,187730,DB00741,Hydrocortisone
,820709,reserve,"Peak TSH response to TRH decreased from 16.4 to 5.8 muU/ml (P less than 0.005), as did TSH reserve from 1.58 to 0.54 mU - min/ml (P less than 0.005).",The effect of glucocorticoid administration on human pituitary secretion of thyrotropin and prolactin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/820709/),[-·min·mu] / [ml],0.54,187731,DB00741,Hydrocortisone
,820709,T3,"Although Basal T4 and fT4 did not change significantly, dexamethasone did decrease T3 from 106 to 61 ng/dl (P less than 0.001) and fT3 from 174 to 76 pg/dl (P less than 0.05).",The effect of glucocorticoid administration on human pituitary secretion of thyrotropin and prolactin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/820709/),[ng] / [dl],106,187732,DB00741,Hydrocortisone
,820709,T3,"Although Basal T4 and fT4 did not change significantly, dexamethasone did decrease T3 from 106 to 61 ng/dl (P less than 0.001) and fT3 from 174 to 76 pg/dl (P less than 0.05).",The effect of glucocorticoid administration on human pituitary secretion of thyrotropin and prolactin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/820709/),[ng] / [dl],61,187733,DB00741,Hydrocortisone
,820709,fT3,"Although Basal T4 and fT4 did not change significantly, dexamethasone did decrease T3 from 106 to 61 ng/dl (P less than 0.001) and fT3 from 174 to 76 pg/dl (P less than 0.05).",The effect of glucocorticoid administration on human pituitary secretion of thyrotropin and prolactin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/820709/),[pg] / [dl],174,187734,DB00741,Hydrocortisone
,820709,fT3,"Although Basal T4 and fT4 did not change significantly, dexamethasone did decrease T3 from 106 to 61 ng/dl (P less than 0.001) and fT3 from 174 to 76 pg/dl (P less than 0.05).",The effect of glucocorticoid administration on human pituitary secretion of thyrotropin and prolactin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/820709/),[pg] / [dl],76,187735,DB00741,Hydrocortisone
,20150524,first-order rate constant,"The FP population PK parameter estimates of the first-order rate constant, relative clearance, and volume of distribution were 4.07 1/h, 890 L/h, and 9800 L, respectively.",Population pharmacokinetics and pharmacodynamics of inhaled ciclesonide and fluticasone propionate in patients with persistent asthma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20150524/),[1] / [h],4.07,187808,DB00741,Hydrocortisone
,20150524,relative clearance,"The FP population PK parameter estimates of the first-order rate constant, relative clearance, and volume of distribution were 4.07 1/h, 890 L/h, and 9800 L, respectively.",Population pharmacokinetics and pharmacodynamics of inhaled ciclesonide and fluticasone propionate in patients with persistent asthma. ,CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20150524/),[l] / [h],890,187809,DB00741,Hydrocortisone
,20150524,volume of distribution,"The FP population PK parameter estimates of the first-order rate constant, relative clearance, and volume of distribution were 4.07 1/h, 890 L/h, and 9800 L, respectively.",Population pharmacokinetics and pharmacodynamics of inhaled ciclesonide and fluticasone propionate in patients with persistent asthma. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20150524/),l,9800,187810,DB00741,Hydrocortisone
,20150524,first-order absorption rate constant,"The Des-CIC PK parameter estimates of the first-order absorption rate constant were 2.63 1/h, clearance 202 L/h (non-CIC treatment) or 271 L/h (CIC treatment), and volume of distribution 947 L.",Population pharmacokinetics and pharmacodynamics of inhaled ciclesonide and fluticasone propionate in patients with persistent asthma. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20150524/),[1] / [h],2.63,187811,DB00741,Hydrocortisone
,20150524,clearance,"The Des-CIC PK parameter estimates of the first-order absorption rate constant were 2.63 1/h, clearance 202 L/h (non-CIC treatment) or 271 L/h (CIC treatment), and volume of distribution 947 L.",Population pharmacokinetics and pharmacodynamics of inhaled ciclesonide and fluticasone propionate in patients with persistent asthma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20150524/),[l] / [h],202,187812,DB00741,Hydrocortisone
,20150524,clearance,"The Des-CIC PK parameter estimates of the first-order absorption rate constant were 2.63 1/h, clearance 202 L/h (non-CIC treatment) or 271 L/h (CIC treatment), and volume of distribution 947 L.",Population pharmacokinetics and pharmacodynamics of inhaled ciclesonide and fluticasone propionate in patients with persistent asthma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20150524/),[l] / [h],271,187813,DB00741,Hydrocortisone
,20150524,volume of distribution,"The Des-CIC PK parameter estimates of the first-order absorption rate constant were 2.63 1/h, clearance 202 L/h (non-CIC treatment) or 271 L/h (CIC treatment), and volume of distribution 947 L.",Population pharmacokinetics and pharmacodynamics of inhaled ciclesonide and fluticasone propionate in patients with persistent asthma. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20150524/),l,947,187814,DB00741,Hydrocortisone
,20150524,maximum cortisol release rate,"Gender was a significant covariate on the maximum cortisol release rate (male, 3440 µg/h; female, 4310 µg/h).",Population pharmacokinetics and pharmacodynamics of inhaled ciclesonide and fluticasone propionate in patients with persistent asthma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20150524/),[μg] / [h],3440,187815,DB00741,Hydrocortisone
,20150524,maximum cortisol release rate,"Gender was a significant covariate on the maximum cortisol release rate (male, 3440 µg/h; female, 4310 µg/h).",Population pharmacokinetics and pharmacodynamics of inhaled ciclesonide and fluticasone propionate in patients with persistent asthma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20150524/),[μg] / [h],4310,187816,DB00741,Hydrocortisone
,2304422,t1/2,"In contrast to the comparatively short retention of ara-C in the CSF (t1/2 1.8 to 2.9 hours), there was a high accumulation and an extremely long retention of ara-CTP in the leukemic cells (t1/2 8.1 to 36 hours).",Pharmacokinetics of cytosine arabinoside in cerebrospinal fluid and of its metabolite in leukemic cells. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2304422/),h,1.8 to 2.9,188115,DB00741,Hydrocortisone
,2304422,t1/2,"In contrast to the comparatively short retention of ara-C in the CSF (t1/2 1.8 to 2.9 hours), there was a high accumulation and an extremely long retention of ara-CTP in the leukemic cells (t1/2 8.1 to 36 hours).",Pharmacokinetics of cytosine arabinoside in cerebrospinal fluid and of its metabolite in leukemic cells. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2304422/),h,8.1 to 36,188116,DB00741,Hydrocortisone
,16597550,elimination half-life,Plasma pharmacokinetics were dose-linear with an elimination half-life of 2.2 h.,Safety assessment of 4'-thio-beta-D-arabinofuranosylcytosine in the beagle dog suggests a drug-induced centrally mediated effect on the hypothalamic-pituitary-adrenal axis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16597550/),h,2.2,188462,DB00741,Hydrocortisone
,11967038,Intradialytic clearances,Intradialytic clearances were between 120 and 300 mL/min and not sufficient to normalize the steroid concentrations.,Increased cortisol metabolites and reduced activity of 11beta-hydroxysteroid dehydrogenase in patients on hemodialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11967038/),[ml] / [min],120 and 300,188743,DB00741,Hydrocortisone
,6833459,Plasma clearance,"Plasma clearance of total prednisolone in females on OC was 96 +/- 9 (SD) ml/min X 1.73 m2, significantly (P less than 0.001) lower than those in both male and female controls (205 +/- 46 and 187 +/- 22 ml/min X 1.73 m2).",Prednisolone disposition and protein binding in oral contraceptive users. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6833459/),[ml] / [1.73·m2·min],96,188806,DB00741,Hydrocortisone
,6833459,Plasma clearance,"Plasma clearance of total prednisolone in females on OC was 96 +/- 9 (SD) ml/min X 1.73 m2, significantly (P less than 0.001) lower than those in both male and female controls (205 +/- 46 and 187 +/- 22 ml/min X 1.73 m2).",Prednisolone disposition and protein binding in oral contraceptive users. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6833459/),[ml] / [1.73·m2·min],205,188807,DB00741,Hydrocortisone
,6833459,Plasma clearance,"Plasma clearance of total prednisolone in females on OC was 96 +/- 9 (SD) ml/min X 1.73 m2, significantly (P less than 0.001) lower than those in both male and female controls (205 +/- 46 and 187 +/- 22 ml/min X 1.73 m2).",Prednisolone disposition and protein binding in oral contraceptive users. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6833459/),[ml] / [1.73·m2·min],187,188808,DB00741,Hydrocortisone
,15657405,AUC,"In the individualized arm, individualized doses of docetaxel were calculated from the estimated clearance (estimated clearance = 31.177 + [7.655 x 10(-4) x total 6-beta-OHF] - [4.02 x alpha-1 acid glycoprotein] - [0.172 x AST] - [0.125 x age]) and the target AUC of 2.66 mg/L . h.",Randomized pharmacokinetic and pharmacodynamic study of docetaxel: dosing based on body-surface area compared with individualized dosing based on cytochrome P450 activity estimated using a urinary metabolite of exogenous cortisol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15657405/),[mg] / [h·l],2.66,189400,DB00741,Hydrocortisone
,15657405,AUC,"The mean AUC and standard deviation (SD) were 2.71 (range, 2.02 to 3.40 mg/L . h) and 0.40 mg/L . h in the BSA-based arm, and 2.64 (range, 2.15 to 3.07 mg/L . h) and 0.22 mg/L . h in the individualized arm, respectively.",Randomized pharmacokinetic and pharmacodynamic study of docetaxel: dosing based on body-surface area compared with individualized dosing based on cytochrome P450 activity estimated using a urinary metabolite of exogenous cortisol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15657405/),[mg] / [h·l],2.71,189401,DB00741,Hydrocortisone
,15657405,AUC,"The mean AUC and standard deviation (SD) were 2.71 (range, 2.02 to 3.40 mg/L . h) and 0.40 mg/L . h in the BSA-based arm, and 2.64 (range, 2.15 to 3.07 mg/L . h) and 0.22 mg/L . h in the individualized arm, respectively.",Randomized pharmacokinetic and pharmacodynamic study of docetaxel: dosing based on body-surface area compared with individualized dosing based on cytochrome P450 activity estimated using a urinary metabolite of exogenous cortisol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15657405/),[mg] / [h·l],0.40,189402,DB00741,Hydrocortisone
,15657405,AUC,"The mean AUC and standard deviation (SD) were 2.71 (range, 2.02 to 3.40 mg/L . h) and 0.40 mg/L . h in the BSA-based arm, and 2.64 (range, 2.15 to 3.07 mg/L . h) and 0.22 mg/L . h in the individualized arm, respectively.",Randomized pharmacokinetic and pharmacodynamic study of docetaxel: dosing based on body-surface area compared with individualized dosing based on cytochrome P450 activity estimated using a urinary metabolite of exogenous cortisol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15657405/),[mg] / [h·l],2.64,189403,DB00741,Hydrocortisone
,15657405,AUC,"The mean AUC and standard deviation (SD) were 2.71 (range, 2.02 to 3.40 mg/L . h) and 0.40 mg/L . h in the BSA-based arm, and 2.64 (range, 2.15 to 3.07 mg/L . h) and 0.22 mg/L . h in the individualized arm, respectively.",Randomized pharmacokinetic and pharmacodynamic study of docetaxel: dosing based on body-surface area compared with individualized dosing based on cytochrome P450 activity estimated using a urinary metabolite of exogenous cortisol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15657405/),[mg] / [h·l],0.22,189404,DB00741,Hydrocortisone
,28063163,AUC,"Compared to immediate release hydrocortisone, free cortisol levels after 40 mg modified release hydrocortisone in ACC patients were significantly lower (12 ± 3 nmol/l; P = 0·03) resulting in a generally lower AUC (98 ± 21 vs 149 ± 37 nmol h/l; P = 0·02).",Immediate versus modified release hydrocortisone in mitotane-treated patients with adrenocortical cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28063163/),[h·nM] / [l],98,189416,DB00741,Hydrocortisone
,28063163,AUC,"Compared to immediate release hydrocortisone, free cortisol levels after 40 mg modified release hydrocortisone in ACC patients were significantly lower (12 ± 3 nmol/l; P = 0·03) resulting in a generally lower AUC (98 ± 21 vs 149 ± 37 nmol h/l; P = 0·02).",Immediate versus modified release hydrocortisone in mitotane-treated patients with adrenocortical cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28063163/),[h·nM] / [l],149,189417,DB00741,Hydrocortisone
,6698661,half-lives,After intravenous injection the plasma levels of fluocortolone decreased biexponentially with half-lives of 9 +/- 5 min and 1.3 +/- 0.3 h.,The pharmacokinetics of fluocortolone and prednisolone after intravenous and oral administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6698661/),min,9,190201,DB00741,Hydrocortisone
,6698661,half-lives,After intravenous injection the plasma levels of fluocortolone decreased biexponentially with half-lives of 9 +/- 5 min and 1.3 +/- 0.3 h.,The pharmacokinetics of fluocortolone and prednisolone after intravenous and oral administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6698661/),h,1.3,190202,DB00741,Hydrocortisone
,6698661,Total plasma clearance,Total plasma clearance of fluocortolone was calculated to be 7.0 +/- 1.5 ml/min/kg.,The pharmacokinetics of fluocortolone and prednisolone after intravenous and oral administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6698661/),[ml] / [kg·min],7.0,190203,DB00741,Hydrocortisone
,6698661,maximum plasma levels,Oral administrations of fluocortolone revealed maximum plasma levels of 86 +/- 12 ng/ml (10-mg dose) and 174 +/- 34 ng/ml (20-mg dose) after 1.4 +/- 0.2 h.,The pharmacokinetics of fluocortolone and prednisolone after intravenous and oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6698661/),[ng] / [ml],86,190204,DB00741,Hydrocortisone
,6698661,maximum plasma levels,Oral administrations of fluocortolone revealed maximum plasma levels of 86 +/- 12 ng/ml (10-mg dose) and 174 +/- 34 ng/ml (20-mg dose) after 1.4 +/- 0.2 h.,The pharmacokinetics of fluocortolone and prednisolone after intravenous and oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6698661/),[ng] / [ml],174,190205,DB00741,Hydrocortisone
,6698661,t 1/2 alpha,Intravenously administered prednisolone was rapidly distributed (t 1/2 alpha = 5 +/- 3 min) but more slowly eliminated from plasma than fluocortolone (t1/2 beta = 3.1 +/- 0.8 h).,The pharmacokinetics of fluocortolone and prednisolone after intravenous and oral administration. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6698661/),min,5,190206,DB00741,Hydrocortisone
,6698661,t1/2 beta,Intravenously administered prednisolone was rapidly distributed (t 1/2 alpha = 5 +/- 3 min) but more slowly eliminated from plasma than fluocortolone (t1/2 beta = 3.1 +/- 0.8 h).,The pharmacokinetics of fluocortolone and prednisolone after intravenous and oral administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6698661/),h,3.1,190207,DB00741,Hydrocortisone
,6698661,total plasma clearance,Correspondingly a total plasma clearance of 2.2 +/- 0.2 ml/min/kg was calculated.,The pharmacokinetics of fluocortolone and prednisolone after intravenous and oral administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6698661/),[ml] / [kg·min],2.2,190208,DB00741,Hydrocortisone
,6698661,maximum prednisolone plasma levels,Oral administrations revealed maximum prednisolone plasma levels of 172 +/- 25 ng/ml (10-mg dose) and 278 ng/ml (20-mg dose) after 1.6 +/- 0.7 h.,The pharmacokinetics of fluocortolone and prednisolone after intravenous and oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6698661/),[ng] / [ml],172,190209,DB00741,Hydrocortisone
,6698661,maximum prednisolone plasma levels,Oral administrations revealed maximum prednisolone plasma levels of 172 +/- 25 ng/ml (10-mg dose) and 278 ng/ml (20-mg dose) after 1.6 +/- 0.7 h.,The pharmacokinetics of fluocortolone and prednisolone after intravenous and oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6698661/),[ng] / [ml],278,190210,DB00741,Hydrocortisone
higher,6698661,absolute bioavailability,The absolute bioavailability of both corticosteroids was higher than 80% and independent of both dose levels investigated.,The pharmacokinetics of fluocortolone and prednisolone after intravenous and oral administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6698661/),%,80,190211,DB00741,Hydrocortisone
,17921190,EC(50),"An exposure-response relationship was demonstrated, with an estimated EC(50) of 391 nM (total) and 17 nM (free).","Demonstration of proof of mechanism and pharmacokinetics and pharmacodynamic relationship with 4'-cyano-biphenyl-4-sulfonic acid (6-amino-pyridin-2-yl)-amide (PF-915275), an inhibitor of 11 -hydroxysteroid dehydrogenase type 1, in cynomolgus monkeys. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17921190/),nM,391,193001,DB00741,Hydrocortisone
,17921190,EC(50),"An exposure-response relationship was demonstrated, with an estimated EC(50) of 391 nM (total) and 17 nM (free).","Demonstration of proof of mechanism and pharmacokinetics and pharmacodynamic relationship with 4'-cyano-biphenyl-4-sulfonic acid (6-amino-pyridin-2-yl)-amide (PF-915275), an inhibitor of 11 -hydroxysteroid dehydrogenase type 1, in cynomolgus monkeys. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17921190/),nM,17,193002,DB00741,Hydrocortisone
,12386639,clearance,"The clearance of methylprednisolone was significantly reduced in the presence of diltiazem (25.2 L/h versus 16.8 L/h), resulting in a longer half-life (2.28 hours versus 3.12 hours) and increased area under the plasma concentration-time curve (AUC) (871 ng x h/mL versus 1299 ng x h/mL).",Pharmacokinetic and pharmacodynamic interactions between diltiazem and methylprednisolone in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12386639/),[l] / [h],25.2,193169,DB00741,Hydrocortisone
,12386639,clearance,"The clearance of methylprednisolone was significantly reduced in the presence of diltiazem (25.2 L/h versus 16.8 L/h), resulting in a longer half-life (2.28 hours versus 3.12 hours) and increased area under the plasma concentration-time curve (AUC) (871 ng x h/mL versus 1299 ng x h/mL).",Pharmacokinetic and pharmacodynamic interactions between diltiazem and methylprednisolone in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12386639/),[l] / [h],16.8,193170,DB00741,Hydrocortisone
,12386639,half-life,"The clearance of methylprednisolone was significantly reduced in the presence of diltiazem (25.2 L/h versus 16.8 L/h), resulting in a longer half-life (2.28 hours versus 3.12 hours) and increased area under the plasma concentration-time curve (AUC) (871 ng x h/mL versus 1299 ng x h/mL).",Pharmacokinetic and pharmacodynamic interactions between diltiazem and methylprednisolone in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12386639/),h,2.28,193171,DB00741,Hydrocortisone
,12386639,half-life,"The clearance of methylprednisolone was significantly reduced in the presence of diltiazem (25.2 L/h versus 16.8 L/h), resulting in a longer half-life (2.28 hours versus 3.12 hours) and increased area under the plasma concentration-time curve (AUC) (871 ng x h/mL versus 1299 ng x h/mL).",Pharmacokinetic and pharmacodynamic interactions between diltiazem and methylprednisolone in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12386639/),h,3.12,193172,DB00741,Hydrocortisone
,12386639,area under the plasma concentration-time curve (AUC),"The clearance of methylprednisolone was significantly reduced in the presence of diltiazem (25.2 L/h versus 16.8 L/h), resulting in a longer half-life (2.28 hours versus 3.12 hours) and increased area under the plasma concentration-time curve (AUC) (871 ng x h/mL versus 1299 ng x h/mL).",Pharmacokinetic and pharmacodynamic interactions between diltiazem and methylprednisolone in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12386639/),[h·ng] / [ml],871,193173,DB00741,Hydrocortisone
,12386639,area under the plasma concentration-time curve (AUC),"The clearance of methylprednisolone was significantly reduced in the presence of diltiazem (25.2 L/h versus 16.8 L/h), resulting in a longer half-life (2.28 hours versus 3.12 hours) and increased area under the plasma concentration-time curve (AUC) (871 ng x h/mL versus 1299 ng x h/mL).",Pharmacokinetic and pharmacodynamic interactions between diltiazem and methylprednisolone in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12386639/),[h·ng] / [ml],1299,193174,DB00741,Hydrocortisone
,12386639,50% inhibitory concentration,"The 50% inhibitory concentration values were 0.446 ng/mL versus 0.780 ng/mL for cortisol, 9.20 ng/mL versus 10.7 ng/mL for T-helper cells, and 18.5 ng/mL versus 20.9 ng/mL for T-suppressor cells (P >.05).",Pharmacokinetic and pharmacodynamic interactions between diltiazem and methylprednisolone in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12386639/),[ng] / [ml],0.446,193175,DB00741,Hydrocortisone
,12386639,50% inhibitory concentration,"The 50% inhibitory concentration values were 0.446 ng/mL versus 0.780 ng/mL for cortisol, 9.20 ng/mL versus 10.7 ng/mL for T-helper cells, and 18.5 ng/mL versus 20.9 ng/mL for T-suppressor cells (P >.05).",Pharmacokinetic and pharmacodynamic interactions between diltiazem and methylprednisolone in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12386639/),[ng] / [ml],0.780,193176,DB00741,Hydrocortisone
,12386639,50% inhibitory concentration,"The 50% inhibitory concentration values were 0.446 ng/mL versus 0.780 ng/mL for cortisol, 9.20 ng/mL versus 10.7 ng/mL for T-helper cells, and 18.5 ng/mL versus 20.9 ng/mL for T-suppressor cells (P >.05).",Pharmacokinetic and pharmacodynamic interactions between diltiazem and methylprednisolone in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12386639/),[ng] / [ml],9.20,193177,DB00741,Hydrocortisone
,12386639,50% inhibitory concentration,"The 50% inhibitory concentration values were 0.446 ng/mL versus 0.780 ng/mL for cortisol, 9.20 ng/mL versus 10.7 ng/mL for T-helper cells, and 18.5 ng/mL versus 20.9 ng/mL for T-suppressor cells (P >.05).",Pharmacokinetic and pharmacodynamic interactions between diltiazem and methylprednisolone in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12386639/),[ng] / [ml],10.7,193178,DB00741,Hydrocortisone
,12386639,50% inhibitory concentration,"The 50% inhibitory concentration values were 0.446 ng/mL versus 0.780 ng/mL for cortisol, 9.20 ng/mL versus 10.7 ng/mL for T-helper cells, and 18.5 ng/mL versus 20.9 ng/mL for T-suppressor cells (P >.05).",Pharmacokinetic and pharmacodynamic interactions between diltiazem and methylprednisolone in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12386639/),[ng] / [ml],18.5,193179,DB00741,Hydrocortisone
,12386639,50% inhibitory concentration,"The 50% inhibitory concentration values were 0.446 ng/mL versus 0.780 ng/mL for cortisol, 9.20 ng/mL versus 10.7 ng/mL for T-helper cells, and 18.5 ng/mL versus 20.9 ng/mL for T-suppressor cells (P >.05).",Pharmacokinetic and pharmacodynamic interactions between diltiazem and methylprednisolone in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12386639/),[ng] / [ml],20.9,193180,DB00741,Hydrocortisone
,239546,Total body clearance,Total body clearance of aminopyrine as obtained after an oral test dose increases more than twofold from 251 to 551 ml/min upon phenobarbital treatment.,Comparison of methods to study enzyme induction in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/239546/),[ml] / [min],251,195875,DB00741,Hydrocortisone
,239546,Total body clearance,Total body clearance of aminopyrine as obtained after an oral test dose increases more than twofold from 251 to 551 ml/min upon phenobarbital treatment.,Comparison of methods to study enzyme induction in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/239546/),[ml] / [min],551,195876,DB00741,Hydrocortisone
,19567522,bioavailability,"We report a 14.5-year-old boy with CAH who had reduced bioavailability [42% (normal 80% orally and 100% by im route)] and increased clearance [half-life 50 min (normal range, 70-100 min)] of oral doses of hydrocortisone leading to ambient serum 17-hydroxyprogesterone concentrations of 400 nmol/liter (14.5 ng/ml) and androstenedione concentrations of 24.9 nmol/liter (7.1 ng/ml).",Management of altered hydrocortisone pharmacokinetics in a boy with congenital adrenal hyperplasia using a continuous subcutaneous hydrocortisone infusion. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19567522/),%,42,196903,DB00741,Hydrocortisone
,19567522,bioavailability,"We report a 14.5-year-old boy with CAH who had reduced bioavailability [42% (normal 80% orally and 100% by im route)] and increased clearance [half-life 50 min (normal range, 70-100 min)] of oral doses of hydrocortisone leading to ambient serum 17-hydroxyprogesterone concentrations of 400 nmol/liter (14.5 ng/ml) and androstenedione concentrations of 24.9 nmol/liter (7.1 ng/ml).",Management of altered hydrocortisone pharmacokinetics in a boy with congenital adrenal hyperplasia using a continuous subcutaneous hydrocortisone infusion. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19567522/),%,80,196904,DB00741,Hydrocortisone
,19567522,bioavailability,"We report a 14.5-year-old boy with CAH who had reduced bioavailability [42% (normal 80% orally and 100% by im route)] and increased clearance [half-life 50 min (normal range, 70-100 min)] of oral doses of hydrocortisone leading to ambient serum 17-hydroxyprogesterone concentrations of 400 nmol/liter (14.5 ng/ml) and androstenedione concentrations of 24.9 nmol/liter (7.1 ng/ml).",Management of altered hydrocortisone pharmacokinetics in a boy with congenital adrenal hyperplasia using a continuous subcutaneous hydrocortisone infusion. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19567522/),%,100,196905,DB00741,Hydrocortisone
,6376143,clearance,Intrinsic prednisolone clearance differed less than three-fold (range 0.10-0.27 l/kg X h) between the patients and was relatively stable at different times in each of them.,Clinical value of assessing prednisolone pharmacokinetics before and after renal transplantation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6376143/),[l] / [h·kg],0.10-0.27,197981,DB00741,Hydrocortisone
greater,6376143,clearance,"If rejection occurred, however, a high clearance (greater than or equal to 0.20 l/kg X h) appeared to be deleterious for the outcome (p less than 0.05).",Clinical value of assessing prednisolone pharmacokinetics before and after renal transplantation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6376143/),[l] / [h·kg],0.20,197982,DB00741,Hydrocortisone
lower,6376143,clearance,"7 out of 8 cases of steroid-related complications (steroid diabetes, psychosis, duodenal ulcer, perforation of the colon and osteonecrosis) occurred in patients with a clearance lower than 0.16 l/kg X h (ns).",Clinical value of assessing prednisolone pharmacokinetics before and after renal transplantation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6376143/),[l] / [h·kg],0.16,197983,DB00741,Hydrocortisone
greater,6376143,clearance,"The one-year graft survival rate was 67% in patients with a clearance greater than or equal to 0.16 l/kg X h, compared to 85% in patients with a lower clearance (ns).",Clinical value of assessing prednisolone pharmacokinetics before and after renal transplantation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6376143/),[l] / [h·kg],0.16,197984,DB00741,Hydrocortisone
,33626793,maximal serum concentration (Cmax),The overall mean maximal serum concentration (Cmax) was 114.0 μg/L and was achieved at an average time to maximal concentration (Tmax) of 1.43 h.,Prednisolone Replacement Therapy Mimics the Circadian Rhythm More Closely Than Other Glucocorticoids. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33626793/),[μg] / [l],114.0,199429,DB00741,Hydrocortisone
,33626793,time to maximal concentration (Tmax),The overall mean maximal serum concentration (Cmax) was 114.0 μg/L and was achieved at an average time to maximal concentration (Tmax) of 1.43 h.,Prednisolone Replacement Therapy Mimics the Circadian Rhythm More Closely Than Other Glucocorticoids. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33626793/),h,1.43,199430,DB00741,Hydrocortisone
,33626793,area under the curve to 24 h (AUC0-24h),"Total glucocorticoid exposure was represented by the mean area under the curve to 24 h (AUC0-24h), which was 518.2 μg|·|h/L.",Prednisolone Replacement Therapy Mimics the Circadian Rhythm More Closely Than Other Glucocorticoids. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33626793/),[|h·μg|] / [l],518.2,199431,DB00741,Hydrocortisone
,27813051,area under the curve (AUC),"The median (interquartile range) area under the curve (AUC) for cortisol was not different for patients, compared with controls [55.63 (32.91-151.07) nmol*min*l-1 vs. 37.49 (27.41-52.00) nmol*min*l-1; p=0.098, respectively], whereas the peak cortisol Cmax was higher in patients [32.61 (5.75-146.19) nmol/l vs. 8.96 (6.96-12.23) nmol/l; p=0.013], compared with controls.",Salivary Cortisol and Cortisone do not Appear to be Useful Biomarkers for Monitoring Hydrocortisone Replacement in Addison's Disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27813051/),[min·nM] / [l],55.63,200161,DB00741,Hydrocortisone
,27813051,area under the curve (AUC),"The median (interquartile range) area under the curve (AUC) for cortisol was not different for patients, compared with controls [55.63 (32.91-151.07) nmol*min*l-1 vs. 37.49 (27.41-52.00) nmol*min*l-1; p=0.098, respectively], whereas the peak cortisol Cmax was higher in patients [32.61 (5.75-146.19) nmol/l vs. 8.96 (6.96-12.23) nmol/l; p=0.013], compared with controls.",Salivary Cortisol and Cortisone do not Appear to be Useful Biomarkers for Monitoring Hydrocortisone Replacement in Addison's Disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27813051/),[min·nM] / [l],37.49,200162,DB00741,Hydrocortisone
,27813051,peak cortisol Cmax,"The median (interquartile range) area under the curve (AUC) for cortisol was not different for patients, compared with controls [55.63 (32.91-151.07) nmol*min*l-1 vs. 37.49 (27.41-52.00) nmol*min*l-1; p=0.098, respectively], whereas the peak cortisol Cmax was higher in patients [32.61 (5.75-146.19) nmol/l vs. 8.96 (6.96-12.23) nmol/l; p=0.013], compared with controls.",Salivary Cortisol and Cortisone do not Appear to be Useful Biomarkers for Monitoring Hydrocortisone Replacement in Addison's Disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27813051/),[nM] / [l],32.61,200163,DB00741,Hydrocortisone
,27813051,peak cortisol Cmax,"The median (interquartile range) area under the curve (AUC) for cortisol was not different for patients, compared with controls [55.63 (32.91-151.07) nmol*min*l-1 vs. 37.49 (27.41-52.00) nmol*min*l-1; p=0.098, respectively], whereas the peak cortisol Cmax was higher in patients [32.61 (5.75-146.19) nmol/l vs. 8.96 (6.96-12.23) nmol/l; p=0.013], compared with controls.",Salivary Cortisol and Cortisone do not Appear to be Useful Biomarkers for Monitoring Hydrocortisone Replacement in Addison's Disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27813051/),[nM] / [l],8.96,200164,DB00741,Hydrocortisone
,27813051,AUC,"The AUC for cortisone [23.65 (6.10-54.76) nmol*min*l-1 vs. 227.73 (200.10-280.52) nmol*min*l-1; p≤ 0.001, respectively], and peak cortisone Cmax was lower in patients than in controls [11.11 (2.91-35.85) nmol/l vs. 33.12 (25.97-39.95) nmol/l; p=0.002].",Salivary Cortisol and Cortisone do not Appear to be Useful Biomarkers for Monitoring Hydrocortisone Replacement in Addison's Disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27813051/),[min·nM] / [l],23.65,200165,DB00741,Hydrocortisone
,27813051,AUC,"The AUC for cortisone [23.65 (6.10-54.76) nmol*min*l-1 vs. 227.73 (200.10-280.52) nmol*min*l-1; p≤ 0.001, respectively], and peak cortisone Cmax was lower in patients than in controls [11.11 (2.91-35.85) nmol/l vs. 33.12 (25.97-39.95) nmol/l; p=0.002].",Salivary Cortisol and Cortisone do not Appear to be Useful Biomarkers for Monitoring Hydrocortisone Replacement in Addison's Disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27813051/),[min·nM] / [l],227.73,200166,DB00741,Hydrocortisone
,27813051,peak cortisone Cmax,"The AUC for cortisone [23.65 (6.10-54.76) nmol*min*l-1 vs. 227.73 (200.10-280.52) nmol*min*l-1; p≤ 0.001, respectively], and peak cortisone Cmax was lower in patients than in controls [11.11 (2.91-35.85) nmol/l vs. 33.12 (25.97-39.95) nmol/l; p=0.002].",Salivary Cortisol and Cortisone do not Appear to be Useful Biomarkers for Monitoring Hydrocortisone Replacement in Addison's Disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27813051/),[nM] / [l],11.11,200167,DB00741,Hydrocortisone
,27813051,peak cortisone Cmax,"The AUC for cortisone [23.65 (6.10-54.76) nmol*min*l-1 vs. 227.73 (200.10-280.52) nmol*min*l-1; p≤ 0.001, respectively], and peak cortisone Cmax was lower in patients than in controls [11.11 (2.91-35.85) nmol/l vs. 33.12 (25.97-39.95) nmol/l; p=0.002].",Salivary Cortisol and Cortisone do not Appear to be Useful Biomarkers for Monitoring Hydrocortisone Replacement in Addison's Disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27813051/),[nM] / [l],33.12,200168,DB00741,Hydrocortisone
,5103749,metabolic clearance rate,"The mean dihydrotestosterone metabolic clearance rate was higher in men (336 liters/24 hr per m(2) [range, 239-448]) than in women (153 liters/24 hr per m(2) [range, 108-184]).",The metabolic clearance rate and origin of plasma dihydrotestosterone in man and its conversion to the 5-alpha-androstanediols. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/5103749/),[24·h·l] / [m(2],336,200510,DB00741,Hydrocortisone
,5103749,metabolic clearance rate,"The mean dihydrotestosterone metabolic clearance rate was higher in men (336 liters/24 hr per m(2) [range, 239-448]) than in women (153 liters/24 hr per m(2) [range, 108-184]).",The metabolic clearance rate and origin of plasma dihydrotestosterone in man and its conversion to the 5-alpha-androstanediols. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/5103749/),[24·h·l] / [m(2],153,200511,DB00741,Hydrocortisone
,7781199,clearance,"The clearance was about 280 ml/hr/kg, volume of distribution was 1.1 l/kg, t1/2 was 2.7 hr, and fraction unbound was 0.2.",Methylprednisolone pharmacokinetics and pharmacodynamics in chronic renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7781199/),[ml] / [h·kg],280,201017,DB00741,Hydrocortisone
,7781199,volume of distribution,"The clearance was about 280 ml/hr/kg, volume of distribution was 1.1 l/kg, t1/2 was 2.7 hr, and fraction unbound was 0.2.",Methylprednisolone pharmacokinetics and pharmacodynamics in chronic renal failure. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7781199/),[l] / [kg],1.1,201018,DB00741,Hydrocortisone
,7781199,t1/2,"The clearance was about 280 ml/hr/kg, volume of distribution was 1.1 l/kg, t1/2 was 2.7 hr, and fraction unbound was 0.2.",Methylprednisolone pharmacokinetics and pharmacodynamics in chronic renal failure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7781199/),h,2.7,201019,DB00741,Hydrocortisone
,7781199,fraction unbound,"The clearance was about 280 ml/hr/kg, volume of distribution was 1.1 l/kg, t1/2 was 2.7 hr, and fraction unbound was 0.2.",Methylprednisolone pharmacokinetics and pharmacodynamics in chronic renal failure. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7781199/),,0.2,201020,DB00741,Hydrocortisone
,6662164,half-life,Betamethasone phosphate disappeared rapidly from plasma (mean half-life = 4.7 min) as betamethasone levels rose.,Pharmacokinetics of betamethasone in healthy adults after intravenous administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6662164/),min,4.7,201240,DB00741,Hydrocortisone
,6662164,half-life,The terminal slow disposition phase had a mean half-life of 6.5 h.,Pharmacokinetics of betamethasone in healthy adults after intravenous administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6662164/),h,6.5,201241,DB00741,Hydrocortisone
,12680886,plasma AUC,"After inhalation, geometric least square means were significantly lower in the COPD group for the plasma AUC (1961 vs 2996 pg ml-1 h-1 for COPD and controls, respectively; P = 0.03) and the Cmax (235 vs 421 pg ml-1 for COPD and controls, respectively; P = 0.03).",Pharmacokinetics and systemic effects of inhaled fluticasone propionate in chronic obstructive pulmonary disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12680886/),[pg] / [h·ml],1961,201549,DB00741,Hydrocortisone
,12680886,plasma AUC,"After inhalation, geometric least square means were significantly lower in the COPD group for the plasma AUC (1961 vs 2996 pg ml-1 h-1 for COPD and controls, respectively; P = 0.03) and the Cmax (235 vs 421 pg ml-1 for COPD and controls, respectively; P = 0.03).",Pharmacokinetics and systemic effects of inhaled fluticasone propionate in chronic obstructive pulmonary disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12680886/),[pg] / [h·ml],2996,201550,DB00741,Hydrocortisone
,12680886,Cmax,"After inhalation, geometric least square means were significantly lower in the COPD group for the plasma AUC (1961 vs 2996 pg ml-1 h-1 for COPD and controls, respectively; P = 0.03) and the Cmax (235 vs 421 pg ml-1 for COPD and controls, respectively; P = 0.03).",Pharmacokinetics and systemic effects of inhaled fluticasone propionate in chronic obstructive pulmonary disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12680886/),[pg] / [ml],235,201551,DB00741,Hydrocortisone
,12680886,Cmax,"After inhalation, geometric least square means were significantly lower in the COPD group for the plasma AUC (1961 vs 2996 pg ml-1 h-1 for COPD and controls, respectively; P = 0.03) and the Cmax (235 vs 421 pg ml-1 for COPD and controls, respectively; P = 0.03).",Pharmacokinetics and systemic effects of inhaled fluticasone propionate in chronic obstructive pulmonary disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12680886/),[pg] / [ml],421,201552,DB00741,Hydrocortisone
,23746590,peak meloxicam concentrations,"Mean peak meloxicam concentrations were 3.61±0 0.21 and 3.27±0.14 μg/mL with average elimination half-lives of 38.62±5.87 and 35.81±6.26 h for MEL-PRE and MEL-POST, respectively.",The effect of timing of oral meloxicam administration on physiological responses in calves after cautery dehorning with local anesthesia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23746590/),[μg] / [ml],3.61,202278,DB00741,Hydrocortisone
,23746590,peak meloxicam concentrations,"Mean peak meloxicam concentrations were 3.61±0 0.21 and 3.27±0.14 μg/mL with average elimination half-lives of 38.62±5.87 and 35.81±6.26 h for MEL-PRE and MEL-POST, respectively.",The effect of timing of oral meloxicam administration on physiological responses in calves after cautery dehorning with local anesthesia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23746590/),[μg] / [ml],3.27,202279,DB00741,Hydrocortisone
,23746590,elimination half-lives,"Mean peak meloxicam concentrations were 3.61±0 0.21 and 3.27±0.14 μg/mL with average elimination half-lives of 38.62±5.87 and 35.81±6.26 h for MEL-PRE and MEL-POST, respectively.",The effect of timing of oral meloxicam administration on physiological responses in calves after cautery dehorning with local anesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23746590/),h,38.62,202280,DB00741,Hydrocortisone
,23746590,elimination half-lives,"Mean peak meloxicam concentrations were 3.61±0 0.21 and 3.27±0.14 μg/mL with average elimination half-lives of 38.62±5.87 and 35.81±6.26 h for MEL-PRE and MEL-POST, respectively.",The effect of timing of oral meloxicam administration on physiological responses in calves after cautery dehorning with local anesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23746590/),h,35.81,202281,DB00741,Hydrocortisone
,9081401,objective response rate,"One patient achieved a complete response (CR) and 4 patients a partial response (PR), with an objective response rate of 36% (95% CI 13% to 65%).","Letrozole, a new oral non-steroidal aromastase inhibitor in treating postmenopausal patients with advanced breast cancer. A pilot study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9081401/),%,36,202460,DB00741,Hydrocortisone
,9081401,duration of response,"Median duration of response was 24 months, ranging from 4 to 44 months.","Letrozole, a new oral non-steroidal aromastase inhibitor in treating postmenopausal patients with advanced breast cancer. A pilot study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9081401/),month,24,202461,DB00741,Hydrocortisone
,27416887,Tlag,"The population estimates of PK parameters (inter-individual variability) were: Tlag 0.65 h (98%), apparent clearance 40 l h-1 (49%) and apparent volume of distribution 78 l (75%).",Pharmacokinetics of oral fludrocortisone in septic shock. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27416887/),h,0.65,202889,DB00741,Hydrocortisone
,27416887,apparent clearance,"The population estimates of PK parameters (inter-individual variability) were: Tlag 0.65 h (98%), apparent clearance 40 l h-1 (49%) and apparent volume of distribution 78 l (75%).",Pharmacokinetics of oral fludrocortisone in septic shock. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27416887/),[l] / [h],40,202890,DB00741,Hydrocortisone
,27416887,apparent volume of distribution,"The population estimates of PK parameters (inter-individual variability) were: Tlag 0.65 h (98%), apparent clearance 40 l h-1 (49%) and apparent volume of distribution 78 l (75%).",Pharmacokinetics of oral fludrocortisone in septic shock. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27416887/),l,78,202891,DB00741,Hydrocortisone
,27416887,Plasma half-life,"Plasma half-life was estimated at 1.35 h (95% CI, 0.84-2.03) and area under the curve of plasma concentrations was estimated at 1.25 μg h l-1 (95% CI, 1.09-1.46).",Pharmacokinetics of oral fludrocortisone in septic shock. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27416887/),h,1.35,202892,DB00741,Hydrocortisone
,27416887,area under the curve of plasma concentrations,"Plasma half-life was estimated at 1.35 h (95% CI, 0.84-2.03) and area under the curve of plasma concentrations was estimated at 1.25 μg h l-1 (95% CI, 1.09-1.46).",Pharmacokinetics of oral fludrocortisone in septic shock. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27416887/),[h·μg] / [l],1.25,202893,DB00741,Hydrocortisone
,28806969,AUC0-inf,"Based on the plasma pharmacokinetics and urinary profiles, 20β-dihydroprednisolone was confirmed as the main prednisolone-derived metabolite, being detected in the biological fluids of all 12 bovines (plasma AUC0-inf of 121 h μg L-1 and urinary concentration > 0.695 μg L-1).",Pharmacokinetic and urinary profiling reveals the prednisolone/cortisol ratio as a valid biomarker for prednisolone administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28806969/),[h·μg] / [l],121,203536,DB00741,Hydrocortisone
,10919685,PEF,"Mean PEF at baseline was 334 l min(-1) in sequence group 1 (HFA 134a-->CFC pMDI) and this increased to 357 l min(-1) and 366 l min(-1) during treatment with the HFA 134a and CFC pMDI, respectively.",Clinical efficacy and safety of fluticasone propionate 1 mg twice daily administered via a HFA 134a pressurized metered dose inhaler to patients with severe asthma. U.K. study group. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10919685/),[l] / [min],334,204818,DB00741,Hydrocortisone
,10919685,PEF,"Mean PEF at baseline was 334 l min(-1) in sequence group 1 (HFA 134a-->CFC pMDI) and this increased to 357 l min(-1) and 366 l min(-1) during treatment with the HFA 134a and CFC pMDI, respectively.",Clinical efficacy and safety of fluticasone propionate 1 mg twice daily administered via a HFA 134a pressurized metered dose inhaler to patients with severe asthma. U.K. study group. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10919685/),[l] / [min],357,204819,DB00741,Hydrocortisone
,10919685,PEF,"Mean PEF at baseline was 334 l min(-1) in sequence group 1 (HFA 134a-->CFC pMDI) and this increased to 357 l min(-1) and 366 l min(-1) during treatment with the HFA 134a and CFC pMDI, respectively.",Clinical efficacy and safety of fluticasone propionate 1 mg twice daily administered via a HFA 134a pressurized metered dose inhaler to patients with severe asthma. U.K. study group. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10919685/),[l] / [min],366,204820,DB00741,Hydrocortisone
,10919685,PEF,"In sequence group 2 (CFC-->HFA 134a pMDI) mean PEF at baseline was 297 l min(-1) and this increased to 336 l min(-1) and 328 l min(-1) during treatment with the HFA 134a and CFC pMDI, respectively.",Clinical efficacy and safety of fluticasone propionate 1 mg twice daily administered via a HFA 134a pressurized metered dose inhaler to patients with severe asthma. U.K. study group. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10919685/),[l] / [min],297,204821,DB00741,Hydrocortisone
,10919685,PEF,"In sequence group 2 (CFC-->HFA 134a pMDI) mean PEF at baseline was 297 l min(-1) and this increased to 336 l min(-1) and 328 l min(-1) during treatment with the HFA 134a and CFC pMDI, respectively.",Clinical efficacy and safety of fluticasone propionate 1 mg twice daily administered via a HFA 134a pressurized metered dose inhaler to patients with severe asthma. U.K. study group. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10919685/),[l] / [min],336,204822,DB00741,Hydrocortisone
,10919685,PEF,"In sequence group 2 (CFC-->HFA 134a pMDI) mean PEF at baseline was 297 l min(-1) and this increased to 336 l min(-1) and 328 l min(-1) during treatment with the HFA 134a and CFC pMDI, respectively.",Clinical efficacy and safety of fluticasone propionate 1 mg twice daily administered via a HFA 134a pressurized metered dose inhaler to patients with severe asthma. U.K. study group. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10919685/),[l] / [min],328,204823,DB00741,Hydrocortisone
,1800704,absolute bioavailability,Only a very small part of the rectal dose (100 mg) was absorbed; the mean absolute bioavailability was 2%.,Pharmacokinetics and rectal bioavailability of hydrocortisone acetate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1800704/),%,2,204900,DB00741,Hydrocortisone
,1800704,Maximum hydrocortisone levels,Maximum hydrocortisone levels were reached after 2 h and averaged 35 ng/mL.,Pharmacokinetics and rectal bioavailability of hydrocortisone acetate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1800704/),[ng] / [ml],35,204901,DB00741,Hydrocortisone
,6722226,half-life,Since these data were obtained 17 hr after ingestion of dexamethasone (half-life 3.5-5 hr) any conclusions about an inverse correlation between dexamethasone and corticosteroid plasma concentrations would be speculative.,Plasma dexamethasone concentrations and differential suppression response of cortisol and corticosterone in depressives and controls. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6722226/),h,3.5-5,206812,DB00741,Hydrocortisone
,31557666,tmax,"All bioactive components were absorbed very rapidly, and their tmax were detected in plasma from 30 min to 1.40 h.",Combined extracts of Echinacea angustifolia DC. and Zingiber officinale Roscoe in softgel capsules: Pharmacokinetics and immunomodulatory effects assessed by gene expression profiling. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31557666/),min,30,208596,DB00741,Hydrocortisone
,31557666,tmax,"All bioactive components were absorbed very rapidly, and their tmax were detected in plasma from 30 min to 1.40 h.",Combined extracts of Echinacea angustifolia DC. and Zingiber officinale Roscoe in softgel capsules: Pharmacokinetics and immunomodulatory effects assessed by gene expression profiling. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31557666/),h,1.40,208597,DB00741,Hydrocortisone
,31557666,peak concentrations,"The peak concentrations of tetraene, 6-gingerol, 6-shogaol and their glucuronide metabolites were 14.74, 5.66, 9.25, 29.2 and 22.24 ng/ml, respectively.",Combined extracts of Echinacea angustifolia DC. and Zingiber officinale Roscoe in softgel capsules: Pharmacokinetics and immunomodulatory effects assessed by gene expression profiling. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31557666/),[ng] / [ml],14.74,208598,DB00741,Hydrocortisone
,31557666,peak concentrations,"The peak concentrations of tetraene, 6-gingerol, 6-shogaol and their glucuronide metabolites were 14.74, 5.66, 9.25, 29.2 and 22.24 ng/ml, respectively.",Combined extracts of Echinacea angustifolia DC. and Zingiber officinale Roscoe in softgel capsules: Pharmacokinetics and immunomodulatory effects assessed by gene expression profiling. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31557666/),[ng] / [ml],5.66,208599,DB00741,Hydrocortisone
,31557666,peak concentrations,"The peak concentrations of tetraene, 6-gingerol, 6-shogaol and their glucuronide metabolites were 14.74, 5.66, 9.25, 29.2 and 22.24 ng/ml, respectively.",Combined extracts of Echinacea angustifolia DC. and Zingiber officinale Roscoe in softgel capsules: Pharmacokinetics and immunomodulatory effects assessed by gene expression profiling. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31557666/),[ng] / [ml],9.25,208600,DB00741,Hydrocortisone
,31557666,peak concentrations,"The peak concentrations of tetraene, 6-gingerol, 6-shogaol and their glucuronide metabolites were 14.74, 5.66, 9.25, 29.2 and 22.24 ng/ml, respectively.",Combined extracts of Echinacea angustifolia DC. and Zingiber officinale Roscoe in softgel capsules: Pharmacokinetics and immunomodulatory effects assessed by gene expression profiling. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31557666/),[ng] / [ml],29.2,208601,DB00741,Hydrocortisone
,31557666,peak concentrations,"The peak concentrations of tetraene, 6-gingerol, 6-shogaol and their glucuronide metabolites were 14.74, 5.66, 9.25, 29.2 and 22.24 ng/ml, respectively.",Combined extracts of Echinacea angustifolia DC. and Zingiber officinale Roscoe in softgel capsules: Pharmacokinetics and immunomodulatory effects assessed by gene expression profiling. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31557666/),[ng] / [ml],22.24,208602,DB00741,Hydrocortisone
,7867560,AU,"Subcutaneous dose of 0.03 or 0.1 mg/kg increased plasma cortisol AUCs by 60% (P = NS) and 150% (P < 0.03) over the control value (2461 +/- 935 ng/min.ml) and increased cortisol peaks by 80% (P = NS) and 200% (P < 0.01), respectively, over the control value (38.3 +/- 12.3 ng/ml).","Activity of a novel nonpeptidyl growth hormone secretagogue, L-700,653, in swine. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7867560/),[ng] / [min·ml],2461,212224,DB00741,Hydrocortisone
,7867560,peaks,"Continuous i.v. infusion of L-700,653, at either 0.01 or 0.1 mg/kg BW.h over a 180-min period, increased GH AUCs by 60% (P = NS) or 470% (P < 0.01) and GH peaks by 190% (P = NS) or 1520% (P < 0.01), respectively, over the control value (589 +/- 313 ng/min.ml; 7.0 +/- 11.1 ng/ml).","Activity of a novel nonpeptidyl growth hormone secretagogue, L-700,653, in swine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7867560/),[ng] / [ml],7.0,212225,DB00741,Hydrocortisone
,21879982,distribution half-life,"Median distribution half-life was 0.50 hours (range, 0.24 to 0.67 hours); elimination half-life was 6.1 hours (range, 5.0 to 6.4 hours).","Pharmacokinetics of intra-articular, intravenous, and intramuscular administration of triamcinolone acetonide and its effect on endogenous plasma hydrocortisone and cortisone concentrations in horses. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21879982/),h,0.50,215233,DB00741,Hydrocortisone
,21879982,elimination half-life,"Median distribution half-life was 0.50 hours (range, 0.24 to 0.67 hours); elimination half-life was 6.1 hours (range, 5.0 to 6.4 hours).","Pharmacokinetics of intra-articular, intravenous, and intramuscular administration of triamcinolone acetonide and its effect on endogenous plasma hydrocortisone and cortisone concentrations in horses. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21879982/),h,6.1,215234,DB00741,Hydrocortisone
,21879982,Transfer half-life,"Transfer half-life of TA from joint to plasma was 5.2 hours (range, 0.49 to 73 hours); elimination half-life was 23.8 hours (range, 18.9 to 32.2 hours).","Pharmacokinetics of intra-articular, intravenous, and intramuscular administration of triamcinolone acetonide and its effect on endogenous plasma hydrocortisone and cortisone concentrations in horses. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21879982/),h,5.2,215235,DB00741,Hydrocortisone
,21879982,elimination half-life,"Transfer half-life of TA from joint to plasma was 5.2 hours (range, 0.49 to 73 hours); elimination half-life was 23.8 hours (range, 18.9 to 32.2 hours).","Pharmacokinetics of intra-articular, intravenous, and intramuscular administration of triamcinolone acetonide and its effect on endogenous plasma hydrocortisone and cortisone concentrations in horses. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21879982/),h,23.8,215236,DB00741,Hydrocortisone
,21879982,Maximum plasma concentration,"Maximum plasma concentration following i.a. administration was 2.0 ng/mL (range, 0.94 to 2.5 ng/mL), and was attained at 10 hours (range, 8 to 12 hours).","Pharmacokinetics of intra-articular, intravenous, and intramuscular administration of triamcinolone acetonide and its effect on endogenous plasma hydrocortisone and cortisone concentrations in horses. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21879982/),[ng] / [ml],2.0,215237,DB00741,Hydrocortisone
,21879982,Maximum plasma concentration,"Maximum plasma concentration following i.m. administration was 0.34 ng/mL (range, 0.20 to 0.48 ng/mL) and was attained at 13.0 hours (range, 12 to 16 hours); concentration was still quantifiable at 360 hours.","Pharmacokinetics of intra-articular, intravenous, and intramuscular administration of triamcinolone acetonide and its effect on endogenous plasma hydrocortisone and cortisone concentrations in horses. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21879982/),[ng] / [ml],0.34,215238,DB00741,Hydrocortisone
,15098802,area under the prednisolone concentration-time curve,"No significant differences were observed for the mean +/- SD area under the prednisolone concentration-time curve (3739 +/- 992 vs 3498 +/- 797 microg x hr/L, respectively), clearance (8.58 +/- 2.62 vs 8.92 +/- 2.05 L/hr, respectively), volume of distribution (39.5 +/- 12.4 vs 38.2 +/- 9.9 L, respectively), elimination half-life (3.32 +/- 0.83 vs 3.05 +/- 0.80 hrs, respectively), or duration of plasma cortisol suppression (23.5 +/- 3.1 vs 22.0 +/- 4.2 hrs, respectively).",Lack of a fluoxetine effect on prednisolone disposition and cortisol suppression. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15098802/),[h·μg] / [l],3739,216252,DB00741,Hydrocortisone
,15098802,area under the prednisolone concentration-time curve,"No significant differences were observed for the mean +/- SD area under the prednisolone concentration-time curve (3739 +/- 992 vs 3498 +/- 797 microg x hr/L, respectively), clearance (8.58 +/- 2.62 vs 8.92 +/- 2.05 L/hr, respectively), volume of distribution (39.5 +/- 12.4 vs 38.2 +/- 9.9 L, respectively), elimination half-life (3.32 +/- 0.83 vs 3.05 +/- 0.80 hrs, respectively), or duration of plasma cortisol suppression (23.5 +/- 3.1 vs 22.0 +/- 4.2 hrs, respectively).",Lack of a fluoxetine effect on prednisolone disposition and cortisol suppression. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15098802/),[h·μg] / [l],3498,216253,DB00741,Hydrocortisone
,15098802,clearance,"No significant differences were observed for the mean +/- SD area under the prednisolone concentration-time curve (3739 +/- 992 vs 3498 +/- 797 microg x hr/L, respectively), clearance (8.58 +/- 2.62 vs 8.92 +/- 2.05 L/hr, respectively), volume of distribution (39.5 +/- 12.4 vs 38.2 +/- 9.9 L, respectively), elimination half-life (3.32 +/- 0.83 vs 3.05 +/- 0.80 hrs, respectively), or duration of plasma cortisol suppression (23.5 +/- 3.1 vs 22.0 +/- 4.2 hrs, respectively).",Lack of a fluoxetine effect on prednisolone disposition and cortisol suppression. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15098802/),[l] / [h],8.58,216254,DB00741,Hydrocortisone
,15098802,clearance,"No significant differences were observed for the mean +/- SD area under the prednisolone concentration-time curve (3739 +/- 992 vs 3498 +/- 797 microg x hr/L, respectively), clearance (8.58 +/- 2.62 vs 8.92 +/- 2.05 L/hr, respectively), volume of distribution (39.5 +/- 12.4 vs 38.2 +/- 9.9 L, respectively), elimination half-life (3.32 +/- 0.83 vs 3.05 +/- 0.80 hrs, respectively), or duration of plasma cortisol suppression (23.5 +/- 3.1 vs 22.0 +/- 4.2 hrs, respectively).",Lack of a fluoxetine effect on prednisolone disposition and cortisol suppression. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15098802/),[l] / [h],8.92,216255,DB00741,Hydrocortisone
,15098802,volume of distribution,"No significant differences were observed for the mean +/- SD area under the prednisolone concentration-time curve (3739 +/- 992 vs 3498 +/- 797 microg x hr/L, respectively), clearance (8.58 +/- 2.62 vs 8.92 +/- 2.05 L/hr, respectively), volume of distribution (39.5 +/- 12.4 vs 38.2 +/- 9.9 L, respectively), elimination half-life (3.32 +/- 0.83 vs 3.05 +/- 0.80 hrs, respectively), or duration of plasma cortisol suppression (23.5 +/- 3.1 vs 22.0 +/- 4.2 hrs, respectively).",Lack of a fluoxetine effect on prednisolone disposition and cortisol suppression. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15098802/),l,39.5,216256,DB00741,Hydrocortisone
,15098802,volume of distribution,"No significant differences were observed for the mean +/- SD area under the prednisolone concentration-time curve (3739 +/- 992 vs 3498 +/- 797 microg x hr/L, respectively), clearance (8.58 +/- 2.62 vs 8.92 +/- 2.05 L/hr, respectively), volume of distribution (39.5 +/- 12.4 vs 38.2 +/- 9.9 L, respectively), elimination half-life (3.32 +/- 0.83 vs 3.05 +/- 0.80 hrs, respectively), or duration of plasma cortisol suppression (23.5 +/- 3.1 vs 22.0 +/- 4.2 hrs, respectively).",Lack of a fluoxetine effect on prednisolone disposition and cortisol suppression. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15098802/),l,38.2,216257,DB00741,Hydrocortisone
,15098802,elimination half-life,"No significant differences were observed for the mean +/- SD area under the prednisolone concentration-time curve (3739 +/- 992 vs 3498 +/- 797 microg x hr/L, respectively), clearance (8.58 +/- 2.62 vs 8.92 +/- 2.05 L/hr, respectively), volume of distribution (39.5 +/- 12.4 vs 38.2 +/- 9.9 L, respectively), elimination half-life (3.32 +/- 0.83 vs 3.05 +/- 0.80 hrs, respectively), or duration of plasma cortisol suppression (23.5 +/- 3.1 vs 22.0 +/- 4.2 hrs, respectively).",Lack of a fluoxetine effect on prednisolone disposition and cortisol suppression. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15098802/),h,3.32,216258,DB00741,Hydrocortisone
,15098802,elimination half-life,"No significant differences were observed for the mean +/- SD area under the prednisolone concentration-time curve (3739 +/- 992 vs 3498 +/- 797 microg x hr/L, respectively), clearance (8.58 +/- 2.62 vs 8.92 +/- 2.05 L/hr, respectively), volume of distribution (39.5 +/- 12.4 vs 38.2 +/- 9.9 L, respectively), elimination half-life (3.32 +/- 0.83 vs 3.05 +/- 0.80 hrs, respectively), or duration of plasma cortisol suppression (23.5 +/- 3.1 vs 22.0 +/- 4.2 hrs, respectively).",Lack of a fluoxetine effect on prednisolone disposition and cortisol suppression. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15098802/),h,3.05,216259,DB00741,Hydrocortisone
,15098802,elimination half-life,"No significant differences were observed for the mean +/- SD area under the prednisolone concentration-time curve (3739 +/- 992 vs 3498 +/- 797 microg x hr/L, respectively), clearance (8.58 +/- 2.62 vs 8.92 +/- 2.05 L/hr, respectively), volume of distribution (39.5 +/- 12.4 vs 38.2 +/- 9.9 L, respectively), elimination half-life (3.32 +/- 0.83 vs 3.05 +/- 0.80 hrs, respectively), or duration of plasma cortisol suppression (23.5 +/- 3.1 vs 22.0 +/- 4.2 hrs, respectively).",Lack of a fluoxetine effect on prednisolone disposition and cortisol suppression. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15098802/),h,23.5,216260,DB00741,Hydrocortisone
,15098802,elimination half-life,"No significant differences were observed for the mean +/- SD area under the prednisolone concentration-time curve (3739 +/- 992 vs 3498 +/- 797 microg x hr/L, respectively), clearance (8.58 +/- 2.62 vs 8.92 +/- 2.05 L/hr, respectively), volume of distribution (39.5 +/- 12.4 vs 38.2 +/- 9.9 L, respectively), elimination half-life (3.32 +/- 0.83 vs 3.05 +/- 0.80 hrs, respectively), or duration of plasma cortisol suppression (23.5 +/- 3.1 vs 22.0 +/- 4.2 hrs, respectively).",Lack of a fluoxetine effect on prednisolone disposition and cortisol suppression. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15098802/),h,22.0,216261,DB00741,Hydrocortisone
,15098802,duration,"No significant differences were observed for the mean +/- SD area under the prednisolone concentration-time curve (3739 +/- 992 vs 3498 +/- 797 microg x hr/L, respectively), clearance (8.58 +/- 2.62 vs 8.92 +/- 2.05 L/hr, respectively), volume of distribution (39.5 +/- 12.4 vs 38.2 +/- 9.9 L, respectively), elimination half-life (3.32 +/- 0.83 vs 3.05 +/- 0.80 hrs, respectively), or duration of plasma cortisol suppression (23.5 +/- 3.1 vs 22.0 +/- 4.2 hrs, respectively).",Lack of a fluoxetine effect on prednisolone disposition and cortisol suppression. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15098802/),h,23.5,216262,DB00741,Hydrocortisone
,15098802,duration,"No significant differences were observed for the mean +/- SD area under the prednisolone concentration-time curve (3739 +/- 992 vs 3498 +/- 797 microg x hr/L, respectively), clearance (8.58 +/- 2.62 vs 8.92 +/- 2.05 L/hr, respectively), volume of distribution (39.5 +/- 12.4 vs 38.2 +/- 9.9 L, respectively), elimination half-life (3.32 +/- 0.83 vs 3.05 +/- 0.80 hrs, respectively), or duration of plasma cortisol suppression (23.5 +/- 3.1 vs 22.0 +/- 4.2 hrs, respectively).",Lack of a fluoxetine effect on prednisolone disposition and cortisol suppression. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15098802/),h,22.0,216263,DB00741,Hydrocortisone
,15505444,BIS,"In a randomized, prospective design, 20 patients received propofol at a target concentration of 3 microg/ml, whereas in 20 patients propofol was titrated to maintain a BIS value of 40-50.",Impact of bispectral index monitoring on stress response and propofol consumption in patients undergoing coronary artery bypass surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15505444/),,40-50,216645,DB00741,Hydrocortisone
,6879456,plasma elimination half-life,"The plasma elimination half-life for TAC, 86 min, was also calculated to be significantly longer than that for cortisol, 8 min.",Comparative distribution and metabolism of triamcinolone acetonide and cortisol in the rat embryomaternal unit. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6879456/),min,86,220221,DB00741,Hydrocortisone
,6879456,plasma elimination half-life,"The plasma elimination half-life for TAC, 86 min, was also calculated to be significantly longer than that for cortisol, 8 min.",Comparative distribution and metabolism of triamcinolone acetonide and cortisol in the rat embryomaternal unit. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6879456/),min,8,220222,DB00741,Hydrocortisone
,6879456,elimination half-life,The elimination half-life for unchanged TAC in the embryos was 142 min compared to 22 min for cortisol.,Comparative distribution and metabolism of triamcinolone acetonide and cortisol in the rat embryomaternal unit. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6879456/),min,142,220223,DB00741,Hydrocortisone
,6879456,elimination half-life,The elimination half-life for unchanged TAC in the embryos was 142 min compared to 22 min for cortisol.,Comparative distribution and metabolism of triamcinolone acetonide and cortisol in the rat embryomaternal unit. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6879456/),min,22,220224,DB00741,Hydrocortisone
,19620655,apparent volume of distribution,"Mean intravenous salicylate apparent volume of distribution was 0.2 +/- 0.005 L/kg, total body clearance was 4.3 +/- 0.2 mL/min.kg, and elimination half-life was 36.9 +/- 1.2 min.",Analgesic efficacy of sodium salicylate in an amphotericin B-induced bovine synovitis-arthritis model. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19620655/),[l] / [kg],0.2,220864,DB00741,Hydrocortisone
,19620655,total body clearance,"Mean intravenous salicylate apparent volume of distribution was 0.2 +/- 0.005 L/kg, total body clearance was 4.3 +/- 0.2 mL/min.kg, and elimination half-life was 36.9 +/- 1.2 min.",Analgesic efficacy of sodium salicylate in an amphotericin B-induced bovine synovitis-arthritis model. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19620655/),[ml] / [kg·min],4.3,220865,DB00741,Hydrocortisone
,19620655,elimination half-life,"Mean intravenous salicylate apparent volume of distribution was 0.2 +/- 0.005 L/kg, total body clearance was 4.3 +/- 0.2 mL/min.kg, and elimination half-life was 36.9 +/- 1.2 min.",Analgesic efficacy of sodium salicylate in an amphotericin B-induced bovine synovitis-arthritis model. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19620655/),min,36.9,220866,DB00741,Hydrocortisone
,18387858,protein binding,"Since the protein binding of prednisolone did not change in the presence of prednisone (114.0 ng/ml), it appeared that prednisone produced from the therapeutic dose of prednisolone did not affect the unbound fraction of prednisolone.","Simultaneous determination of prednisolone, prednisone, cortisol, and cortisone in plasma by GC-MS: estimating unbound prednisolone concentration in patients with nephrotic syndrome during oral prednisolone therapy. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18387858/),[ng] / [ml],114.0,221418,DB00741,Hydrocortisone
,11736861,systemic availability,"The systemic availability of budesonide via Turbuhaler (39%) was significantly higher than that of fluticasone via Diskus (13%) (ratio 3.0 [2.5, 3.6] with 95% confidence interval [CI]), and via pMDI (21%) (ratio 1.8 [1.3, 2.3]).","Pharmacokinetics and systemic activity of fluticasone via Diskus and pMDI, and of budesonide via Turbuhaler. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11736861/),%,39,221734,DB00741,Hydrocortisone
,11736861,systemic availability,"The systemic availability of budesonide via Turbuhaler (39%) was significantly higher than that of fluticasone via Diskus (13%) (ratio 3.0 [2.5, 3.6] with 95% confidence interval [CI]), and via pMDI (21%) (ratio 1.8 [1.3, 2.3]).","Pharmacokinetics and systemic activity of fluticasone via Diskus and pMDI, and of budesonide via Turbuhaler. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11736861/),%,13,221735,DB00741,Hydrocortisone
,11736861,systemic availability,"The systemic availability of budesonide via Turbuhaler (39%) was significantly higher than that of fluticasone via Diskus (13%) (ratio 3.0 [2.5, 3.6] with 95% confidence interval [CI]), and via pMDI (21%) (ratio 1.8 [1.3, 2.3]).","Pharmacokinetics and systemic activity of fluticasone via Diskus and pMDI, and of budesonide via Turbuhaler. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11736861/),%,21,221736,DB00741,Hydrocortisone
,7143223,elimination half-lives,Subsequent drug elimination was monophasic with mean elimination half-lives increasing from 1.2 hr for the 5-mg dose to 1.7 hr for the 40-mg dose.,Effect of dose size on the pharmacokinetics of oral hydrocortisone suspension. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7143223/),h,1.2,221740,DB00741,Hydrocortisone
,7143223,elimination half-lives,Subsequent drug elimination was monophasic with mean elimination half-lives increasing from 1.2 hr for the 5-mg dose to 1.7 hr for the 40-mg dose.,Effect of dose size on the pharmacokinetics of oral hydrocortisone suspension. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7143223/),h,1.7,221741,DB00741,Hydrocortisone
,10829051,clearance (CL),Docetaxel clearance (CL) and area under the concentration-time curve averaged 24.5 +/- 6.4 L/h/m(2) and 2.66 +/- 0.91 mg/L 8729.,Correlation between docetaxel clearance and estimated cytochrome P450 activity by urinary metabolite of exogenous cortisol. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10829051/),[h·l] / [m(2],24.5,222671,DB00741,Hydrocortisone
,10829051,area under the concentration-time curve,Docetaxel clearance (CL) and area under the concentration-time curve averaged 24.5 +/- 6.4 L/h/m(2) and 2.66 +/- 0.91 mg/L 8729.,Correlation between docetaxel clearance and estimated cytochrome P450 activity by urinary metabolite of exogenous cortisol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10829051/),[mg] / [l],2.66,222672,DB00741,Hydrocortisone
,20614688,total clearance (CL(tot)),"Following a 10 mg x kg(-1) intravenous bolus dose, the total clearance (CL(tot)) of PRN (27.0 +/- 1.4 mL x min(-1) kg(-1)) was significantly lower than that of LE (67.4 +/- 11.6 mL x min(-1) kg(-1)) or delta1-CA (53.8 +/- 1.4 mL x min(-1) kg(-1)) indicating that the metabolism/elimination of PRN in the liver (primarily, conjugation) may be less efficient than that of LE (primarily, hydrolysis) or delta1-CA (unchanged).",Pharmacokinetics and delta1-cortienic acid excretion after intravenous administration of prednisolone and loteprednol etabonate in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20614688/),[ml] / [kg·min],27.0,223387,DB00741,Hydrocortisone
,20614688,total clearance (CL(tot)),"Following a 10 mg x kg(-1) intravenous bolus dose, the total clearance (CL(tot)) of PRN (27.0 +/- 1.4 mL x min(-1) kg(-1)) was significantly lower than that of LE (67.4 +/- 11.6 mL x min(-1) kg(-1)) or delta1-CA (53.8 +/- 1.4 mL x min(-1) kg(-1)) indicating that the metabolism/elimination of PRN in the liver (primarily, conjugation) may be less efficient than that of LE (primarily, hydrolysis) or delta1-CA (unchanged).",Pharmacokinetics and delta1-cortienic acid excretion after intravenous administration of prednisolone and loteprednol etabonate in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20614688/),[ml] / [kg·min],67.4,223388,DB00741,Hydrocortisone
,20614688,total clearance (CL(tot)),"Following a 10 mg x kg(-1) intravenous bolus dose, the total clearance (CL(tot)) of PRN (27.0 +/- 1.4 mL x min(-1) kg(-1)) was significantly lower than that of LE (67.4 +/- 11.6 mL x min(-1) kg(-1)) or delta1-CA (53.8 +/- 1.4 mL x min(-1) kg(-1)) indicating that the metabolism/elimination of PRN in the liver (primarily, conjugation) may be less efficient than that of LE (primarily, hydrolysis) or delta1-CA (unchanged).",Pharmacokinetics and delta1-cortienic acid excretion after intravenous administration of prednisolone and loteprednol etabonate in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20614688/),[ml] / [kg·min],53.8,223389,DB00741,Hydrocortisone
,20614688,volume of distribution (Vd(ss)),The volume of distribution (Vd(ss)) of PRN (823 +/- 78 mL x kg(-1)) was significantly lower than that of LE (3078 +/- 79 mL x kg(-1)) indicating that LE is more distributed to lipophilic tissues.,Pharmacokinetics and delta1-cortienic acid excretion after intravenous administration of prednisolone and loteprednol etabonate in rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20614688/),[ml] / [kg],823,223390,DB00741,Hydrocortisone
,20614688,volume of distribution (Vd(ss)),The volume of distribution (Vd(ss)) of PRN (823 +/- 78 mL x kg(-1)) was significantly lower than that of LE (3078 +/- 79 mL x kg(-1)) indicating that LE is more distributed to lipophilic tissues.,Pharmacokinetics and delta1-cortienic acid excretion after intravenous administration of prednisolone and loteprednol etabonate in rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20614688/),[ml] / [kg],3078,223391,DB00741,Hydrocortisone
,10514351,constant current,"MCP, an antiemetic, low molecular weight, cationic drug intended for systemic delivery, was delivered from the anode of IP systems at a constant current of 100 microA/cm(2).",Effect of transdermal iontophoresis codelivery of hydrocortisone on metoclopramide pharmacokinetics and skin-induced reactions in human subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10514351/),[μa] / [cm(2],100,223550,DB00741,Hydrocortisone
,10514351,steady-state MCP flux,"In both groups, a steady-state MCP flux of about 100 microg/(cm(2) x h) was achieved after only 1 h of transport, and input rate dropped dramatically immediately after removal of the system.",Effect of transdermal iontophoresis codelivery of hydrocortisone on metoclopramide pharmacokinetics and skin-induced reactions in human subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10514351/),[μg] / [cm(2)·h],100,223551,DB00741,Hydrocortisone
,10514351,flux,"In vitro, HC flux through human epidermis from an MCP plus HC formulation was 2.8 +/- 1.1 microg/(cm(2) x h) after 4 h transport at 100 microA/cm(2), suggesting negligible systemic exposure to hydrocortisone.",Effect of transdermal iontophoresis codelivery of hydrocortisone on metoclopramide pharmacokinetics and skin-induced reactions in human subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10514351/),[μg] / [cm(2)·h],2.8,223552,DB00741,Hydrocortisone
,23719680,AUC,"The average estimate of AUC producing 50 % of maximum effect (AUC50) was similar for the serum cortisol and urine cortisol models with values of 1,556 and 1,686 pg · h/mL, respectively.",The relationship between fluticasone furoate systemic exposure and cortisol suppression. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23719680/),[h·pg] / [ml],"1,556",223676,DB00741,Hydrocortisone
,23719680,AUC,"The average estimate of AUC producing 50 % of maximum effect (AUC50) was similar for the serum cortisol and urine cortisol models with values of 1,556 and 1,686 pg · h/mL, respectively.",The relationship between fluticasone furoate systemic exposure and cortisol suppression. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23719680/),[h·pg] / [ml],"1,686",223677,DB00741,Hydrocortisone
,23719680,maximum effect (AUC50),"The average estimate of AUC producing 50 % of maximum effect (AUC50) was similar for the serum cortisol and urine cortisol models with values of 1,556 and 1,686 pg · h/mL, respectively.",The relationship between fluticasone furoate systemic exposure and cortisol suppression. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23719680/),[h·pg] / [ml],"1,556",223678,DB00741,Hydrocortisone
,23719680,maximum effect (AUC50),"The average estimate of AUC producing 50 % of maximum effect (AUC50) was similar for the serum cortisol and urine cortisol models with values of 1,556 and 1,686 pg · h/mL, respectively.",The relationship between fluticasone furoate systemic exposure and cortisol suppression. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23719680/),[h·pg] / [ml],"1,686",223679,DB00741,Hydrocortisone
,23719680,AUC50,"The values of AUC50 of 1,556 and 1,686 pg·h/mL, respectively, are several times higher than average fluticasone furoate AUC24 values observed at clinical doses of fluticasone furoate (≤200 μg).",The relationship between fluticasone furoate systemic exposure and cortisol suppression. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23719680/),[h·pg] / [ml],"1,556",223680,DB00741,Hydrocortisone
,23719680,AUC50,"The values of AUC50 of 1,556 and 1,686 pg·h/mL, respectively, are several times higher than average fluticasone furoate AUC24 values observed at clinical doses of fluticasone furoate (≤200 μg).",The relationship between fluticasone furoate systemic exposure and cortisol suppression. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23719680/),[h·pg] / [ml],"1,686",223681,DB00741,Hydrocortisone
,23719680,AUC24,"The models predict a fluticasone furoate AUC24 of 1,000 pg·h/mL would be required to reduce 24-h serum cortisol or 24-h urine cortisol excretion by 20 and 17 %, respectively.",The relationship between fluticasone furoate systemic exposure and cortisol suppression. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23719680/),[h·pg] / [ml],"1,000",223682,DB00741,Hydrocortisone
,3950871,half-times,"From in vitro assay, it was shown that hydrolysis of MPA to MP was rapid both in blood (half-times from 11.8 to 21.7 min) and in synovial fluid (half-times from 45.6 to 130.3 min).",Bovine plasma and synovial fluid kinetics of methylprednisolone and methylprednisolone acetate after intra-articular administration of methylprednisolone acetate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3950871/),min,11.8 to 21.7,224538,DB00741,Hydrocortisone
,3950871,half-times,"From in vitro assay, it was shown that hydrolysis of MPA to MP was rapid both in blood (half-times from 11.8 to 21.7 min) and in synovial fluid (half-times from 45.6 to 130.3 min).",Bovine plasma and synovial fluid kinetics of methylprednisolone and methylprednisolone acetate after intra-articular administration of methylprednisolone acetate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3950871/),min,45.6 to 130.3,224539,DB00741,Hydrocortisone
,3950871,systemic availability,"After intra-articular administration of MPA as a suspension (200 mg in toto), both MP and MPA decline very rapidly and, 24 hr after injection, less than 1% of the dose was present in the synovial fluid, but systemic availability of MP during the first 24 hr was only 30% of the dose.",Bovine plasma and synovial fluid kinetics of methylprednisolone and methylprednisolone acetate after intra-articular administration of methylprednisolone acetate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3950871/),%,30,224540,DB00741,Hydrocortisone
,3950871,apparent half-time,"After this delay, the synovial fluid concentration decreased very slowly with an apparent half-time of 18 days.",Bovine plasma and synovial fluid kinetics of methylprednisolone and methylprednisolone acetate after intra-articular administration of methylprednisolone acetate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3950871/),d,18,224541,DB00741,Hydrocortisone
,18308795,response (area-under-the-curve,"Mean response (area-under-the-curve) over the first 4 hours (SD): 172.0 nmol/L (22.3) for placebo, 258.3 nmol/L (72.6) for 100 mg, 328.47 nmol/L (84.6) for 200 mg and 387.3 nmol/L (82.4) for 300 mg 5-HTP.",Pharmacology of rising oral doses of 5-hydroxytryptophan with carbidopa. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18308795/),[nM] / [l],172.0,224639,DB00741,Hydrocortisone
,18308795,response (area-under-the-curve,"Mean response (area-under-the-curve) over the first 4 hours (SD): 172.0 nmol/L (22.3) for placebo, 258.3 nmol/L (72.6) for 100 mg, 328.47 nmol/L (84.6) for 200 mg and 387.3 nmol/L (82.4) for 300 mg 5-HTP.",Pharmacology of rising oral doses of 5-hydroxytryptophan with carbidopa. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18308795/),[nM] / [l],258.3,224640,DB00741,Hydrocortisone
,18308795,response (area-under-the-curve,"Mean response (area-under-the-curve) over the first 4 hours (SD): 172.0 nmol/L (22.3) for placebo, 258.3 nmol/L (72.6) for 100 mg, 328.47 nmol/L (84.6) for 200 mg and 387.3 nmol/L (82.4) for 300 mg 5-HTP.",Pharmacology of rising oral doses of 5-hydroxytryptophan with carbidopa. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18308795/),[nM] / [l],328.47,224641,DB00741,Hydrocortisone
,18308795,response (area-under-the-curve,"Mean response (area-under-the-curve) over the first 4 hours (SD): 172.0 nmol/L (22.3) for placebo, 258.3 nmol/L (72.6) for 100 mg, 328.47 nmol/L (84.6) for 200 mg and 387.3 nmol/L (82.4) for 300 mg 5-HTP.",Pharmacology of rising oral doses of 5-hydroxytryptophan with carbidopa. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18308795/),[nM] / [l],387.3,224642,DB00741,Hydrocortisone
,18308795,oral clearance,5-HTP kinetics were adequately described using a one-compartment model with first-order absorption and a lag time (mean oral clearance 28 L/h interindividual coefficient of variation 31%).,Pharmacology of rising oral doses of 5-hydroxytryptophan with carbidopa. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18308795/),[l] / [h],28,224643,DB00741,Hydrocortisone
,954224,MCR,"In all six patients studied, the MCR of cortisol increased during metyrapone load from an average of 12-3 +/- 5-0 (SD) l/h to 29-6 +/- 15-7 (SD) l/h or corrected for body weight 3-0 +/- 1-1 (SD) ml/kg b.w./min to 7-1 +/- 2-5 (SD) ml/kg b.w./min.",Quantitation of the accelerating effect of metyrapone on cortisol metabolism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/954224/),[l] / [h],12-3,226036,DB00741,Hydrocortisone
,954224,MCR,"In all six patients studied, the MCR of cortisol increased during metyrapone load from an average of 12-3 +/- 5-0 (SD) l/h to 29-6 +/- 15-7 (SD) l/h or corrected for body weight 3-0 +/- 1-1 (SD) ml/kg b.w./min to 7-1 +/- 2-5 (SD) ml/kg b.w./min.",Quantitation of the accelerating effect of metyrapone on cortisol metabolism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/954224/),[l] / [h],29-6,226037,DB00741,Hydrocortisone
,954224,MCR,"In all six patients studied, the MCR of cortisol increased during metyrapone load from an average of 12-3 +/- 5-0 (SD) l/h to 29-6 +/- 15-7 (SD) l/h or corrected for body weight 3-0 +/- 1-1 (SD) ml/kg b.w./min to 7-1 +/- 2-5 (SD) ml/kg b.w./min.",Quantitation of the accelerating effect of metyrapone on cortisol metabolism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/954224/),,7-1,226038,DB00741,Hydrocortisone
,12386638,terminal half-life,"The mean terminal half-life of budesonide was prolonged from 1.6 to 6.2 hours (ie, 3.7-fold; range, 1.5-fold to 9.3-fold; P <.001) by itraconazole.",Plasma concentrations of inhaled budesonide and its effects on plasma cortisol are increased by the cytochrome P4503A4 inhibitor itraconazole. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12386638/),h,1.6 to 6.2,227770,DB00741,Hydrocortisone
,18611115,elimination half-life,"The short elimination half-life of hydrocortisone (approximately 1.5 h) when given in traditional immediate-release dosage forms requires two or more dose administrations per day, with high peaks and low trough values in between.",Replacement therapy of oral hydrocortisone in adrenal insufficiency: the influence of gastrointestinal factors. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18611115/),h,1.5,228070,DB00741,Hydrocortisone
,10372727,area under the curve (AUC) 0-12 h,"The intake of 50 mg DHEA led to an increase in serum DHEAS to mean levels of young adult men, whereas 100 mg DHEA induced supraphysiological concentrations [placebo vs. 50 mg DHEA vs. 100 mg DHEA; area under the curve (AUC) 0-12 h (mean +/- SD) for DHEA, 108 +/- 22 vs.",Biotransformation of oral dehydroepiandrosterone in elderly men: significant increase in circulating estrogens. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10372727/),,108,228141,DB00741,Hydrocortisone
,10372727,AUC 0-12 h,"349 +/- 72 nmol/L x h; AUC 0-12 h for DHEAS, 33 +/- 9 vs. 114 +/- 19 vs. 164 +/- 36 micromol/L x h].",Biotransformation of oral dehydroepiandrosterone in elderly men: significant increase in circulating estrogens. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10372727/),[μM] / [h·l],33,228142,DB00741,Hydrocortisone
,10372727,AUC 0-12 h,"349 +/- 72 nmol/L x h; AUC 0-12 h for DHEAS, 33 +/- 9 vs. 114 +/- 19 vs. 164 +/- 36 micromol/L x h].",Biotransformation of oral dehydroepiandrosterone in elderly men: significant increase in circulating estrogens. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10372727/),[μM] / [h·l],114,228143,DB00741,Hydrocortisone
,10372727,AUC 0-12 h,"349 +/- 72 nmol/L x h; AUC 0-12 h for DHEAS, 33 +/- 9 vs. 114 +/- 19 vs. 164 +/- 36 micromol/L x h].",Biotransformation of oral dehydroepiandrosterone in elderly men: significant increase in circulating estrogens. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10372727/),[μM] / [h·l],164,228144,DB00741,Hydrocortisone
,10372727,AUC 0-12 h,"In contrast, 17beta-estradiol and estrone significantly increased in a dose-dependent manner to concentrations still within the upper normal range for men [placebo vs. 50 mg DHEA vs. 100 mg DHEA; AUC 0-12 h for 17beta-estradiol, 510 +/- 198 vs. 635 +/- 156 vs.",Biotransformation of oral dehydroepiandrosterone in elderly men: significant increase in circulating estrogens. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10372727/),,510,228145,DB00741,Hydrocortisone
,10372727,AUC 0-12 h,"In contrast, 17beta-estradiol and estrone significantly increased in a dose-dependent manner to concentrations still within the upper normal range for men [placebo vs. 50 mg DHEA vs. 100 mg DHEA; AUC 0-12 h for 17beta-estradiol, 510 +/- 198 vs. 635 +/- 156 vs.",Biotransformation of oral dehydroepiandrosterone in elderly men: significant increase in circulating estrogens. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10372727/),,635,228146,DB00741,Hydrocortisone
,10372727,AUC 0-12 h,"700 +/- 209 pmol/L x h (P < 0.0001); AUC 0-12 h for estrone, 1443 +/- 269 vs. 2537 +/- 434 vs. 3254 +/- 671 pmol/L x h (P < 0.0001)].",Biotransformation of oral dehydroepiandrosterone in elderly men: significant increase in circulating estrogens. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10372727/),[pM] / [h·l],1443,228147,DB00741,Hydrocortisone
,10372727,AUC 0-12 h,"700 +/- 209 pmol/L x h (P < 0.0001); AUC 0-12 h for estrone, 1443 +/- 269 vs. 2537 +/- 434 vs. 3254 +/- 671 pmol/L x h (P < 0.0001)].",Biotransformation of oral dehydroepiandrosterone in elderly men: significant increase in circulating estrogens. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10372727/),[pM] / [h·l],2537,228148,DB00741,Hydrocortisone
,10372727,AUC 0-12 h,"700 +/- 209 pmol/L x h (P < 0.0001); AUC 0-12 h for estrone, 1443 +/- 269 vs. 2537 +/- 434 vs. 3254 +/- 671 pmol/L x h (P < 0.0001)].",Biotransformation of oral dehydroepiandrosterone in elderly men: significant increase in circulating estrogens. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10372727/),[pM] / [h·l],3254,228149,DB00741,Hydrocortisone
,15034704,C(max),The median C(max) was now statistically significantly reduced from 35 ng/ml to 7.5 ng/ml.,Rifampicin seems to act as both an inducer and an inhibitor of the metabolism of repaglinide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15034704/),[ng] / [ml],35,229421,DB00741,Hydrocortisone
,15034704,C(max),The median C(max) was now statistically significantly reduced from 35 ng/ml to 7.5 ng/ml.,Rifampicin seems to act as both an inducer and an inhibitor of the metabolism of repaglinide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15034704/),[ng] / [ml],7.5,229422,DB00741,Hydrocortisone
,3311551,AUC ratio,"This cortisol AUC ratio was reduced from 0.45 (methylprednisolone) to 0.39 (methylprednisolone plus ketoconazole), suggesting that ketoconazole modestly enhanced (P less than 0.01) cortisol suppression.",Ketoconazole effects on methylprednisolone disposition and their joint suppression of endogenous cortisol. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3311551/),,0.45,229623,DB00741,Hydrocortisone
,3311551,AUC ratio,"This cortisol AUC ratio was reduced from 0.45 (methylprednisolone) to 0.39 (methylprednisolone plus ketoconazole), suggesting that ketoconazole modestly enhanced (P less than 0.01) cortisol suppression.",Ketoconazole effects on methylprednisolone disposition and their joint suppression of endogenous cortisol. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3311551/),,0.39,229624,DB00741,Hydrocortisone
,9516720,half-life,"In conscious sodium replete sheep with a parotid fistula, infusion of CBX (40 mg/h for 10 days) did not increase mean arterial pressure, or change sodium and potassium status or plasma renin concentration, but significantly increased the half-life of 1,2[3H] cortisol from 18.6 +/- 4.0 to 38.8 +/- 3.9 min (p < 0.05) and reduced the blood clearance rate of cortisol (BCR) from 31 +/- 3 to 15 +/- 4 L/h (p < 0.01).",Carbenoxolone does not cause a syndrome of mineralocorticoid excess in sheep. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9516720/),min,18.6,230574,DB00741,Hydrocortisone
,9516720,half-life,"In conscious sodium replete sheep with a parotid fistula, infusion of CBX (40 mg/h for 10 days) did not increase mean arterial pressure, or change sodium and potassium status or plasma renin concentration, but significantly increased the half-life of 1,2[3H] cortisol from 18.6 +/- 4.0 to 38.8 +/- 3.9 min (p < 0.05) and reduced the blood clearance rate of cortisol (BCR) from 31 +/- 3 to 15 +/- 4 L/h (p < 0.01).",Carbenoxolone does not cause a syndrome of mineralocorticoid excess in sheep. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9516720/),min,38.8,230575,DB00741,Hydrocortisone
,9516720,blood clearance rate of cortisol (BCR),"In conscious sodium replete sheep with a parotid fistula, infusion of CBX (40 mg/h for 10 days) did not increase mean arterial pressure, or change sodium and potassium status or plasma renin concentration, but significantly increased the half-life of 1,2[3H] cortisol from 18.6 +/- 4.0 to 38.8 +/- 3.9 min (p < 0.05) and reduced the blood clearance rate of cortisol (BCR) from 31 +/- 3 to 15 +/- 4 L/h (p < 0.01).",Carbenoxolone does not cause a syndrome of mineralocorticoid excess in sheep. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9516720/),[l] / [h],31,230576,DB00741,Hydrocortisone
,9516720,blood clearance rate of cortisol (BCR),"In conscious sodium replete sheep with a parotid fistula, infusion of CBX (40 mg/h for 10 days) did not increase mean arterial pressure, or change sodium and potassium status or plasma renin concentration, but significantly increased the half-life of 1,2[3H] cortisol from 18.6 +/- 4.0 to 38.8 +/- 3.9 min (p < 0.05) and reduced the blood clearance rate of cortisol (BCR) from 31 +/- 3 to 15 +/- 4 L/h (p < 0.01).",Carbenoxolone does not cause a syndrome of mineralocorticoid excess in sheep. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9516720/),[l] / [h],15,230577,DB00741,Hydrocortisone
,9516720,secretion rate,The reduction in cortisol BCR was associated with reduction in cortisol secretion rate from 433 +/- 116 to 181 +/- 79 nmol/h (p < 0.01).,Carbenoxolone does not cause a syndrome of mineralocorticoid excess in sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9516720/),[nM] / [h],433,230578,DB00741,Hydrocortisone
,9516720,secretion rate,The reduction in cortisol BCR was associated with reduction in cortisol secretion rate from 433 +/- 116 to 181 +/- 79 nmol/h (p < 0.01).,Carbenoxolone does not cause a syndrome of mineralocorticoid excess in sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9516720/),[nM] / [h],181,230579,DB00741,Hydrocortisone
,3234253,Oral bioavailability,"Oral bioavailability was essentially 100 percent, ruling out impaired absorption.",Rapid methylprednisolone clearance in a patient with cystic fibrosis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3234253/),%,100,234170,DB00741,Hydrocortisone
,186476,MCR,"In control subjects, the MCR (plasma) of both steroids increased by 29% (aldosterone: from 936 +/- 57 to 1204 +/- 55 l/day/m2, cortisol: from 205 +/- 12 to 264 +/- 17 l/day/m2 +/- SE) after ACTH (12 units/h) for 1 to 4 h, and by 20 and 32%, respectively, after cortisol (12 mg/h) for 1 to 2 h.",The effect of ACTH and cortisol on aldosterone and cortisol clearance and distribution in plasma and whole blood. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/186476/),[l] / [d·m2],936,234823,DB00741,Hydrocortisone
,186476,MCR,"In control subjects, the MCR (plasma) of both steroids increased by 29% (aldosterone: from 936 +/- 57 to 1204 +/- 55 l/day/m2, cortisol: from 205 +/- 12 to 264 +/- 17 l/day/m2 +/- SE) after ACTH (12 units/h) for 1 to 4 h, and by 20 and 32%, respectively, after cortisol (12 mg/h) for 1 to 2 h.",The effect of ACTH and cortisol on aldosterone and cortisol clearance and distribution in plasma and whole blood. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/186476/),[l] / [d·m2],1204,234824,DB00741,Hydrocortisone
,186476,MCR,"In control subjects, the MCR (plasma) of both steroids increased by 29% (aldosterone: from 936 +/- 57 to 1204 +/- 55 l/day/m2, cortisol: from 205 +/- 12 to 264 +/- 17 l/day/m2 +/- SE) after ACTH (12 units/h) for 1 to 4 h, and by 20 and 32%, respectively, after cortisol (12 mg/h) for 1 to 2 h.",The effect of ACTH and cortisol on aldosterone and cortisol clearance and distribution in plasma and whole blood. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/186476/),[l] / [d·m2],205,234825,DB00741,Hydrocortisone
,186476,MCR,"In control subjects, the MCR (plasma) of both steroids increased by 29% (aldosterone: from 936 +/- 57 to 1204 +/- 55 l/day/m2, cortisol: from 205 +/- 12 to 264 +/- 17 l/day/m2 +/- SE) after ACTH (12 units/h) for 1 to 4 h, and by 20 and 32%, respectively, after cortisol (12 mg/h) for 1 to 2 h.",The effect of ACTH and cortisol on aldosterone and cortisol clearance and distribution in plasma and whole blood. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/186476/),[l] / [d·m2],264,234826,DB00741,Hydrocortisone
,186476,MCR,"In contrast, aldosterone MCR (whole blood) did not change with ACTH or cortisol administration (from 1276 +/- 57 to 1330 +/- 59 l/day/m2), indicating that the plasma MCR increase results from a redistribution of aldosterone from plasma to red cells.",The effect of ACTH and cortisol on aldosterone and cortisol clearance and distribution in plasma and whole blood. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/186476/),[l] / [d·m2],1276,234827,DB00741,Hydrocortisone
,186476,MCR,"In contrast, aldosterone MCR (whole blood) did not change with ACTH or cortisol administration (from 1276 +/- 57 to 1330 +/- 59 l/day/m2), indicating that the plasma MCR increase results from a redistribution of aldosterone from plasma to red cells.",The effect of ACTH and cortisol on aldosterone and cortisol clearance and distribution in plasma and whole blood. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/186476/),[l] / [d·m2],1330,234828,DB00741,Hydrocortisone
,186476,extraction,"Aldosterone splanchnic extraction was 92 +/- 1% (n = 12) with normal morning cortisol levels, and extraction was unchanged after ACTH administration.",The effect of ACTH and cortisol on aldosterone and cortisol clearance and distribution in plasma and whole blood. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/186476/),%,92,234829,DB00741,Hydrocortisone
,186476,MCR,"For cortisol, however, the splanchnic extraction increased from 8 +/- 0.8% to 17.8 +/- 5.0%, and the MCR (whole blood) likewise increased by 15 to 31% (from 295 +/- 23 to 357 +/- 30 l/day/m2), after ACTH or cortisol administration.",The effect of ACTH and cortisol on aldosterone and cortisol clearance and distribution in plasma and whole blood. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/186476/),[l] / [d·m2],295,234830,DB00741,Hydrocortisone
,186476,MCR,"For cortisol, however, the splanchnic extraction increased from 8 +/- 0.8% to 17.8 +/- 5.0%, and the MCR (whole blood) likewise increased by 15 to 31% (from 295 +/- 23 to 357 +/- 30 l/day/m2), after ACTH or cortisol administration.",The effect of ACTH and cortisol on aldosterone and cortisol clearance and distribution in plasma and whole blood. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/186476/),[l] / [d·m2],357,234831,DB00741,Hydrocortisone
,7306425,systemic availability,The average systemic availability of the drug by this route was estimated to be 30% by 3 h.,Sublingual buprenorphine used postoperatively: clinical observations and preliminary pharmacokinetic analysis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7306425/),%,30,235710,DB00741,Hydrocortisone
,7398193,rate,Four subjects absorbed hydrocortisone slowly from both enemas at a mean rate of 0.361 hr-1 and five subjects absorbed hydrocortisone rapidly from both preparations at a mean rate of 1.05 hr-1 (p < 0.001).,Bioavailability of hydrocortisone retention enemas in relation to absorption kinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7398193/),1/[h],0.361,235754,DB00741,Hydrocortisone
,7398193,rate,Four subjects absorbed hydrocortisone slowly from both enemas at a mean rate of 0.361 hr-1 and five subjects absorbed hydrocortisone rapidly from both preparations at a mean rate of 1.05 hr-1 (p < 0.001).,Bioavailability of hydrocortisone retention enemas in relation to absorption kinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7398193/),1/[h],1.05,235755,DB00741,Hydrocortisone
,7398193,bioavailability,The bioavailability of hydrocortisone retention enemas ws 0.810 and 0.502 in slow and rapid absorbers (p < 0.01).,Bioavailability of hydrocortisone retention enemas in relation to absorption kinetics. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7398193/),,0.810,235756,DB00741,Hydrocortisone
,7398193,bioavailability,The bioavailability of hydrocortisone retention enemas ws 0.810 and 0.502 in slow and rapid absorbers (p < 0.01).,Bioavailability of hydrocortisone retention enemas in relation to absorption kinetics. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7398193/),,0.502,235757,DB00741,Hydrocortisone
,20017819,plasma concentration,"After IV administration, the plasma concentration of methadone at 10 minutes was 82.1 +/- 9.2 ng mL(-1) (mean +/- SD), the terminal half-life was 3.9 +/- 1.0 hours, the volume of distribution 9.2 +/- 3.3 L kg(-1) and plasma clearance 27.9 +/- 7.6 mL minute(-1) kg(-1).",Clinical pharmacology of methadone in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20017819/),[ng] / [ml],82.1,236919,DB00741,Hydrocortisone
,20017819,terminal half-life,"After IV administration, the plasma concentration of methadone at 10 minutes was 82.1 +/- 9.2 ng mL(-1) (mean +/- SD), the terminal half-life was 3.9 +/- 1.0 hours, the volume of distribution 9.2 +/- 3.3 L kg(-1) and plasma clearance 27.9 +/- 7.6 mL minute(-1) kg(-1).",Clinical pharmacology of methadone in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20017819/),h,3.9,236920,DB00741,Hydrocortisone
,20017819,volume of distribution,"After IV administration, the plasma concentration of methadone at 10 minutes was 82.1 +/- 9.2 ng mL(-1) (mean +/- SD), the terminal half-life was 3.9 +/- 1.0 hours, the volume of distribution 9.2 +/- 3.3 L kg(-1) and plasma clearance 27.9 +/- 7.6 mL minute(-1) kg(-1).",Clinical pharmacology of methadone in dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20017819/),[l] / [kg],9.2,236921,DB00741,Hydrocortisone
,20017819,plasma clearance,"After IV administration, the plasma concentration of methadone at 10 minutes was 82.1 +/- 9.2 ng mL(-1) (mean +/- SD), the terminal half-life was 3.9 +/- 1.0 hours, the volume of distribution 9.2 +/- 3.3 L kg(-1) and plasma clearance 27.9 +/- 7.6 mL minute(-1) kg(-1).",Clinical pharmacology of methadone in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20017819/),[ml] / [kg·minute],27.9,236922,DB00741,Hydrocortisone
,20017819,time to maximal plasma concentration,"After SC administration, time to maximal plasma concentration was 1.26 +/- 1.04 hours and maximal plasma concentration of methadone was 23.9 +/- 14.4 ng mL(-1), the terminal half-life was 10.7 +/- 4.3 hours and bioavailability was 79 +/- 22%.",Clinical pharmacology of methadone in dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20017819/),h,1.26,236923,DB00741,Hydrocortisone
,20017819,maximal plasma concentration,"After SC administration, time to maximal plasma concentration was 1.26 +/- 1.04 hours and maximal plasma concentration of methadone was 23.9 +/- 14.4 ng mL(-1), the terminal half-life was 10.7 +/- 4.3 hours and bioavailability was 79 +/- 22%.",Clinical pharmacology of methadone in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20017819/),[ng] / [ml],23.9,236924,DB00741,Hydrocortisone
,20017819,terminal half-life,"After SC administration, time to maximal plasma concentration was 1.26 +/- 1.04 hours and maximal plasma concentration of methadone was 23.9 +/- 14.4 ng mL(-1), the terminal half-life was 10.7 +/- 4.3 hours and bioavailability was 79 +/- 22%.",Clinical pharmacology of methadone in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20017819/),h,10.7,236925,DB00741,Hydrocortisone
,20017819,bioavailability,"After SC administration, time to maximal plasma concentration was 1.26 +/- 1.04 hours and maximal plasma concentration of methadone was 23.9 +/- 14.4 ng mL(-1), the terminal half-life was 10.7 +/- 4.3 hours and bioavailability was 79 +/- 22%.",Clinical pharmacology of methadone in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20017819/),%,79,236926,DB00741,Hydrocortisone
,2894938,Vmax,"At 0.5 mM SMZ and variable [acetyl-CoA], Vmax increased 3-fold from 82 +/- 20 to 244 +/- 43 mumol/min/organ, while at 0.5 mM acetyl-CoA and variable [SMZ], Vmax increased 2.8-fold from 75 +/- 19 to 208 +/- 41 mumol/min/organ.",Induction of sulfamethazine acetylation by hydrocortisone in the rabbit. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2894938/),[μM] / [min·organ],82,237685,DB00741,Hydrocortisone
,2894938,Vmax,"At 0.5 mM SMZ and variable [acetyl-CoA], Vmax increased 3-fold from 82 +/- 20 to 244 +/- 43 mumol/min/organ, while at 0.5 mM acetyl-CoA and variable [SMZ], Vmax increased 2.8-fold from 75 +/- 19 to 208 +/- 41 mumol/min/organ.",Induction of sulfamethazine acetylation by hydrocortisone in the rabbit. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2894938/),[μM] / [min·organ],244,237686,DB00741,Hydrocortisone
,2894938,Vmax,"At 0.5 mM SMZ and variable [acetyl-CoA], Vmax increased 3-fold from 82 +/- 20 to 244 +/- 43 mumol/min/organ, while at 0.5 mM acetyl-CoA and variable [SMZ], Vmax increased 2.8-fold from 75 +/- 19 to 208 +/- 41 mumol/min/organ.",Induction of sulfamethazine acetylation by hydrocortisone in the rabbit. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2894938/),[μM] / [min·organ],75,237687,DB00741,Hydrocortisone
,2894938,Vmax,"At 0.5 mM SMZ and variable [acetyl-CoA], Vmax increased 3-fold from 82 +/- 20 to 244 +/- 43 mumol/min/organ, while at 0.5 mM acetyl-CoA and variable [SMZ], Vmax increased 2.8-fold from 75 +/- 19 to 208 +/- 41 mumol/min/organ.",Induction of sulfamethazine acetylation by hydrocortisone in the rabbit. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2894938/),[μM] / [min·organ],208,237688,DB00741,Hydrocortisone
,12830002,peak plasma concentrations,Patients with PBC stage IV showed significantly higher peak plasma concentrations (4.9 +/- 3.5 vs.,Pharmacokinetics and pharmacodynamic action of budesonide in early- and late-stage primary biliary cirrhosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12830002/),,4.9,238429,DB00741,Hydrocortisone
,12830002,areas under the plasma concentration-time curves (AUC),1.5 +/- 0.4 ng/mL; P <.05) and areas under the plasma concentration-time curves (AUC) (23.2 +/- 16.8 vs.,Pharmacokinetics and pharmacodynamic action of budesonide in early- and late-stage primary biliary cirrhosis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12830002/),,23.2,238430,DB00741,Hydrocortisone
,12830002,AUC,"Equally, AUC of budesonide were significantly increased under a multiple dose regimen on day 21 (14.0 +/- 11.6 vs.",Pharmacokinetics and pharmacodynamic action of budesonide in early- and late-stage primary biliary cirrhosis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12830002/),,14.0,238431,DB00741,Hydrocortisone
,1600051,absolute bioavailability,"Comparison of these data with those obtained after intravenous administration enabled assessment of absolute bioavailability, which was 30.0 +/- 15.1% in healthy volunteers vs. 16.4 +/- 14.8% in patients (P = 0.09).",Pharmacokinetics and absolute rectal bioavailability of hydrocortisone acetate in distal colitis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1600051/),%,30.0,239722,DB00741,Hydrocortisone
,1600051,absolute bioavailability,"Comparison of these data with those obtained after intravenous administration enabled assessment of absolute bioavailability, which was 30.0 +/- 15.1% in healthy volunteers vs. 16.4 +/- 14.8% in patients (P = 0.09).",Pharmacokinetics and absolute rectal bioavailability of hydrocortisone acetate in distal colitis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1600051/),%,16.4,239723,DB00741,Hydrocortisone
,1600051,Maximal concentrations,"Maximal concentrations of hydrocortisone were also decreased in patients, 277 +/- 215 nmol/L vs. 610 +/- 334 nmol/L (P = 0.03).",Pharmacokinetics and absolute rectal bioavailability of hydrocortisone acetate in distal colitis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1600051/),[nM] / [l],277,239724,DB00741,Hydrocortisone
,1600051,Maximal concentrations,"Maximal concentrations of hydrocortisone were also decreased in patients, 277 +/- 215 nmol/L vs. 610 +/- 334 nmol/L (P = 0.03).",Pharmacokinetics and absolute rectal bioavailability of hydrocortisone acetate in distal colitis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1600051/),[nM] / [l],610,239725,DB00741,Hydrocortisone
,1600051,times to peak concentration,"There was a nonsignificant tendency to faster absorption of hydrocortisone in patients vs. healthy volunteers, as the times to peak concentration were, respectively, 2.5 +/- 1.2 h vs. 2.8 +/- 0.8 h (P = 0.64), and the mean absorption times were 1.96 +/- 1.45 h vs. 2.54 +/- 1.62 h (P = 0.46).",Pharmacokinetics and absolute rectal bioavailability of hydrocortisone acetate in distal colitis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1600051/),h,2.5,239726,DB00741,Hydrocortisone
,1600051,times to peak concentration,"There was a nonsignificant tendency to faster absorption of hydrocortisone in patients vs. healthy volunteers, as the times to peak concentration were, respectively, 2.5 +/- 1.2 h vs. 2.8 +/- 0.8 h (P = 0.64), and the mean absorption times were 1.96 +/- 1.45 h vs. 2.54 +/- 1.62 h (P = 0.46).",Pharmacokinetics and absolute rectal bioavailability of hydrocortisone acetate in distal colitis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1600051/),h,2.8,239727,DB00741,Hydrocortisone
,1600051,mean absorption times,"There was a nonsignificant tendency to faster absorption of hydrocortisone in patients vs. healthy volunteers, as the times to peak concentration were, respectively, 2.5 +/- 1.2 h vs. 2.8 +/- 0.8 h (P = 0.64), and the mean absorption times were 1.96 +/- 1.45 h vs. 2.54 +/- 1.62 h (P = 0.46).",Pharmacokinetics and absolute rectal bioavailability of hydrocortisone acetate in distal colitis. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1600051/),h,1.96,239728,DB00741,Hydrocortisone
,1600051,mean absorption times,"There was a nonsignificant tendency to faster absorption of hydrocortisone in patients vs. healthy volunteers, as the times to peak concentration were, respectively, 2.5 +/- 1.2 h vs. 2.8 +/- 0.8 h (P = 0.64), and the mean absorption times were 1.96 +/- 1.45 h vs. 2.54 +/- 1.62 h (P = 0.46).",Pharmacokinetics and absolute rectal bioavailability of hydrocortisone acetate in distal colitis. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1600051/),h,2.54,239729,DB00741,Hydrocortisone
,32652643,apparent clearance,"Cortisol was characterized by a one-compartment model with apparent clearance and volume of distribution estimated at 22.9 L/h/70 kg and 41.1 L/70 kg, respectively.",An integrated PK-PD model for cortisol and the 17-hydroxyprogesterone and androstenedione biomarkers in children with congenital adrenal hyperplasia. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32652643/),[l] / [70·h·kg],22.9,240366,DB00741,Hydrocortisone
,32652643,volume of distribution,"Cortisol was characterized by a one-compartment model with apparent clearance and volume of distribution estimated at 22.9 L/h/70 kg and 41.1 L/70 kg, respectively.",An integrated PK-PD model for cortisol and the 17-hydroxyprogesterone and androstenedione biomarkers in children with congenital adrenal hyperplasia. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32652643/),[l] / [70·kg],41.1,240367,DB00741,Hydrocortisone
,32652643,IC50,"The IC50 values of cortisol concentrations for cortisol, 17-hydroxyprogesterone and androstenedione were estimated to be 1.36, 0.45 and 0.75 μg/dL, respectively.",An integrated PK-PD model for cortisol and the 17-hydroxyprogesterone and androstenedione biomarkers in children with congenital adrenal hyperplasia. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32652643/),[μg] / [dl],1.36,240368,DB00741,Hydrocortisone
,32652643,IC50,"The IC50 values of cortisol concentrations for cortisol, 17-hydroxyprogesterone and androstenedione were estimated to be 1.36, 0.45 and 0.75 μg/dL, respectively.",An integrated PK-PD model for cortisol and the 17-hydroxyprogesterone and androstenedione biomarkers in children with congenital adrenal hyperplasia. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32652643/),[μg] / [dl],0.45,240369,DB00741,Hydrocortisone
,32652643,IC50,"The IC50 values of cortisol concentrations for cortisol, 17-hydroxyprogesterone and androstenedione were estimated to be 1.36, 0.45 and 0.75 μg/dL, respectively.",An integrated PK-PD model for cortisol and the 17-hydroxyprogesterone and androstenedione biomarkers in children with congenital adrenal hyperplasia. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32652643/),[μg] / [dl],0.75,240370,DB00741,Hydrocortisone
,32652643,Half-lives,"Half-lives of cortisol, 17-hydroxyprogesterone and androstenedione were 60, 47 and 77 minutes, respectively.",An integrated PK-PD model for cortisol and the 17-hydroxyprogesterone and androstenedione biomarkers in children with congenital adrenal hyperplasia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32652643/),min,60,240371,DB00741,Hydrocortisone
,32652643,Half-lives,"Half-lives of cortisol, 17-hydroxyprogesterone and androstenedione were 60, 47 and 77 minutes, respectively.",An integrated PK-PD model for cortisol and the 17-hydroxyprogesterone and androstenedione biomarkers in children with congenital adrenal hyperplasia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32652643/),min,47,240372,DB00741,Hydrocortisone
,32652643,Half-lives,"Half-lives of cortisol, 17-hydroxyprogesterone and androstenedione were 60, 47 and 77 minutes, respectively.",An integrated PK-PD model for cortisol and the 17-hydroxyprogesterone and androstenedione biomarkers in children with congenital adrenal hyperplasia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32652643/),min,77,240373,DB00741,Hydrocortisone
,2913280,metabolic clearance (Clm),The administration of hydrocortisone (HC; 75 mg/kg i.v. daily for 10 days) to rabbits significantly increased the metabolic clearance (Clm) of sulfamethazine (SMZ) from 1.92 +/- 0.05 to 2.85 +/- 0.06 liters/hr/kg (P less than 0.01).,In vivo mechanisms for the enhanced acetylation of sulfamethazine in the rabbit after hydrocortisone treatment. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2913280/),[l] / [h·kg],1.92,242217,DB00741,Hydrocortisone
,2913280,metabolic clearance (Clm),The administration of hydrocortisone (HC; 75 mg/kg i.v. daily for 10 days) to rabbits significantly increased the metabolic clearance (Clm) of sulfamethazine (SMZ) from 1.92 +/- 0.05 to 2.85 +/- 0.06 liters/hr/kg (P less than 0.01).,In vivo mechanisms for the enhanced acetylation of sulfamethazine in the rabbit after hydrocortisone treatment. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2913280/),[l] / [h·kg],2.85,242218,DB00741,Hydrocortisone
,2913280,availability,"However, p.o. availability of SMZ was similar before (0.42 +/- 0.06) and after (0.39 +/- 0.03) steroid treatment.",In vivo mechanisms for the enhanced acetylation of sulfamethazine in the rabbit after hydrocortisone treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2913280/),,0.42,242219,DB00741,Hydrocortisone
,2913280,availability,"However, p.o. availability of SMZ was similar before (0.42 +/- 0.06) and after (0.39 +/- 0.03) steroid treatment.",In vivo mechanisms for the enhanced acetylation of sulfamethazine in the rabbit after hydrocortisone treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2913280/),,0.39,242220,DB00741,Hydrocortisone
,2913280,total liver blood flow,"Furthermore, total liver blood flow as measured by the radioactive microsphere technique was increased (P less than 0.01) from 3.64 +/- 0.15 to 5.12 +/- 0.54 liters/hr/kg by HC treatment.",In vivo mechanisms for the enhanced acetylation of sulfamethazine in the rabbit after hydrocortisone treatment. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2913280/),[l] / [h·kg],3.64,242221,DB00741,Hydrocortisone
,2913280,total liver blood flow,"Furthermore, total liver blood flow as measured by the radioactive microsphere technique was increased (P less than 0.01) from 3.64 +/- 0.15 to 5.12 +/- 0.54 liters/hr/kg by HC treatment.",In vivo mechanisms for the enhanced acetylation of sulfamethazine in the rabbit after hydrocortisone treatment. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2913280/),[l] / [h·kg],5.12,242222,DB00741,Hydrocortisone
,2913280,intestinal extraction,These data predicted that intestinal extraction ranged from 0.11 to 0.15 in untreated rabbits and from 0.11 to 0.16 in HC-treated rabbits.,In vivo mechanisms for the enhanced acetylation of sulfamethazine in the rabbit after hydrocortisone treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2913280/),,0.11 to 0.15,242223,DB00741,Hydrocortisone
,2913280,intestinal extraction,These data predicted that intestinal extraction ranged from 0.11 to 0.15 in untreated rabbits and from 0.11 to 0.16 in HC-treated rabbits.,In vivo mechanisms for the enhanced acetylation of sulfamethazine in the rabbit after hydrocortisone treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2913280/),,0.11 to 0.16,242224,DB00741,Hydrocortisone
,2037709,AUC,"On days 1 and 22, respectively, the AUC (micrograms.hr/mL) (mean +/- SD) was 160.5 +/- 19.5 and 124 +/- 22.2 in group I, 152 +/- 25 and 152.8 +/- 33.9 in group II; the Kel (hr-1) was .0211 +/- .0030 and .0264 +/- .0040 in group I, .0219 +/- .0036 and .0216 +/- .0053 in group II.",Induction of fluconazole metabolism by rifampin: in vivo study in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2037709/),[h·μg] / [ml],160.5,243153,DB00741,Hydrocortisone
,2037709,AUC,"On days 1 and 22, respectively, the AUC (micrograms.hr/mL) (mean +/- SD) was 160.5 +/- 19.5 and 124 +/- 22.2 in group I, 152 +/- 25 and 152.8 +/- 33.9 in group II; the Kel (hr-1) was .0211 +/- .0030 and .0264 +/- .0040 in group I, .0219 +/- .0036 and .0216 +/- .0053 in group II.",Induction of fluconazole metabolism by rifampin: in vivo study in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2037709/),[h·μg] / [ml],124,243154,DB00741,Hydrocortisone
,2037709,AUC,"On days 1 and 22, respectively, the AUC (micrograms.hr/mL) (mean +/- SD) was 160.5 +/- 19.5 and 124 +/- 22.2 in group I, 152 +/- 25 and 152.8 +/- 33.9 in group II; the Kel (hr-1) was .0211 +/- .0030 and .0264 +/- .0040 in group I, .0219 +/- .0036 and .0216 +/- .0053 in group II.",Induction of fluconazole metabolism by rifampin: in vivo study in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2037709/),[h·μg] / [ml],152,243155,DB00741,Hydrocortisone
,2037709,AUC,"On days 1 and 22, respectively, the AUC (micrograms.hr/mL) (mean +/- SD) was 160.5 +/- 19.5 and 124 +/- 22.2 in group I, 152 +/- 25 and 152.8 +/- 33.9 in group II; the Kel (hr-1) was .0211 +/- .0030 and .0264 +/- .0040 in group I, .0219 +/- .0036 and .0216 +/- .0053 in group II.",Induction of fluconazole metabolism by rifampin: in vivo study in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2037709/),[h·μg] / [ml],152.8,243156,DB00741,Hydrocortisone
,2037709,Kel,"On days 1 and 22, respectively, the AUC (micrograms.hr/mL) (mean +/- SD) was 160.5 +/- 19.5 and 124 +/- 22.2 in group I, 152 +/- 25 and 152.8 +/- 33.9 in group II; the Kel (hr-1) was .0211 +/- .0030 and .0264 +/- .0040 in group I, .0219 +/- .0036 and .0216 +/- .0053 in group II.",Induction of fluconazole metabolism by rifampin: in vivo study in humans. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2037709/),1/[h],.0211,243157,DB00741,Hydrocortisone
,2037709,Kel,"On days 1 and 22, respectively, the AUC (micrograms.hr/mL) (mean +/- SD) was 160.5 +/- 19.5 and 124 +/- 22.2 in group I, 152 +/- 25 and 152.8 +/- 33.9 in group II; the Kel (hr-1) was .0211 +/- .0030 and .0264 +/- .0040 in group I, .0219 +/- .0036 and .0216 +/- .0053 in group II.",Induction of fluconazole metabolism by rifampin: in vivo study in humans. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2037709/),1/[h],.0264,243158,DB00741,Hydrocortisone
,2037709,Kel,"On days 1 and 22, respectively, the AUC (micrograms.hr/mL) (mean +/- SD) was 160.5 +/- 19.5 and 124 +/- 22.2 in group I, 152 +/- 25 and 152.8 +/- 33.9 in group II; the Kel (hr-1) was .0211 +/- .0030 and .0264 +/- .0040 in group I, .0219 +/- .0036 and .0216 +/- .0053 in group II.",Induction of fluconazole metabolism by rifampin: in vivo study in humans. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2037709/),1/[h],.0219,243159,DB00741,Hydrocortisone
,2037709,Kel,"On days 1 and 22, respectively, the AUC (micrograms.hr/mL) (mean +/- SD) was 160.5 +/- 19.5 and 124 +/- 22.2 in group I, 152 +/- 25 and 152.8 +/- 33.9 in group II; the Kel (hr-1) was .0211 +/- .0030 and .0264 +/- .0040 in group I, .0219 +/- .0036 and .0216 +/- .0053 in group II.",Induction of fluconazole metabolism by rifampin: in vivo study in humans. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2037709/),1/[h],.0216,243160,DB00741,Hydrocortisone
,7886801,clearance,"In the black patients, the mean clearance of methylprednisolone (206 +/- 70 ml/hr/kg) was significantly slower with a smaller volume of distribution (0.95 +/- 0.32 L/kg) when compared with the white group (327 +/- 129 ml/hr/kg, P = 0.03; volume of distribution = 1.33 +/- 0.27 L/kg, P = 0.015).","Methylprednisolone pharmacokinetics, cortisol response, and adverse effects in black and white renal transplant recipients. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7886801/),[ml] / [h·kg],206,243352,DB00741,Hydrocortisone
,7886801,volume of distribution,"In the black patients, the mean clearance of methylprednisolone (206 +/- 70 ml/hr/kg) was significantly slower with a smaller volume of distribution (0.95 +/- 0.32 L/kg) when compared with the white group (327 +/- 129 ml/hr/kg, P = 0.03; volume of distribution = 1.33 +/- 0.27 L/kg, P = 0.015).","Methylprednisolone pharmacokinetics, cortisol response, and adverse effects in black and white renal transplant recipients. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7886801/),[l] / [kg],0.95,243353,DB00741,Hydrocortisone
,7886801,volume of distribution,"In the black patients, the mean clearance of methylprednisolone (206 +/- 70 ml/hr/kg) was significantly slower with a smaller volume of distribution (0.95 +/- 0.32 L/kg) when compared with the white group (327 +/- 129 ml/hr/kg, P = 0.03; volume of distribution = 1.33 +/- 0.27 L/kg, P = 0.015).","Methylprednisolone pharmacokinetics, cortisol response, and adverse effects in black and white renal transplant recipients. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7886801/),[ml] / [h·kg],327,243354,DB00741,Hydrocortisone
,7886801,volume of distribution,"In the black patients, the mean clearance of methylprednisolone (206 +/- 70 ml/hr/kg) was significantly slower with a smaller volume of distribution (0.95 +/- 0.32 L/kg) when compared with the white group (327 +/- 129 ml/hr/kg, P = 0.03; volume of distribution = 1.33 +/- 0.27 L/kg, P = 0.015).","Methylprednisolone pharmacokinetics, cortisol response, and adverse effects in black and white renal transplant recipients. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7886801/),[l] / [kg],1.33,243355,DB00741,Hydrocortisone
,7886801,total cortisol,"Despite chronic methylprednisolone therapy, a definite 24-hr cortisol response pattern was noted in 15 of the 18 patients with a mean total cortisol AUC of 732 +/- 443 ng.hr/ml in blacks and 539 +/- 361 ng.hr/ml in whites (P = 0.17, black vs. white).","Methylprednisolone pharmacokinetics, cortisol response, and adverse effects in black and white renal transplant recipients. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7886801/),[h·ng] / [ml],732,243356,DB00741,Hydrocortisone
,7886801,AUC,"Despite chronic methylprednisolone therapy, a definite 24-hr cortisol response pattern was noted in 15 of the 18 patients with a mean total cortisol AUC of 732 +/- 443 ng.hr/ml in blacks and 539 +/- 361 ng.hr/ml in whites (P = 0.17, black vs. white).","Methylprednisolone pharmacokinetics, cortisol response, and adverse effects in black and white renal transplant recipients. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7886801/),[h·ng] / [ml],732,243357,DB00741,Hydrocortisone
,7886801,AUC,"Despite chronic methylprednisolone therapy, a definite 24-hr cortisol response pattern was noted in 15 of the 18 patients with a mean total cortisol AUC of 732 +/- 443 ng.hr/ml in blacks and 539 +/- 361 ng.hr/ml in whites (P = 0.17, black vs. white).","Methylprednisolone pharmacokinetics, cortisol response, and adverse effects in black and white renal transplant recipients. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7886801/),[h·ng] / [ml],539,243358,DB00741,Hydrocortisone
,7886801,suppression half-life,The mean cortisol suppression half-life was 4.31 +/- 1.54 hr in black recipients and 4.11 +/- 1.49 hr in whites (P = 0.48).,"Methylprednisolone pharmacokinetics, cortisol response, and adverse effects in black and white renal transplant recipients. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7886801/),h,4.31,243359,DB00741,Hydrocortisone
,7886801,suppression half-life,The mean cortisol suppression half-life was 4.31 +/- 1.54 hr in black recipients and 4.11 +/- 1.49 hr in whites (P = 0.48).,"Methylprednisolone pharmacokinetics, cortisol response, and adverse effects in black and white renal transplant recipients. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7886801/),h,4.11,243360,DB00741,Hydrocortisone
,7886801,AUC,The mean return cortisol AUC for the black patients was 327 +/- 279 ng.hr/ml and 370 +/- 207 ng.hr/ml for white patients (P = 0.28).,"Methylprednisolone pharmacokinetics, cortisol response, and adverse effects in black and white renal transplant recipients. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7886801/),[h·ng] / [ml],327,243361,DB00741,Hydrocortisone
,7886801,AUC,The mean return cortisol AUC for the black patients was 327 +/- 279 ng.hr/ml and 370 +/- 207 ng.hr/ml for white patients (P = 0.28).,"Methylprednisolone pharmacokinetics, cortisol response, and adverse effects in black and white renal transplant recipients. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7886801/),[h·ng] / [ml],370,243362,DB00741,Hydrocortisone
,7886801,nadir,"The serum cortisol nadir for black patients was 12.3 +/- 7.2 ng/ml, which was significantly higher than the cortisol nadir in white patients (6.4 +/- 4.4 ng/ml; P = 0.03).","Methylprednisolone pharmacokinetics, cortisol response, and adverse effects in black and white renal transplant recipients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7886801/),[ng] / [ml],12.3,243363,DB00741,Hydrocortisone
,7886801,nadir,"The serum cortisol nadir for black patients was 12.3 +/- 7.2 ng/ml, which was significantly higher than the cortisol nadir in white patients (6.4 +/- 4.4 ng/ml; P = 0.03).","Methylprednisolone pharmacokinetics, cortisol response, and adverse effects in black and white renal transplant recipients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7886801/),[ng] / [ml],6.4,243364,DB00741,Hydrocortisone
,7666079,duration of response,The median duration of response was 12 months.,Suramin and hydrocortisone: determining drug efficacy in androgen-independent prostate cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7666079/),month,12,246781,DB00741,Hydrocortisone
,27781421,area under the curve (AUC),"Following single doses of fosdagrocorat, the PK of PF-00251802 and its metabolite PF-04015475 were similar between Japanese (PF-00251802: mean area under the curve (AUC)<sub>inf</sub> (range across doses), 791 - 3,460 ng×h/mL; individual half-life (t<sub>1/2</sub>) 14.1 - 28.9 hours; PF-04015475: mean AUC<sub>inf</sub>, 395 - 1,740 ng×h/mL; individual t<sub>1/2</sub> 21.6 - 40.3 hours) and Western (PF-00251802: mean AUC<sub>inf</sub>, 750 - 4,150 ng×h/mL; individual t<sub>1/2</sub> 17.7 - 40.4 hours; PF-04015475: mean AUC<sub>inf</sub>, 394 - 2,160 ng×h/mL; individual t<sub>1/2</sub> 24.5 - 63.7 hours) subjects.","Pharmacokinetics and food-effect of fosdagrocorat (PF-04171327), a dissociated agonist of the glucocorticoid receptor, in healthy adult Caucasian and Japanese subjects . ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27781421/),[h·ng] / [ml],"791 - 3,460",247136,DB00741,Hydrocortisone
,27781421,half-life (t<sub>1/2<,"Following single doses of fosdagrocorat, the PK of PF-00251802 and its metabolite PF-04015475 were similar between Japanese (PF-00251802: mean area under the curve (AUC)<sub>inf</sub> (range across doses), 791 - 3,460 ng×h/mL; individual half-life (t<sub>1/2</sub>) 14.1 - 28.9 hours; PF-04015475: mean AUC<sub>inf</sub>, 395 - 1,740 ng×h/mL; individual t<sub>1/2</sub> 21.6 - 40.3 hours) and Western (PF-00251802: mean AUC<sub>inf</sub>, 750 - 4,150 ng×h/mL; individual t<sub>1/2</sub> 17.7 - 40.4 hours; PF-04015475: mean AUC<sub>inf</sub>, 394 - 2,160 ng×h/mL; individual t<sub>1/2</sub> 24.5 - 63.7 hours) subjects.","Pharmacokinetics and food-effect of fosdagrocorat (PF-04171327), a dissociated agonist of the glucocorticoid receptor, in healthy adult Caucasian and Japanese subjects . ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27781421/),h,14.1 - 28.9,247137,DB00741,Hydrocortisone
,27781421,AUC<sub>,"Following single doses of fosdagrocorat, the PK of PF-00251802 and its metabolite PF-04015475 were similar between Japanese (PF-00251802: mean area under the curve (AUC)<sub>inf</sub> (range across doses), 791 - 3,460 ng×h/mL; individual half-life (t<sub>1/2</sub>) 14.1 - 28.9 hours; PF-04015475: mean AUC<sub>inf</sub>, 395 - 1,740 ng×h/mL; individual t<sub>1/2</sub> 21.6 - 40.3 hours) and Western (PF-00251802: mean AUC<sub>inf</sub>, 750 - 4,150 ng×h/mL; individual t<sub>1/2</sub> 17.7 - 40.4 hours; PF-04015475: mean AUC<sub>inf</sub>, 394 - 2,160 ng×h/mL; individual t<sub>1/2</sub> 24.5 - 63.7 hours) subjects.","Pharmacokinetics and food-effect of fosdagrocorat (PF-04171327), a dissociated agonist of the glucocorticoid receptor, in healthy adult Caucasian and Japanese subjects . ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27781421/),[h·ng] / [ml],"395 - 1,740",247138,DB00741,Hydrocortisone
,27781421,t<sub>1/2</sub>,"Following single doses of fosdagrocorat, the PK of PF-00251802 and its metabolite PF-04015475 were similar between Japanese (PF-00251802: mean area under the curve (AUC)<sub>inf</sub> (range across doses), 791 - 3,460 ng×h/mL; individual half-life (t<sub>1/2</sub>) 14.1 - 28.9 hours; PF-04015475: mean AUC<sub>inf</sub>, 395 - 1,740 ng×h/mL; individual t<sub>1/2</sub> 21.6 - 40.3 hours) and Western (PF-00251802: mean AUC<sub>inf</sub>, 750 - 4,150 ng×h/mL; individual t<sub>1/2</sub> 17.7 - 40.4 hours; PF-04015475: mean AUC<sub>inf</sub>, 394 - 2,160 ng×h/mL; individual t<sub>1/2</sub> 24.5 - 63.7 hours) subjects.","Pharmacokinetics and food-effect of fosdagrocorat (PF-04171327), a dissociated agonist of the glucocorticoid receptor, in healthy adult Caucasian and Japanese subjects . ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27781421/),h,21.6 - 40.3,247139,DB00741,Hydrocortisone
,27781421,AUC<sub>,"Following single doses of fosdagrocorat, the PK of PF-00251802 and its metabolite PF-04015475 were similar between Japanese (PF-00251802: mean area under the curve (AUC)<sub>inf</sub> (range across doses), 791 - 3,460 ng×h/mL; individual half-life (t<sub>1/2</sub>) 14.1 - 28.9 hours; PF-04015475: mean AUC<sub>inf</sub>, 395 - 1,740 ng×h/mL; individual t<sub>1/2</sub> 21.6 - 40.3 hours) and Western (PF-00251802: mean AUC<sub>inf</sub>, 750 - 4,150 ng×h/mL; individual t<sub>1/2</sub> 17.7 - 40.4 hours; PF-04015475: mean AUC<sub>inf</sub>, 394 - 2,160 ng×h/mL; individual t<sub>1/2</sub> 24.5 - 63.7 hours) subjects.","Pharmacokinetics and food-effect of fosdagrocorat (PF-04171327), a dissociated agonist of the glucocorticoid receptor, in healthy adult Caucasian and Japanese subjects . ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27781421/),[h·ng] / [ml],"750 - 4,150",247140,DB00741,Hydrocortisone
,27781421,t<sub>1/2<,"Following single doses of fosdagrocorat, the PK of PF-00251802 and its metabolite PF-04015475 were similar between Japanese (PF-00251802: mean area under the curve (AUC)<sub>inf</sub> (range across doses), 791 - 3,460 ng×h/mL; individual half-life (t<sub>1/2</sub>) 14.1 - 28.9 hours; PF-04015475: mean AUC<sub>inf</sub>, 395 - 1,740 ng×h/mL; individual t<sub>1/2</sub> 21.6 - 40.3 hours) and Western (PF-00251802: mean AUC<sub>inf</sub>, 750 - 4,150 ng×h/mL; individual t<sub>1/2</sub> 17.7 - 40.4 hours; PF-04015475: mean AUC<sub>inf</sub>, 394 - 2,160 ng×h/mL; individual t<sub>1/2</sub> 24.5 - 63.7 hours) subjects.","Pharmacokinetics and food-effect of fosdagrocorat (PF-04171327), a dissociated agonist of the glucocorticoid receptor, in healthy adult Caucasian and Japanese subjects . ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27781421/),h,17.7 - 40.4,247141,DB00741,Hydrocortisone
,27781421,AUC<sub>,"Following single doses of fosdagrocorat, the PK of PF-00251802 and its metabolite PF-04015475 were similar between Japanese (PF-00251802: mean area under the curve (AUC)<sub>inf</sub> (range across doses), 791 - 3,460 ng×h/mL; individual half-life (t<sub>1/2</sub>) 14.1 - 28.9 hours; PF-04015475: mean AUC<sub>inf</sub>, 395 - 1,740 ng×h/mL; individual t<sub>1/2</sub> 21.6 - 40.3 hours) and Western (PF-00251802: mean AUC<sub>inf</sub>, 750 - 4,150 ng×h/mL; individual t<sub>1/2</sub> 17.7 - 40.4 hours; PF-04015475: mean AUC<sub>inf</sub>, 394 - 2,160 ng×h/mL; individual t<sub>1/2</sub> 24.5 - 63.7 hours) subjects.","Pharmacokinetics and food-effect of fosdagrocorat (PF-04171327), a dissociated agonist of the glucocorticoid receptor, in healthy adult Caucasian and Japanese subjects . ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27781421/),,394 - 2,247142,DB00741,Hydrocortisone
,9131947,Systemic availability,"Systemic availability, mainly attributable to pulmonary deposition, was 15.6 [13.6-18.0]% of the nominal dose.",Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9131947/),%,15.6,247414,DB00741,Hydrocortisone
,16988492,peak plasma progesterone concentrations,"The means (+/- SE) of the peak plasma progesterone concentrations after the 3, 6, 12 and 25 IU ACTH challenge tests were 0.6 +/- 0.1, 1.3 +/- 0.4, 1.5 +/- 0.3 and 2.4 +/- 0.3 ng/ml, respectively.",Plasma cortisol and progesterone responses to low doses of adrenocorticotropic hormone in ovariectmized lactating cows. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16988492/),[ng] / [ml],0.6,248400,DB00741,Hydrocortisone
,16988492,peak plasma progesterone concentrations,"The means (+/- SE) of the peak plasma progesterone concentrations after the 3, 6, 12 and 25 IU ACTH challenge tests were 0.6 +/- 0.1, 1.3 +/- 0.4, 1.5 +/- 0.3 and 2.4 +/- 0.3 ng/ml, respectively.",Plasma cortisol and progesterone responses to low doses of adrenocorticotropic hormone in ovariectmized lactating cows. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16988492/),[ng] / [ml],1.3,248401,DB00741,Hydrocortisone
,16988492,peak plasma progesterone concentrations,"The means (+/- SE) of the peak plasma progesterone concentrations after the 3, 6, 12 and 25 IU ACTH challenge tests were 0.6 +/- 0.1, 1.3 +/- 0.4, 1.5 +/- 0.3 and 2.4 +/- 0.3 ng/ml, respectively.",Plasma cortisol and progesterone responses to low doses of adrenocorticotropic hormone in ovariectmized lactating cows. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16988492/),[ng] / [ml],1.5,248402,DB00741,Hydrocortisone
,16988492,peak plasma progesterone concentrations,"The means (+/- SE) of the peak plasma progesterone concentrations after the 3, 6, 12 and 25 IU ACTH challenge tests were 0.6 +/- 0.1, 1.3 +/- 0.4, 1.5 +/- 0.3 and 2.4 +/- 0.3 ng/ml, respectively.",Plasma cortisol and progesterone responses to low doses of adrenocorticotropic hormone in ovariectmized lactating cows. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16988492/),[ng] / [ml],2.4,248403,DB00741,Hydrocortisone
,16988492,peak plasma cortisol concentrations,"The means of the peak plasma cortisol concentrations in the 3 cows after the ACTH challenge were 14.0 +/- 1.5, 17.0 +/- 2.5, 23.3 +/- 3.0, and 33.3 +/- 7.0 ng/ml, respectively.",Plasma cortisol and progesterone responses to low doses of adrenocorticotropic hormone in ovariectmized lactating cows. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16988492/),[ng] / [ml],14.0,248404,DB00741,Hydrocortisone
,16988492,peak plasma cortisol concentrations,"The means of the peak plasma cortisol concentrations in the 3 cows after the ACTH challenge were 14.0 +/- 1.5, 17.0 +/- 2.5, 23.3 +/- 3.0, and 33.3 +/- 7.0 ng/ml, respectively.",Plasma cortisol and progesterone responses to low doses of adrenocorticotropic hormone in ovariectmized lactating cows. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16988492/),[ng] / [ml],17.0,248405,DB00741,Hydrocortisone
,16988492,peak plasma cortisol concentrations,"The means of the peak plasma cortisol concentrations in the 3 cows after the ACTH challenge were 14.0 +/- 1.5, 17.0 +/- 2.5, 23.3 +/- 3.0, and 33.3 +/- 7.0 ng/ml, respectively.",Plasma cortisol and progesterone responses to low doses of adrenocorticotropic hormone in ovariectmized lactating cows. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16988492/),[ng] / [ml],23.3,248406,DB00741,Hydrocortisone
,16988492,peak plasma cortisol concentrations,"The means of the peak plasma cortisol concentrations in the 3 cows after the ACTH challenge were 14.0 +/- 1.5, 17.0 +/- 2.5, 23.3 +/- 3.0, and 33.3 +/- 7.0 ng/ml, respectively.",Plasma cortisol and progesterone responses to low doses of adrenocorticotropic hormone in ovariectmized lactating cows. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16988492/),[ng] / [ml],33.3,248407,DB00741,Hydrocortisone
,568534,t 1/2s,Salivary aminopyrine t 1/2s were approximately 50% longer at 8 P.M. (2.1 +/- 0.7 hr) than at 8 A.M. (1.4 +/- 0.3 hr).,Diurnal rhythms of aminopyrine metabolism: failure to sleep deprivation to affect them. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/568534/),h,2.1,248581,DB00741,Hydrocortisone
,568534,t 1/2s,Salivary aminopyrine t 1/2s were approximately 50% longer at 8 P.M. (2.1 +/- 0.7 hr) than at 8 A.M. (1.4 +/- 0.3 hr).,Diurnal rhythms of aminopyrine metabolism: failure to sleep deprivation to affect them. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/568534/),h,1.4,248582,DB00741,Hydrocortisone
,568534,metabolic clearance rates,Mean aminopyrine metabolic clearance rates decreased 20% from 8 A.M. (418.2 +/- 152.0 ml/min) to 8 P.M. (335.3 +/- 107.6 ml/min).,Diurnal rhythms of aminopyrine metabolism: failure to sleep deprivation to affect them. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/568534/),[ml] / [min],418.2,248583,DB00741,Hydrocortisone
,568534,metabolic clearance rates,Mean aminopyrine metabolic clearance rates decreased 20% from 8 A.M. (418.2 +/- 152.0 ml/min) to 8 P.M. (335.3 +/- 107.6 ml/min).,Diurnal rhythms of aminopyrine metabolism: failure to sleep deprivation to affect them. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/568534/),[ml] / [min],335.3,248584,DB00741,Hydrocortisone
,568534,apparent volumes of distribution (aVd),There were nonsignificant changes in mean aminopyrine apparent volumes of distribution (aVd) which increased only slightly from 53.1 +/- 20.6 L at 8 A.M. to 59.7 +/- 26.5 L at 8 P.M.,Diurnal rhythms of aminopyrine metabolism: failure to sleep deprivation to affect them. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/568534/),l,53.1,248585,DB00741,Hydrocortisone
,568534,apparent volumes of distribution (aVd),There were nonsignificant changes in mean aminopyrine apparent volumes of distribution (aVd) which increased only slightly from 53.1 +/- 20.6 L at 8 A.M. to 59.7 +/- 26.5 L at 8 P.M.,Diurnal rhythms of aminopyrine metabolism: failure to sleep deprivation to affect them. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/568534/),l,59.7,248586,DB00741,Hydrocortisone
,42427,half-life,"The elimination of diazepam was significantly altered having a half-life of 37 h before and 18 h afterwards combined with a significant increase in total body clearance after the induction period, although the volume of distribution remained unaltered.",The effect of enzyme induction on diazepam metabolism in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/42427/),h,37,249060,DB00741,Hydrocortisone
,42427,half-life,"The elimination of diazepam was significantly altered having a half-life of 37 h before and 18 h afterwards combined with a significant increase in total body clearance after the induction period, although the volume of distribution remained unaltered.",The effect of enzyme induction on diazepam metabolism in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/42427/),h,18,249061,DB00741,Hydrocortisone
,42427,half-life,"The formation of the main metabolite N-desmethyldiazepam was not changed, but its elimination was increased having a half-life of 139 or 58 h respectively.",The effect of enzyme induction on diazepam metabolism in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/42427/),h,139,249062,DB00741,Hydrocortisone
,42427,half-life,"The formation of the main metabolite N-desmethyldiazepam was not changed, but its elimination was increased having a half-life of 139 or 58 h respectively.",The effect of enzyme induction on diazepam metabolism in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/42427/),h,58,249063,DB00741,Hydrocortisone
,16148423,apparent clearance,"The mean PK parameters estimates of apparent clearance and apparent volume of distribution were 302 L/h and 1310 L, respectively.",Model-based covariate pharmacokinetic analysis and lack of cortisol suppression by the new inhaled corticosteroid ciclesonide using a novel cortisol release model. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16148423/),[l] / [h],302,250366,DB00741,Hydrocortisone
,16148423,apparent volume of distribution,"The mean PK parameters estimates of apparent clearance and apparent volume of distribution were 302 L/h and 1310 L, respectively.",Model-based covariate pharmacokinetic analysis and lack of cortisol suppression by the new inhaled corticosteroid ciclesonide using a novel cortisol release model. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16148423/),l,1310,250367,DB00741,Hydrocortisone
,8250719,maximum concentration,The mean of maximum concentration of HCS was 26.38 mg/L.,[Pharmacokinetics and pharmacodynamics of hydrocortisone in asthmatic children]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8250719/),[mg] / [l],26.38,250413,DB00741,Hydrocortisone
,8250719,half-life,The concentration of HCS decreased rapidly with a half-life of 0.09 hr (5.38 min).,[Pharmacokinetics and pharmacodynamics of hydrocortisone in asthmatic children]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8250719/),h,0.09,250414,DB00741,Hydrocortisone
,8250719,half-life,"The concentration of hydrocortisone reached to a peak value of 4.96 mg/L after 10 min, and then decreased with a half-life of 1.24 hour.",[Pharmacokinetics and pharmacodynamics of hydrocortisone in asthmatic children]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8250719/),h,1.24,250415,DB00741,Hydrocortisone
,1564126,area under concentration,"For example, for free prednisolone, the intravenous area under concentration was 1,144 +/- 195 ng.h/mL and 1,244 +/- 140 ng.h/mL, and the systemic availability after oral prednisone was 53 +/- 10% and 51 +/- 12% with placebo and tenidap, respectively.",Effect of the anti-inflammatory agent tenidap on the pharmacokinetics and pharmacodynamics of prednisolone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1564126/),[h·ng] / [ml],"1,144",251239,DB00741,Hydrocortisone
,1564126,area under concentration,"For example, for free prednisolone, the intravenous area under concentration was 1,144 +/- 195 ng.h/mL and 1,244 +/- 140 ng.h/mL, and the systemic availability after oral prednisone was 53 +/- 10% and 51 +/- 12% with placebo and tenidap, respectively.",Effect of the anti-inflammatory agent tenidap on the pharmacokinetics and pharmacodynamics of prednisolone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1564126/),[h·ng] / [ml],"1,244",251240,DB00741,Hydrocortisone
,1564126,systemic availability,"For example, for free prednisolone, the intravenous area under concentration was 1,144 +/- 195 ng.h/mL and 1,244 +/- 140 ng.h/mL, and the systemic availability after oral prednisone was 53 +/- 10% and 51 +/- 12% with placebo and tenidap, respectively.",Effect of the anti-inflammatory agent tenidap on the pharmacokinetics and pharmacodynamics of prednisolone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1564126/),%,53,251241,DB00741,Hydrocortisone
,1564126,systemic availability,"For example, for free prednisolone, the intravenous area under concentration was 1,144 +/- 195 ng.h/mL and 1,244 +/- 140 ng.h/mL, and the systemic availability after oral prednisone was 53 +/- 10% and 51 +/- 12% with placebo and tenidap, respectively.",Effect of the anti-inflammatory agent tenidap on the pharmacokinetics and pharmacodynamics of prednisolone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1564126/),%,51,251242,DB00741,Hydrocortisone
,1564126,renal clearance,"The renal clearance of prednisolone was significantly reduced after tenidap pretreatment, however (from 143 to 77 mL/min/1.73 m2).",Effect of the anti-inflammatory agent tenidap on the pharmacokinetics and pharmacodynamics of prednisolone. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1564126/),[ml] / [1.73·m2·min],143 to 77,251243,DB00741,Hydrocortisone
,8829484,peak value,A peak value of 196.6 ng ml-1 cortisol-d5 was observed 30 min after cortisol-d5 administration.,Pharmacokinetic studies of cortisol after oral administration of deuterium-labelled cortisol to a normal human subject. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8829484/),[ng] / [ml],196.6,252205,DB00741,Hydrocortisone
,8829484,peak value,"The peak value of cortisone-d5 was 15.5 ng ml-1 40 min after cortisol-d5 administration, and thereafter cortisone-d5 declined in parallel with the slower decline phase of cortisol-d5.",Pharmacokinetic studies of cortisol after oral administration of deuterium-labelled cortisol to a normal human subject. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8829484/),[ng] / [ml],15.5,252206,DB00741,Hydrocortisone
,8829484,plasma concentrations,The plasma concentrations fell as low as 26.9 ng ml-1 for cortisol-d5 and 4.6 ng ml-1 for cortisone-d5 4 h after cortisol-d5 administration.,Pharmacokinetic studies of cortisol after oral administration of deuterium-labelled cortisol to a normal human subject. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8829484/),[ng] / [ml],26.9,252207,DB00741,Hydrocortisone
,8829484,plasma concentrations,The plasma concentrations fell as low as 26.9 ng ml-1 for cortisol-d5 and 4.6 ng ml-1 for cortisone-d5 4 h after cortisol-d5 administration.,Pharmacokinetic studies of cortisol after oral administration of deuterium-labelled cortisol to a normal human subject. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8829484/),[ng] / [ml],4.6,252208,DB00741,Hydrocortisone
,6290048,metabolic clearance rate,The metabolic clearance rate for five subjects was 799 +/- 89 liters/24 hr (470 +/- 47 liters/24 hr/sq m) before and 751 +/- 93 liters/24 hr (444 +/- 57 liters/24 hr/sq m) during therapy.,Effects of aminoglutethimide on delta 5-androstenediol metabolism in postmenopausal women with breast cancer. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6290048/),[l] / [24·h],799,252501,DB00741,Hydrocortisone
,6290048,metabolic clearance rate,The metabolic clearance rate for five subjects was 799 +/- 89 liters/24 hr (470 +/- 47 liters/24 hr/sq m) before and 751 +/- 93 liters/24 hr (444 +/- 57 liters/24 hr/sq m) during therapy.,Effects of aminoglutethimide on delta 5-androstenediol metabolism in postmenopausal women with breast cancer. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6290048/),[l] / [24·h·m·sq],470,252502,DB00741,Hydrocortisone
,6290048,metabolic clearance rate,The metabolic clearance rate for five subjects was 799 +/- 89 liters/24 hr (470 +/- 47 liters/24 hr/sq m) before and 751 +/- 93 liters/24 hr (444 +/- 57 liters/24 hr/sq m) during therapy.,Effects of aminoglutethimide on delta 5-androstenediol metabolism in postmenopausal women with breast cancer. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6290048/),[l] / [24·h],751,252503,DB00741,Hydrocortisone
,6290048,metabolic clearance rate,The metabolic clearance rate for five subjects was 799 +/- 89 liters/24 hr (470 +/- 47 liters/24 hr/sq m) before and 751 +/- 93 liters/24 hr (444 +/- 57 liters/24 hr/sq m) during therapy.,Effects of aminoglutethimide on delta 5-androstenediol metabolism in postmenopausal women with breast cancer. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6290048/),[l] / [24·h·m·sq],444,252504,DB00741,Hydrocortisone
,11422002,area under the methylprednisolone concentration-time curve,Itraconazole increased the mean area under the methylprednisolone concentration-time curve from 2773 ng ml-1 h to 7011 ng ml-1 h (P < 0.001) and the elimination half-life from 3.2 h to 5.5 h (P < 0.001).,Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11422002/),[h·ng] / [ml],2773,252860,DB00741,Hydrocortisone
,11422002,area under the methylprednisolone concentration-time curve,Itraconazole increased the mean area under the methylprednisolone concentration-time curve from 2773 ng ml-1 h to 7011 ng ml-1 h (P < 0.001) and the elimination half-life from 3.2 h to 5.5 h (P < 0.001).,Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11422002/),[h·ng] / [ml],7011,252861,DB00741,Hydrocortisone
,11422002,elimination half-life,Itraconazole increased the mean area under the methylprednisolone concentration-time curve from 2773 ng ml-1 h to 7011 ng ml-1 h (P < 0.001) and the elimination half-life from 3.2 h to 5.5 h (P < 0.001).,Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11422002/),h,3.2,252862,DB00741,Hydrocortisone
,11422002,elimination half-life,Itraconazole increased the mean area under the methylprednisolone concentration-time curve from 2773 ng ml-1 h to 7011 ng ml-1 h (P < 0.001) and the elimination half-life from 3.2 h to 5.5 h (P < 0.001).,Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11422002/),h,5.5,252863,DB00741,Hydrocortisone
,16988208,highest observed concentration in plasma (C(max)),"After repeated administration of H perforatum, highest observed concentration in plasma (C(max)) and area under the concentration-time curve (AUC) were significantly decreased for ivabradine (32.7 +/- 16.6 vs 15.4 +/- 7.0 ng/mL, P < .01; 114 +/- 39.1 vs 43.7 +/- 12.0 ng x h/mL, P < .01, respectively), and for S18982 (C(max), 6.8 +/- 3.7 vs 5.1 +/- 2.0 ng/mL, P < .05; AUC, 56.2 +/- 23.4 vs 38.3 +/- 25.1 ng x h/mL, P < .01).","Effects of Hypericum perforatum on ivabradine pharmacokinetics in healthy volunteers: an open-label, pharmacokinetic interaction clinical trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16988208/),[ng] / [ml],32.7,253231,DB00741,Hydrocortisone
,16988208,highest observed concentration in plasma (C(max)),"After repeated administration of H perforatum, highest observed concentration in plasma (C(max)) and area under the concentration-time curve (AUC) were significantly decreased for ivabradine (32.7 +/- 16.6 vs 15.4 +/- 7.0 ng/mL, P < .01; 114 +/- 39.1 vs 43.7 +/- 12.0 ng x h/mL, P < .01, respectively), and for S18982 (C(max), 6.8 +/- 3.7 vs 5.1 +/- 2.0 ng/mL, P < .05; AUC, 56.2 +/- 23.4 vs 38.3 +/- 25.1 ng x h/mL, P < .01).","Effects of Hypericum perforatum on ivabradine pharmacokinetics in healthy volunteers: an open-label, pharmacokinetic interaction clinical trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16988208/),[ng] / [ml],15.4,253232,DB00741,Hydrocortisone
,16988208,area under the concentration-time curve (AUC),"After repeated administration of H perforatum, highest observed concentration in plasma (C(max)) and area under the concentration-time curve (AUC) were significantly decreased for ivabradine (32.7 +/- 16.6 vs 15.4 +/- 7.0 ng/mL, P < .01; 114 +/- 39.1 vs 43.7 +/- 12.0 ng x h/mL, P < .01, respectively), and for S18982 (C(max), 6.8 +/- 3.7 vs 5.1 +/- 2.0 ng/mL, P < .05; AUC, 56.2 +/- 23.4 vs 38.3 +/- 25.1 ng x h/mL, P < .01).","Effects of Hypericum perforatum on ivabradine pharmacokinetics in healthy volunteers: an open-label, pharmacokinetic interaction clinical trial. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16988208/),[h·ng] / [ml],114,253233,DB00741,Hydrocortisone
,16988208,area under the concentration-time curve (AUC),"After repeated administration of H perforatum, highest observed concentration in plasma (C(max)) and area under the concentration-time curve (AUC) were significantly decreased for ivabradine (32.7 +/- 16.6 vs 15.4 +/- 7.0 ng/mL, P < .01; 114 +/- 39.1 vs 43.7 +/- 12.0 ng x h/mL, P < .01, respectively), and for S18982 (C(max), 6.8 +/- 3.7 vs 5.1 +/- 2.0 ng/mL, P < .05; AUC, 56.2 +/- 23.4 vs 38.3 +/- 25.1 ng x h/mL, P < .01).","Effects of Hypericum perforatum on ivabradine pharmacokinetics in healthy volunteers: an open-label, pharmacokinetic interaction clinical trial. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16988208/),[h·ng] / [ml],43.7,253234,DB00741,Hydrocortisone
,16988208,C(max),"After repeated administration of H perforatum, highest observed concentration in plasma (C(max)) and area under the concentration-time curve (AUC) were significantly decreased for ivabradine (32.7 +/- 16.6 vs 15.4 +/- 7.0 ng/mL, P < .01; 114 +/- 39.1 vs 43.7 +/- 12.0 ng x h/mL, P < .01, respectively), and for S18982 (C(max), 6.8 +/- 3.7 vs 5.1 +/- 2.0 ng/mL, P < .05; AUC, 56.2 +/- 23.4 vs 38.3 +/- 25.1 ng x h/mL, P < .01).","Effects of Hypericum perforatum on ivabradine pharmacokinetics in healthy volunteers: an open-label, pharmacokinetic interaction clinical trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16988208/),[ng] / [ml],6.8,253235,DB00741,Hydrocortisone
,16988208,C(max),"After repeated administration of H perforatum, highest observed concentration in plasma (C(max)) and area under the concentration-time curve (AUC) were significantly decreased for ivabradine (32.7 +/- 16.6 vs 15.4 +/- 7.0 ng/mL, P < .01; 114 +/- 39.1 vs 43.7 +/- 12.0 ng x h/mL, P < .01, respectively), and for S18982 (C(max), 6.8 +/- 3.7 vs 5.1 +/- 2.0 ng/mL, P < .05; AUC, 56.2 +/- 23.4 vs 38.3 +/- 25.1 ng x h/mL, P < .01).","Effects of Hypericum perforatum on ivabradine pharmacokinetics in healthy volunteers: an open-label, pharmacokinetic interaction clinical trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16988208/),[ng] / [ml],5.1,253236,DB00741,Hydrocortisone
,16988208,AUC,"After repeated administration of H perforatum, highest observed concentration in plasma (C(max)) and area under the concentration-time curve (AUC) were significantly decreased for ivabradine (32.7 +/- 16.6 vs 15.4 +/- 7.0 ng/mL, P < .01; 114 +/- 39.1 vs 43.7 +/- 12.0 ng x h/mL, P < .01, respectively), and for S18982 (C(max), 6.8 +/- 3.7 vs 5.1 +/- 2.0 ng/mL, P < .05; AUC, 56.2 +/- 23.4 vs 38.3 +/- 25.1 ng x h/mL, P < .01).","Effects of Hypericum perforatum on ivabradine pharmacokinetics in healthy volunteers: an open-label, pharmacokinetic interaction clinical trial. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16988208/),[h·ng] / [ml],56.2,253237,DB00741,Hydrocortisone
,16988208,AUC,"After repeated administration of H perforatum, highest observed concentration in plasma (C(max)) and area under the concentration-time curve (AUC) were significantly decreased for ivabradine (32.7 +/- 16.6 vs 15.4 +/- 7.0 ng/mL, P < .01; 114 +/- 39.1 vs 43.7 +/- 12.0 ng x h/mL, P < .01, respectively), and for S18982 (C(max), 6.8 +/- 3.7 vs 5.1 +/- 2.0 ng/mL, P < .05; AUC, 56.2 +/- 23.4 vs 38.3 +/- 25.1 ng x h/mL, P < .01).","Effects of Hypericum perforatum on ivabradine pharmacokinetics in healthy volunteers: an open-label, pharmacokinetic interaction clinical trial. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16988208/),[h·ng] / [ml],38.3,253238,DB00741,Hydrocortisone
,15726657,AUC,"Metabolite formation was enhanced by rifampicin, but not by UDCA (e.g., AUC(16alpha-hydroxyprednisolone)/AUC(budesonide) in patients: baseline, 8.6 +/- 3.9; UDCA, 10.7 +/- 7.1; rifampicin, 527.0 +/- 248.7).",No relevant effect of ursodeoxycholic acid on cytochrome P450 3A metabolism in primary biliary cirrhosis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15726657/),,8.6,253862,DB00741,Hydrocortisone
,15726657,AUC,"Metabolite formation was enhanced by rifampicin, but not by UDCA (e.g., AUC(16alpha-hydroxyprednisolone)/AUC(budesonide) in patients: baseline, 8.6 +/- 3.9; UDCA, 10.7 +/- 7.1; rifampicin, 527.0 +/- 248.7).",No relevant effect of ursodeoxycholic acid on cytochrome P450 3A metabolism in primary biliary cirrhosis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15726657/),,10.7,253863,DB00741,Hydrocortisone
,15726657,AUC,"Metabolite formation was enhanced by rifampicin, but not by UDCA (e.g., AUC(16alpha-hydroxyprednisolone)/AUC(budesonide) in patients: baseline, 8.6 +/- 3.9; UDCA, 10.7 +/- 7.1; rifampicin, 527.0 +/- 248.7).",No relevant effect of ursodeoxycholic acid on cytochrome P450 3A metabolism in primary biliary cirrhosis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15726657/),,527.0,253864,DB00741,Hydrocortisone
,9505980,Maximum concentration,Maximum concentration levels of 3 to 9 ng/mL of flunisolide were observed after 0.2 to 0.3 hours for all of the investigated doses.,Pharmacokinetic/pharmacodynamic evaluation of systemic effects of flunisolide after inhalation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9505980/),[ng] / [ml],3 to 9,254834,DB00741,Hydrocortisone
,9505980,terminal half-life,The terminal half-life ranged from 1.3 to 1.7 hours.,Pharmacokinetic/pharmacodynamic evaluation of systemic effects of flunisolide after inhalation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9505980/),h,1.3 to 1.7,254835,DB00741,Hydrocortisone
,7641363,area under the plasma active renin versus time curve (0 to 24 hours),"After combined losartan-captopril administration, the area under the plasma active renin versus time curve (0 to 24 hours) was significantly increased when compared with either losartan or captopril alone (6404 +/- 2961 pg.h.mL-1 versus 3105 +/- 1461 pg.h.mL-1 versus 2092 +/- 867 pg.h.mL-1, respectively, P < .05).",Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7641363/),[h·pg] / [ml],6404,255254,DB00741,Hydrocortisone
,7641363,area under the plasma active renin versus time curve (0 to 24 hours),"After combined losartan-captopril administration, the area under the plasma active renin versus time curve (0 to 24 hours) was significantly increased when compared with either losartan or captopril alone (6404 +/- 2961 pg.h.mL-1 versus 3105 +/- 1461 pg.h.mL-1 versus 2092 +/- 867 pg.h.mL-1, respectively, P < .05).",Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7641363/),[h·pg] / [ml],3105,255255,DB00741,Hydrocortisone
,7641363,area under the plasma active renin versus time curve (0 to 24 hours),"After combined losartan-captopril administration, the area under the plasma active renin versus time curve (0 to 24 hours) was significantly increased when compared with either losartan or captopril alone (6404 +/- 2961 pg.h.mL-1 versus 3105 +/- 1461 pg.h.mL-1 versus 2092 +/- 867 pg.h.mL-1, respectively, P < .05).",Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7641363/),[h·pg] / [ml],2092,255256,DB00741,Hydrocortisone
,7097848,half-times of elimination,"The half-times of elimination were similar; 335 and 291 min, respectively, for DXM alcohol and DXM 21 isonicotinate.",Dexamethasone in cattle: pharmacokinetics and action on the adrenal gland. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7097848/),min,335,256185,DB00741,Hydrocortisone
,7097848,half-times of elimination,"The half-times of elimination were similar; 335 and 291 min, respectively, for DXM alcohol and DXM 21 isonicotinate.",Dexamethasone in cattle: pharmacokinetics and action on the adrenal gland. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7097848/),min,291,256186,DB00741,Hydrocortisone
,7097848,bioavailability,Peak plasma concentrations were reached at 3 to 4 h post injection and bioavailability was approximately 70%.,Dexamethasone in cattle: pharmacokinetics and action on the adrenal gland. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7097848/),%,70,256187,DB00741,Hydrocortisone
,15968885,Cmax,"In the single dose administration, Cmax and mean AUC0-infinity linearly increased up to 63,167 ng/ml and 311,960 ng x h/ml at the 800 mg dose level, respectively; tmax and t1/2 ranged from 2 - 3 hours and from 9.5 - 15.5 hours, respectively.","Safety, tolerability and pharmacokinetics of oral S-3304, a novel matrix metalloproteinase inhibitor, in single and multiple dose escalation studies in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15968885/),[ng] / [ml],"63,167",258530,DB00741,Hydrocortisone
,15968885,AUC0-infinity,"In the single dose administration, Cmax and mean AUC0-infinity linearly increased up to 63,167 ng/ml and 311,960 ng x h/ml at the 800 mg dose level, respectively; tmax and t1/2 ranged from 2 - 3 hours and from 9.5 - 15.5 hours, respectively.","Safety, tolerability and pharmacokinetics of oral S-3304, a novel matrix metalloproteinase inhibitor, in single and multiple dose escalation studies in healthy volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15968885/),[h·ng] / [ml],"311,960",258531,DB00741,Hydrocortisone
,15968885,tmax,"In the single dose administration, Cmax and mean AUC0-infinity linearly increased up to 63,167 ng/ml and 311,960 ng x h/ml at the 800 mg dose level, respectively; tmax and t1/2 ranged from 2 - 3 hours and from 9.5 - 15.5 hours, respectively.","Safety, tolerability and pharmacokinetics of oral S-3304, a novel matrix metalloproteinase inhibitor, in single and multiple dose escalation studies in healthy volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15968885/),h,2 - 3,258532,DB00741,Hydrocortisone
,15968885,t1/2,"In the single dose administration, Cmax and mean AUC0-infinity linearly increased up to 63,167 ng/ml and 311,960 ng x h/ml at the 800 mg dose level, respectively; tmax and t1/2 ranged from 2 - 3 hours and from 9.5 - 15.5 hours, respectively.","Safety, tolerability and pharmacokinetics of oral S-3304, a novel matrix metalloproteinase inhibitor, in single and multiple dose escalation studies in healthy volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15968885/),h,9.5 - 15.5,258533,DB00741,Hydrocortisone
,15968885,Cmax,"High-fat diets reduced Cmax from 21,565 ng/ml to 14,095 ng/ml but did not alter AUC0-infinity.","Safety, tolerability and pharmacokinetics of oral S-3304, a novel matrix metalloproteinase inhibitor, in single and multiple dose escalation studies in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15968885/),[ng] / [ml],"21,565",258534,DB00741,Hydrocortisone
,15968885,Cmax,"High-fat diets reduced Cmax from 21,565 ng/ml to 14,095 ng/ml but did not alter AUC0-infinity.","Safety, tolerability and pharmacokinetics of oral S-3304, a novel matrix metalloproteinase inhibitor, in single and multiple dose escalation studies in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15968885/),[ng] / [ml],"14,095",258535,DB00741,Hydrocortisone
,15968885,t1/2,The AUC of one dosing interval and Cmax did not change after multiple doses but t1/2 increased from 9.5 - 10.0 hours to 12.5 - 13.5 hours.,"Safety, tolerability and pharmacokinetics of oral S-3304, a novel matrix metalloproteinase inhibitor, in single and multiple dose escalation studies in healthy volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15968885/),h,9.5 - 10.0,258536,DB00741,Hydrocortisone
,15968885,t1/2,The AUC of one dosing interval and Cmax did not change after multiple doses but t1/2 increased from 9.5 - 10.0 hours to 12.5 - 13.5 hours.,"Safety, tolerability and pharmacokinetics of oral S-3304, a novel matrix metalloproteinase inhibitor, in single and multiple dose escalation studies in healthy volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15968885/),h,12.5 - 13.5,258537,DB00741,Hydrocortisone
,8636290,production rate,"Five days of fasting induced a 1.8-fold increase in the 24-h endogenous cortisol production rate (fed, 2504 +/- 308; fasted, 4528 +/- 488 nmol/L distribution volume; P < 0.006).",Fasting as a metabolic stress paradigm selectively amplifies cortisol secretory burst mass and delays the time of maximal nyctohemeral cortisol concentrations in healthy men. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8636290/),[nM] / [l],2504,260312,DB00741,Hydrocortisone
,8636290,production rate,"Five days of fasting induced a 1.8-fold increase in the 24-h endogenous cortisol production rate (fed, 2504 +/- 308; fasted, 4528 +/- 488 nmol/L distribution volume; P < 0.006).",Fasting as a metabolic stress paradigm selectively amplifies cortisol secretory burst mass and delays the time of maximal nyctohemeral cortisol concentrations in healthy men. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8636290/),[nM] / [l],4528,260313,DB00741,Hydrocortisone
,8636290,distribution,"Five days of fasting induced a 1.8-fold increase in the 24-h endogenous cortisol production rate (fed, 2504 +/- 308; fasted, 4528 +/- 488 nmol/L distribution volume; P < 0.006).",Fasting as a metabolic stress paradigm selectively amplifies cortisol secretory burst mass and delays the time of maximal nyctohemeral cortisol concentrations in healthy men. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8636290/),[nM] / [l],2504,260314,DB00741,Hydrocortisone
,8636290,distribution,"Five days of fasting induced a 1.8-fold increase in the 24-h endogenous cortisol production rate (fed, 2504 +/- 308; fasted, 4528 +/- 488 nmol/L distribution volume; P < 0.006).",Fasting as a metabolic stress paradigm selectively amplifies cortisol secretory burst mass and delays the time of maximal nyctohemeral cortisol concentrations in healthy men. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8636290/),[nM] / [l],4528,260315,DB00741,Hydrocortisone
,8636290,mass of,"This enhanced cortisol production rate was accounted for by a 1.6-fold increase in the mass of cortisol secreted per burst (fed, 115 +/- 12.1; fasted, 183 +/- 17.3 nmol/L; P < 0.02).",Fasting as a metabolic stress paradigm selectively amplifies cortisol secretory burst mass and delays the time of maximal nyctohemeral cortisol concentrations in healthy men. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8636290/),[nM] / [l],115,260316,DB00741,Hydrocortisone
,8636290,mass of,"This enhanced cortisol production rate was accounted for by a 1.6-fold increase in the mass of cortisol secreted per burst (fed, 115 +/- 12.1; fasted, 183 +/- 17.3 nmol/L; P < 0.02).",Fasting as a metabolic stress paradigm selectively amplifies cortisol secretory burst mass and delays the time of maximal nyctohemeral cortisol concentrations in healthy men. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8636290/),[nM] / [l],183,260317,DB00741,Hydrocortisone
,8636290,number,"Moreover, the number of computer-resolved cortisol secretory bursts per 24 h (fed, 22 +/- 1.4; fasted, 25 +/- 2.0; P = NS) and the interburst interval (fed, 65 +/- 4.0; fasted, 57 +/- 4.4 min) did not change significantly during a 5-day fast.",Fasting as a metabolic stress paradigm selectively amplifies cortisol secretory burst mass and delays the time of maximal nyctohemeral cortisol concentrations in healthy men. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8636290/),,22,260318,DB00741,Hydrocortisone
,8636290,number,"Moreover, the number of computer-resolved cortisol secretory bursts per 24 h (fed, 22 +/- 1.4; fasted, 25 +/- 2.0; P = NS) and the interburst interval (fed, 65 +/- 4.0; fasted, 57 +/- 4.4 min) did not change significantly during a 5-day fast.",Fasting as a metabolic stress paradigm selectively amplifies cortisol secretory burst mass and delays the time of maximal nyctohemeral cortisol concentrations in healthy men. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8636290/),,25,260319,DB00741,Hydrocortisone
,8636290,interburst interval,"Moreover, the number of computer-resolved cortisol secretory bursts per 24 h (fed, 22 +/- 1.4; fasted, 25 +/- 2.0; P = NS) and the interburst interval (fed, 65 +/- 4.0; fasted, 57 +/- 4.4 min) did not change significantly during a 5-day fast.",Fasting as a metabolic stress paradigm selectively amplifies cortisol secretory burst mass and delays the time of maximal nyctohemeral cortisol concentrations in healthy men. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8636290/),min,65,260320,DB00741,Hydrocortisone
,8636290,interburst interval,"Moreover, the number of computer-resolved cortisol secretory bursts per 24 h (fed, 22 +/- 1.4; fasted, 25 +/- 2.0; P = NS) and the interburst interval (fed, 65 +/- 4.0; fasted, 57 +/- 4.4 min) did not change significantly during a 5-day fast.",Fasting as a metabolic stress paradigm selectively amplifies cortisol secretory burst mass and delays the time of maximal nyctohemeral cortisol concentrations in healthy men. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8636290/),min,57,260321,DB00741,Hydrocortisone
,8636290,half-life,"The calculated half-life of endogenous cortisol was not significantly altered by fasting (fed, 108 +/- 9.7; fasted, 129 +/- 11 min).",Fasting as a metabolic stress paradigm selectively amplifies cortisol secretory burst mass and delays the time of maximal nyctohemeral cortisol concentrations in healthy men. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8636290/),min,108,260322,DB00741,Hydrocortisone
,8636290,half-life,"The calculated half-life of endogenous cortisol was not significantly altered by fasting (fed, 108 +/- 9.7; fasted, 129 +/- 11 min).",Fasting as a metabolic stress paradigm selectively amplifies cortisol secretory burst mass and delays the time of maximal nyctohemeral cortisol concentrations in healthy men. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8636290/),min,129,260323,DB00741,Hydrocortisone
,2156886,MCR,"The MCR and plasma half-life of BNP were 2.69 L/min and 3.1 min, respectively.",Brain natriuretic peptide administered to man: actions and metabolism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2156886/),[l] / [min],2.69,260878,DB00741,Hydrocortisone
,2156886,plasma half-life,"The MCR and plasma half-life of BNP were 2.69 L/min and 3.1 min, respectively.",Brain natriuretic peptide administered to man: actions and metabolism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2156886/),min,3.1,260879,DB00741,Hydrocortisone
<,16045952,fT4,One 9.9-year-old administered prednisone 0.5mg/kg p.o. was found to be hypothyroid (TSH: 351microIU/mL; fT4: <2pg/mL; fT3: <1pg/mL); four age-matched normal boys (aged 6.6+/-4.9 years) served as a control group.,Pharmacokinetics of prednisone and prednisolone in a case of hypothyroidism: effect of replacement therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16045952/),[pg] / [ml],2,262136,DB00741,Hydrocortisone
<,16045952,fT3,One 9.9-year-old administered prednisone 0.5mg/kg p.o. was found to be hypothyroid (TSH: 351microIU/mL; fT4: <2pg/mL; fT3: <1pg/mL); four age-matched normal boys (aged 6.6+/-4.9 years) served as a control group.,Pharmacokinetics of prednisone and prednisolone in a case of hypothyroidism: effect of replacement therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16045952/),[pg] / [ml],1,262137,DB00741,Hydrocortisone
,16045952,total AUC,"In comparison with the controls, the hypothyroid boy showed a marked increase in the total AUC of prednisone (3360microg h/L versus 215+/-83microg h/L) and prednisolone (4040microg h/L versus 724+/-77microg h/L), and an altered pattern of endogenous cortisol, which is known to be impaired in hypothyroid subjects.",Pharmacokinetics of prednisone and prednisolone in a case of hypothyroidism: effect of replacement therapy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16045952/),[h·μg] / [l],3360,262138,DB00741,Hydrocortisone
,16045952,total AUC,"In comparison with the controls, the hypothyroid boy showed a marked increase in the total AUC of prednisone (3360microg h/L versus 215+/-83microg h/L) and prednisolone (4040microg h/L versus 724+/-77microg h/L), and an altered pattern of endogenous cortisol, which is known to be impaired in hypothyroid subjects.",Pharmacokinetics of prednisone and prednisolone in a case of hypothyroidism: effect of replacement therapy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16045952/),[h·μg] / [l],215,262139,DB00741,Hydrocortisone
,16045952,total AUC,"In comparison with the controls, the hypothyroid boy showed a marked increase in the total AUC of prednisone (3360microg h/L versus 215+/-83microg h/L) and prednisolone (4040microg h/L versus 724+/-77microg h/L), and an altered pattern of endogenous cortisol, which is known to be impaired in hypothyroid subjects.",Pharmacokinetics of prednisone and prednisolone in a case of hypothyroidism: effect of replacement therapy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16045952/),[h·μg] / [l],4040,262140,DB00741,Hydrocortisone
,16045952,total AUC,"In comparison with the controls, the hypothyroid boy showed a marked increase in the total AUC of prednisone (3360microg h/L versus 215+/-83microg h/L) and prednisolone (4040microg h/L versus 724+/-77microg h/L), and an altered pattern of endogenous cortisol, which is known to be impaired in hypothyroid subjects.",Pharmacokinetics of prednisone and prednisolone in a case of hypothyroidism: effect of replacement therapy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16045952/),[h·μg] / [l],724,262141,DB00741,Hydrocortisone
,16045952,AUCs,"After 6 months of thyroxine replacement therapy (75microg/day), the AUCs of prednisone and prednisolone returned to normal values (prednisone: 248microg h/L; prednisolone: 528microg h/L), as did the pattern of circadian cortisol secretion.",Pharmacokinetics of prednisone and prednisolone in a case of hypothyroidism: effect of replacement therapy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16045952/),[h·μg] / [l],248,262142,DB00741,Hydrocortisone
,16045952,AUCs,"After 6 months of thyroxine replacement therapy (75microg/day), the AUCs of prednisone and prednisolone returned to normal values (prednisone: 248microg h/L; prednisolone: 528microg h/L), as did the pattern of circadian cortisol secretion.",Pharmacokinetics of prednisone and prednisolone in a case of hypothyroidism: effect of replacement therapy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16045952/),[h·μg] / [l],528,262143,DB00741,Hydrocortisone
,20528006,duration of absorption,"The pharmacokinetic parameters (intersubject variability) were the following: duration of absorption 0.54 hour, volume of distribution 38.7 L (39.7%) and clearance 12.1 L/h (23.2%).",Pharmacokinetic evidence for suboptimal treatment of adrenal insufficiency with currently available hydrocortisone tablets. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20528006/),h,0.54,263871,DB00741,Hydrocortisone
,20528006,volume of distribution,"The pharmacokinetic parameters (intersubject variability) were the following: duration of absorption 0.54 hour, volume of distribution 38.7 L (39.7%) and clearance 12.1 L/h (23.2%).",Pharmacokinetic evidence for suboptimal treatment of adrenal insufficiency with currently available hydrocortisone tablets. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20528006/),l,38.7,263872,DB00741,Hydrocortisone
,20528006,clearance,"The pharmacokinetic parameters (intersubject variability) were the following: duration of absorption 0.54 hour, volume of distribution 38.7 L (39.7%) and clearance 12.1 L/h (23.2%).",Pharmacokinetic evidence for suboptimal treatment of adrenal insufficiency with currently available hydrocortisone tablets. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20528006/),[l] / [h],12.1,263873,DB00741,Hydrocortisone
,1524961,time taken,The difference in time taken (median and range) to maximum suppression of cortisol was statistically significant (P less than 0.05) between P (2.5 h; 2-4 h) and EP (4 h; 3-12 h) preparations administered to volunteers.,A pharmacokinetic and pharmacodynamic comparison of plain and enteric-coated prednisolone tablets. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1524961/),h,2.5,264178,DB00741,Hydrocortisone
,1524961,time taken,The difference in time taken (median and range) to maximum suppression of cortisol was statistically significant (P less than 0.05) between P (2.5 h; 2-4 h) and EP (4 h; 3-12 h) preparations administered to volunteers.,A pharmacokinetic and pharmacodynamic comparison of plain and enteric-coated prednisolone tablets. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1524961/),h,4,264179,DB00741,Hydrocortisone
,1524961,maximum suppression,The difference in time taken (median and range) to maximum suppression of cortisol was statistically significant (P less than 0.05) between P (2.5 h; 2-4 h) and EP (4 h; 3-12 h) preparations administered to volunteers.,A pharmacokinetic and pharmacodynamic comparison of plain and enteric-coated prednisolone tablets. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1524961/),h,2.5,264180,DB00741,Hydrocortisone
,1524961,maximum suppression,The difference in time taken (median and range) to maximum suppression of cortisol was statistically significant (P less than 0.05) between P (2.5 h; 2-4 h) and EP (4 h; 3-12 h) preparations administered to volunteers.,A pharmacokinetic and pharmacodynamic comparison of plain and enteric-coated prednisolone tablets. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1524961/),h,4,264181,DB00741,Hydrocortisone
,3743619,peak levels,"After ingestion of 20, 50 and 100 mg, the peak levels were 199, 419 and 812 ng/ml, respectively.",Fluocortolone: pharmacokinetics and effect on plasma cortisol level. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3743619/),[ng] / [ml],199,264859,DB00741,Hydrocortisone
,3743619,peak levels,"After ingestion of 20, 50 and 100 mg, the peak levels were 199, 419 and 812 ng/ml, respectively.",Fluocortolone: pharmacokinetics and effect on plasma cortisol level. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3743619/),[ng] / [ml],419,264860,DB00741,Hydrocortisone
,3743619,peak levels,"After ingestion of 20, 50 and 100 mg, the peak levels were 199, 419 and 812 ng/ml, respectively.",Fluocortolone: pharmacokinetics and effect on plasma cortisol level. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3743619/),[ng] / [ml],812,264861,DB00741,Hydrocortisone
,3743619,half-life,Post-maximum plasma levels declined monoexponentially with a half-life of 1.76 h.,Fluocortolone: pharmacokinetics and effect on plasma cortisol level. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3743619/),h,1.76,264862,DB00741,Hydrocortisone
,3743619,Plasma half-life (t1/2,"Plasma half-life (t1/2 = 1.76 h), volume of distribution (1.03 l/kg) and oral clearance (6.9 ml/min/kg) were independent of the dose.",Fluocortolone: pharmacokinetics and effect on plasma cortisol level. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3743619/),h,1.76,264863,DB00741,Hydrocortisone
,3743619,volume of distribution,"Plasma half-life (t1/2 = 1.76 h), volume of distribution (1.03 l/kg) and oral clearance (6.9 ml/min/kg) were independent of the dose.",Fluocortolone: pharmacokinetics and effect on plasma cortisol level. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3743619/),[l] / [kg],1.03,264864,DB00741,Hydrocortisone
,3743619,oral clearance,"Plasma half-life (t1/2 = 1.76 h), volume of distribution (1.03 l/kg) and oral clearance (6.9 ml/min/kg) were independent of the dose.",Fluocortolone: pharmacokinetics and effect on plasma cortisol level. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3743619/),[ml] / [kg·min],6.9,264865,DB00741,Hydrocortisone
,1319455,half-life,"In man, the half-life of hCRH (30.5 +/- 3.3 min; mean +/- S.E.M.) was significantly (P less than 0.001) less than that of oCRH (42.8 +/- 6.4 min).",A comparison of the clearance of ovine and human corticotrophin-releasing hormone (CRH) in man and sheep: a possible role for CRH-binding protein. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1319455/),min,30.5,266613,DB00741,Hydrocortisone
,1319455,half-life,"In man, the half-life of hCRH (30.5 +/- 3.3 min; mean +/- S.E.M.) was significantly (P less than 0.001) less than that of oCRH (42.8 +/- 6.4 min).",A comparison of the clearance of ovine and human corticotrophin-releasing hormone (CRH) in man and sheep: a possible role for CRH-binding protein. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1319455/),min,42.8,266614,DB00741,Hydrocortisone
,1319455,half-life,"In sheep, there was no significant difference between the half-life of hCRH (46.5 +/- 7.2 min) and that of oCRH (39.8 +/- 10.1 min); these half-lives were also significantly (P less than 0.001) longer than that of hCRH in man.",A comparison of the clearance of ovine and human corticotrophin-releasing hormone (CRH) in man and sheep: a possible role for CRH-binding protein. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1319455/),min,46.5,266615,DB00741,Hydrocortisone
,1319455,half-life,"In sheep, there was no significant difference between the half-life of hCRH (46.5 +/- 7.2 min) and that of oCRH (39.8 +/- 10.1 min); these half-lives were also significantly (P less than 0.001) longer than that of hCRH in man.",A comparison of the clearance of ovine and human corticotrophin-releasing hormone (CRH) in man and sheep: a possible role for CRH-binding protein. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1319455/),min,39.8,266616,DB00741,Hydrocortisone
,16422998,AUC(0-infinity),"Pharmacokinetic parameters of budesonide following single-dose administration (e.g. AUC(0-infinity) 7.7+/-5.1 h ng/mL, C(max) 1.8+/-1.2 ng/mL) did not change upon multiple dosing.",Pharmacokinetics and pharmacodynamic action of budesonide in children with Crohn's disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16422998/),[h·ng] / [ml],7.7,268408,DB00741,Hydrocortisone
,16422998,C(max),"Pharmacokinetic parameters of budesonide following single-dose administration (e.g. AUC(0-infinity) 7.7+/-5.1 h ng/mL, C(max) 1.8+/-1.2 ng/mL) did not change upon multiple dosing.",Pharmacokinetics and pharmacodynamic action of budesonide in children with Crohn's disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16422998/),[ng] / [ml],1.8,268409,DB00741,Hydrocortisone
,31100113,peak plasma firocoxib concentrations (Cmax),"Mean (±SEM) peak plasma firocoxib concentrations (Cmax) were 107.90 ± 15.18, 157.50 ± 24.91, 343.68 ± 78.89, and 452.83 ± 90.27 ng/mL in sows receiving 0.5, 1.0, 1.5, and 2.0 mg/kg firocoxib, respectively, and 9.53 ± 1.21, 31.04 ± 6.79, 53.30 ± 11.1, and 44.03 ± 7.47 ng/mL in their respective piglets.","Transmammary delivery of firocoxib to piglets reduces stress and improves average daily gain after castration, tail docking, and teeth clipping1. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31100113/),[ng] / [ml],107.90,268777,DB00741,Hydrocortisone
,31100113,peak plasma firocoxib concentrations (Cmax),"Mean (±SEM) peak plasma firocoxib concentrations (Cmax) were 107.90 ± 15.18, 157.50 ± 24.91, 343.68 ± 78.89, and 452.83 ± 90.27 ng/mL in sows receiving 0.5, 1.0, 1.5, and 2.0 mg/kg firocoxib, respectively, and 9.53 ± 1.21, 31.04 ± 6.79, 53.30 ± 11.1, and 44.03 ± 7.47 ng/mL in their respective piglets.","Transmammary delivery of firocoxib to piglets reduces stress and improves average daily gain after castration, tail docking, and teeth clipping1. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31100113/),[ng] / [ml],157.50,268778,DB00741,Hydrocortisone
,31100113,peak plasma firocoxib concentrations (Cmax),"Mean (±SEM) peak plasma firocoxib concentrations (Cmax) were 107.90 ± 15.18, 157.50 ± 24.91, 343.68 ± 78.89, and 452.83 ± 90.27 ng/mL in sows receiving 0.5, 1.0, 1.5, and 2.0 mg/kg firocoxib, respectively, and 9.53 ± 1.21, 31.04 ± 6.79, 53.30 ± 11.1, and 44.03 ± 7.47 ng/mL in their respective piglets.","Transmammary delivery of firocoxib to piglets reduces stress and improves average daily gain after castration, tail docking, and teeth clipping1. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31100113/),[ng] / [ml],343.68,268779,DB00741,Hydrocortisone
,31100113,peak plasma firocoxib concentrations (Cmax),"Mean (±SEM) peak plasma firocoxib concentrations (Cmax) were 107.90 ± 15.18, 157.50 ± 24.91, 343.68 ± 78.89, and 452.83 ± 90.27 ng/mL in sows receiving 0.5, 1.0, 1.5, and 2.0 mg/kg firocoxib, respectively, and 9.53 ± 1.21, 31.04 ± 6.79, 53.30 ± 11.1, and 44.03 ± 7.47 ng/mL in their respective piglets.","Transmammary delivery of firocoxib to piglets reduces stress and improves average daily gain after castration, tail docking, and teeth clipping1. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31100113/),[ng] / [ml],452.83,268780,DB00741,Hydrocortisone
,31100113,peak plasma firocoxib concentrations (Cmax),"Mean (±SEM) peak plasma firocoxib concentrations (Cmax) were 107.90 ± 15.18, 157.50 ± 24.91, 343.68 ± 78.89, and 452.83 ± 90.27 ng/mL in sows receiving 0.5, 1.0, 1.5, and 2.0 mg/kg firocoxib, respectively, and 9.53 ± 1.21, 31.04 ± 6.79, 53.30 ± 11.1, and 44.03 ± 7.47 ng/mL in their respective piglets.","Transmammary delivery of firocoxib to piglets reduces stress and improves average daily gain after castration, tail docking, and teeth clipping1. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31100113/),[ng] / [ml],9.53,268781,DB00741,Hydrocortisone
,31100113,peak plasma firocoxib concentrations (Cmax),"Mean (±SEM) peak plasma firocoxib concentrations (Cmax) were 107.90 ± 15.18, 157.50 ± 24.91, 343.68 ± 78.89, and 452.83 ± 90.27 ng/mL in sows receiving 0.5, 1.0, 1.5, and 2.0 mg/kg firocoxib, respectively, and 9.53 ± 1.21, 31.04 ± 6.79, 53.30 ± 11.1, and 44.03 ± 7.47 ng/mL in their respective piglets.","Transmammary delivery of firocoxib to piglets reduces stress and improves average daily gain after castration, tail docking, and teeth clipping1. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31100113/),[ng] / [ml],31.04,268782,DB00741,Hydrocortisone
,31100113,peak plasma firocoxib concentrations (Cmax),"Mean (±SEM) peak plasma firocoxib concentrations (Cmax) were 107.90 ± 15.18, 157.50 ± 24.91, 343.68 ± 78.89, and 452.83 ± 90.27 ng/mL in sows receiving 0.5, 1.0, 1.5, and 2.0 mg/kg firocoxib, respectively, and 9.53 ± 1.21, 31.04 ± 6.79, 53.30 ± 11.1, and 44.03 ± 7.47 ng/mL in their respective piglets.","Transmammary delivery of firocoxib to piglets reduces stress and improves average daily gain after castration, tail docking, and teeth clipping1. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31100113/),[ng] / [ml],53.30,268783,DB00741,Hydrocortisone
,31100113,peak plasma firocoxib concentrations (Cmax),"Mean (±SEM) peak plasma firocoxib concentrations (Cmax) were 107.90 ± 15.18, 157.50 ± 24.91, 343.68 ± 78.89, and 452.83 ± 90.27 ng/mL in sows receiving 0.5, 1.0, 1.5, and 2.0 mg/kg firocoxib, respectively, and 9.53 ± 1.21, 31.04 ± 6.79, 53.30 ± 11.1, and 44.03 ± 7.47 ng/mL in their respective piglets.","Transmammary delivery of firocoxib to piglets reduces stress and improves average daily gain after castration, tail docking, and teeth clipping1. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31100113/),[ng] / [ml],44.03,268784,DB00741,Hydrocortisone
,31100113,plasma terminal half-life,Mean plasma terminal half-life values ranged from 26 to 31 h in sows and 30 to 48 h in piglets.,"Transmammary delivery of firocoxib to piglets reduces stress and improves average daily gain after castration, tail docking, and teeth clipping1. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31100113/),h,26 to 31,268785,DB00741,Hydrocortisone
,31100113,plasma terminal half-life,Mean plasma terminal half-life values ranged from 26 to 31 h in sows and 30 to 48 h in piglets.,"Transmammary delivery of firocoxib to piglets reduces stress and improves average daily gain after castration, tail docking, and teeth clipping1. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31100113/),h,30 to 48,268786,DB00741,Hydrocortisone
,4041330,half-life,"In the anticonvulsant-treated group, the half-life of cortisol in plasma (73 +/- 5 min, mean +/- s.e. mean) and saliva (83 +/- 5 min, mean +/- s.e. mean) was reduced significantly (P less than 0.01 plasma, P less than 0.05 saliva) from that observed in healthy volunteers.",Anticonvulsant therapy and cortisol elimination. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4041330/),min,73,269970,DB00741,Hydrocortisone
,4041330,half-life,"In the anticonvulsant-treated group, the half-life of cortisol in plasma (73 +/- 5 min, mean +/- s.e. mean) and saliva (83 +/- 5 min, mean +/- s.e. mean) was reduced significantly (P less than 0.01 plasma, P less than 0.05 saliva) from that observed in healthy volunteers.",Anticonvulsant therapy and cortisol elimination. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4041330/),min,83,269971,DB00741,Hydrocortisone
,16024008,total oral diltiazem clearance,"The mean values of total oral diltiazem clearance of subjects with *1/*1, *1/*3 and *3/*3 were 183.4 +/- 39.4, 197.9 +/- 49.6 and 293.6 +/- 141.1 (l/h), respectively, and were not significantly different among the 3 genotype groups.",Effects of the CYP3A5 genetic polymorphism on the pharmacokinetics of diltiazem. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16024008/),[l] / [h],183.4,270072,DB00741,Hydrocortisone
,16024008,total oral diltiazem clearance,"The mean values of total oral diltiazem clearance of subjects with *1/*1, *1/*3 and *3/*3 were 183.4 +/- 39.4, 197.9 +/- 49.6 and 293.6 +/- 141.1 (l/h), respectively, and were not significantly different among the 3 genotype groups.",Effects of the CYP3A5 genetic polymorphism on the pharmacokinetics of diltiazem. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16024008/),[l] / [h],197.9,270073,DB00741,Hydrocortisone
,16024008,total oral diltiazem clearance,"The mean values of total oral diltiazem clearance of subjects with *1/*1, *1/*3 and *3/*3 were 183.4 +/- 39.4, 197.9 +/- 49.6 and 293.6 +/- 141.1 (l/h), respectively, and were not significantly different among the 3 genotype groups.",Effects of the CYP3A5 genetic polymorphism on the pharmacokinetics of diltiazem. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16024008/),[l] / [h],293.6,270074,DB00741,Hydrocortisone
,25926431,half-life,"Pharmacokinetic parameters, i.e., half-life, rate of elimination, clearance, and area under the curve, were 23.03 hours, 0.03 hour(-1), 6.6 × 10(-5) l⋅hour(-1), and 1.03 (mg/l)*h, respectively.",Metabolite profiling and pharmacokinetic evaluation of hydrocortisone in a perfused three-dimensional human liver bioreactor. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25926431/),h,23.03,270777,DB00741,Hydrocortisone
,25926431,rate of elimination,"Pharmacokinetic parameters, i.e., half-life, rate of elimination, clearance, and area under the curve, were 23.03 hours, 0.03 hour(-1), 6.6 × 10(-5) l⋅hour(-1), and 1.03 (mg/l)*h, respectively.",Metabolite profiling and pharmacokinetic evaluation of hydrocortisone in a perfused three-dimensional human liver bioreactor. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25926431/),1/[hour],0.03,270778,DB00741,Hydrocortisone
,25926431,area under the curve,"Pharmacokinetic parameters, i.e., half-life, rate of elimination, clearance, and area under the curve, were 23.03 hours, 0.03 hour(-1), 6.6 × 10(-5) l⋅hour(-1), and 1.03 (mg/l)*h, respectively.",Metabolite profiling and pharmacokinetic evaluation of hydrocortisone in a perfused three-dimensional human liver bioreactor. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25926431/),[mg] / [h·l)],1.03,270779,DB00741,Hydrocortisone
less,1541734,excretion,The 24-h excretion of radiolabel in urine was less than 4% for fructose and glucose at birth and at d 7.,"The clearance of carbon-14-fructose, carbon-14-glucose, and carbon-14-sorbitol by calves at birth and 7 days of age. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1541734/),%,4,271272,DB00741,Hydrocortisone
,24487120,renal clearance,"Oat3(-/-) mice showed significantly reduced renal clearance of 6β-OHF (CL(renal, 6β-OHF)) compared with wild-type mice (18.1 ± 1.5 versus 7.60 ± 1.8 ml/min/kg).","6β-Hydroxycortisol is an endogenous probe for evaluation of drug-drug interactions involving a multispecific renal organic anion transporter, OAT3/SLC22A8, in healthy subjects. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24487120/),[ml] / [kg·min],18.1,271646,DB00741,Hydrocortisone
,24487120,renal clearance,"Oat3(-/-) mice showed significantly reduced renal clearance of 6β-OHF (CL(renal, 6β-OHF)) compared with wild-type mice (18.1 ± 1.5 versus 7.60 ± 1.8 ml/min/kg).","6β-Hydroxycortisol is an endogenous probe for evaluation of drug-drug interactions involving a multispecific renal organic anion transporter, OAT3/SLC22A8, in healthy subjects. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24487120/),[ml] / [kg·min],7.60,271647,DB00741,Hydrocortisone
,24487120,CL,"Oat3(-/-) mice showed significantly reduced renal clearance of 6β-OHF (CL(renal, 6β-OHF)) compared with wild-type mice (18.1 ± 1.5 versus 7.60 ± 1.8 ml/min/kg).","6β-Hydroxycortisol is an endogenous probe for evaluation of drug-drug interactions involving a multispecific renal organic anion transporter, OAT3/SLC22A8, in healthy subjects. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24487120/),[ml] / [kg·min],18.1,271648,DB00741,Hydrocortisone
,24487120,CL,"Oat3(-/-) mice showed significantly reduced renal clearance of 6β-OHF (CL(renal, 6β-OHF)) compared with wild-type mice (18.1 ± 1.5 versus 7.60 ± 1.8 ml/min/kg).","6β-Hydroxycortisol is an endogenous probe for evaluation of drug-drug interactions involving a multispecific renal organic anion transporter, OAT3/SLC22A8, in healthy subjects. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24487120/),[ml] / [kg·min],7.60,271649,DB00741,Hydrocortisone
,24487120,CL,"Consequently, CL(renal, 6β-OHF) (milliliters per minute) decreased significantly from 231 ± 11 to 135 ± 9 and from 225 ± 26 to 141 ± 12 after probenecid administration in studies 1 and 2, respectively.","6β-Hydroxycortisol is an endogenous probe for evaluation of drug-drug interactions involving a multispecific renal organic anion transporter, OAT3/SLC22A8, in healthy subjects. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24487120/),[milliliters] / [min],231,271650,DB00741,Hydrocortisone
,24487120,CL,"Consequently, CL(renal, 6β-OHF) (milliliters per minute) decreased significantly from 231 ± 11 to 135 ± 9 and from 225 ± 26 to 141 ± 12 after probenecid administration in studies 1 and 2, respectively.","6β-Hydroxycortisol is an endogenous probe for evaluation of drug-drug interactions involving a multispecific renal organic anion transporter, OAT3/SLC22A8, in healthy subjects. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24487120/),[milliliters] / [min],135,271651,DB00741,Hydrocortisone
,24487120,CL,"Consequently, CL(renal, 6β-OHF) (milliliters per minute) decreased significantly from 231 ± 11 to 135 ± 9 and from 225 ± 26 to 141 ± 12 after probenecid administration in studies 1 and 2, respectively.","6β-Hydroxycortisol is an endogenous probe for evaluation of drug-drug interactions involving a multispecific renal organic anion transporter, OAT3/SLC22A8, in healthy subjects. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24487120/),[milliliters] / [min],225,271652,DB00741,Hydrocortisone
,24487120,CL,"Consequently, CL(renal, 6β-OHF) (milliliters per minute) decreased significantly from 231 ± 11 to 135 ± 9 and from 225 ± 26 to 141 ± 12 after probenecid administration in studies 1 and 2, respectively.","6β-Hydroxycortisol is an endogenous probe for evaluation of drug-drug interactions involving a multispecific renal organic anion transporter, OAT3/SLC22A8, in healthy subjects. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24487120/),[milliliters] / [min],141,271653,DB00741,Hydrocortisone
,3580023,plasma half-life,"The hemisuccinate ester is hydrolyzed relatively quickly with a plasma half-life between 18 and 25 min, and the resulting prednisolone has a plasma half-life of 3.5-3.7 h.",[Pharmacokinetics and pharmacodynamics of prednisolone following extremely high dosage as prednisolone hemisuccinate]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3580023/),min,18 and 25,272214,DB00741,Hydrocortisone
,3580023,plasma half-life,"The hemisuccinate ester is hydrolyzed relatively quickly with a plasma half-life between 18 and 25 min, and the resulting prednisolone has a plasma half-life of 3.5-3.7 h.",[Pharmacokinetics and pharmacodynamics of prednisolone following extremely high dosage as prednisolone hemisuccinate]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3580023/),h,3.5-3.7,272215,DB00741,Hydrocortisone
